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Abstract
Benzodiazepines are a class of compounds that were initially developed for medicinal purposes.
Multiple benzodiazepines have appeared as ‘new psychoactive substances’ on the illicit drug
market and have never been developed for medicinal use. Very little pharmacokinetic data exists
regarding them. This information is valuable as it allows the prediction and interpretation of
their effects in humans and aids with forensic and toxicological work.
In this work the lipophilicity (log D7.4), the pKa and the plasma protein binding were determined
for benzodiazepines appearing as new psychoactive substances and these were compared to
theoretical values from software packages. ACD/I-LAB returned the most accurate values for
log D7.4 and plasma protein binding while ADMET Predictor returned the most accurate values
for pKa. None of the software packages were able to predict parameters to a sufficient degree
of accuracy and in vitro data is currently preferable.
An improved relationship to calculate the volume of distribution at steady state (Vdss) by using
the Øie-Tozer equation, the log D7.4, the pKa and the plasma protein binding of benzodiazepines
was developed. The Vdss of benzodiazepines could be predicted to within a 1.11-fold accuracy.
The blood to plasma concentration ratios of six benzodiazepines appearing as new psychoac-
tive substances were determined. Despite the small dataset a large variation in ratios was
observed, from 0.57 for phenazepam to 1.18 for pyrazolam, highlighting the need for accurate
pharmacokinetic data.
The metabolic characterisation of illicit compounds is an important aid in toxicological inter-
pretations. This is commonly performed in vitro using human hepatocellular carcinoma cell
lines and the choice of cell line is crucial in order to obtain reliable results. The C3A and
HepaRG cell lines were characterised with respect to six major phase I metabolic enzymes.
HepaRG was shown to have a greater expression of these enzymes and thus have a superior
utility in a metabolic study.
The metabolism of 12 benzodiazepines appearing as new psychoactive substances was investi-
gated with the HepaRG cell line. Some of the benzodiazepines were observed to have different
metabolic pathways to those previously reported. This again highlights the need for accurate
experimental data in order to assess the pharmacokinetics of new psychoactive substances.
v
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Chapter 1
Introduction
1.1 Substance abuse
The term ‘substances of abuse’ commonly refers to three categories of compounds; specific
drugs of abuse, medications and toxins [1]. Substances have been abused for hundreds if not
thousands of years as a result of their psychoactive effects [2]. Psychoactive substances are
broadly defined as:
“compounds that when consumed can affect the central nervous system of a person by
stimulation or depression resulting in hallucinations or a significant disturbance, or significant
change to, motor function, thinking, behaviour, perception, awareness or mood.” [3,4]
The earliest substances of abuse were plant-based, for example; alcohol, opium, cocaine and
cannabis [2]. Various cooperative international attempts have been made to control the trade
and supply of illicitly-used compounds as a result of their damaging effects upon health. The
Single Convention on Narcotic Drugs of 1961 aimed to control cannabis and a variety of opi-
oids [5]. This was followed by the Convention on Psychotropic Substances of 1971 which
aimed to control compounds not specified in the previous convention such as; phenethylamines,
tryptamines, cathinones, synthetic cannabinoids, barbiturates and benzodiazepines [6]. All of
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these substances are commonly abused [1]. In order to circumvent and evade these interna-
tional controls, a variety of compounds have emerged and are abused that are not regulated
under either convention [7]. This circumvention of existing legislation is often known as a ‘cat
and mouse game’ and is exemplified by the appearance of compounds differing by a single
atom from those that are controlled substances [8]. Compounds that appear as substances of
abuse and that are not under international control are known as ‘new psychoactive substances’
(NPS) [9]. In terms of the control of new psychoactive substances in the United Kingdom; the
Psychoactive Substances Bill became law in 2016 [7]. This law aimed to control any substances
which were not under control of the Misuse of Drugs Act 1971 and were capable of producing
a psychoactive effect, with exemptions for compounds such as caffeine, alcohol and tobacco [7].
1.2 The Rise of New Psychoactive Substances
NPS are defined by the United Nations Office on Drugs and Crime (UNODC) as being:
“substances of abuse, either in a pure form or a preparation, that are not controlled by the
1961 Single Convention on Narcotic Drugs or the 1971 Convention on Psychotropic
Substances, but which may pose a public health threat.”[9]
The word ‘new’ refers to the substance appearing on the illicit drug market and not whether it
is an entirely new compound. Many of these compounds have been previously synthesised and
patented during the early stages of drug development [9]. NPS are usually grouped by similarity
in structure and pharmacological mechanism of action. These include synthetic cannabinoids,
cathinones, opioids, phenylethylamines, piperazines, tryptamines, benzodiazepines and plant
derivatives such as khat [10-19].
In Europe, the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is
responsible for monitoring the availability and illicit use of NPSs [20]. The number of NPSs
has increased markedly in recent years and peaked in 2014 with 101 compounds being reported
to the EMCDDA. This total then decreased to 98 compounds in 2015, to 66 compounds in
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2016 and to 51 compounds in 2017 [21-24]. This increase and decrease can be seen in Figure
1.1 with the data obtained from the EMCDDA [20-22,25-31]. In total over 620 compounds are
currently monitored in Europe by the EMCDDA as NPS [31].
Figure 1.1: Number of NPSs reported to the EU Early Warning System by year since 2005
[20-22,25-31].
1.3 Benzodiazepines as Medicinally-Important Com-
pounds
One group of NPSs to emerge are the benzodiazepines which were initially developed for medic-
inal use [16,32]. Benzodiazepines have sedative, anticonvulsant and anxiolytic properties and
are medicinally important for the treatment of epilepsy, anxiety, muscle spasms and alcohol
withdrawal syndrome [33-38]. Benzodiazepines are typically prescribed on a short-term basis
as longer durations of use can lead to cognitive problems such as amnesia, tolerance and de-
pendence [38-41]. Severe withdrawal symptoms can occur with abrupt discontinuation of use
[42,43]. Benzodiazepines succeeded the use of barbiturates in most medicinal areas as their
lower addictive nature purportedly left them less open to abuse [44].
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1.4 Benzodiazepines as Drugs of Abuse
Despite having a lower abuse liability and being less addictive than the barbiturates, the anx-
iolytic and sedative effects of benzodiazepines still cause them to be misused [45,46]. Ben-
zodiazepines are often misused concurrently with opioids, often to increase the effects gained
from the use of either of these drugs in isolation [47-52]. It is thought that rather than affect
the pharmacokinetics of opioids, co-ingestion of benzodiazepines with opioids instead affects
the pharmacodynamics of opioids [48]. Research suggests that at least some of the analgesic,
anxiolytic effects of benzodiazepines are as a result of their binding to opioid receptors [53-56].
It is suggested that benzodiazepines increase the ‘high’ or rewarding effects of opioid ingestion
[57,58]. The pharmacodynamics of benzodiazepines will be discussed in greater detail in Section
1.9.
The co-ingestion of benzodiazepines and opioids can lead to respiratory depression and death
[59-61]. The main binding site for benzodiazepines, the GABAA receptor (see Section 1.9), is
co-expressed in the central nervous system (CNS) with opioid receptors [62]. It is thought that
both receptors are co-expressed in areas of the CNS that are responsible for ventilatory control
and interactions of opioids and benzodiazepines at these sites may contribute to respiratory
depression [60]. Benzodiazepine use in combination with alcohol is known to lead to excessive
sedation and it has also been reported that high levels of alcohol and benzodiazepine intake
can also cause respiratory depression [63,64].
Benzodiazepines are widely misused in the UK. For example, one report indicated that ben-
zodiazepines (including prescription diazepam and the new psychoactive substance etizolam,
see Section 1.6) were implicated or involved in 552 drug-related deaths (DRDs) in Scotland in
2017 (59 % of the total). In 336 out of 552 DRDs, the only drugs found to be present were
benzodiazepines which were also new psychoactive substances. In the majority of these the
benzodiazepine was etizolam [65]. In England and Wales, benzodiazepines were involved in
6383 DRDs from 1993 - 2016 [66]. The benzodiazepine found in the majority of these cases was
diazepam (53 %) and DRDs involving benzodiazepines were noted to be increasing [66].
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Another form of misuse for benzodiazepines comes from attempted self-medication by users
[67,68]. Research conducted in the UK using an online questionnaire suggests that the most
common reasons given by users for self-medication were to help with sleep (66 % of respondents)
and to cope with stress (37 %) [69].
The side-effects caused by benzodiazepine use when under prescription was recognised very early
on in the 1960s [70,71]. Dependence and addiction were reported when using benzodiazepines
long-term, as was severe withdrawal syndrome following abrupt discontinuation of use [72].
Their side-effects and their potential for misuse led to 35 benzodiazepines and their closely-
related derivatives being placed under control by the United Nations (UN) Convention on
Psychotropic Substances of 1971 [6].
In terms of comparison to other substances of abuse, benzodiazepines are held to have a greater
potential for physical harm than drugs such as alcohol, cannabis, LSD and ecstasy, a greater
potential for dependence than drugs such as ketamine, amphetamine, cannabis, LSD and ecstasy
and a greater potential for social harm than amphetamine, cannabis, LSD and ecstasy [73].
1.5 The Structure of Benzodiazepines
The most common benzodiazepines are the 1,4-benzodiazepines. Their basic structure is a
fused benzene ring and a diazepine ring with an additional phenyl ring typically being present
at position 5 (Figure 1.2A). Other benzodiazepines exist, such as 1,5-benzodiazepines and 2,3-
benzodiazepines but their use is outside the scope of this research as they are not thought to
be illicitly used in a widespread manner, possibly as a result of their lack of sedative effects
when compared to 1,4-benzodiazepines [74-76]. In addition to 1,4-benzodiazepines, a number of
derivatives exist that are often grouped under the generic umbrella of ‘benzodiazepines’ as they
have similar structures and they act on the same pharmacological target [16]. These include
triazolobenzodiazepines (Figure 1.2B), oxazolobenzodiazepines (Figure 1.2C) and thienotria-
zolodiazepines (Figure 1.2D). Despite the thienotriazolodiazepines not being ‘true’ benzodi-
azepines in the sense that they contain a thiophene ring rather than a benzene ring, they are
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often grouped together as ‘benzodiazepines’ as they have the same pharmacological mechanism
of action and similar pharmacokinetics [77]. For simplicity this trend will be continued in this
work.
Benzodiazepines are often substituted with functional groups at various positions. These typi-
cally take the form of a halogen atom (Cl, Br, F) or nitro group (NO2) substitution at position
2 (Figure 1.2D), position 7 (Figures 1.2A and 1.2E) or position 8 (Figure 1.2B). Substitution
on position 1 (Figure 1.2A and Figure 1.2B) by an amine-, alkane- or alkene-containing group
is common. Less common but still observed is substitution at position 3 (Figure 1.2A) with a
hydroxyl or methyl group. The R2’ position on the phenyl ring often has a substituent, usually
a halogen atom. The majority of benzodiazepines that do not have an additional triazole ring
(i.e. 1,4-benzodiazepines) contain a carbonyl group on position 2 (Figure 1.2A).
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Figure 1.2: Structures of a 1,4-benzodiazepine, a triazolobenzodiazepine, an oxazolobenzodi-
azepine, a thienotriazolodiazepine and a thienodiazepine.
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1.6 Benzodiazepines as New Psychoactive Substances
There are currently 27 benzodiazepines that have emerged on the illicit drug market as NPSs
(Table 1.1, data collected from the EMCDDA). To distinguish these benzodiazepines from those
that are used medicinally, the term “NPS-benzodiazepine(s)” will be used from here onwards
to refer to them.
In addition to the benzodiazepines controlled under the UN Convention on Psychotropic Sub-
stances 1971, there are other benzodiazepines that are medically-licensed and prescribed in
various countries around the world. By virtue of existing outside of this legislation, when they
are used illicitly in countries where they are not licensed they are denoted as being NPS. Three
of these to appear as NPSs are phenazepam (originally prescribed in Russia), etizolam (orig-
inally prescribed in Japan and India) and flutazolam (originally prescribed in Japan) [78-80].
Other NPS-benzodiazepines to appear were simply patented and not developed further into
marketable drugs (e.g. pyrazolam), are metabolites of medically-used benzodiazepines (e.g.
desalkylflurazepam) or never gained marketing approval (e.g. adinazolam) [16,81,82]. A sum-
mary of the names of these compounds, the year that they were patented (if any) and the year
that they were reported to the EMCDDA is shown in Table 1.1 [20-22,25-31].
In Europe, 1,4-benzodiazepines, triazolobenzodiazepines, oxazolobenzodiazepines, thienodi-
azepines and thienotriazolodiazepines have all appeared as NPSs [16]. Their names and struc-
tures are listed in Tables 1.2 to 1.6.
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Table 1.1: NPS-benzodiazepine, year patented and year reported to the EMCDDA
Compound Year patented Year reported to the EMCDDA References
3-Hydroxyphenazepam Not reported 2016 [31]
4’-Chlorodiazepam 1964 2016 [31,83]
Adinazolam 1976 2015 [22,84]
Bentazepam 1978 2018 [85,86]
Bromazolam 1976 2016 [31,87]
Clonazolam 1971 2015 [22,88]
Cloniprazepam Not reported 2016 [31]
Desalkylflurazepam Not reported 2016 [89]
Deschloroetizolam 1998 2014 [21,89]
Desmethylflunitrazepam 1963 2016 [31,91]
Diclazepam 1964 2013 [29,83]
Difludiazepam 1970 2017 [92,93]
Etizolam 1978 2011 [27,94]
Flualprazolam Not reported 2018 [95]
Flubromazepam 1962 2013 [29,96]
Flubromazolam 1978 2014 [21,97]
Fluclotizolam 1979 2018 [95,98]
Flunitrazolam Not reported 2016 [31]
Flutazolam 1970 2014 [86,99]
Meclonazepam 1975 2014 [21,100]
Methyl-clonazepam Not reported 2018 [95]
Metizolam 1988 2015 [22,101]
Nifoxipam 1985 2015 [22,91]
Nitrazolam 1971 2015 [22,102]
Phenazepam 1974 2007 [20,78]
Pyrazolam 1979 2012 [28,103]
Thionordazepam 1972 2017 [104,105]
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Table 1.2: The substitutions of 1,4-benzodiazepines appearing as NPSs (From Figure 1.2A)
Compound R1 R2’ R3 R7 R4’ R6’
3-Hydroxyphenazepam H Cl OH Br H H
4’-Chlorodiazepam CH3 H H Cl Cl H
Adinazolam CH3 H H Cl Cl H
Cloniprazepam Methylcyclopropane Cl H NO2 H H
Desalkylflurazepam H F H Cl H H
Desmethylflunitrazepam H F H NO2 H H
Diclazepam CH3 Cl H Cl H H
Difludiazepam CH3 F H Cl H F
Flubromazepam H F H Br H H
Meclonazepam H Cl CH3 NO2 H H
Methyl-clonazepam CH3 Cl H NO2 H H
Nifoxipam H F OH NO2 H H
Phenazepam H Cl H Br H H
Thionordazepam1 H H H Cl H H
1Thionordazepam has a sulphur atom rather than an oxygen atom at the R2 posi-
tion
Table 1.3: The substitutions of triazolobenzodiazepines appearing as NPSs (From Figure 1.2B)
Compound R1 R2’ R8
Adinazolam CH2N(CH3)3 H Cl
Bromazolam CH3 H Br
Clonazolam CH3 Cl NO2
Flualprazolam CH3 F Cl
Flubromazolam CH3 F Br
Flunitrazolam CH3 F NO2
Nitrazolam CH3 H NO2
Pyrazolam1 CH3 None Br
1Pyrazolam has a pyridine ring rather than a
phenyl ring at position 6
Table 1.4: The substitutions of thienotriazolobenzodiazepines appearing as NPSs (From Figure
1.2C)
Compound R2 R2’ R9
Deschloroetizolam CH2CH3 H CH3
Etizolam CH2CH3 Cl CH3
Fluclotizolam Cl F CH3
Metizolam CH2CH3 Cl H
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Table 1.5: The substitutions and name of a thienodiazepine appearing as an NPS (From Figure
1.2D)
Compound R2’ R7 R10
Bentazepam1 H H H
1Bentazepam has an additional
benzene ring (part of a benzoth-
iophene system) attached to its
thiophene ring
Table 1.6: The substitutions and name of an oxazolobenzodiazepine appearing as an NPS (From
Figure 1.2E)
Compound R2’ R7 R10
Flutazolam1 F CH2CH2OH Cl
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1.7 Physicochemical Properties of Benzodiazepines
The physicochemical properties of compounds affect their pharmacokinetics and pharmaco-
dynamics. Therefore knowledge of physicochemical properties is an important prerequisite in
pharmaceutical development and is also important for the prediction of pharmacokinetic prop-
erties [106,107]. This will be expanded upon in the relevant Sections (1.7.1 and 1.7.2) of this
work. Two physicochemical properties will be discussed here with regards to benzodiazepines;
their lipophilicity and their pKa.
1.7.1 Lipophilicity
The lipophilicity of a compound is commonly measured by the partition constant (P), a ratio
of the distribution between two phases; water and an organic phase such as octanol [105].
Compounds interact with organic phases via Van der Waals forces and with a water phase
via hydrogen bonding or dipolar forces [108]. When the partition coefficient is measured with
an aqueous phase other than water, it is known as the distribution coefficient (D). The most
common aqueous phase for the measurement of D is a buffer with a pH mimicking the pH
of physiological system, for example 7.4 for the human body [109]. This will be referred to
henceforth as the log D7.4. The values for P and D are usually given as the base-10 logarithm
and denoted as log P or log D7.4 respectively for ease of comparison between different molecules.
The lipophilicity of a molecule affects its absorption within the body. Highly lipophilic drugs
are hydrophobic and poorly soluble in aqueous solutions which can have implications for their
absorption inside the body in gastrointestinal fluid or blood [110]. Cell membranes are com-
monly accepted to consist of phospholipids arranged in a bilayer formation [111]. The transfer
of drugs across the cell membrane is mediated by two processes, active transport and passive
diffusion. For most drugs, passage across the cell membrane occurs by passive diffusion and the
effect of lipophilicity on this process has been well-reviewed [112]. Drugs that are too lipophilic
typically exhibit a preferential association with the cell membrane and have poor absorption
across the membrane into target tissues [112].
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Following absorption into the body, the distribution of a compound within the body is also
affected by its lipophilicity. Drugs that are very lipophilic can engage in off-target binding to
other structures within the body which is generally referred to as drug promiscuity [113]. Drug
promiscuity is undesirable as exemplified by the propensity of highly-lipophilic compounds to
bind to the human ether-a-go-go related gene (hERG)-encoded potassium channel and cause
fatal cardiac arrhythmias [114,115]. A higher lipophilicity is also typically associated with
increased plasma protein binding which will be discussed in further detail in Section 1.8.1
[116]. As a general rule the more lipophilic a compound is, the easier it is for the compound
to cross the blood-brain barrier (BBB) and distribute within the brain [117]. However many
highly-lipophilic drugs often experience a lower than expected BBB partition as a result of
them being substrates for ATP-binding cassette (ABC) transporters which are highly-efficient
proteins capable of quickly removing compounds from the central nervous system [117,118].
The majority of drugs are metabolised in the liver by the oxidative CYP450 enzyme family
and this pharmacokinetic process will be discussed in greater detail in Section 1.8.4 [119,120].
Lipophilicity affects CYP450 enzyme metabolism and the relationship generally follows a
parabolic arc; compound affinity increases for CYP450 enzymes up to a certain value for
lipophilicity and thereafter the affinity rapidly decreases as a result of the compound being
too hydrophobic [121,122].
The excretion of a compound also has the potential to be affected by its lipophilicity. As many
drugs are excreted via the kidneys in a process known as glomerular filtration they require a
reasonable degree of water solubility. Drugs that are highly lipophilic may not be adequately
metabolised into hydrophilic compounds and must be reabsorbed and metabolised into more
hydrophilic compounds in order to facilitate their excretion [123].
The previously-discussed effects of lipophilicity on absorption, distribution, metabolism and
excretion means that it is an important parameter in the initial stages of drug development
[110,124].
Attempts are often made to relate physicochemical parameters and/or molecular descriptors
to pharmacokinetics or other biological activity of compounds, this is known as quantitative-
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structure-activity-relationship (QSAR) modelling [125,126]. This allows for basic measurements
regarding physicochemical properties to be conducted and then utilised to predict more complex
parameters thus allowing for rapid screening of compounds and a theoretical assessment of their
potential activity in the body [127]. The importance of lipophilicity measurements for QSAR
has been well-reviewed and it is often regarded as one of the most important parameters in
QSAR models [121,126]
Benzodiazepines typically have reasonably high values for lipophilicity and thus they undergo
rapid absorption into the body, accumulate in lipid-high areas of the body, partition with ease
across cell membranes, experience a high distribution within the brain and have a high volume
of distribution [128-133].
The log P values of ten NPS-benzodiazepines were recently published in 2017 with a view to
making them available for the estimation of pharmacological and toxicological properties of
NPS-benzodiazepines [134].
The lipophilicity of a compound, as well as other parameters such as plasma protein binding and
pKa can be used to predict a pharmacokinetic parameter known as the volume of distribution
and this has been previously demonstrated for some benzodiazepines [135]. This is described
in further detail in Section 1.8.2.
Various methods exist for measuring the log D7.4but the most common is the so-called ‘shake-
flask’ method [136]. Here a known mass of the compound is dissolved and allowed to equilibrate
in equal volumes of octanol and a buffer at pH 7.4 [136]. Following equilibration the concentra-
tions in each phase are determined, typically with HPLC-DAD or LC-MS. Further discussion
of analytical methods such as these will take place in Section 1.10. This process is depicted in
Figure 1.3. Although this experimental measurement of log D7.4 can be time-consuming as it
requires equilibration of the two phases followed by separation and analysis it is generally con-
sidered the ‘gold-standard’ for determining lipophilicity as it is accurate, precise and repeatable
measurements can also be obtained [136,137].
To reduce the time taken to generate log D7.4values a variety of software packages exist in order
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to provide theoretical values [109]. A common method of predicting log D7.4relies on totalling
the individual contributions to lipophilicity from each atom or fragment of a molecule [125,138].
However lipophilicity is not a simple addition and therefore corrections are often included; for
example some approaches assess how these fragments or atoms interact in an intramolecu-
lar manner along with their lipophilicity descriptors [136]. More complex approaches exist
which involve topological and molecular orbital descriptors and these have been well-reviewed
[139,140].
Figure 1.3: The shake-flask method for measuring log D7.4 [133].
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1.7.2 pKa
The pKa of a compound is the base-10 logarithm of its acid dissociation constant (Ka) [141].
It is essentially a measure of the strength of an acid or base in solution; in other words its
propensity to dissociate into a proton and an anion. Compounds can have multiple pKa values
for each ionisable site that they contain [142].
Knowledge of the pKa of a compound is important during pharmaceutical development espe-
cially when used in conjunction with other parameters such as molecular weight and lipophilic-
ity [106,141,143]. pKa directly influences physicochemical parameters such as the log D7.4 and
solubility and hence indirectly influences pharmacokinetic parameters such as absorption and
distribution [141,144]. Ionised compounds have a greater solubility in aqueous solutions as a
result of their increased polarity. This increased solubility and hydrophilicity comes at a cost
of reduced lipophilicity. The effect of this reduced lipophilicity is that the permeability of
compounds through biological membranes is decreased and hence ionised compounds tend to
have a lower permeability compared to neutral compounds [145]. Ionised drugs are not able
to diffuse easily across hepatocyte membranes in the liver and as a result are more likely to
undergo renal clearance [146,147].
The pKa of compounds has been used in pharmacokinetic modelling for predicting the volume
of distribution [107,148]. This is discussed in greater detail in Section 1.8.2. The pKa of
benzodiazepines has also been postulated to be important in determining the extent of their
distribution into adipose tissue as well as predicting their post-mortem distribution [149,150]. A
model capable of predicting post-mortem distribution with an R2 of 0.98 has been reported for
benzodiazepines where ionisation (i.e. pKa) exerted significant impact [149]. Benzodiazepine
distribution into adipose tissue was found to be significantly related to pKa but unrelated to
lipophilicity (as log P) [150].
Benzodiazepines either have one pKa value (e.g. flunitrazepam with 1.8) or two pKa values
(e.g. clonazepam with 1.5 and 10.5) [151,152]. As mentioned previously each pKa value refers
to a separate site of ionisation on the molecule. The first pKa value for benzodiazepines refers
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to the deprotonation of the nitrogen cation at position 4 and the second pKa refers to the
deprotonation of the nitrogen atom at position 1 (from Figure 1.2A) [153]. The deprotonation
of the nitrogen atom at position 1 is thought to be resonance-stabilised with the negatively-
charged oxygen atom [153]. This can be visualised in Figure 1.4 for clonazepam.
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Figure 1.4: pKa values and structures for clonazepam [148,149].
A variety of methods exist for measuring pKa such as potentiometry, calorimetry and elec-
trophoresis and these have been well-reviewed [154,155]. A commonly used method is capillary
electrophoresis because of its efficiency, ease of use and the low concentrations (in the order of
ng mL-1) that are required [156,157]. In this technique, ions are separated using an applied elec-
trical voltage as a result of their differing electrophoretic mobilities [158]. The electrophoretic
mobility of a compound describes its rate of movement when an electrical field is applied in a
specific solution [159]. A compound in its unionised state has no electrophoretic mobility. Once
an electrical voltage is applied and the compound is fully ionised then its electrophoretic mo-
bility is at its maximum [160]. Between this minimum and maximum electrophoretic mobility
there exist various intermediate mobilities that are dependent on the pH of the solution. The
effective electrophoretic mobility of a compound can be calculated with knowledge of the differ-
ence in migration time between the test compound and a neutral marker compound (Equation
1.1) [156].
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µeff = (
LdLt
V
)(
1
ta
− 1
tm
) (1.1)
Equation 1.1 Determination of effective mobility where µeff is the effective mobility, ta is the
migration time for the test compound (in seconds), tm is the migration time for the neutral
marker (in seconds), Ld is the total length from the capillary inlet to the detection window
(cm), Lt is the total capillary length (in cm) and V is the applied voltage.
Once the effective mobility of a compound has been determined at a specific pH, it can be
related to the pKa of a compound through Equations 1.2 and 1.3.
µeff =
α× 10-pH
10-pKa + 10-pH
(1.2)
Equation 1.2 Relationship between effective mobility at a specific pH and the pKa of a compound
where µeff is the effective mobility, pH is the pH of the buffer solution, pKa is the compound
pKa and α is a fitting constant for acidic compounds equal to the electrophoretic mobility of
the ionised form of the compound with the subscript denoting to the order of ionization.
µeff =
b1(10
-pH)2 + a110
-pKa110-pKa2
(10-pH)2 + a110-pKa110-pH + 10-pKa110-pKa2
(1.3)
Equation 1.3 Relationship between effective mobility at a specific pH and the pKa of a compound
where µeff is the effective mobility, pH is the pH of the buffer solution, pKa is the compound
pKa and α and β are a fitting constants equal to the electrophoretic mobilities of the ionised
forms of the compound with the subscript denoting to the order of ionization for acidic and
basic compounds respectively.
Equation 1.2 describes the relationship between the effective electrophoretic mobility of a com-
pound and its pKa when it contains one ionisable basic group and Equation 1.3 describes the
relationship between the effective electrophoretic mobility of a compound and its pKa when it
contains both an ionisable basic and acidic group [161]. In equations 1.2 and 1.3, a and b are
constants.
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As determination of pKa by capillary electrophoresis requires measurement of the elec-
trophoretic mobility of a compound at a range of pH values, often in triplicate, it can be
time-consuming even with automated equipment. Therefore multiple theoretical approaches
exist. Some of these are similar to those used for predicting log D7.4 in that they take into
account the contributions of individual atoms and fragments in a compound or use training
datasets of compounds with known pKa values [162]. Linear free-energy relationships, often
based on Hammett-Taft methods are commonly used [142]. A linear free-energy relationship
describes two parallel sets of reactions where changes to the first reaction affect the second
reaction in the same manner [159]. Hammett-Taft equations take into account the electronic
effects of substituents in a compound, namely their ability to donate and withdraw electrons
[163]. The use of different software packages to predict pKa values has been well-reviewed [162].
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1.8 Pharmacokinetics of Benzodiazepines
Benzodiazepines have various routes of administration, however oral is the most common route
of administration overall, with injective routes of administration being more common amongst
opiate users [47,164,165]. The pharmacokinetics of NPS-benzodiazepines have been previously
reviewed [16]. Three pharmacokinetic parameters;the plasma protein binding, the volume of
distribution at steady state and the blood to plasma ratio will be discussed here along with the
pharmacokinetic phase of metabolism.
1.8.1 Plasma Protein Binding
Whole blood consists of blood cells (45 % by volume) and a liquid component known as plasma
(55 % by volume) [166]. The plasma can be subdivided into water (92 %), proteins (7 %)
and inorganic ions (1 %) [167]. Following absorption, compounds in the body typically bind in
a reversible manner to plasma proteins [168]. Important plasma proteins for binding include
human serum albumin (HSA), alpha-1 acid glycoprotein (α1AGp) and lipoproteins [169]. Acidic
and neutral compounds preferentially bind to human serum albumin and basic compounds to
alpha-1 acid glycoprotein although this is a simplistic description and many compounds bind
to both human serum albumin and α1AGp as well as additional proteins or components within
the blood such as lipoproteins or erythrocytes [168,170174].
The fraction that is not bound to plasma proteins (known as the unbound or free fraction) is re-
sponsible for a pharmacological effect of a compound and undergoes metabolism and excretion
[168]. Therefore plasma protein binding directly affects the pharmacokinetics of a compound
and this has been well-reviewed [168]. The clearance of a compound (the rate at which it is
removed from a specific volume of blood) from the body can be affected by plasma protein
binding as only the free fraction of a compound is metabolised and excreted, therefore com-
pounds with high plasma protein binding generally have a lower clearance from the body and
thus an increased half-life (t1/2) [175,176]. High protein binding is generally defined as being
greater than 95 % [177]. Plasma protein binding is highly correlated with cerebrospinal fluid
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concentrations for benzodiazepines [178]. Plasma protein binding is an important determinant
of the volume of distribution along with tissue binding and this will be discussed in more detail
in Section 1.8.2 [168,179]. Knowledge of plasma protein binding is therefore important to help
characterise the pharmacokinetics of drugs as it allows predictions to be made prior to, or in
the absence of, in vivo studies.
As mentioned previously, the majority of plasma protein binding is to human serum albumin
and alpha-1 acid glycoprotein. Human serum albumin is a globular protein that consists of
three domains (I, II and III), with each domain further separated into two subdomains (A and
B) [180-183]. Diazepam and other benzodiazepines have been observed to bind to a site known
as the IIIA subdomain [172-186]. It has been observed that flunitrazepam does not generally
bind to the IIIA site and that benzodiazepines which do not bind to the IIA site are unlikely to
experience a large binding affinity to HSA [187]. Several benzodiazepines have also been shown
to bind to alpha-1 acid glycoprotein although at a lower affinity than human serum albumin
[188]. The majority of benzodiazepines are highly protein-bound such as diazepam which is
96.8 - 99 % bound [189,190]. Some benzodiazepines experience lower plasma protein binding
such as alprazolam which is 68.9 - 76.7 % bound [191,192].
Plasma protein binding has been reported to be concentration-independent for a number of
benzodiazepines within the concentration ranges found during typical therapeutic use [189,193].
For example the plasma protein binding of diazepam, alprazolam and flunitrazepam remains
unchanged in the concentration of 10 ng mL-1 to 10000 ng mL-1 [189].
A number of methods exist for the measurement of the plasma protein binding of a compound
such as equilibrium dialysis, ultracentrifugation and ultrafiltration [194]. Equilibrium dialysis
is often referred to as the ‘gold standard’ for measuring plasma protein binding because of its
accuracy and reproducibility [195]. In equilibrium dialysis, plasma and an appropriate buffer are
placed into two chambers separated by a semi-permeable membrane with a specific molecular-
weight-cut-off for proteins (Figure 1.5). The compound is then spiked into the plasma or buffer
and left to equilibrate. Following equilibration the resultant concentrations are measured and
the plasma protein binding calculated using Equation 1.4.
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fu = 1− Cplasma − Cbuffer
Cplasma
(1.4)
Equation 1.4 Determination of plasma protein binding where fu is the fraction unbound in
plasma, Cplasma is the compound concentration in plasma and Cbuffer is the compound concen-
tration in buffer.
Figure 1.5: Equilibrium dialysis procedure for determining plasma protein binding where the
plasma and buffer are separated by a membrane with a specific molecular cut-off and are left
to equilibrate [173].
As with pKa and log D7.4, various theoretical approaches have attempted to predict the plasma
protein binding of compounds. However plasma protein binding is extremely complex as a result
of the multiple proteins and different sites that compounds can bind to as well as physicochem-
ical factors affecting binding [196]. Many of the most precise models focus upon predicting
plasma protein binding for small, structurally-related compounds as a result of the errors when
analysing large, diverse datasets [167]. Models are generally complex with multiple molecular
descriptors requiring a reasonable amount of computational power to generate plasma protein
binding values [197,198]. Lipophilicity correlates well with plasma protein binding and thus
theoretical approaches often attempt to utilise this relationship as well as other molecular de-
scriptors [176,196]. In the most basic sense, compounds with a greater lipophilicity typically
experience a greater plasma protein binding [113]. Lipophilicity is thought to be one of the
most important factors in determining compound binding to human serum albumin, especially
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for binding at the site responsible for the binding of diazepam [199,200].
1.8.2 Volume of Distribution at Steady State
The volume of distribution at steady state (Vdss) is a pharmacokinetic parameter that describes
the theoretical volume that would be required to contain a drug so that the concentration of
this would be equal to the concentration of the drug in the plasma under steady-state equi-
librium [141]. Therefore, it does not relate to a physical volume, rather it is a proportionality
factor. Steady-state equilibrium conditions can take the form of intravenous or multiple drug
administration [201].
The distribution of a drug is another important parameter during pharmaceutical development
as it relates to the half-life of a drug and therefore its duration of action [144]. If two compounds
are ingested at the same dose, the compound with a lower Vdss could require more frequent
dosing to produce the same concentrations in the body and thus pharmacological effect [201]. A
greater Vdss means that less of the compound is actually present in the plasma and instead it is
distributed into the tissues and therefore unavailable for elimination from the body. Therefore
compounds with a greater Vdss have a reduced clearance.
Compounds with a Vdss that is lower than 0.6 L kg
-1 (the approximate total body water content
in humans) are termed as having a low volume of distribution, those with a Vdss greater than
5 L kg-1 have a high volume of distribution and those compounds in between these values have
a moderate volume of distribution [144].
The benzodiazepine lorazepam has a longer duration of action compared to diazepam and it
is thought that this is as a result of its vastly lower volume of distribution as well as a slow
diffusion across the blood-brain-barrier [202-204].
The experimental Vdss is typically calculated from the intravenous administration of a com-
pound into the body and then measurement of the concentrations of the compound in the
plasma [205]. As a result of the time-consuming methodology and difficulty of intravenous
studies as well as debates around the ethics of the use of animals in experiments, theoretical
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approaches exist to predict the volume of distribution such as QSAR modelling [206,207]. It
should be noted that the Vdss can also be calculated from a plot of plasma concentration ver-
sus time but this must be corrected for bioavailability; another pharmacokinetic parameter not
widely measured and requiring in vivo data [144].
The volume of distribution at steady state is related to both the plasma protein binding (Vp)
and the tissue binding of a compound (Vt) (Equation 1.5).
V dss = V p + V T
fu
fut
(1.5)
Equation 1.5 Relationship between the volume of distribution, tissue binding and plasma protein
binding where Vp is the plasma volume, VT is the tissue volume, fu is the fraction unbound in
plasma and fut is the fraction unbound in tissues.
Tissues are defined as any part of the body in which drug can be contained [144]. Basic
and neutral compounds typically experience binding to tissues and thus have a low fut [144].
Changes in the plasma protein binding do not always affect the tissue binding of a compound
and therefore there is often no direct relationship between a change in the plasma protein
binding and the volume of distribution [179]. Where two compounds have identical plasma
protein binding, a compound that experiences a higher binding to the tissues will also have a
higher volume of distribution [148].
One approach to predict the volume of distribution at steady state is the use of the Øie-Tozer
equation which utilises a number of physiological parameters [104,145]. Compared to other
methods such as allometric scaling, use of the Øie-Tozer equation is generally held to be one
of the more accurate models and is reasonably straightforward to use as the required datasets
are easy to gather [204]. The Øie-Tozer equation is displayed in Equation 1.6.
V dss = V p(1 +RE/I + (fuV p(
V E
V p
−RE/I) + V Rfu
fu
(1.6)
Equation 1.6 Øie-Tozer equation for the calculation of the volume of distribution at steady
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state where fu is the fraction of the compound unbound in plasma, fut is the fraction of the
compound unbound in tissues, V p is the plasma volume, V E is the extracellular fluid volume
and RE/I is the ratio of extravascular to intravascular proteins.
Multiple forms of compound-tissue binding occur within the body and as such these small
contributions are not experimentally determinable, therefore it is assumed that these are non-
specific [1074,148]. The plasma volume (V p) is 0.0436 L kg
-1 for humans), the extracellular fluid
volume (V E) 0.151 L kg
-1 for humans and the ratio of extravascular to intravascular proteins
(RE/I) is 1.4 for humans. These are all averaged values and the RE/I ratio only describes human
serum albumin distribution [107,148].
The fraction unbound in tissues can only be obtained from in vivo experiments which are often
unfeasible and it is not a routine measurement in pharmacokinetic studies [209]. However
other measurements are routine in pharmacokinetic studies such as the V dss and fu. If these
two values are experimentally known then Equation 1.6 can be rearranged to calculate fut in
Equation 1.7.
fut =
V Rfu
V dss − V p − fuV E − (1− fu)RE/IV p (1.7)
Equation 1.7 Rearranged Øie-Tozer equation for the calculation of the fraction unbound in
tissues
The fraction unbound in tissues is related to the fraction unbound in plasma (i.e. the plasma
protein binding). If experimental values exist for a series of compounds that have known values
for the plasma protein binding and tissue binding as well as other physicochemical descriptors
such as log D7.4 and pKa then the relationship between the aforementioned parameters can
be derived using multiple linear regression. Once this relationship has been determined, the
fraction unbound in tissues can be theoretically calculated with knowledge of plasma protein
binding, log D7.4 and pKa which are relatively easy to measure in vitro. After the fraction
unbound in tissues has been calculated, this value of fut can then be substituted into Equation
1.7 along with the value for fu to give a value for V dss. This process is summarised in Figure
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1.6.
Figure 1.6: Process for determining volume of distribution from log D7.4, pKa and plasma
protein binding [104,145].
This process has previously been reported for sets of 64 and 120 compounds obtaining good
correlations between Vdss, the log D7.4 and the fraction of a compound ionised at pH 7.4 (fi7.4)
[107,148]. In particular the use of fu, fi7.4 and log D7.4 has been reported to give an R
2 of 0.8737
with a 1.86 mean-fold error for 12 benzodiazepines [107,148]. Hence, accurate values for the
log D7.4, pKa and plasma protein binding of NPS-benzodiazepines can allow predictions to be
made about their Vdss. The pKa is necessary for the calculation of the fraction ionised at pH
7.4 as these parameters are related by the Hendelson-Hasselbalch equation (Equation 1.8).
pH = pKa + log
ionised
unionised
(1.8)
Equation 1.8 The Hendelson-Hasselbalch equation
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1.8.3 Blood to Plasma Ratio
As discussed in Section 1.8.1, compounds bind to plasma proteins. However, they can also
experience binding to blood cells (which consist of 45 % of the total volume of whole blood)
[167]. The blood to plasma concentration ratio describes the ratio of the concentrations of an
administered compound in the blood and the plasma at equilibrium.
A closely-related parameter is the blood to plasma partition coefficient (Ke/p), which describes
the ratio between the concentration of a compound in red blood cells to the concentration of a
compound in plasma.
If a compound experiences extensive binding to components in the blood then any pharmacoki-
netic parameters calculated solely from plasma concentrations are likely to be incorrect [210].
Compounds that have a blood to plasma concentration ratio in favour of them partitioning
into the blood will have a lower sensitivity to an analytical method that is purely analysing
the plasma [211]. Therefore, knowledge of a compound’s blood to plasma concentration ratio
allows an informed decision to be made regarding analysis of the blood or plasma.
Clinical laboratories and medical evaluations typically analyse compound concentrations within
the plasma. Forensic laboratories and post-mortem investigations will often measure concen-
trations solely in whole blood [212]. Reliable interpretations from these analyses and any
equivalences drawn will therefore require knowledge of the blood to plasma concentration ratio
[213].
Blood to plasma concentration ratios have been previously published in the literature for a
range of illicitly-used compounds that are of toxicological interest and significance. These
include 3,4-methylenedioxymethamphetamine (MDMA), δ9-Tetrahydrocannabinol (THC), γ-
hydroxybutyric acid (GHB), phencyclidine (PCP), zopiclone and opiates such as morphine,
oxycodone and fentanyl [210,214-218].
Although the main use of blood to plasma concentration ratios has been the interpretation of
toxicological analyses, the ratios have still found utility in predicting concentration-time profiles
for some drugs [219]. The blood to plasma concentration ratio can also be used to calculate the
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clearance of a drug from the plasma [220]. The hepatic clearance in vivo can be estimated using
in vitro experiments with human hepatocytes [221]. This has been demonstrated for the NPS-
benzodiazepine flubromazolam [222]. For the calculation of the hepatic clearance, knowledge
of the blood to plasma concentration ratio of a compound is required [221].
A common method for the measurement of the blood to plasma partition coefficient has been
well-described in the literature [223]. In this method the compound is spiked into equal volumes
of plasma and whole blood and allowed to equilibrate. The blood is then centrifuged to yield the
plasma. The concentrations of the compound in both volumes of plasma are then analysed and
with this knowledge the blood to plasma partition coefficient can be calculated with Equation
1.9.
Ke/p =
1
H
× (CPref
CP
− 1) + 1 (1.9)
Equation 1.9 Calculation of the red blood cell partition coefficient where KE/P is the red blood
cell partition coefficient, H is the haematocrit, CPref is the concentration of the test analyte in
the reference plasma and CP is the concentration of the test analyte in the plasma separated
from the whole blood.
The blood to plasma partition coefficient and the blood to plasma concentration ratio can be
interconverted with Equation 1.10.
Kb/p = (Ke/p ×H) + (1−H) (1.10)
Equation 1.10 Conversion between the blood to plasma partition coefficient (Ke/p) and the
blood to plasma concentration ratio (Kb/p) with the haematocrit (H).
1.8.4 Metabolism
Metabolism, also known as biotransformation, is an important pharmacokinetic phase for xeno-
biotics prior to their elimination or excretion from the body [224]. The majority of metabolic
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processes occur in the liver [224]. The main purpose of metabolism is to remove the com-
pound from the body - typically by increasing its aqueous solubility. One additional effect of
metabolism is the conversion of compounds that are pharmacologically inactive into those that
have a pharmacological effect, a process known as bioactivation [225]. The metabolic processes
is divided into two phases; phase I and phase II [226-228].
Phase I metabolism involves the introduction of a polar or reactive functional group into the
compound in order to increase its water solubility. The most common phase I reactions are
oxidation, reduction and hydrolysis [227]. The cytochrome P450 enzyme family is a large group
of haemoproteins responsible for the majority of phase I oxidative metabolism of compounds
within the liver [229]. Cytochrome P450 enzymes are named with the letters ‘CYP’ denoting the
enzyme superfamily (cytochrome) and then a number, letter and number denoting the family,
subfamily and individual gene respectively [230]. The majority of compound metabolism is
mediated by a small group of cytochrome (CYP) enzymes (CYP 1A2, 2C9, 2C19, 2D6, 2E1
and 3A4/5) [119,120,231]. Other enzymes are involved in phase I metabolism such as aldo-keto
reductases and esterases responsible for catalysing hydrolytic reactions [232,233].
The metabolism of benzodiazepines is mainly mediated by CYP3A4/A5 and CYP2C19 enzymes
[234-242]. CYP1A2, CYP2B6 and CYP2D6 are also thought to contribute to the metabolism
of some benzodiazepines [241,243-246]. The specific metabolic reactions are typically hydrox-
ylation at position 3 (Figure 1.2A) or position 4 (Figure 1.2B). Dealkylation at position 1
(Figure 1.2A) is also common. This is exemplified for diazepam where both hydroxylation and
demethylation occur, leading to the presence of three different metabolites within the body;
nordiazepam, temazepam and oxazepam (Figure 1.7). This effect has also been observed for
NPS-benzodiazepines such as diclazepam, which is metabolised to the prescription benzodi-
azepines lorazepam, lormetazepam and delorazepam [247]. These metabolites often known as
‘active metabolites’ as they are responsible for the majority of the observed pharmacological
activity for a compound [225].
In terms of specific metabolic pathways for benzodiazepines, hydroxylation on alkyl groups
present at position 1 (Figure 1.2B) for triazolobenzodiazepines and position 9 for thienotria-
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zolodiazepines (Figure 1.2C) often occurs [248,249]. Reduction of the nitro group to an amine
occurs for those benzodiazepines with substituted nitro groups, typically at position R7 (Figure
1.2A) or position R8 (Figure 1.2B) [249]. Some benzodiazepines, such as lorazepam and ox-
azepam, do not undergo phase I metabolism and instead progress directly to phase II metabolic
processes as a result of the presence of a hydroxyl group on position 3 (Figure 1.2A) [250]. De-
bromination has been reported for one NPS-benzodiazepine, flubromazepam [251]. Demethyla-
tion and hydroxylation reactions, and a demonstration of how benzodiazepines are metabolised
into other benzodiazepines, can be seen in Figure 1.7.
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Figure 1.7: Phase I metabolism of diazepam [230-238].
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Phase II metabolism is generally performed by a class of enzymes known as transferases [228].
Uridine 5’-diphospho-glucuronosyltransferases (UGTs) are thought to be responsible for the
majority of phase II metabolism [252]. Their metabolic role is the addition of a molecule of
glucuronic acid to compounds in a process known as glucuronidation [228]. The end result
is an increase in the aqueous solubility of a compound so that it can be efficiently excreted.
Glucuronidation of benzodiazepines by UGTs is typical on hydroxyl groups such as position
R3 for oxazepam (Figure 1.8) [253].
Certain benzodiazepines experience metabolic contributions from other enzymes such as
N-acetyltransferase 2 (NAT2) which acetylates the phase I metabolite of clonazepam, 7-
aminoclonazepam (Figure 1.9) [254].
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Figure 1.8: Phase II metabolism of oxazepam [249].
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Figure 1.9: Phase II metabolism of clonazepam [250].
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Characterising the metabolic pathways of compounds in vitro is an important aspect of phar-
maceutical development in a forensic and chemical toxicology context, such methods allow iden-
tification of the use of illict drugs even if the parent compound is no longer detectable [255].
As mentioned previously, benzodiazepines are metabolised in phase I reactions by CYP450 en-
zymes and in phase II reactions by UGTs, NAT2 and other enzymes. Therefore, it is important
for any in vitro method to allow compounds to be exposed to sufficient levels of enzymatic
activity.
The metabolic pathways of many of these NPS-benzodiazepines have been previously assessed
in vivo as a result of self-ingestion experiments and collection of forensic samples from criminal
cases and intoxicated patients in hospitals as well as in vitro experiments using cryopreserved
primary human hepatocytes (PHHs), human liver microsomes (HLMs) and isolated phase II
metabolic enzymes [256-260]. Authentic toxicological samples are often unavailable and the
use of animals is often undesirable and subject to ethical restrictions hence the use of in vitro
investigations.
One form of in vitro experiments to determine metabolism is the use of primary human hep-
atocytes; they are often the ‘first-choice’ or ’gold-standard’ for the metabolic characterisation
of compounds [261]. They express a full complement of phase I and II enzymes and generate
metabolites in an extremely similar manner to those produced in vivo [262]. However their use
can be cost-prohibitive and loss of metabolic function during incubation is often observed [263].
Primary human hepatocytes are extracted from human livers and can be cultured in an appro-
priate environment or cryopreserved for later use. HLMs are another technique also commonly
used to study metabolic pathways as these subcellular fractions often have a good expression
of CYP450 enzymes [264]. However these levels can be variable and they lack expression of
phase II enzymes [264]. Another method of identifying metabolic pathways in vitro is the use
of human hepatocellular carcinoma cell lines [261].
The human hepatocellular carcinoma cell line HepG2 is often used as an in vitro model to
identify metabolic pathways as it contains a variety of CYP450 enzymes although typically
with lower expressions compared to primary human hepatocytes and human liver microsomes
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[265,266]. The C3A cell line is a patented clonal derivative of the human hepatocellular car-
cinoma cell line HepG2 [267]. The C3A cell line derivative was selected for strong contact
inhibition of growth, high albumin production, high production of alpha fetoprotein and an
ability to grow in glucose-deficient medium [268]. It is also reported to be more metabolically
active than its parent cell line and also to express a phenotype closer to that of primary human
hepatocytes [269,270]. Without the use of tissue engineering methods, metabolic characterisa-
tion has only been conducted for the C3A cell line with regards to the CYP3A4/5 and CYP1A2
[269]. It was reported that they have a much lower turnover of metabolic substrates (testos-
terone for CYP3A4/5, phenacetin for CYP1A2) than the another cell line known as HepaRG
[269].
The levels of CYP enzymes in hepatoma cell lines are known to be inducible following treatment
of the cell culture with 1 % DMSO (v/v in typical cell culture medium). This inductive potential
has been observed for the parent line of the C3A cells, HepG2, as well as other cell lines such
as Huh7 [271,272].
The HepaRG cell line is a human hepatocellular carcinoma cell line that has been well-
characterised [261,273277]. It is provided as a differentiated single-use cell line [269]. The
HepaRG cell line is reported to express high levels of CYP1A2, CYP2B6, CYP2C9, CYP2C19
and CYP3A4 [269,275,277]. The HepaRG cell line is derived from an individual who had a low
expression of CYP2D6 resulting in a relatively low proportion of this enzyme compared to the
other CYP enzymes it expresses [274,277].
The expression of CYP450 enzymes can vary markedly in HepG2 and other human hepatocel-
lular carcinoma cell lines and thus it is recommended that the levels of these enzymes should be
characterised before use [278]. One commonly-used set of guidelines for the characterisation of
enzyme levels in vitro are those published by the Food and Drug Administration (FDA) [279].
The FDA recommend that six enzymes be expressed; CYP1A2, CYP2B6, CYP2C19, CYP2C9,
CYP2D6, CYP3A4/5, as these are responsible for the phase I metabolism of the majority of
pharmaceutical compounds [119,120,231]. Recommended substrates for specific enzymes are
phenacetin for CYP1A2, bupropion for CYP2B6, S-mephenytoin for CYP2C19, diclofenac for
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CYP2C9, dextromethorphan for CYP2D6 and testosterone for CYP3A4/5 [279].
Various computer programs are available both commercially and as freeware to attempt pre-
diction of the metabolic pathways of compounds [280]. Their methods are typically based
upon identifying structural features that are suitable as sites of metabolism by the relevant
enzymes. These structural features are often based upon those found on experimentally deter-
mined metabolic pathways of compounds. Studies on the metabolism of NPS-benzodiazepines
conducted using HLMs often attempt to predict the expected metabolites from comparison
with clinically-used benzodiazepines. This allows their structures to be input into software
which can then search the resultant mass spectra for signs of these metabolites [251].
1.9 The Pharmacodynamics of Benzodiazepines
Although no work in this thesis has been directly conducted upon the pharmacodynamics of
benzodiazepines, a brief overview will be given here in order to add context to their use as new
psychoactive substances.
Benzodiazepines exert their effects through reversible binding to gamma-Aminobutyric acid A
(GABAA) receptors in the brain [281]. The GABAA receptor is pentameric and its isoform can
vary as a result of the seven subunit groups (α 1-6, β 1-3 γ 1-3, δ, , pi, ω) that it can consist of
[281]. However in the human brain the most common GABAA receptor isoform contains two α
subunits, two β subunits and a single γ subunit (Figure ) [281,282]. There are two binding sites
for the neurotransmitter gamma-Aminobutyric acid (GABA) [283]. These sites exist between
the α1 and β2 subunits and an allosteric benzodiazepine binding site (BZD site) also exists
between the α1 and γ2 subunits [284-286]. A number of other binding sites also exist on the
GABAA receptor however benzodiazepines are not known to bind to any of these and they are
not depicted on Figure 1.10 [287,288].
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Figure 1.10: Example composition of an α2β2γ1 GABAA receptor [277,278].
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GABAA receptors are ligand-gated ion channels; they open to selectively allow chloride (Cl-)
ions through following the binding of a ligand (in this case GABA) [289]. A membrane potential
exists in the GABAA receptor as a result of the difference in electric potentials on each side of
the receptor. Binding of GABA to the receptor causes an influx of Cl- ions through the central
pore which results in the membrane potential becoming more electrically negative (known as
hyperpolarisation) [289]. A reduction in neurotransmission is observed and this is known as an
inhibitory postsynaptic potential [[290]. When benzodiazepines bind to the benzodiazepine site
the conformation of the whole GABAA receptor is transformed into one that allows GABA to
bind with a greater affinity [291,292]. The result of this is an increased frequency in the opening
of the Cl- pore and thus an increase in number of the hyperpolarisation events mentioned earlier
[[293]. This decreases the likelihood of a successful action potential occurring as the excitatory
threshold is too great to be reached by depolarisation [294].
The structure of benzodiazepines greatly affects their binding affinity to GABAA receptors.
For 1,4-benzodiazepines the carbonyl group at position 2 is essential for binding affinity. Other
functional groups important for binding affinity are; lipophilic or electronically-charged groups
at position 7, electrophilic or bulky groups at position 2’ and molar refractivity (i.e. polaris-
ability, or the propensity of a molecule to form dipoles) combined with a low steric bulk at
position 1 (Figure 1.2A) [285]. The substitution of a triazole ring onto a 1,4-benzodiazepine
that previously possessed a low affinity for the GABAA receptor typically increases the affinity
of the compound. However the same is not true for compounds that already possess a high
affinity for the GABAA receptor [285]. Benzodiazepines containing substitutions at the R6’ or
R8 positions experience a lower binding affinity to GABAA receptors (Figure 1.2B) [295].
A recent NPS-benzodiazepine to emerge in 2017 was 4’-chlorodiazepam. The phenyl ring is
substituted at the 4’ position rather than the 2’ position (Figure 1.2A); the former substitution
is more common amongst benzodiazepines. Instead of binding to the GABAA receptor, 4’-
chlorodiazepam binds to the translocator protein (TSPO) which was previously known as the
peripheral benzodiazepine receptor [292,293]. TSPO is distributed in various regions of the body
and has been investigated as a therapeutic drug target [296,297]. While 1,4-benzodiazepines
such as diazepam also experience some limited binding to TSPO, their pharmacological effects
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are believed to occur from their interaction with GABAA receptors [301303].
1.10 Analytical Methods for the Detection of Benzodi-
azepines
As a result of their widespread use, a large number of analytical methods to detect and quantify
benzodiazepines in a variety of matrices are available and have been described in the literature
[304]. Benzodiazepines are prominent in both forensic cases and toxicological investigations in
a medical setting and therefore careful analysis and quantitation is often necessary [305307].
1.10.1 Benzodiazepine Extraction from Biological Samples
The complex nature of matrices such as blood, plasma, cell culture or human liver microsomes
means that compounds must often be extracted in order to decrease interferences in analytical
equipment. These interferences can occur as a result of the presence of various proteins and
inorganic materials in the samples [308]. Matrix interference can cause signal suppression or
enhancement in mass spectrometry therefore decreasing the accuracy and precision of this
analytical method for certain samples [209]. Types of extraction include solid-phase extraction
(SPE), liquid-liquid extraction (LLE) and protein precipitation [308].
SPE is usually based upon SPE cartridges which consist of an internally-lined cylinder con-
taining a specific sorbent [310]. Firstly, the cartridge is conditioned (typically with an organic
solvent) to reduce interferences and increase the surface area available for solute retention
[311]. The sample solution is then passed through the cartridge and the solute adsorbs onto
the sorbent. An organic solvent or water is then often passed through the cartridge to remove
interferences. Finally the solute is desorbed with another organic solvent and collected [311].
Protein precipitation is another common extraction method. This is facilitated by the addition
of an organic solvent such as acetonitrile that has been ice-cooled, causing the proteins to de-
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nature and precipitate. Centrifugation is then applied to pelletise proteins and the supernatant
is collected and analysed.
Protein precipitation has been demonstrated for NPS-benzodiazepines incubated with human
liver microsomes or primary human hepatocytes [312315]. However benzodiazepine extrac-
tions also often take place with the use of solid-phase extraction cartridges [316,317]. Careful
evaluation of the most suitable method for extraction is often necessary [318].
1.10.2 Liquid chromatography (LC)
In the most basic sense, liquid chromatography is an analytical technique to separate com-
pounds. LC is used to separate and quantify compounds based on their hydrophobicity [319].
It is based on the theory of a stationary phase and a mobile phase that have different hy-
drophobicities. Compounds with a hydrophobicity closer in nature to that of the stationary
phase will be attracted to the stationary phase and thus elute more slowly. The converse is also
true; compounds with a hydrophobicity more similar to the mobile phase will not interact to a
great degree with the stationary phase and elute in a quicker fashion [320]. The volume ratio of
organic solvent flowing through the chromatographic system is often increased over time which
is known as gradient elution. Elution at a constant volume ratio of organic solvent is known as
isocratic elution [320].
It is often utilised in a technique known as high-performance liquid chromatography (HPLC)
where samples are passed through a column at high pressure. The most common is reversed-
phase HPLC. In this technique, the mobile phase is polar and the stationary phase (i.e. the
internal column) is non-polar. The polar mobile phase causes hydrophilic compounds to typ-
ically be retained in the mobile phase and therefore elute first while hydrophobic compounds
bind or interact with the non-polar stationary phase and experience a later elution. The polar
mobile phase is typically formulated of a buffer and a solvent such as acetonitrile. The point
at which a compound elutes is known as its retention time [320].
HPLC is typically coupled to a diode array detector (DAD). Diode array detectors are capable
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of recording absorbance over the ultraviolet-visible wavelength range of 190 - 800 nm [321].
The absorbance of a compound depends upon its molecular structure as it is determined by
the excitation of electrons in molecular orbitals as a result of the excess energy gifted by the
electromagnetic radiation [322]. Compounds with different structures will produce different
absorbance readings and differentiation between them is therefore possible. HPLC is also often
coupled to a mass spectrometer, the theory of which will be discussed in Section 1.10.4.
1.10.3 Gas chromatography (GC)
Gas-chromatography (GC) is a widely-used method for the detection and quantitation of com-
pounds. Gas-chromatography works in a similar manner to LC in that a stationary phase and
a mobile phase are used to separate analytes. However in gas-chromatography the stationary
phase is liquid (a non-volatile liquid internally contained upon a column) and the mobile phase
is a gas. gas-chromatography can be used to analyse gases, volatile solids or liquids. Only the
analysis of compounds dissolved in liquids is of interest here.
Upon injection onto the system the liquid sample is thermally vaporised. The vaporised sample
is then eluted through the column by applying a carrier gas. The carrier gas is typically inert
such as helium [323]. The column is contained within an oven, the temperature of which can be
programmed to adjust with time. Splitless injection is often used in GC and in this method all
the analyte present in a sample will be injected onto the column. This allows for the analysis
of low concentrations (ng mL-1).
Some benzodiazepines are thermally labile and this can potentially cause problems when at-
tempting to analyse them with GC-MS [324]. To improve their thermal stability and the
sensitivity of a GC-MS method towards them, benzodiazepines are often derivatised prior to
analysis [324]. This is typically achieved by the addition of a silyl group to the compound [325].
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1.10.4 Mass spectrometry (MS)
Mass spectrometry is an analytical technique that can differentiate between ions based on their
mass to charge (m/z ) ratio. The m/z is calculated by dividing the mass number of an ion by
its charge [108].
Mass spectrometry consists of a number of steps. Firstly, the compound is ionised with an
appropriate ion source. The ion source will differ depending on the nature of the analysis
and type of analytical instrument (LC vs GC). The ion source for gas-chromatography is most
commonly electron ionisation (EI). Here, a filament is heated to produce electrons which are
then accelerated with an electric field to form an electron beam. The vaporised sample is
then bombarded with the electron beam, causing ionisation and fragmentation [326]. The ion
source for liquid chromatography is often electrospray ionisation (ESI). In this process the
solution containing the sample is sprayed from the capillary via a nebulising nozzle. The nozzle
has a strong electrical potential applied and serves to create a fine spray of charged droplets
[327]. These charged droplets undergo evaporation of the mobile phase, eventually resulting
in molecular ions with no solvent remaining [328]. The evaporation of the solvent is typically
facilitated by heat or the application of a gas [328].
The second step, following the production of the ions is mass separation. Ions are separated
according to their m/z ratios by the application of electric or magnetic fields [329]. A mass
analyser (quadrupole) is commonly used for this purpose. In this method four parallel metal
rods are contained equidistant from one another. Voltages (direct current and a superimposed
radio frequency) are applied to diagonally-opposite pairs of rods. The applied voltages cause
the ions to traverse through the quadrupole and oscillate. With the variation of the applied
voltages only ions of a specific m/z will successfully pass through the quadrupole; other ions
will experience large oscillations, collide with the metal rods and will not reach the detector
[328].
Another form of mass separation is from the use of time-of-flight (TOF) mass spectrometry
(TOF-MS). The TOF analyser applies an electrical field to accelerate all ions in an equal
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manner. Once the ions have equal kinetic energies they enter a flight tube that does not
contain any applied electrical fields. The kinetic energy of the ions can be described by 1⁄2 mv,
where m is the mass and v is the velocity of the specific ion [330]. Therefore two ions with
different masses but the same kinetic energy will have different velocities through the flight
tube [330]. Ions with a lower mass will have a greater velocity and thus a shorter flight time.
The time taken to reach the detector through the flight tube can be related to the m/z ratio
of each individual ion which has been well described and is computed automatically [330-332].
TOF-MS is an example of high-resolution mass spectrometry (HRMS). HRMS is a term often
used to describe mass spectrometers that can distinguish between compounds with a high mass-
accuracy and a high resolution. HRMS is capable of detecting analytes to 0.001 atomic mass
units. An advantage of this method is that it is extremely selective because of high mass-
accuracy. However two compounds with the same molecular mass and charge and may produce
two peaks of the same m/z and differentiation between them may not be possible. The two
compounds would have to separated chromatographically and their different retention times
would have to be matched to those of a standard of these compounds. This a disadvantage
when analysing multiple compounds in the same chromatographic analysis and can necessitate
the use of (often costly) standards.
To combat this problem, the quadrupole mass analyser is itself often contained within a system
known as a triple quadrupole (TQ). In this system, as the name suggests, there are three
quadrupoles connected in a linear fashion. The first quadrupole serves to select an ion of
interest based upon its m/z. The selected ion then enters the second quadrupole where it is
exposed to a collision gas causing further fragmentation. The second quadrupole contains only
an applied radio frequency rather than both an applied direct current and radio frequency. The
third quadrupole can then further select ions by their m/z and they can enter the detector.
This analytical method is known as LC-MS/MS. In the second quadrupole, compounds that
have the same m/z will fragment into product ions in a different manner to each other. This
allows differentiation between these compounds and can also provide structural information
about the compound. A TOF analyser can also be included as part of this system; the third
quadrupole on the TQ is replaced by a TOF analyser to give a quantitative TOF (QTOF)
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instrument [333].
The third step in mass spectrometry is analysis of the separated ions as they enter a detector
capable of differentiating between the ions and recording the observed response [329].
Liquid chromatography coupled to time of flight mass spectrometry (TOF-MS) is one of the
most common methods used to analyse NPS-benzodiazepines because of its reliability and its
ability to detect low concentrations (in the order of ng mL-1) [134,333].
1.11 Research Aims
It is clear that there is a deficit of physicochemical and pharmacokinetic data for benzodi-
azepines [16]. Knowledge of the plasma protein binding of benzodiazepines has been shown to
help correlate their in vitro receptor binding potential to their EC50 values (the concentration
of a drug that produces a half-maximal response) therefore illustrating how pharmacokinetics
can aid the prediction of pharmacodynamic properties [334]. The collection and collation of
this data will allow the development of more accurate and precise modelling of the effects of
benzodiazepines within the body and also aid in toxicological interpretations regarding the
illicit use of benzodiazepines.
As mentioned in Section 1.10, a variety of methods have been used for the detection and
quantitation of benzodiazepines. Therefore one aim was to develop and validate analytical
methods capable of quantitating NPS-benzodiazepines.
A series of interlinked research aims have also been devised which are the determination of
two physicochemical parameters (pKa and log D7.4) and a pharmacokinetic parameter (plasma
protein binding) and the use of these three parameters to predict a pharmacokinetic parameter
(Vdss) using the Øie-Tozer equation.
As many physicochemical and pharmacokinetic parameters can be theoretically estimated, an-
other aim of this work is to compare experimental values (to be determined in this work) to
theoretical values and judge whether theoretical values are a suitable replacement.
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An important pharmacokinetic parameter discussed was the blood to plasma concentration
ratio (Section 1.8.3) and an aim of this work is to determine this parameter for a series of
NPS-benzodiazepines.
Knowledge of the metabolism of a compound is extremely important in knowing the fate of
a compound and its metabolites within the body. The need for characterisation of cell cul-
tures before using them to investigate the unknown metabolism of compounds was discussed
previously (Section 1.8.4). Therefore another aim is to characterise two cell lines (C3A and
HepaRG) and to use the most appropriate of these to investigate the metabolism of a series of
NPS-benzodiazepines.
Investigation of the above pharmacokinetic and physicochemical parameters will add to the
knowledge of NPS-benzodiazepines and allow more accurate and reliable predictions to be
made about their pharmacokinetics.
Chapter 2
Experimental
2.1 Materials
2.1.1 Compounds and Reagents
Alprazolam, clonazepam, diazepam, flunitrazepam, nitrazepam, oxazepam, prazepam,
temazepam, dextromethorphan, diclofenac, omeprazole, phenacetin, testosterone, chlorpro-
mazine and quinine were obtained from Sigma-Aldrich (Dorset, UK).
3-Hydroxyphenazepam, 4’-chlorodiazepam, desalkylflurazepam, deschloroetizolam, diclazepam,
etizolam, flubromazepam, flubromazolam, meclonazepam, nitrazolam, phenazepam and pyra-
zolam were obtained from Chiron AS (Trondheim, Norway). All compounds were received as
powdered solids.
Dimethyl sulfoxide (DMSO), methanol, phosphoric acid, sodium hydrogen phosphate heptahy-
drate, sodium dihydrogen phosphate, disodium hydrogen phosphate, acetic acid, sodium acetate
trihydrate, boric acid, sodium hydroxide, hydrochloric acid, sodium chloride and octan-1-ol were
obtained from Fisher Scientific (Leicestershire, UK). Phosphate buffered saline (PBS) tablets
were obtained from Sigma-Aldrich (Dorset, UK).
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2.1.2 Biological Samples
Human plasma and blood (pooled, from three male donors and three female donors) was ob-
tained from Seralab (West Sussex, UK). Plasma was received frozen with sodium citrate as
an anticoagulant and kept frozen (-20 °C) until use. Blood was received chilled with sodium
citrate as an anticoagulant and kept chilled (4 °C) until use. Both plasma and blood were used
prior to their expiration dates.
2.1.3 Cell Cultures
The human hepatocellular carcinoma cell line C3A was obtained frozen from Heriot-Watt Uni-
versity (Edinburgh, UK) at passage 29 and kept frozen (-80 °C, liquid nitrogen) until use. The
human hepatocellular carcinoma cell line HepaRG was obtained frozen from Fisher Scientific
(Loughborough, UK) and kept frozen (-80 °C, liquid nitrogen) until use.
2.2 HPLC-DAD
The HPLC-DAD analysis discussed in this Section was used for analysis and quantitation of
benzodiazepine concentrations for the log D7.4 experiments and the plasma protein binding
experiments.
2.2.1 Equipment
Analysis was carried out using a Dionex (Surrey, UK) UltiMate 3000 HPLC system equipped
with an UltiMate 3000 Pump, UltiMate 3000 Autosampler, UltiMate 3000 Column Compart-
ment, UltiMate 3000 Photodiode Array Detector and Chromeleon software. Separation was
achieved with a Waters (Hertfordshire, UK) Spherisorb analytical column, C18 5 µM 80 A˚ (4.6
× 150 mm) with an attached guard column identically packed to the analytical column.
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2.2.2 Conditions
The internal column temperature was kept constant at 25 °C and a flow rate of 0.8 mL min-1
was set. Injection volumes for the log D7.4 experiments were 25 µL for the octanol phase and
100 µL for the phosphate buffer phase so that a dilution step was not necessary. Compound
concentrations were retrospectively corrected. Injection volumes of 100 µL were used for the
plasma protein binding experiments. A 46:54 (v/v) ratio of acetonitrile and sodium phosphate
buffer (pH 3.0, 25 mM) was applied for 25 minutes. All compounds eluted within this time.
The eluent was monitored by UV detection at 230 nm.
2.2.3 Validation
The method was validated in terms of linearity, limit of quantitation (LOQ), limit of detection
(LOD), accuracy and precision. This was performed according to the ICH guidelines [335].
Linearity
The linearity of this method was measured by constructing a five-point calibration plot of the
area under the curve (AUC) of each compound against its concentration which spanned from
0.0004 to 0.25 mg mL-1 (n=3).
LOQ and LOD
The limits of detection and quantitation were determined from the signal-to-noise ratio. The
baseline response of the blank samples was recorded. The peak heights on the spectra at the
retention time of the compound were compared to the peak heights at that same time on blank
samples. A ratio of 10:1 for the compound response to the baseline response was used for the
LOQ and a ratio of 3:1 for the LOD.
Accuracy
Accuracy was determined through comparison of the percentage recovery at three concentra-
tions (0.25, 0.01 and 0.0004 mg mL-1).
Precision
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Precision was determined from the calculation of the standard deviation and relative standard
deviation (RSD) of the compound peak areas at three concentrations (0.25, 0.01 and 0.0004
mg mL-1).
2.3 GC-MS
The GC-MS analysis discussed in this Section was used for analysis and quantitation of ben-
zodiazepine concentrations for the blood/plasma ratio experiments.
2.3.1 Equipment
The GC-MS method used an Agilent 7890B GC instrument with a 7693 autosampler and a
5977A MSD mass spectrometer. The column was a HP-5 MS 5 % phenyl 95 % methylpolysilox-
ane fused silica capillary column (30 m × 0.25 mm, thickness 0.25 mm).
2.3.2 Conditions
The inlet port temperature was set at 280 °C, transfer line temperature was set at 250 °C. The
carrier gas was helium and the flow rate was a constant flow of 1.2 mL min-1. Splitless injection
volumes of 1 - 2 µL were used. The temperature program consisted of an initial temperature
of 60 °C for two minutes followed by a 30 °C/min ramp to 280 °C and a 10-minute hold at 280
°C. The MS was operated in positive electron impact mode and the electron energy was 70.0
eV. Source temperature was 230 °C and the quadrupole temperature was 150 °C.
2.3.3 Data Analysis
Qualitative data analysis was conducted using ChemStation version F.01.01.2317 to confirm
the presence of the analytes using their respective m/z values for qualifier ions (Table 2.1).
One quantifier ion was selected for quantification of the analyte (underlined in Table 2.1).
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Table 2.1: Compound, retention time and target ions (quantification ion underlined) for GC-MS
Compound Retention Time (minutes) Target Ions
Chlorpromazine 9.66 58, 86, 272, 318
Diazepam 9.50 165, 221, 256, 283
Nitrazepam 13.20 206, 234, 253, 280
Quinine 10.76 96, 136, 215, 287
Deschloroetizolam 13.71 77, 239, 279, 308
Diclazepam 9.93 255, 283, 291, 318
Etizolam 14.40 239, 266, 313, 342
Flubromazolam 13.97 181, 222, 341, 370
Meclonazepam 11.72 240, 286, 294, 328
Phenazepam 9.80 75, 285, 321, 350
Pyrazolam 8.23 78, 205, 274, 353
2.3.4 Validation
The method was validated in terms of linearity, limit of quantitation (LOQ), limit of detection
(LOD), accuracy and precision according to ICH guidelines [335].
Linearity
Five concentrations (250, 100, 50, 25, 10 µM) were used to assess the relationship between
concentration and instrument response. Three replicate injections were performed for each
concentration.
Weighting factors (1/x or 1/x2) are often applied to transform the data in order to obtain a
suitable fit [336,337]. The appropriateness of using a weighting factor was determined by con-
ducting a two-sample F-test for variances to assess the variance in instrument response between
the highest and lowest concentrations. The two-sample F-test for variances was conducted us-
ing the Data Analysis tools in Microsoft Excel. If the resultant p value was greater than 0.05
then there was no statistical difference between the two variances. If the resultant p value was
lower than 0.05 then a statistically-significant difference existed between the two variances and
a weighting factor was applied.
If a weighting factor was required, the use of a 1/x or 1/x2 transformation was assessed by
means of a plot of the variance at each concentration versus the concentration. If the variance
at each concentration followed a linear relationship with concentration, then this meant that
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a 1/x weighting factor was used. If the variance at each concentration followed a non-linear
parabolic relationship with concentration, then this meant that a 1/x2 weighting factor was
required.
With knowledge of the appropriate weighting factor, the most appropriate model could then
be assessed. Two models are typically used to describe data in GC-MS; linear and quadratic
(Equations 2.1 and 2.2 respectively)
y = mx+ c (2.1)
Equation 2.1 Equation for a linear relationship between concentration and instrumental re-
sponse
y = ax2 + bx+ c (2.2)
Equation 2.2 Equation for a quadratic relationship between concentration and instrumental
response
The model that adequately describes the relationship between concentration and instrument
response while remaining the simplest model is the one preferred. To assess the appropriateness
of a linear or quadratic model, a two-way analysis of variance (ANOVA) test was performed
using the Data Analysis tools in Microsoft Excel. Both linear and quadratic models were used to
generate theoretical values. The variance (square of the standard deviation) of these theoretical
values when compared to the experimental values was calculated. The two-way ANOVA test
was performed on the variances and generated a p value to compare the models. If the p-value
was greater than 0.05 then this indicated that the change in variance when changing from
a linear to a quadratic model was significant and that a quadratic model was most suitable.
However, if the converse was true and the p value was less than 0.05 then this indicated that
the increase in variance was not significant and a linear model was the most suitable.
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LOQ and LOD
The limits of detection and quantitation were determined from the signal-to-noise ratio.
The baseline response of blank samples was recorded. The peak heights on the spectra at
the retention time of the compound were compared to the peak heights at that same time on
blank samples. A ratio of 10:1 for the compound response to the baseline response was used
for the LOQ and a ratio of 3:1 for the LOD.
Accuracy
Accuracy assessed for each compound through three replicate injections of three concentra-
tions; 10, 50 and 250 µM and experimental instrument response was compared to theoretical
instrument response from the calibration plot.
Precision
The inter-day and intra-day precision were measured at three concentrations which spanned the
analytical range of the method; 10, 50 and 250 µM. Three replicate injections at each concen-
tration were used and the standard deviation and relative standard deviation were calculated.
2.4 Extraction Procedure Development
Four benzodiazepines were chosen as test benzodiazepines for the methods; alprazolam, di-
azepam, nitrazepam and oxazepam. Stock solutions of these four benzodiazepines were formu-
lated to yield a concentration of 20 mM in DMSO. Benzodiazepines were spiked into plasma
at a concentration of 10 µM (final DMSO concentration 0.2 %). The extraction procedure was
as follows; ice-cold acetonitrile was added (4:1 ratio), samples were centrifuged (10,000 rpm,
20 minutes) and the supernatant was then collected and evaporated using a flow of nitrogen
(TurboVap). Blank controls were also performed where the benzodiazepines were spiked into
acetonitrile rather than plasma. Three repetitions were performed for each benzodiazepine and
all samples analysed using the HPLC-DAD method detailed in Section 2.2. The extraction
efficiency was calculated from Equation 2.3.
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Extraction efficiency (%) =
Plasma concentration
Control concentration
× 100 (2.3)
Equation 2.3 Calculation of extraction efficiency for protein precipitation.
2.5 Log D7.4
2.5.1 Experimental Log D7.4 Measurements
Sodium phosphate buffer (0.01 M) was formulated using deionised water (Barnstead UltraPure)
and filtered through a 0.45 µM Nylon Phenex filter membrane (Phenomenex, Cheshire, UK)
using a Millipore filtration apparatus (Merck Millipore, Hertfordshire, UK).
Compounds were dissolved in methanol at a concentration of 1 mg mL-1. Aliquots of com-
pound solution were evaporated with a flow of nitrogen using a TurboVap to yield 0.20 mg of
compound. Equal volumes (700 µL) of sodium phosphate buffer (0.01 M, pH 7.4) and octanol
were added and the samples were vortexed for 30 seconds.
The samples were transferred into 1.5 mL Eppendorf microcentrifuge tubes and placed on a
Stuart SB3 rotator (Bibby Scientific, Staffordshire UK) and rotated at 40 rpm for four hours.
Samples were then centrifuged at 10,000 rpm for 20 minutes. The octanol and buffer phases
were separated and collected. Each log D7.4 determination was repeated in triplicate.
2.5.2 Sample Analysis
Analysis of the octanol and buffer phases was achieved on an HPLC-DAD, details of which can
be found in Section 2.2.
2.5.3 Calculation of Log D7.4
Values for log D7.4 were calculated from Equation 2.4.
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logD7.4 =
Compound Concentration in Buffer
Compound Concentration in Octanol
(2.4)
Equation 2.4 Calculation of log D7.4.
2.5.4 Method Development
Aliquots of 200 µL were evaporated to yield 0.2 mg of compound. This was then dissolved in
equal volumes of octanol and phosphate buffer (pH 7.4, 0.01 M); 700 µL of each phase. These
were then rotated to facilitate equilibration for a set period of time; 2 hours, 4 hours or 6 hours.
2.5.5 Theoretical Log D7.4 Predictions
Theoretical log D7.4 were generated using the free, online software ACD/I-Lab (which makes use
of the EPSRC funded National Chemical Database Service hosted by the Royal Society of Chem-
istry) and two commercial software packages; MarvinSketch (version 17.28.0) (ChemAxon) and
ADMET Predictor (Simulations Plus) [334-336].
2.6 pKa Measurements
2.6.1 Equipment
Compound migration times were determined using a Beckman Coulter P/ACE MDQ Capillary
Electrophoresis System with a diode array detector (Beckman-Coulter, High Wycombe, UK).
The internal capillary temperature was set at 25 °C using the liquid cooling system. Sample
injection was conducted at 1.0 psi for 10 seconds and then 20 kV voltage was applied during
separations. The capillary was rinsed between each run in the following manner; NaOH applied
at 20 psi for 1.0 minute followed by the appropriate buffer for the next repeat at 20 psi for 2.0
minutes.
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2.6.2 Experimental pKa Measurements
Phosphate, acetate and borate buffers were utilised as described elsewhere with a pH spacing of
0.5 pH units (Table 2.2) [341]. All buffers had an ionic strength of I =0.05 and a concentration of
0.05 M. Sodium chloride was used to adjust the ionic strength and hydrochloric acid (0.1 M) or
sodium hydroxide (0.1 M) were used to adjust the pH values if necessary. The pH was measured
with a Jenway 3505 pH meter (Jenway, Essex, UK) which was calibrated before use. Buffers
were filtered prior to use through a 0.45 µM Nylon Phenex filter membrane (Phenomenex,
Cheshire, UK) using a Millipore filtration apparatus (Merck Millipore, Hertfordshire, UK).
Table 2.2: Reagents used for each pH
pH Reagent Masses, Volumes and Concentrations
1.5 22.30 g Na4P2O7 ·10H2O, 818.59 mL H3PO4 (1 M)
2.0 22.30 g Na4P2O7 ·10H2O, 287.69 mL H3PO4 (1 M)
2.5 22.30 g Na4P2O7 ·10H2O, 154.54 mL H3PO4 (1 M), 0.3247 g NaCl
3.0 6.22 mL H3PO4 (1 M), 5.25 g NaH2PO4
3.5 2.06 mL H3PO4 (1 M), 5.75 g NaH2PO4, 0.1076 g NaCl
4.0 40.96 mL CH3COOH, 0.7413 g CH3COONa, 2.39 g NaCl
5.0 15.42 mL CH3COOH, 2.84 g CH3COONa, 0.8956 g NaCl
6.0 2.13 mL CH3COOH, 3.93 g CH3COONa, 0.1248 g NaCl
7.0 2.72 g NaH2PO4, 3.88 g Na2HPO4
8.0 0.4595 g NaH2PO4, 6.55 g Na2HPO4
9.0 3.09 g H3BO3, 24.11 mL NaOH (1 M), 1.51 g NaCl
10.0 3.09 g H3BO3, 44.13 mL NaOH (1 M)
10.5 0.9247 g NaH2CO3, 4.13 g Na2CO3
11.0 0.2514 g NaH2CO3, 4.98 g Na2CO3
11.5 3.09 g H3BO3, 58.81 mL NaOH (1 M)
12.0 3.09 g H3BO3, 76.39 mL NaOH (1 M)
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Compounds were dissolved in methanol at a concentration of 1 mg mL-1. Solutions were diluted
to 0.25 mg mL-1 with deionised water (Barnstead UltraPure) and contained DMSO as the elec-
troosmotic flow marker (1 % v/v). DMSO (1 % v/v) in deionised water (Barnstead UltraPure)
was run at each pH before experimental repeats to ensure that an expected electrophoretic
mobility was obtained.
2.6.3 Calculation of pKa Values
Experimentally determined values for the effective mobility (µeff) were obtained using Equations
2.5 and 2.6.
µeff =
α× 10-pH
10-pKa + 10-pH
(2.5)
Equation 2.5 Relationship between effective mobility at a specific pH and the pKa of a com-
pound.
µeff =
b1(10
-pH)2 + a110
-pKa110-pKa2
(10-pH)2 + a110-pKa110-pH + 10-pKa110-pKa2
(2.6)
Equation 2.6 Relationship between effective mobility at a specific pH and the pKa of a com-
pound.
The Microsoft Excel add-in, Solver, was used to calculate the pKa value using least-squares
regression. Initial best-guess estimates for the pKa and α values were used to calculate theo-
retical effective mobilities and the squared difference (the residuals) between these theoretical
values and experimental values was then calculated and then this was minimised by varying
the values for pKa and α. Each pKa measurement was repeated in triplicate.
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2.6.4 Theoretical Prediction of the pKa Values of Benzodiazepines
Theoretical pKa values were generated using the free, online software ACD/I-Lab (which
makes use of the EPSRC funded National Chemical Database Service hosted by the Royal
Society of Chemistry) and two commercial software packages; MarvinSketch (version 17.28.0)
(ChemAxon) and ADMET Predictor (Simulations Plus) [338-340].
2.7 Plasma Protein Binding Measurements
2.7.1 Experimental Plasma Protein Binding Measurements
Plasma protein binding values were determined using the commonly-used method of equilibrium
dialysis [342]. Frozen plasma was thawed at room temperature prior to the experiments. The
pH was measured with a Jenway 3505 pH meter (Jenway, Essex, UK) which was calibrated
before use. Plasma pH was found to be within the physiological range of 7.38 - 7.42 and
adjustment was not required [343].
PBS tablets were dissolved in deionised water (Barnstead UltraPure) to yield a buffer solution
that contained 0.01 M phosphate, 0.0027M KCl, and 0.137 M NaCl, pH 7.4 at 25 °C. Stock
solutions of compounds in DMSO at a concentration of 10 mM were created and were diluted
with PBS prior to the experiments to yield working solutions at a concentration of 200 µM.
Reusable Single-Sample Fast Micro-Equilibrium Dialyzers (500 µL volume) were obtained from
Harvard Apparatus (Cambridge, UK), as were cellulose acetate membranes with a molecular
weight cut-off (MWCO) of 10,000 Da.
The membranes were soaked for 30 minutes in deionised water (Barnstead UltraPure) and
rinsed thoroughly. 30 µL of compound working solution was added to 270 µL of plasma to
yield a final concentration of 20 µM of compound (final DMSO concentration 0.2 %). This
was placed in one chamber and 500 µL of PBS was placed in the second chamber. The Micro-
Equilibrium Dialyzers were then placed into a shaking waterbath held at 37 °C for 24 hours.
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The temperature was monitored with a Sentry Thermometer (Fisher Scientific, Leicestershire,
UK). After 24 hours had elapsed, the samples were extracted from each chamber, matrix
matched (with blank plasma or blank buffer). Ice-cold acetonitrile at a 4:1 ratio was then
added to precipitate proteins. The samples were centrifuged at 10,000 rpm for 20 minutes and
the supernatant was recovered and evaporated using a flow of nitrogen with a TurboVap. Each
plasma protein binding measurement was repeated in triplicate.
2.7.2 HPLC-DAD Analysis
The evaporated samples were reconstituted in 200 µL of acetonitrile and analysed using HPLC-
DAD. Details of this analysis are given in Section 2.2.
2.7.3 Calculation of Plasma Protein Binding
Plasma protein binding (PPB) was calculated using the experimental plasma concentration
(P exp) and the experimental buffer concentration (Bexp) according to Equation 2.7.
PPB (%) = 100× P exp −Bexp
P exp
(2.7)
Equation 2.7 Calculation of plasma protein binding .
For those benzodiazepines that were highly protein bound and had a concentration in the
buffer phase that was below the limit of quantitation (LOQ), the buffer concentration was
calculated indirectly using Equation 2.8 which involved the experimental plasma concentration
and the total expected concentration (P tot), determined using a calibration plot. The total
expected concentration was adjusted using a previously-determined correction factor (CF ) for
the extraction efficiency ( 95 %). This indirectly-calculated buffer concentration was then input
into Equation 2.7 to generate plasma protein binding values.
Bexp = P totCF − P exp (2.8)
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Equation 2.8 Indirect calculations of the concentration of drugs in the buffer phase.
2.7.4 Method Development
Eight benzodiazepines were used to determine the appropriate length of equilibration (alprazo-
lam, clonazepam, diazepam, flunitrazepam, nitrazepam, oxazepam, prazepam and temazepam).
They had literature plasma protein binding values of 60 - 99 %.
2.7.5 Theoretical Prediction of Plasma Protein Binding
Theoretical plasma protein binding values were obtained from two sources used for log D7.4 and
pKa; ACD/I-Lab Lab (which makes use of the EPSRC funded National Chemical Database
Service hosted by the Royal Society of Chemistry) and ADMET Predictor (Simulations Plus)
and one source available as a free online resource, PreADMET (version 2.0) [338,340,344].
2.8 Volume of Distribution at Steady State
Values for Vdss, fu, log D7.4 and fi7.4 for 18 benzodiazepines were obtained from a variety
of literature sources. No log D7.4 and pKa data was available for some benzodiazepines and
these were predicted using ACD/I-lab software online. For nine benzodiazepines (alprazolam,
clonazepam, desmethyldiazepam, diazepam, flunitrazepam, nitrazepam, oxazepam, temazepam
and triazolam) log D7.4, pKa and plasma protein binding values were determined within this
research and those values were used in the prediction of Vdss.
Multiple linear regression was performed using the R language programming environment [345].
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2.9 Blood to Plasma Ratio
2.9.1 Experimental Determination of the Blood to Plasma Ratio
Whole blood was centrifuged at 2500 rpm for 20 minutes to separate the plasma from other
blood components. This was performed on the day of the experiments. The resultant plasma
was extracted and stored at 4 °C until use (typically within 2 hours).
Test analytes were dissolved in DMSO to yield stock solutions at a concentration of 5 mM. These
stock solutions were subsequently diluted with PBS (pH 7.4) to produce working solutions at
a concentration of 50 µM. Appropriate volumes of working solutions were added to blood or
plasma to yield a final compound concentration of 5 µM (final solvent concentrations were 0.1
%). The treated whole blood or plasma samples were incubated for 1 hour at 37 °C.
Following incubation, the blood sample was centrifuged at 2500 rpm for 20 minutes and the
plasma extracted. Ice-cold acetonitrile was added to extracted plasma and reference plasma
(4:1 ratio) to induce protein precipitation. The plasma was centrifuged at 10,000 rpm to 20
minutes, the supernatant collected and evaporated to dryness under a stream of nitrogen using
a TurboVap.
2.9.2 Sample Analysis
The evaporated samples were reconstituted in 50 - 150 µL acetonitrile and analysed using
GC-MS. Details of the analysis with GC-MS can be found in Section 2.3.
2.9.3 Calculation of the Blood to Plasma Partition Coefficient
Once concentrations had been determined with GC-MS, the blood to plasma partition coeffi-
cient was calculated using Equation 2.9.
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Ke/p =
1
H
× (CPref
CP
− 1) + 1 (2.9)
Equation 2.9 Calculation of the red blood cell partition coefficient where KE/P is the red blood
cell partition coefficient, H is the haematocrit, CPref is the concentration of the analyte in the
reference plasma and CP the concentration of the analyte in the plasma separated from the
whole blood.
The haematocrit of the pooled blood was given as 41 % by the supplier Seralab.
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2.10 Metabolic Studies
2.10.1 C3A Cell Line
Stock solutions of the substrates (phenacetin, bupropion, omeprazole, diclofenac, dextromethor-
phan and testosterone) were formulated in DMSO and subsequently diluted with the cell culture
medium to obtain the desired concentrations for their Km values (Table 2.4). The final con-
centration of the DMSO in these solutions did not exceed 0.1 %.
The C3A cells were maintained as an adherent cell line in 75 cm2 Nunc EasYFlasks (Fisher
Scientific, Leicestershire, UK) with the use of Gibco Minimum Essential Medium supplemented
with 10 % fetal bovine serum, 1 × non-essential amino acids and 1 × sodium pyruvate in a 37
°C, 5 % CO2 atmosphere. Medium was replaced every two to three days. Cells were passaged as
required by using TrypLE Express enzyme. The C3A cells were seeded in 96-well microplates
at a density of 3.3 × 105 cells per mL. At 60 % confluence the medium was replaced with one
containing the test substrates at their respective Km values (Table 2.4). The cells were then
incubated with the substrates for 24 hours. The cell culture medium was collected for each
substrate. Ice-cold acetonitrile was added at a 4:1 ratio and the samples centrifuged at 10,000
rpm for 20 minutes. The supernatant was extracted and evaporated with a flow of nitrogen
using a TurboVap. All samples were stored at -20 °C until analysis.
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Table 2.3: Substrates and their Km values for CYP450 enzymes
CYP450 enzyme Substrate Concentration (µM) Metabolite Reference
CYP1A2 Phenacetin 50 Paracetamol [346]
CYP2B6 Bupropion 100 2-OH-bupropion [346]
CYP2C19 Omeprazole 20 5-OH-omeprazole [346]
CYP2C9 Diclofenac 5 4-OH-diclofenac [347]
CYP2D6 Dextromethorphan 5 Dextrorphan [346]
CYP3A4/5 Testosterone 100 6-OH-testosterone [346]
2.10.2 C3A Cells Treated with DMSO
The same procedure was conducted as described for the C3A cells other than that at 60 %
confluence the medium was replaced with one containing 1 % (v/v) DMSO. Cultures were
incubated for 20 days and the culture medium was replaced every 2 - 3 days. Cells were
passaged upon reaching 60 % confluence. Following 20 days the cells were incubated with
the test substrates; phenacetin, bupropion, diclofenac, dextromethorphan, testosterone and
omeprazole at their respective Km values. Following 24 hours of incubation the cell culture
medium was collected for each substrate. Ice-cold acetonitrile was added at a 4:1 ratio and
the samples centrifuged at 10,000 rpm for 20 minutes. The supernatant was extracted and
evaporated with a flow of nitrogen using a TurboVap. All samples were stored at -20 °C until
analysis.
2.10.3 Cell Counts
Estimations of the number of cells in culture for the C3A cells and DMSO-treated cells were
performed by removing the cell culture medium and adding an appropriate volume of TrypLE
Express Enzyme (1X) to remove the adherent cells. 100 µL of the resulting suspension was
then stained with Tryphan Blue. The cells were counted using a haemocytometer.
2.10.4 HepaRG Cells
The HepaRG cells were seeded at 1.20 × 106 cells/mL in 24-well Collagen I coated microplates.
Cell medium was Williams Medium E with 1 % to which HepaRG Thaw, Plate and General
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Purpose Working Medium was added. The cells were cultured at 37 °C in a 5 % CO2 atmo-
sphere. Four hours after plating, the media was removed and replaced with one containing the
substrates at their respective Km values (Table 2.10.1). The cell culture medium was collected
for each substrate after 24 hours of incubation. Ice-cold acetonitrile was added at a 4:1 ratio
and the samples centrifuged at 10,000 rpm for 20 minutes. The supernatant was extracted and
evaporated with a flow of nitrogen using a TurboVap. All samples were stored at -20 °C until
analysis.
2.10.5 The Metabolism of NPS-Benzodiazepines
The NPS-benzodiazepines were incubated with HepaRG cells at a concentration of 10 µM. The
same procedure for extraction was followed as is described in Section 2.10.4.
2.10.6 LC-MS/MS Analysis of Metabolites
Samples were processed by the internal mass spectrometry service at the University of Hud-
dersfield. The supernatant that was collected in the previous sections was analysed using an
Agilent 6530 Quadrupole Time-of-Flight (QTOF) LC/MS in the positive ionisation mode (ESI)
attached to an Agilent 1290 Infinity HPLC instrument.
Two chromatographic methods were used. The first analysed the compounds incubated with
the C3A and C3A-DMSO cell lines (bupropion, dextromethorphan, diclofenac, omeprazole,
phenacetin and testosterone).
The mobile phases consisted of 0.1 % formic acid in acetonitrile (mobile phase A) and 0.1
% formic acid in water (mobile phase B). The flow rate was set at 0.5 mL min-1 and the
proportions of the mobile phases at 0, 6, 12, 18, 36, 43, 43.1 and 46 minutes were 90/10, 90/10,
70/30, 70/30, 10/90, 10/90, 90/10 and 90/10 respectively. Separation was achieved with an
ACE C18-AR column (250 × 4.6 mm, 5 µM) (Advanced Chromatography Technologies Ltd,
Aberdeen, Scotland). The optimised VCap voltage and temperature were set at 3000 V and
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300 °C. Octopole OCT 1 RF Vpp voltage was 750 V and the fragmentor voltage was 175 V.
Nebuliser pressure was 35 psi and drying gas flow rate was 8 L min-1.
Following this, method optimisation took place for the analysis of the compounds incu-
bated with the HepaRG cell lines (bupropion, dextromethorphan, diclofenac, omeprazole,
phenacetin, testosterone, 3-hydroxyphenazepam, 4’-chlorodiazepam, desalkylflurazepam, de-
schloroetizolam, diclazepam, etizolam, flubromazepam, flubromazolam, meclonazepam, nitra-
zolam, phenazepam and pyrazolam).
For this method mobile phases consisted of 0.1 % formic acid in acetonitrile (mobile phase A)
and 0.1 % formic acid in water (mobile phase B). The flow rate was set at 0.5 mL min-1 and
the proportions of the mobile phases at 0, 6, 12, 18, 36, 48, 48.1, 55 minutes were 90/10, 90/10,
70/30, 70/30, 10/90, 10/90, 90/10 and 90/10 respectively. Separation was achieved with an
ACE C18-AR column (250 × 4.6 mm, 5 µM) (Advanced Chromatography Technologies Ltd,
Aberdeen, Scotland). The optimised VCap voltage and temperature were set at 3000 V and
300 °C. Octopole OCT 1 RF Vpp voltage was 750 V and the fragmentor voltage was 150 V.
Nebuliser pressure was 40 psi and drying gas flow rate was 8 L min-1.
The main differences between the methods are a lower fragmentor voltage for the second method
(150 V compared to 175 V) and a higher nebuliser pressure (40 psi compared to 35 psi).
The extracted cell culture media for omeprazole, a pure standard of omeprazole sulfide (0.01
mg mL-1) and a pure standard omeprazole sulfone (0.01 mg mL-1) were analysed using an
Agilent 6210 Time-of-Flight (TOF) mass spectrometer (MS) operating in positive ionisation
(Dual ESI) mode. Gas temperature was 350 °C, fragmentor voltage was 150 V, Octopole OCT
1 RF Vpp was 250 V, nebuliser pressure was 40 psi and the drying gas flow rate was 10 L min
-1.
Skimmer voltage was 65 V and VCap voltage was 5000 V.
Chapter 3
Method Development and Validation
3.1 Validation of an HPLC-DAD Analytical Method
3.1.1 Introduction
HPLC-DAD was chosen to determine NPS-benzodiazepine concentrations for the log D7.4 and
plasma protein binding experiments as it is a common laboratory instrument and the devel-
opment of methods and operation of instrumentation is generally held to be easier than that
of mass spectrometry methods [348,349]. In addition many modern HPLC-DAD instruments
are automated through the use of autosamplers so that multiple samples can be programmed
to run in one sequence [350]. Although numerous validated HPLC-DAD methods exist for the
quantification of benzodiazepines, none have been described in literature for the analysis of
NPS-benzodiazepines [351,352].
The majority of this work to develop and validate an HPLC-DAD method for the analysis of
NPS-benzodiazepines has already been published [353]. The HPLC-DAD method was validated
according to ICH guidelines for linearity, limit of detection (LOD), limit of quantitation (LOQ),
accuracy and precision [335]. Validation of analytical methods is important to ensure that
reliable results are obtained through assessing the accuracy and precision of a method.
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3.1.2 Results
Linearity
The linearity of an analytical method refers to the propensity of the measurements (e.g. peak
area or peak height) to be proportional to the actual concentration of compound in the samples
[354]. The method was linear over the concentration range 0.0004 - 0.25 mg mL - 1 for all
compounds. A high R2 value for all compounds indicates a linear concentration-response and
a suitable method (Table 3.1).
LOD and LOQ
The limit of quantitation is the lowest concentration that can be quantified with precision and
accuracy while the limit of detection is the lowest concentration that can be detected although
not quantified with accuracy and precision [354]. All compounds generally had comparable
limits of detection and quantitation when compared with reported values in literature (Table
3.1). Pyrazolam exhibited the lowest response to the HPLC-DAD method, with a LOQ of
263.9 ng mL - 1 and a LOD of 82.0 ng mL - 1. The observed LODs and LOQs were similar to
that of other published HPLC-DAD methods for benzodiazepines such as alprazolam (LOQ 300
ng mL - 1) and diazepam, oxazepam and temazepam (LOD 50 ng mL - 1, LOQ 100 ng mL - 1)
[355,356].
Accuracy and Precision
The accuracy of an analytical method refers to the closeness of a measured value to that of
an accepted reference value [354]. Precision refers to the closeness of measured values of the
same homogenous sample to one another and ensures that the same method will produce the
same results with low variation [354]. Accuracy was determined through comparison of the
percentage recovery at three concentrations; 0.25, 0.01 and 0.0004 mg mL - 1 (n=3) as this
covered the linear range assessed for this method. Percentage recovery was generally within
2 % (Table 3.2) and thus deemed to be acceptable as this was similar to reported accuracies
for other HPLC-DAD methods for the quantitation of benzodiazepines [356]. Precision was
determined from the calculation of the standard deviation and relative standard deviation
(RSD) of the compound peak areas at three concentrations; 0.25, 0.01 and 0.0004 mg mL - 1
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(n=3). High levels of precision for all benzodiazepines were recorded (Table 2) and were similar
to levels of precision reported in literature previously for benzodiazepines with methods also
using HPLC-DAD analysis [357,358].
3.1.3 Discussion
The HPLC-DAD analytical method described is suitable for the analysis of the NPS-
benzodiazepines as judged by the linearity of the method in the established range and the
high precision and accuracy obtained. The limits of quantitation and detection were similar to
those reported elsewhere in literature.
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3.2 Validation of an GC-MS Analytical Method
3.2.1 Introduction
GC-MS is a common method used for the quantitation of drugs in forensic science [359]. GC-MS
is widely-used and high accuracy and precision can be achieved with its use [360]. Validation
of any analytical method is critical in order to ensure that any results obtained from it are
reliable and the use of the method is appropriate [354]. For this analytical method this took
place according to the ICH guidelines [335].
Quinine and chlorpromazine were included for the GC-MS method as they were used in the
blood to plasma concentration ratio experiments, further details about this can be found in
Section 8.
3.2.2 Results
The high sensitivity of the GC-MS towards benzodiazepines was evident by the large peak
heights gained. This is exemplified by Figure 3.1; nitrazepam at a concentration of 250 µM or
70.3 µg mL-1. High sensitivity is a typical characteristic of mass spectrometry methods and is
a large factor behind their use.
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Figure 3.1: A chromatogram of nitrazepam at a concentration of 250 µM run using the method
described in Section 2.3
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Linearity
The linearity of an analytical method refers to whether a proportional response is obtained
between the concentration of analyte in the sample and the resultant instrumental response
(e.g. abundance) [361].
If a statistical difference exists between the variance at the highest concentration and the
variance at the lowest concentration, then a weighting factor is typically applied to the data
[336,337]. The variance is calculated as the square of the standard deviation. Using the Data
Analysis tools in Microsoft Excel a two-sample F-test for variances can be performed, yielding
a p value. If the p value was greater than 0.05 then this indicated that the difference in the
variance at the highest concentration was not statistically significant when compared to the
difference in the variance at the lowest concentration. If the p value was lower than 0.05 then
this indicated that the difference in the variance at the highest concentration was statistically
significant when compared to the difference in the variance at the lowest concentration. If the
difference in variances was found to be statistically significant (p < 0.05) then a weighting
factor was applied. This is typically a 1/x or 1/x2 weighting factor and can be performed in
the Agilent software. A plot of the variance at each concentration versus the concentration was
computed. If a linear relationship between variance and concentration is observed then a 1/x
weighting factor is used, whereas if a parabolic relationship between variance and concentration
is observed then a 1/x2 weighting factor is used.
An example of a parabolic relationship between variance and concentration is shown in Figure
3.2 for chlorpromazine and an example of a linear relationship between variance and concen-
tration is shown in Figure 3.3.
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Figure 3.2: A plot of the variance against concentration for chlorpromazine
Figure 3.3: A plot of the variance against concentration for phenazepam
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As discussed in Section 2.3, with knowledge of the weighting factor, the plot of data points can
be fitted with either a linear (Equation 2.1) or quadratic (Equation 2.2) model.
The most appropriate model to use is the one that is the simplest but still adequately describes
the relationship. The models can be compared using a two-way analysis of variation (ANOVA)
test which can be performed using the Data Analysis tools in Microsoft Excel.
In this test, both linear and quadratic models are used to calculate a theoretical instrumental
response for each of the five concentrations. The variation between the theoretical instrumental
response and the experimental instrumental response (for both models) is then compared. A p
value is obtained to describe the statistical significance of the models. If the p value is greater
than 0.05 then the difference between models is not statistically significant and the quadratic
model does not give a better fit to the data than the linear model. The purpose of this is to
choose the simplest model to describe the data. The data used to determine the linearity is
displayed in Table 3.3.
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Accuracy and Precision
The accuracy of an analytical method is the closeness of an experimental value to that of a
reference value while the precision of an analytical method describes the closeness of replicates
to one another [335]. Interday and intraday accuracy was assessed for each compound through
three repetitions of three concentrations; 10, 50 and 250 µM and experimental instrument
response was compared to the theoretical instrument response from a calibration plot. The
results are displayed in Table 3.4.
The interday and intraday precision was measured at three concentrations as they spanned the
analytical range of the method; 10, 50 and 250 µM. Three repetitions at each concentration
were used and the relative standard deviation was calculated. The results are displayed in
Table 3.4.
LOD and LOQ
The LOD is the lowest concentration of an analyte that is detectable by the analytical method,
while the LOQ is the lowest concentration of an analyte that is detectable by the analytical
while maintaining an acceptable level of accuracy and precision [382]. The values of the LOD
and LOQ are displayed in Table 3.5.
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Table 3.5: Limits of quantitation and detection for compounds using the GC-MS method
Compound LOQ (ng mL-1) LOD (ng mL-1)
Chlorpromazine 235.9 130.7
Diazepam 170.8 76.9
Nitrazepam 472.5 140.6
Quinine 525.6 159.0
Diclazepam 242.6 92.6
Deschloroetizolam 410.2 138.8
Etizolam 438.8 96.0
Meclonazepam 359.4 89.0
Phenazepam 262.2 73.4
Pyrazolam 492.4 134.6
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3.2.3 Discussion
Thermal decomposition of nitrazepam has been observed when analysing with GC-MS and
7-aminonitrazepam is formed through reduction [362]. Peak shoulders or separate peaks are
observed with this decomposition. However, no such peaks were observed in this work, possibly
as a result of the lower temperature used in this method; 280 °C versus 300 °C described in
literature [362]. This is evident in Figure 3.1, a chromatogram of the instrumental response
against time for nitrazepam at a concentration of 250 µM (70.3 µg mL-1).
Linearity
Parabolic responses of the variance per concentration were identified for chlorpromazine, qui-
nine, deschloroetizolam, etizolam and pyrazolam. Therefore a 1/x2 weighting factor was used.
All other compounds had a 1/x weighting factor applied. Linearity was good, with the lowest
R2 being 0.9700 for etizolam and the highest being an R2 of 0.9918 for nitrazepam. These
R2 values for the linearity of the concentration-response plots were similar to those seen in
literature for the GC-MS analysis of benzodiazepines [359,362-364].
Accuracy and Precision
The best interday accuracy was 100.3 % for pyrazolam at a concentration of 50 µM and the
lowest interday accuracy was 109.2 % for chlorpromazine at 250 µM. The best intraday accu-
racy was 101.2 % for nitrazepam at 10 µM and the lowest intraday accuracy was 91.5 % for
diclazepam at a concentration of 50 µM.
The lowest interday precision observed was a relative standard deviation of 14.3 % for meclon-
azepam at 50 µM and the highest interday precision was 3.8 % for phenazepam and pyrazolam
both at 10 µM. The lowest intraday precision was a relative standard deviation of 11.0 % for
etizolam at a concentration of 10 µM and the highest intraday precision was a relative standard
deviation of 2.4 % for pyrazolam at a concentration of 250 µM.
All calculated values for accuracy and precision were within the previously-specified criteria of
± 15 % which is similar to other GC-MS methods described in literature [365].
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LOD and LOQ
The limits of quantitation and detection can be found in Table 3.5.
The lowest LOD was 73.4 ng mL-1 for phenazepam while the highest was 159.0 ng mL-1 for
quinine. The lowest LOQ was 170.8 ng mL-1 for diazepam while the highest was 525.6 ng mL-1
for quinine.
The limits of detection and quantitation were lower than those reported elsewhere in literature
for similar GC-MS methods. Diazepam was determined as having an LOD of 76.9 ng mL-1 in
this work versus 8 - 38.6 ng mL-1 elsewhere and an LOQ of 170.8 ng mL-1 in this work against
an LOQ 103 - 116.9 ng mL-1 elsewhere [364].
Quinine has a reported LOD of 12.2 ng mL-1 versus 159.0 ng mL-1 in this work and an LOQ of
40.6 ng mL-1 versus 525.6 mg mL-1 in this work [366].
The differences in the limits of quantitation and detection can be explained by the lack of
sensitivity of the mass spectrometer used. In addition the method was not fully optimised as
obtaining low limits of detection and quantitation was not the primary aim of this validation
process. The primary use of this method was to quantitate compound concentrations for the
blood to plasma concentration ratio experiments as detailed in Section 8. Based upon the data
presented regarding the good linearity of the method and the high accuracy and precision, the
method was suitably validated.
Chapter 4
The log D7.4 of NPS-benzodiazepines
4.1 Introduction
As discussed in Section 1.7.1, the log D7.4 of a compound affects all pharmacokinetic parameters
such as its absorption through biological membranes, its distribution within the body (e.g.
plasma protein binding) and its metabolism and its excretion [112,113]. As a result of its
effects on these pharmacokinetic processes, knowledge of the log D7.4 is especially important
for pharmacokinetic modelling [121,126]. Benzodiazepines are absorbed quickly within the body
and distribute well into the brain because of their relatively high lipophilicity with the majority
of benzodiazepines having a log D7.4 between 2-3 [128-133].
Although high-throughput methods exist for the determination of log D7.4, the shake-flask
method is generally considered the ‘gold standard’ as it is accurate and precise and can be
performed easily with standard laboratory equipment and reagents [136,137]. The shake-flask
method typically only requires octanol, reagents for formulating an appropriate buffer, a method
to separate the two phases (e.g. a centrifuge) and a method to analyse the compound concen-
trations (e.g. any of a variety of spectroscopic methods) [136]. The aims of the work in this
Section were to develop and validate an appropriate shake-flask method for the benzodiazepines
under investigation. This took place by comparing the log D7.4 values obtained for eight test
benzodiazepines that were equilibrated for three time periods; one, four or six hours.
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Once an appropriate method of measuring log D7.4 had been developed, the aim was to de-
termine the log D7.4 of 12 NPS-benzodiazepines. These experimental values could then be
compared to theoretical values in order to evaluate whether theoretical predictions could re-
place experimentally-determined values. Log D7.4 values play a crucial role in the prediction of
pharmacokinetic parameters such as the volume of distribution at steady state [135]. The gener-
ation of log D7.4 values in this Section will therefore also be used to predict this pharmacokinetic
parameter. The majority of this work to determine the log D7.4 values of NPS-benzodiazepines,
compare them to theoretical predictions from software packages and subsequent analysis of the
values has been published [353].
4.2 Results
4.2.1 Log D7.4 Method Development
The calculated log D7.4 values for the eight test benzodiazepines equilibrating for 1, 4 or 6 hours
are listed in Table 4.1. An unpaired t test was used to compare the values calculated at 4 and
6 hours.
4.2.2 Theoretical log D7.4 values of benzodiazepines
The most suitable length of equilibration was selected for the determination of the log D7.4 of
the NPS-benzodiazepines in the study. The experimental values are listed in Table 4.1.
4.2.3 Theoretical log D7.4 of NPS-benzodiazepines
Following the experimental determination of log D7.4, the theoretical values were generated and
compared by means of the absolute error. This was performed for both the test benzodiazepines
and the NPS-benzodiazepines.
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4.3 Discussion
4.3.1 Log D7.4 method development
There are large variations in literature of experimentally-determined log D7.4 values. For exam-
ple, the compound nortriptyline has a reported log D7.4 of both 1.1 and 2.05 with both methods
using the shake-flask method; just under a ten-fold difference in lipophilicity [372,373]. Another
compound, atenolol, has reported log D7.4 values of -1.88 and -0.16 with both methods also
using the shake-flask method [374,375]. This is approximately a 52-fold difference in reported
lipophilicity. It is clear that factors exist that are responsible for the large variation in log
D7.4 values observed in literature. The composition of the buffer has long been known to play
an important role in experimentally-determined log D7.4 values [372]. However, experimental
determination of log D7.4 values is often not the primary focus of many studies; instead the
majority of these studies are attempting to correlate log P or log D7.4 values with other phys-
iochemical properties and biological effects of the compounds. Thus it can be seen in literature
that a selection of different buffers are often employed. A recent study calculated log D7.4
values for 29 compounds using eight different buffers and found significant differences existed
between the different buffer systems [376]. It was observed that although there was some rela-
tionship observed with polar surface area and molecular polarisability, the resulting differences
in log D7.4 values were unpredictable [376]. The large variation in published log D7.4 values in
literature is an observable effect of this. Use of a 0.01 M phosphate buffer has been shown to
give an exact correlation of partition coefficients determined in the octanol-phosphate system
for acidic and neutral drugs [377]. The use of a 0.01 M phosphate buffer is common and it is
easily formulated using standard laboratory reagents [375].
The volume of 700 µL for each phase (1400 µL total) was chosen as this volume fits comfortably
inside a 1500 µL microcentrifuge tube which was required for phase separation by centrifugation.
The values at one hour typically fell between log D7.4 values of 0 - 1. A log D7.4 value of 0
indicates an equal distribution between the octanol and buffer phases (i.e. a D value of 1 which
would give a base-10 logarithm value of 0). Equal distribution between octanol and a buffer
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phase for highly-lipophilic compounds such as the benzodiazepines indicates insufficient time
for equilibration. The log D7.4 obtained at 4 and 6 hours were more reasonable and either within
the range of, or close to, established values in literature. The values observed at 4 and 6 hours
were compared by means of an unpaired t test. The p values were not statistically significant
for all eight test benzodiazepines. Therefore, to decrease the time taken for measurements, four
hours was chosen and log D7.4 at four hours was used.
4.3.2 Experimental log D7.4
Alprazolam exhibited a slightly lower log D7.4 of 2.10 compared to a literature range of 2.12 -
2.16 [367,368]. Clonazepam exhibited a similar log D7.4 of 2.40 versus a single literature value
that could be found of 2.41 [367,369]. Diazepam had a log D7.4 of 2.81 within its literature
range of 2.79 - 2.99 [367-370]. Flunitrazepam was slightly lower than literature range with a
log D7.4 of 2.05 versus 2.06 - 2.14 [367-369]. Nitrazepam had a similar log D7.4 to its literature
range of 2.13 - 2.16 [367,369]. Oxazepam was within its literature range of 2.13 - 2.24 with
a log D7.4 of 2.24 [369,371]. Prazepam was slightly above its literature range of 3.7 - 3.73
with a log D7.4 of 3.74 [367,369]. Temazepam had a calculated log D7.4 of 2.32 was versus
literature values of 1.79 - 2.19 [367,369]. Although 0.13 log units higher than the greatest
literature value there was a low standard deviation and all of the other experimental values for
the benzodiazepines were in agreement with their literature values. In addition to this in the
method development experiments, a value of 2.30 was observed for temazepam at 6 hours of
equilibration. As discussed earlier, the log D7.4 is dependent upon the method used to measure
it including the choice of buffer and strength of the buffer. No such information was given for
the reported values in literature and therefore it may be that the method in this work has a
greater accuracy for measuring the log D7.4 of benzodiazepines.
The experimental log D7.4 values of the NPS-benzodiazepines under investigation are listed in
Table 4.2. Similar to the test benzodiazepines, the NPS-benzodiazepines in this work were
found to be highly lipophilic with the majority having log D7.4 values above 2. Only one NPS-
benzodiazepine had a previously-reported value in literature which was desalkylflurazepam
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with 2.78 [367]. A value of 2.82 was returned in this work with a standard deviation of 0.09.
The lowest log D7.4 value observed was for pyrazolam, with 0.97. The highest log D7.4 value
observed was for phenazepam, with 3.25. The other ten benzodiazepines were in the range of
2.40 (etizolam and flubromazolam) to 2.87 (flubromazepam). These log D7.4 values of between
2 and 3 are common for benzodiazepines, with seven of the eight test benzodiazepines falling
into this range.
The only NPS-benzodiazepine in this work to return a log D7.4 value of less than 2 was pyrazolam
which was found to have a log D7.4 of 0.97. This is an atypical benzodiazepine as it does not
contain a phenyl ring at position 5 and rather contains a pyridin-2-yl ring. Analysing these
molecular fragments in isolation reveals that a phenyl ring has a log D7.4 of 1.56 versus a log D7.4
of 0.62 for a pyridin-2-yl ring [378]. The presence of a bromine atom substituent at position 7 is
also known to lead to a decreased log D7.4 [133]. A prescription benzodiazepine, bromazepam,
also contains a pyridin-2-yl ring and a 7-bromo substitution and has a reported log D7.4 of
1.38 - 1.60 [367,369,370]. In contrast to bromazepam, pyrazolam is a triazolobenzodiazepine
and thus contains an additional triazole ring. This is a known structural feature that has been
well described as decreasing the apparent lipophilicity for other pharmaceutical compounds
[379,380]. The structural features of a pyridin-2-yl ring, a 7-bromo substitution and a triazole
ring are likely to have contributed to the low log D7.4 of pyrazolam that was calculated in this
work.
The lipophilicity (as log P) of ten NPS-benzodiazepines have already been published in liter-
ature with the stated aim of the authors being to make them available for the estimation of
pharmacological and toxicological properties [134]. The work presented here adds to this.
4.3.3 Theoretical log D7.4
Although a small dataset and thus more strongly influenced by the error in a single value,
the average of the absolute errors was used to give a quick comparison between the gen-
erated values. ACD/I-Lab returned the closest values for the test benzodiazepines and the
NPS-benzodiazepines with average absolute errors 0.18 and 0.28 respectively. ACD/I-Lab was
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closely followed by ADMET Predictor which had average absolute errors of 0.24 for the test
benzodiazepines and 0.37 for the NPS-benzodiazepines. MarvinSketch had an average absolute
error of 0.39 for the test benzodiazepines and 0.97 for the NPS-benzodiazepines.
The greatest absolute errors were given by ACD/I-Lab for pyrazolam (0.79), MarvinSketch for
etizolam (1.66) and by ADMET Predictor again for pyrazolam (1.06). Pyrazolam has a very
low log D7.4 value of 0.97 and the theoretical software packages may have failed to take into
account the reduced lipophilicity likely as a result of the pyridine-2-yl ring it contains.
The second highest absolute error for MarvinSketch was for pyrazolam (1.39). The Consensus
model used by MarvinSketch makes use of a model described in literature using multivariate
regression [381]. This model is known to calculate a log P (octanol-water partition coefficient)
for pyridine of 1.20 versus an experimental log P of 0.64, vastly overestimating the contribution
of the pyridine group towards lipophilicity and this may be a factor behind the overestimation
of lipophilicity [381].
However, this does not explain the large absolute error returned by MarvinSketch for etizolam
(1.66). Although etizolam is a thienodiazepine the thiophene group is calculated in literature
model as having a log p of of 1.63 versus an experimental log p of 1.81 [381]. Without knowing
the specific calculations used to generate log D7.4 values it is extremely difficult to attribute
the errors generated in the theoretical log D7.4 values to a specific cause. The inclusion of
the experimental log D7.4 values determined in this work in future predictive software may
prove fruitful in order to improve their accuracy. For the moment it is clear that experimental
log D7.4 is more accurate than the available predictions from these three software packages.
Evaluation of other software packages could prove useful in order to assess whether they hold
any improvement in predicting log D7.4 of NPS-benzodiazepines.
Chapter 5
The pKa of NPS-benzodiazepines
5.1 Introduction
Although pKa is often described as being of secondary importance as a physicochemical param-
eter when compared to log D7.4, the use of pKa has still found great utility in pharmacokinetic
modelling such as predicting the volume of distribution at steady state, adipose tissue dis-
tribution and post-mortem redistribution of benzodiazepines [107,148-150]. pKa is especially
important when utilised in conjunction with other physicochemical parameters such as log
D7.4 [106,141,143]. As the pKa of a compound affects factors such as its solubility in aqueous
media, it indirectly affects pharmacokinetic parameters such as absorption and distribution
[141,144,145].
The pKa values of benzodiazepines have been previously reported to aid correlation between
their log D7.4, plasma protein binding and their volume of distribution at steady state [107,148].
This was discussed in greater detail in Section 1.8.2 but again highlights the importance of
accurate physicochemical knowledge.
In this study capillary electrophoresis was used to determine pKa values of benzodiazepines as
it is possibly the most common method and can be automated [154,155]. This facilitated quick
and easy determination of pKa values.
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5.2 Results
5.2.1 Experimental pKa and Theoretical pKa
The experimental results for pKa for the test benzodiazepines and NPS-benzodiazepines are
given in Table 5.1.
ACD/I-Lab, MarvinSketch and ADMET Predictor were used to generate theoretical pKa values
for both the test benzodiazepines and NPS-benzodiazepines and the values are provided in Table
5.1.
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5.3 Discussion
5.3.1 Method Development for Capillary Electrophoresis-PDA
Although the Beckman P/ACE MDQ capillary electrophoresis instrument was programmable
and so therefore be automated, multiple problems arose with the use of it for this purpose.
The capillary needle was fragile and during one repeat at one pH required four insertions into
the vials (two rinses, one injection and one separation). For the compounds where two pKa
values were observed, 16 pH levels were needed; 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 7.0, 8.0,
9.0, 10.0, 10.5, 11.0, 11.5 and 12.5. Therefore 64 needle insertions were required for the repeat
of one compound and 196 needle insertions for 3 repeats. The fragility of the capillary needle,
coupled with the unyielding nature of the rubber caps for the vials caused frequent snapping
of the needle. Therefore this could be alleviated to a certain extent by ceasing experiments
once the compound and DMSO marker peaks had co-eluted at the same migration time. This
meant that the compound was unionised and its pKa value could be determined from the
values already determined. For example, in the case of diazepam, both the DMSO marker and
diazepam peaks had co-eluted by the injection at pH 5.0. Further experiments at higher pH
levels up to 12.0 were not necessary; diazepam cannot have another pKa value as there is no
other deprotonation site on the molecule.
The 32 Karat Data Analysis Software was able to quickly identify and integrate peaks. The
only information required from peak integration was the retention times of the compound and
the DMSO marker. From this the migration times could be calculated and the Microsoft Excel
add-in Solver could be used to calculate pKa values.
The pKa of a compound is not a constant and can be affected by temperature, ionic strength and
the solvent dielectric constant [390]. Temperature can be controlled within the capillary elec-
trophoresis instrument and was set at 20 °C. Ionic strength was also controlled, with all buffers
having an ionic strength (I ) of 0.05 as this is a standardised method [341]. As all the com-
pounds were dissolved in methanol at the same concentration prior to capillary electrophoresis,
the solvent dielectric constant was also kept constant.
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The eight test benzodiazepines had pKa values determined in this work that were all within
0.20 pH units of their literature values with a standard deviation that was lower than of 0.07
pH units. These two values of 0.20 and 0.07 for accuracy and precision are the values typically
held to be indicative of a suitable capillary electrophoresis method for determining pKa and
further validation is not required [161].
5.3.2 Experimental pKa
pKa values of 2.83 for etizolam and 2.51 and 11.64 for desalkylflurazepam were calculated in
this work. These compared favourably to their literature values of 2.76 and of 2.57 and 11.76
[388,389].
The lowest value for pKa1 was calculated as 1.25 for 3-hydroxyphenazepam. The presence of
a hydroxyl group decreases the pKa of benzodiazepines as a result of the electron-withdrawing
properties of this substituent [386]. The presence of a chlorine substituent at the R2’ position
is also known to decrease the pKa1 value of 1,4-benzodiazepines [386]. Phenazepam, which is
structurally similar to 3-hydroxyphenazepam except for the omission of a hydroxyl group, had
a higher pKa of 2.19. The hydroxyl group on 3-hydroxyphenazepam led to a decrease in 0.94
pKa units when compared to phenazepam. A similar decrease was observed for temazepam
which differs only from diazepam by the addition of a 3-hydroxyl group. The experimental
pKa of temazepam was 1.45 compared to 3.10 for diazepam, a decrease of 1.65 pKa units. This
relationship is also observed for nitrazepam and clonazepam. Nitrazepam does not contain a
2’-chloro substituent whereas clonazepam does. Nitrazepam has greater pKa1 (3.11 versus 1.55)
and pKa2 (11.02 versus 1.45) values than clonazepam.
Another NPS-benzodiazepine that contains a substituent on the 3-position is meclonazepam.
However, this substitution is a methyl group rather than a hydroxyl group. Meclonazepam is
structurally similar to clonazepam, differing only by the addition of the 3-methyl group. Com-
pared to the experimental pKa1 and pKa2 values of 1.55 and 10.45 for clonazepam, meclon-
azepam exhibited higher values of 2.10 and 11.45 respectively. This indicates that the 3-methyl
substitution will increase the pKa values of benzodiazepines.
5.3. Discussion 97
Deschloroetizolam has an increased pKa1 (4.19) when compared to etizolam (2.83). Etizolam
contains an additional 2’-chloro substituent and this has already been noted to produce a
reduction in the pKa1 value of 1,4-benzodiazepines [386]. A similar reduction also appears to
occur for thienotriazolodiazepines.
4’-Chlorodiazepam and diazepam have similar pKa values of 3.13 and 3.10 respectively, indicat-
ing that the addition of a chlorine substituent on the 4’ position of a 1,4-benzodiazepine does
not greatly affect its pKa. In contrast however, the addition of a chlorine substituent on the 2’
position causes the pKa1 value to decrease from 3.10 (diazepam) to 2.31 (diclazepam).
The change of a 2′ substituent to one that is more electronegative appears to increase the pKa1
and decrease the pKa2 of 1,4-benzodiazepines. Flubromazepam has a 2’-fluoro substituent
which is more electronegative than the 2’-chloro substituent of phenazepam. Flubromazepam
has a higher pKa1 (3.25 versus 2.19) and a lower pKa2 (10.74 versus 11.21). Substituents
with a greater electronegativity have a greater tendency to behave in an electron-withdrawing
manner which can result in a partial deactivation of the aromatic system therefore leading to a
reduction in the number of delocalised electrons. This in turn decreases the stability of negative
charges in the system. As the pKa2 values of 1,4-benzodiazepines are thought to be resonance-
stabilised by delocalisation, any decreases in delocalisation have the effect of increasing the ease
with which a species can be deprotonated. This therefore decreases the pKa2 values which are
resonance-stabilised negative charges on the nitrogen and oxygen atoms.
The change of 7- substituent to one that is less electronegative appears to increase the pKa1 and
decrease the pKa2 of 1,4-benzodiazepines. Flubromazepam has a 7-bromo substituent which is
less electronegative than the 7-chloro substituent of desalkylflurazepam. Flubromazepam has a
higher pKa1 (3.25 versus 2.51) and a lower pKa2 (10.74 versus 11.64) than desalkylflurazepam.
This is the opposite effect observed for substitution by a less electronegative substituent at
the 2’ position. The possible cause of this is that when a substituent at position 7 is less
electronegative it reduces the propensity of that substituent to withdraw electrons. This means
that a greater electron density exists in a more delocalised state in the molecule. The greater
delocalisation stabilises negative charges and increases the ease by which a species can be
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deprotonated.
A wider range of benzodiazepines with substituents at the 2’ and 7 positions for 1,4-
benzodiazepines would be required in order to more fully explore the observed differences
between pKa1 and pKa2.
5.3.3 Theoretical pKa
ADMET Predictor returned predicted values with the closest agreement to experimental pKa
values, with an absolute average error of 0.4 for both the test set and the NPS set. This
was closely followed by ACD/I-Lab which returned absolute average errors of 0.5 for both
sets. MarvinSketch returned average absolute errors of 0.6 for the test set and 0.7 for the
NPS set. MarvinSketch did not predict pKa1 values for oxazepam and temazepam and instead
predicted two pKa2 values for oxazepam (only one of which exists) and one pKa2 value for
temazepam (only a pKa1 value is observed). Large errors were observed in some of the pKa
values returned by the software. For example; a pKa of 2.45 predicted by ACD/I-Lab for
deschloroetizolam versus an experimental pKa of 4.19, a pKa of 1.33 predicted by MarvinSketch
for etizolam versus an experimental pKa of 2.80 and a pKa of 2.98 predicted for flubromazolam
by ADMET Predictor versus an experimental pKa of 2.07. Additionally, all three software
packages predicted multiple other deprotonation sites for some of the benzodiazepines which
are not experimentally observed. The importance of obtaining accurate experimental pKa
values is therefore clear especially if these predictive models are to be improved upon.
Multiple versions of MarvinSketch exist and the accuracy of the pKa predictive software has
been well-reviewed and compared to other programs for several of these versions. One study
that looked at 261 protonation sites found that MarvinSketch 5.1.4. predicted 49.81 % of pKa
values to within ± 0.5 log units and 14.94 % of pKa values to within ± 0.1 log units [162].
However the r2 value was 0.763 which ranked MarvinSketch seventh out of nine programs.
In previous work no statistically-significant difference between the large errors given in pKa
predictions by MarvinSketch 5.2. and pKa predictions given by ACD/I-Lab [391]. However
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other research suggests that ACD/I-Lab is more accurate than MarvinSketch for predicting pKa
values [392]. In this work ACD/I-Lab was more accurate than MarvinSketch for predicting pKa
values. However, at present, none of the software packages were able to generate pKa values
that are as reliable as experimental pKa values.
Chapter 6
The Plasma Protein Binding of
NPS-benzodiazepines
6.1 Introduction
As discussed in Section 1.8.1, the fraction of a compound not bound to plasma proteins
is responsible for the pharmacological effect and it is the unbound fraction that undergoes
metabolism and elimination [166]. Plasma protein binding is therefore an important determi-
nant of pharmacokinetic parameters such as the volume of distribution as steady state [166,177].
Plasma protein binding can be easily determined in vitro, requiring only equilibrium dialysis
equipment and an analytical method capable of quantifying compound concentrations such as
HPLC-DAD or LC-MS [176].
The work described in this Section to determine the plasma protein binding values of NPS-
benzodiazepines, compare them to theoretical predictions from software packages and subse-
quent analysis of the values has previously been published in a peer-reviewed publication [353].
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6.2 Results
6.2.1 Method Development
The eight benzodiazepines chosen for the method development (alprazolam, clonazepam, di-
azepam, flunitrazepam, oxazepam, nitrazepam, prazepam and temazepam) were chosen as they
represent a range of benzodiazepine structures (diazepam is a 1,4-benzodiazepine, alprazolam is
a triazolobenzodiazepine) and have a range of substitutions (prazepam has a bulky substituent
on position 1, flunitrazepam has an NO2 substitution, temazepam has a 3-hydroxy substituent).
The extraction efficiency of the eight benzodiazepines chosen to test the method is shown in
Table 6.1. The average extraction efficiency was 94.9 ± 1.6 % (standard deviation).
The experimental plasma protein binding values after 6 hours and 24 hours, with standard
deviations, are shown in Table 6.2, as are the p values.
Table 6.1: Extraction efficiencies for eight benzodiazepines.
Benzodiazepine Extraction Efficiency ( %) (n=3)
Alprazolam 94.2 ±0.3
Clonazepam 94.9 ±0.8
Diazepam 96.1 ±0.7
Flunitrazepam 96.9 ±1.1
Oxazepam 93.6 ±1.3
Nitrazepam 95.9 ±0.5
Prazepam 93.7 ±2.9
Temazepam 94.0 ±0.4
Table 6.2: Benzodiazepine, literature and experimental plasma protein binding (PPB) for 6
and 24 hours as well as standard deviations.
Compound Literature PPB
Experimental PPB (n=3)
p value (6 and 24 hours) References
6 hours 24 hours
Alprazolam 68.4 - 76.7 90.2 ±9.3 71.6 ±0.5 0.0258 [189,192]
Clonazepam 85.4 - 86.1 93.2 ±3.3 85.5 ±1.1 0.0186 [189,192]
Diazepam 98.4 - 99 98.6 ±3.9 99.0 ±0.2 0.8678 [192,342]
Flunitrazepam 77.5 - 84.5 88.4 ±4.9 78.9 ±1.2 0.0310 [189,192]
Nitrazepam 82.1 - 88.9 94.6 ±2.3 88.4 ±1.8 0.0213 [393,394]
Oxazepam 89.0 - 98.4 99.4 ±1.2 96.9 ±0.1 0.0228 [189,192]
Prazepam 97 98.8 ±1.2 97.4 ±0.5 0.1356 [395]
Temazepam 92 - 96.8 89.9 ±4.3 94.3 ±0.1 0.1511 [189,192]
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Table 6.3: A comparison of the plasma pH at 6 hours and at 24 hours (n=5).
Plasma pH at 0 hours Plasma pH at 24 hours Difference p value
7.41 ±0.03 7.48 ±0.09 +0.07 0.1376
The pH of five blank aliquots of plasma was measured prior to and after 24 hours of equilibra-
tion. The pH increased from 7.41 to 7.48 over the course of 24 hours. An unpaired t test was
performed on the two values and the p value was found to be 0.1376 (Table 6.3).
6.2.2 Experimental and Theoretical Plasma Protein Binding
The most suitable length of equilibration for the determination of plasma protein binding was
determined to be 24 hours. 24 hours was the equilibration time used to determine the plasma
protein binding of 12 NPS-benzodiazepines.
The three software packages ACD/I-Lab, ADMET Predictor and PreADMET generated the-
oretical plasma protein binding values. These values were compared by means of the absolute
error to the experimental values determined previously.
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6.3 Discussion
6.3.1 Method Development
The extraction efficiency from plasma was calculated as being 94.9 %. This was high and
had a low standard deviation of 1.6 % across the eight test benzodiazepines. The extraction
efficiency was only required for calculation of an estimated concentration in the buffer, for those
benzodiazepines that were highly-protein-bound and who had buffer concentrations below the
LOQ determined in Section 2.2.
After six hours of equilibration the plasma protein binding values of all benzodiazepines other
than temazepam were greater than their literature values. Temazepam had a plasma protein
binding value of 89.9 % versus a literature range of 92 - 96.8 % [189,192]. As the compounds
were spiked into the plasma, it is suggested that the passage of the compounds across the
cellulose membranes was extremely slow and required a longer equilibration time of 24 hours.
Although the dialysis apparatus was placed in a shaking waterbath to facilitate equilibration,
there may not have been enough mechanical motion to encourage diffusion across the cellulose
membrane. The result of this lack of equilibration time would have been a greater than ex-
pected concentration in the plasma phase and therefore overestimating plasma protein binding.
However in literature an equilibrium dialysis time of 20 hours has been reported for alprazolam,
diazepam, flunitrazepam oxazepam and temazepam [189,192]. There was no information on the
method used for the determination of the plasma protein binding for prazepam [395]. Plasma
protein binding for nitrazepam was obtained from in vivo data [393,394].
The p values for alprazolam, clonazepam, flunitrazepam, nitrazepam and oxazepam were all
statistically significant when comparing 6 hours and 24 hours of equilibration. For diazepam,
prazepam and temazepam the p values were not statistically significant. These three benzodi-
azepines are all highly-bound to plasma proteins and the potential lack of equilibration did not
have an effect. For benzodiazepines with lower plasma protein binding, 6 hours of equilibration
was in sufficient. After 24 hours of equilibration, the plasma protein binding values calculated
were closer to the values stated in the literature. 24 hours has also been used for equilibration in
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other plasma protein binding experiments, as reported for the NPS-benzodiazepine flubroma-
zolam [222]. For equilibrium dialysis experiments with semipermeable membranes such as the
cellulose membrane used in this work, equilibration times of up to 16 hours have been reported
[211].
After 24 hours, all experimental plasma protein binding values generated were within literature
ranges other than for prazepam. Only one literature value of 97 % for plasma protein binding
was found for prazepam and an experimental value of 97.4 % was determined in this work.
Age and sex of the donor have both been observed as causing differences in the plasma protein
binding of drugs which could explain the ranges observed for plasma protein binding in literature
[397,398]. The experimentally derived values for the test benzodiazepines were typically within
literature ranges with low variations.
The pH of plasma naturally increases throughout the course of equilibrium dialysis experiments
as a result of the loss of CO2 from carbonic acid which acts as a buffer within plasma [399].
The increase in pH during the course of plasma protein binding experiments has been previ-
ously reported for 96-well equilibrium dialysis microplates [399]. These 96-well microplates are
an alternative, high-throughput method of measuring plasma protein binding and consist of
two chambers separated by a membrane, similar to the Harvard Apparatus Micro-Equilibrium
Dialysers used in this work. However, they differ as they are sealed only by a thin adhesive film
over the top which is gas-permeable [400]. The change in pH was also reportedly minimised
when equilibration was conducted in an atmosphere containing 10 % CO2 [399]. It has been
reported that pH changes during equilibrium dialysis are minimised by the use of equipment
consisting of thick polytetrafluoroethylene (PTFE) chambers [399]. The Harvard Apparatus
Micro-Equilibrium Dialysers used in this work were thick (10 mm) PFTE dialysers which were
able to be completely sealed in contrast to the 96-well equilibrium dialysis microplates. In
this work the pH of five blank aliquots of plasma was measured prior to and after 24 hours of
equilibration. The pH increased from 7.41 to 7.48 (n=5) over the course of 24 hours, although
with only five samples the statistical power of this test could be improved upon . An unpaired
t test was performed on the two values and the p value was found to be 0.1376 and thus the
variance between the two values was not statistically significant. The thickness of these Micro-
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Equilibrium Dialysers coupled with their ability to be completely sealed may have reduced the
propensity of the plasma pH to change. In addition, the Micro-Equilibrium Dialysers were
submerged in water which may have further limited the ability of CO2 to diffuse out of the
apparatus.
Although pH does affect the plasma protein binding during equilibrium dialysis, the plasma
protein binding of diazepam has been observed to be very similar over the pH range from 7.2 -
7.8, decreasing by 0.25 % throughout this range and only decreasing by 0.63 % from pH 7.2 to
pH 8.5 [401]. A difference of 0.25 % would be slightly above the standard deviation measured
for diazepam (0.20 %) in this work and a difference of 0.63 % would be well within the standard
deviation measured for other benzodiazepines such as nitrazepam (1.8 %) in this work.
The low standard deviation and closeness to literature values indicates that the proposed
method of equilibrating for 24 hours was therefore found to be suitable for the determina-
tion of plasma protein binding and could be applied to find the plasma protein binding of
NPS-benzodiazepines.
6.3.2 Experimental Plasma Protein Binding
The majority of the NPS-benzodiazepine whose plasma protein binding had not been deter-
mined had a high degree of plasma protein binding (> 90 %) similar to the test benzodiazepines
(data for which can be viewed in Table 6.4). Three NPS-benzodiazepines had literature values
for plasma protein binding. The plasma protein binding values derived in this work agreed with
those found in literature; desalkylflurazepam (experimental 95.5 % versus 96.1 - 96.5 % litera-
ture), etizolam (experimental 92.8 % versus 93 % literature) and flubromazolam (experimental
89.5 % versus literature 89 %) [222,248,396,402].
Pyrazolam had an experimental plasma protein binding of 78.7 % which was far lower than the
next lowest plasma protein binding of 87.2 % for deschloroetizolam. Although low compared to
the rest of the benzodiazepines, some benzodiazepines have even lower plasma protein binding;
for example bromazepam is 60 % bound to plasma proteins [403]. Bromazepam contains a
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Figure 6.1: Molecular structures of diazepam, diclazepam and 4′-chlorodiazepam.
pyridin-2-yl ring rather than a phenyl ring at position 5. This substitution leads to a decrease
in plasma protein binding for 1,4-benzodiazepines [402]. Although pyrazolam is a triazoloben-
zodiazepine the same effect and decrease in plasma protein binding could also occur as it also
contains a pyridin-2-yl ring rather than a phenyl ring at position 5 (Figure 1.2A).
Two NPS-benzodiazepines in this work are structural isomers, 4′-chlorodiazepam and di-
clazepam. Both compounds are structurally related to a test benzodiazepine, diazepam, dif-
fering only by the substitution of a chlorine atom on the 2’ position for diclazepam and the 4’
position for 4′-chlorodiazepam.
4′-Chlorodiazepam exhibits similarly high plasma protein binding compared to diazepam; 98.2
% versus 99.0 %, however diclazepam has a reduced plasma protein binding of 93.8 %. The most
likely reason for this is that substitution of a chlorine atom at the 4′ position is not thought to
greatly affect the plasma protein binding of 1,4-benzodiazepines hence a similar plasma protein
binding is observed for diazepam and 4′-chlorodiazepam [402]. However if this substitution is
present at the 2′ position instead then a decrease in plasma protein binding is observed as a
result of the change in the rotation and orientation of the phenyl ring; such a decrease is noted
in this work for diclazepam [402].
Phenazepam also contains a chlorine atom on the 2’ position and has a plasma protein binding
of 98.3 %. Flubromazepam is structurally identical other than containing a fluorine atom on
the 2’ position instead and has a plasma protein binding of 96.4 %. This decrease in plasma
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protein binding when a 2′-chloro substituent is replaced by a 2′-fluoro substituent is consistent
with previous observations in literature [402].
Another structural feature leading to a decrease in plasma protein binding for 1,4-
benzodiazepines is the addition of a hydroxyl group at position 3 [350]. 3-Hydroxyphenazepam
has this substitution and exhibits a lower plasma protein binding of 97.7 % versus 98.3 % for
phenazepam.
Replacement of a bromine atom at position 7 on 1,4-benzodiazepines by a chlorine atom is
reported to lead to a decrease in plasma protein binding and this is confirmed here with de-
salkylflurazepam containing a 7-chloro substituent and having a plasma protein binding of 95.5
% versus flubromazepam containing a 7-bromo substituent and having a plasma protein binding
of 96.4 % [402].
Deschloroetizolam differs from etizolam by the removal of a chlorine atom on the 2’ position. It
has a lower plasma protein binding of 87.2 % versus 92.8 % whereas the opposite effect would be
expected for the removal of a 2′-chloro substituent from a 1,4-benzodiazepine [402]. Substitution
on the 2′ position may therefore be an important structural feature for thienotriazolodiazepine
plasma protein binding in contrast to 1,4-benzodiazepines.
6.3.3 Theoretical Plasma Protein Binding
Theoretical plasma protein binding values were calculated using the three software packages;
ACD/I-Lab, ADMET Predictor and PreADMET, are provided in Table 6.4. The differences
between the experimental values and the theoretical values were calculated as average absolute
errors.
Plasma protein binding was best predicted by ACD/I-Lab which returned average absolute
errors of 4.4 % for the test benzodiazepines and 3.0 % for the NPS-benzodiazepines. ADMET
Predictor followed closely behind with average absolute errors of 6.8 % for the test benzodi-
azepines and 3.4 % for the NPS-benzodiazepines. PreADMET returned average absolute errors
of 9.9 % for the test benzodiazepines and 5.0 %, compared to experimental determined data
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for the NPS-benzodiazepines. The software packages appeared to be less effective at predict-
ing plasma protein binding of the test benzodiazepines than the NPS-benzodiazepines (Table
6.4). However, an important caveat is that the average absolute error values for the test ben-
zodiazepines were influenced heavily by the small dataset and the presence of alprazolam; the
experimental plasma protein binding was determined as being 71.6 % and the predicted values
were 89.5 % (ACD/I-Lab), 91.2 % (ADMET Predictor) and 95.2 % (PreADMET). It should
be noted that all three predicted values are also outside the range found in literature which
terminates at 76.7 % [189,192]. This is surprising as alprazolam is well-characterised and is the
most widely-prescribed benzodiazepine and psychotropic drug in the United States although it
is only available under private prescription in the United Kingdom [404].
The large errors observed for predictions for benzodiazepines such as alprazolam, which is
widely-prescribed, highlights the necessity for the publication of reliable experimental data as
it improves the accuracy of pharmacokinetic modelling and, if used to build predictive models,
can improve predictive software for parameters such as plasma protein binding. At present the
performance of the three software packages is not a suitable replacement for the experimental
measurement of plasma protein binding.
Chapter 7
The Volume of Distribution at Steady
State of NPS-Benzodiazepines
7.1 Introduction
In Sections 4, 5 and 6, the log D7.4, the pKa and the plasma protein binding of NPS-
benzodiazepines were determined. As mentioned in Section 1.8.2, these three parameters are
critical in predicting the volume of distribution at steady state [107,148]. Together these three
parameters will be used to calculate the fraction of a compound unbound in the tissues of
the body. From the unbound fraction in tissues, the volume of distribution at steady state
can be calculated from the Øie-Tozer equation [208]. The volume of distribution at steady
state has reported to have been calculated for 12 benzodiazepines with a mean-fold error of
1.86 [107,148]. The mean-fold error indicates that a predicted Vdss would be within 0.86 L
kg-1 of its experimental value. The work in this Section aims to improve on the error in these
pharmacokinetic predictions.
There are currently 35 benzodiazepines under international control although this is only a small
proportion of the total benzodiazepine structures possible. Pharmacokinetic data is limited even
for these 35 benzodiazepines, thus limiting the size of the dataset that could be gathered [6].
The fraction unbound in tissues is not a routine pharmacokinetic measurement, nor is the Vdss
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as benzodiazepines are typically administered orally. For some benzodiazepines, no values for
log D7.4 or pKa could be found in literature. As a result these were predicted using ACD/I-Lab
for log D7.4 (α-hydroxymidazolam, adinazolam and brotizolam) and ADMET Predictor for pKa
(adinazolam) as they were found to be the most reliable in previous research (Sections 4.3.3
and 5.3.3). In total seventeen benzodiazepines were included in the training dataset for the
theoretical model. The training dataset was known experimental data from which theoretical
relationships could be derived through nonlinear regression.
The training benzodiazepines and the values found in the literature or calculated theoretically
are shown in Table 7.1.
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7.2 Results
7.2.1 Method Development
The multiple linear regression in the R language programming environment varied the numerical
values in equation 7.1 to give the highest correlation between the known fraction unbound in
tissues log(fut) obtained from experimental data and the fraction unbound in tissues log(fut)
theoretically calculated using the log D7.4, the fraction unbound in plasma, log(fu), and the
fraction ionised at pH 7.4, fi7.4.
The following relationship was obtained (Equation 7.1).
log(fut) = (−0.33478× log(D7.4) + (0.70562× log(fu)) + (0.55955× f i7.4) (7.1)
Equation 7.1 Relationship between log(fut), log(D7.4), log(fu) and f i7.4
The log(fut) was calculated for the seventeen benzodiazepines using Equation 7.1 from their
log(D7.4), log(fu) and f i7.4
and compared against their log(fut) values calculated using Equation 7.1 (i.e. from experimen-
tal Vdss data). A correlation of 0.8641 was obtained (Figure 7.1).
114 Chapter 7. The Volume of Distribution at Steady State of NPS-Benzodiazepines
F
igu
re
7.1:
A
grap
h
of
p
red
icted
log
(f
u
t )
valu
es
versu
s
calcu
lated
log
(f
u
t )
valu
es.
7.3. Discussion 115
7.2.2 Calculation of the Vdss for NPS-benzodiazepines
With knowledge of the relationship between log(fut), log(fu), fi7.4 and log D7.4, the Vdss could
be predicted for the NPS-benzodiazepines whose values for these parameters were previously
determined (Table 7.2).
7.3 Discussion
7.3.1 Method Development
The plot of the log(fut) calculated from Vdss versus the predicted log(fut) returned an R
2 of
0.8641 (Figure 7.1). In other literature an R2 of 0.8737 has been reported for this correlation
between 12 benzodiazepines [107]. The same source in literature reported a 1.86 mean-fold
error for Vdss predictions [107]. In this work an improved mean-fold error of 1.11 was returned
for the prediction of Vdss values meant that, on average, each Vdss value would be accurate to
within 0.11 L kg-1. The highest fold error was observed for brotizolam (2.21). This was the
only thienotriazolodiazepine in the dataset and additionally its log D7.4 value was predicted
using the ACD/I-lab software. The possibility of an error in this value cannot be ruled out
and experimental data would be vastly preferable. Greater knowledge of experimental Vdss
and physicochemical values of benzodiazepines would be valuable in order to provide greater
accuracy in the prediction of future Vdss values.
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7.3.2 The Vdss of NPS-benzodiazepines
Table 7.2: The log D7.4, plasma protein binding (PPB), fraction ionised at pH 7.4 (fi7.4) and
predicted steady state volume of distribution values for 11 NPS-benzodiazepines.
Compound Log D7.4 PPB ( %) fi7.4 Predicted Vdss (L kg
-1)
3-Hydroxyphenazepam 2.54 94.9 0.00000 1.21
4′-Chlorodiazepam 2.75 98.2 0.00005 0.95
Desalkylflurazepam 2.82 95.5 0.00001 1.43
Deschloroetizolam 2.60 81.1 0.00062 1.81
Diclazepam 2.73 93.8 0.00001 1.47
Etizolam 2.40 92.8 0.00003 1.21
Flubromazepam 2.87 96.2 0.00007 1.33
Flubromazolam 2.40 89.5 0.00000 1.35
Meclonazepam 2.64 88.2 0.00001 1.65
Phenazepam 3.25 97.2 0.00001 1.44
Pyrazolam 0.97 78.7 0.00008 0.60
The lowest predicted Vdss was 0.60 L kg
-1 for pyrazolam. Such a low value was not unexpected
as it had the lowest measured log D7.4 of 0.97 and the lowest plasma protein binding of 78.7
%. A Vdss of 0.60
-1 or less is considered a low volume of distribution at steady state [144].
The rest of the NPS-benzodiazepines were considered to have medium volumes of distribution
at steady state. The highest predicted Vdss was 1.81 L kg
-1 for deschloroetizolam. This is a
thienodiazepine and as discussed earlier only one thienodiazepine (brotizolam) was included
in the training set thus potentially affecting the accuracy of this prediction. The rest of the
NPS-benzodiazepines had predicted Vdss values that were broadly similar to the training-set
benzodiazepines.
The NPS-benzodiazepines with the highest Vdss values were deschloroetizolam with 1.81 L
kg-1 and meclonazepam with 1.65 L kg-1. As a result these benzodiazepines would likely have
a greater distribution within the tissues of the body and this fraction will be unavailable for
elimination from the body. They would therefore be expected to have a lower clearance from
the body.
An important exception for these predicted values should be noted for 4′-chlorodiazepam. In
contract to other benzodiazepines in this dataset, this atypical benzodiazepine does not bind
to the GABAA receptor in contrast to the other benzodiazepines in this dataset. Instead it
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binds to the translocator protein (18kDa) (TSPO) which is extensively distributed throughout
the body including in the circulatory and lymphatic systems [421]. Therefore, the fraction
unbound in tissue may not be able to be accurately predicted using this method hence affecting
the accuracy of the obtained Vdss of 0.95 L kg
-1. A future NPS-benzodiazepine to emerge
that, in a similar manner to 4′-chlorodiazepam, does not experience a great deal of binding to
the GABAA receptor may have Vdss values that cannot be predicted by the current method.
Compilation of in vivo data would be necessary in order to assess whether Vdss values can be
accurately predicted by this method.
The work presented in this Section provides proof of concept that pharmacokinetic parameters
such as the volume of distribution at steady state can be predicted with a reasonable reliabil-
ity from parameters derived in vitro, as judged by the high correlation obtained (R2=0.8641
between the log(fut) calculated from the Vdss and the predicted log(fut) predicted by use of the
log D7.4, plasma protein binding (PPB), fraction ionised at pH 7.4 (fi7.4) of the benzodiazepine.
Chapter 8
The Blood to Plasma Ratios of
NPS-Benzodiazepines
8.1 Introduction
Analytes that have a high blood to plasma concentration ratio (Kb/p) will have a greater
sensitivity to an analytical method that is purely analysing the separated plasma. Knowledge
of the Kb/p can therefore provide reliable data to determine whether a quantitative method
should analyse whole blood or plasma. Post-mortem investigations often analyse total blood
concentrations while medical laboratories often analyse plasma concentrations [212]. Knowledge
of the Kb/p of a compound can therefore aid in the interpretation of toxicological results and
allow equivalences to be drawn regarding the concentration of a compound in plasma or blood
[213]. The method used in this work and described previously in the literature requires only
analysis of the concentration of a compound in the plasma [223]. This removes the necessity
of matrix-matching samples and improves the ease and speed of determination of a particular
benzodiazepine. When partitioning into the plasma fraction of the blood is low, an analytical
method utilising the plasma may struggle to quantitate the compound.
As mentioned in Section 1.8.3, many of the benzodiazepines described in the literature have
similar blood to plasma concentration ratios of around 1.00. Therefore additional compounds
118
8.2. Results 119
were required to validate a method to calculate the Kb/p. The two compounds chosen were
chlorpromazine and quinine, as they have blood to plasma concentration ratios of 0.80 - 1.48
and 0.97 - 2.00 respectively depending on the literature source (Table 8.1).
8.2 Results
8.2.1 Method Development
The blood to plasma partition coefficients were calculated for four test compounds in this work;
chlorpromazine, diazepam, nitrazepam and quinine and are listed in Table 8.1. They were then
compared to literature values. As some literature values were reported as either blood to plasma
partition coefficients or blood to plasma concentration ratios, conversion was required with the
use of Equation 8.1. The haematocrit was not listed for any of literature values and therefore
the haematocrit value that was reported for the blood in this work (41 %) was used.
Kb/p = (Ke/p ×H) + (1−H) (8.1)
Equation 8.1 Conversion between the blood to plasma partition coefficient (Ke/p) and the blood
to plasma concentration ratio (Kb/p) with the haematocrit (H).
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8.2.2 The Blood to Plasma Partition Coefficients of NPS-
benzodiazepines
Following development of a suitable method in the Section 8.2.1, the blood to plasma concentra-
tion ratios of six benzodiazepines defined as new psychoactive substances were then calculated
from experimentally derived data (Table 8.2).
Table 8.2: Blood to plasma partition coefficient and concentration ratios of six NPS-
benzodiazepines calculated from experimental data using Equations 2.9 and 8.1
.
Compound Ke/p (n=3) Kb/p (n=3)
Deschloroetizolam 0.23 ±0.15 0.68 ±0.06
Diclazepam 0.55 ±0.12 0.82 ±0.05
Etizolam 0.27 ±0.08 0.70 ±0.03
Meclonazepam 0.57 ±0.20 0.83 ±0.08
Phenazepam -0.05 ±0.32 0.57 ±0.13
Pyrazolam 1.44 ±0.08 1.18 ±0.03
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8.3 Discussion
8.3.1 Method Development
Nitrazepam was chosen as one of the four test compounds as its Kb/p was stated to be 1.00
in humans in literature [135,221]. Using Equation 8.1, this would convert to a Ke/p of 1.00.
However, a large discrepancy was observed following experimental determination in this work
and a Ke/p of 0.09 was obtained. Upon further investigation of the source of the literature value
(of 1.00) it appeared to be based on the results of experiments using the whole blood of rabbits
[429]. Analysis of an additional literature source in humans provide a Kb/p for nitrazepam of
0.57 ±0.27 [425]. With Equation 8.1 this would provide a Ke/p of -0.05. The same source
reports a Kb/p of 0.53 ±0.12 for diazepam [94]. This is similar to the reported Kb/p of 0.58 for
diazepam from other literature sources [212,426]. Therefore, the decision was made to disregard
the literature Kb/p of 1.00 for nitrazepam and used the reported ratio of 0.57 instead [425]. This
was also similar to the Kb/p of 0.63 derived in this work.
Large variations exist in literature for blood to plasma concentration ratios and blood to plasma
partition coefficients. For example, chlorpromazine had a Ke/p range of 0.52 - 2.17 and quinine
had a Ke/p range of 0.93 - 3.44 [422-424,427,428]. Quinine is an anti-malarial drug and in
patients who have malaria the concentration of quinine in red blood cells is much greater than
normal therefore affecting blood to plasma concentration ratios [430]. This is one potential
explanation for the large ranges for blood to plasma partition coefficients observed in literature
for this drug as they may have been unknowingly measured in patients with malaria. The range
for diazepam for the Ke/p was far smaller at -0.15 - -0.02 [212,425,426].
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8.3.2 The Blood to Plasma Ratios of NPS-benzodiazepines
As a result of earlier experiments, only six NPS-benzodiazepines remained in a great enough
quantity to allow the blood to plasma concentration ratio experiments to be conducted.
The measured blood to plasma concentration ratios for the six NPS-benzodiazepines ranged
from 0.57 for phenazepam to 1.18 for pyrazolam. The value of 0.57 for phenazepam indicates
extensive partitioning into the plasma and an extremely low association with red blood cells.
This is similar to diazepam which has a blood to plasma concentration ratio of 0.58 reported
in literature and 0.59 reported in this work [426].
The value of 1.18 for pyrazolam is typical of a more even distribution between the blood cells
and plasma. A similar value for the Kb/p of 1.14 has been reported for lorazepam, however a
far lower value of 0.60 for lorazepam has also been additionally been published in literature
[431]. The large variations in blood to plasma concentration ratios and partition coefficients
was previously noted in Section 8.2.1 for chlorpromazine and quinine and the experimental
determination of more values will help to reliably identify a more accurate value.
Deschloroetizolam and etizolam had similar blood to plasma concentration ratios of 0.68 and
0.70 respectively. Meclonazepam had a blood to plasma concentration ratio of 0.83 which is
close to the value for clonazepam (0.65), a structurally-similar compound which lacks only the
3-methyl group on position 3 (Figure 1.2A) [426].
Published values of the blood to plasma concentration ratios for benzodiazepines could only be
found for 12 benzodiazepines. Those values that are available are 0.53 - 0.56 for midazolam,
0.58 for diazepam, 0.62 for triazolam, 0.70 for adinazolam, 0.75 for flunitrazepam, 0.78 - 0.81
for alprazolam, 0.90 - 1.00 for oxazepam and 1.00 for nitrazepam [210,219,221,406,432-4351].
Additional data from a dissertation (non peer-reviewed, dissertation submitted for a Bachelor of
Health Science) reports blood to plasma ratios of 0.58 for diazepam, 0.58 for desmethyldiazepam
(nordiazepam), 0.62 for temazepam, 0.64 for oxazepam, 0.65 for clonazepam and 0.74 for alpra-
zolam [426]. The limited experimental data determined for the six NPS-benzodiazepines in this
study shows that they have similar blood to plasma ratios to those published in literature for
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related benzodiazepines, however there is a large range observed even with the small number
of compounds used in this work.
As mentioned previously knowledge of the blood to plasma ratio of a compound is important
for the prediction of in vivo clearance from in vitro data from human hepatocytes or human
liver microsome studies [221]. Where blood to plasma ratios are unavailable, it is often assumed
that the blood to plasma ratio is 1.0 [221]. However, such an approach has been demonstrated
to be unreliable for NPS-benzodiazepines in this study.
Although only six NPS-benzodiazepines were studied in this work, a large range of blood to
plasma concentration ratios was observed from 0.57 for phenazepam to 1.18 for pyrazolam.
This work highlights the importance of accurate pharmacokinetic data as equivalences cannot
be drawn between different benzodiazepines.
Chapter 9
Metabolic Characterisation of the C3A
and HepaRG Cell Lines
9.1 Introduction
Since different hepatocellular carcinoma cell lines express differing levels of phase I drug metabolis-
ing enzymes, careful evaluation is required to determine the most suitable cell line for use in
drug metabolism studies [278]. This process involves incubation of the different cell lines with
substrates for the six phase I cytochrome P450 (CYP450) enzymes which are responsible for
the majority of phase I metabolism for pharmaceutical compounds [119,120,231]. The aim of
the work in this chapter intended to serve three purposes. Firstly, to characterise the C3A
cell line fully for six key drug metabolising enzymes (CYP1A2, CYP2B6, CYP2C19, CYP2C9,
CYP2D6 and CYP3A4/5) as this has not yet been reported in literature; secondly to induce
the expression of CYP450 enzymes via incubation with DMSO since this has previously been
reported to be an effective method of inducing enzyme expression [271,272] and finally to repeat
this characterisation with the HepaRG cell line and determine the most suitable cell line for
the determination of the metabolic pathways of NPS-benzodiazepines.
The protocols for the incubation of the test substrates with the cell lines and the analysis with
LC-MS are reported in Section 2.10.
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9.2 Results
9.2.1 CYP1A2
C3A Cells
Following incubation with the C3A cell line, phenacetin was detected at 29.256 minutes (m/z
180.1013 [M+H]+) with a mass difference of 2.93 ppm. The known metabolite of phenacetin,
paracetamol (acetaminophen) was observed with the same retention time of 29.256 minutes
(m/z 152.0705 [M+H]+) with a mass difference of 0.13 ppm. However, there was no chro-
matographic separation of the phenacetin and paracetamol (Figure 9.2). Phenacetin has been
observed to undergo ESI-source fragmentation which produces an ion that is structurally iden-
tical to paracetamol [436]. In-source fragmentation is often observed in mass spectrometers
and has been noted for metabolic studies on sugar-phosphates in yeast cultures [437]. It is
thought to occur in the area of the mass spectrometer between the ion source and the vacuum
chamber [437]. It is therefore more likely that no paracetamol was observed and CYP1A2 is
inactive in this particular cell culture. CYP1A2 has been reported to be expressed in the C3A
cell line [269]. However other research suggests CYP1A2 activity only occurs in the presence
of an inducer [438]. The overlaid extracted ion chromatogram (EICs) of phenazepam and the
in-source degradation product, showing the overlap in retention times are shown in Figure 9.1.
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Figure 9.1: Overlaid EICs for phenacetin and its in-source degradation product following incu-
bation with the C3A cell line.
Figure 9.2: LC-MS analysis and structure of phenacetin following incubation with the C3A cell
line.
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DMSO-treated C3A Cells
Following incubation with the DMSO-treated cell line, phenacetin was again was detected at
28.977 minutes (m/z 180.1017 [M+H]+) (Figure 9.4) with a mass difference of 1.51 ppm. The
metabolite of phenacetin, paracetamol (acetaminophen) was again also observed with the same
retention time of 28.977 minutes (m/z 152.0688 [M+H]+) and a mass difference of 0.38 ppm.
As there was also no chromatographic separation in this sample it is therefore likely that this
was an in-source fragmentation and both the metabolite and CYP1A2 were not present in the
samples (Figure 9.3).
Figure 9.3: Overlaid EICs of phenacetin and its in-source degradation product following incu-
bation with the DMSO-treated C3A cell line.
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Figure 9.4: LC-MS analysis and structure of phenacetin following incubation with the DMSO-
treated C3A cell line.
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HepaRG Cells
In the HepaRG cell line, phenacetin was detected at 28.991 minutes (m/z 180.1018 [M+H]+)
with a mass difference of 0.26 ppm (Figure 9.6). The metabolite paracetamol was detected at
6.098 minutes (m/z 152.0695 [M+H]+) with a mass difference of 7.11 ppm (Figure 9.8). Al-
though a large difference was observed in the retention times for phenacetin and its paracetamol
this is not uncommon; one study in the literature using an HPLC method reports a retention
time of 5.28 minutes for paracetamol and 19.50 minutes for phenacetin [439]. Another reports
a retention time of 3.791 minutes for paracetamol and 9.094 minutes for phenacetin [440].
Additional supporting evidence was provided by the presence of the [M+NH4]
+ adduct (m/z
169.0971) with a mass difference of 0.26 ppm, indicating the presence of paracetamol at 6.098
minutes (Figure 9.8). This data suggests that CYP1A2 was present in the HepaRG cell line.
For the phenacetin that was incubated with the C3A and DMSO-treated C3A cell lines, parac-
etamol was observed at the same retention time as phenacetin and was potentially an ESI-source
fragmentation product. No paracetamol was observed at the retention time for phenacetin in-
cubated with the HepaRG cells. A potential reason behind this could be because of the lower
fragmentor voltage used in the LC-MS method, 150 V compared to 175 V.
The total ion chromatogram (TIC) with the EIC for phenacetin is shown in Figure 9.5 and the
TIC with the EIC for paracetamol is shown in Figure 9.7. The other peaks are likely to be
contaminants from the cell culture media and extraction procedure.
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Figure 9.5: TIC and EIC of phenacetin following incubation with the HepaRG cell line.
Figure 9.6: LC-MS analysis and structure of phenacetin following incubation with the HepaRG
cell line.
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Figure 9.7: TIC and EIC of paracetamol following incubation with the HepaRG cell line.
Figure 9.8: LC-MS analysis and structure of paracetamol following incubation with the HepaRG
cell line.
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9.2.2 CYP2B6
C3A Cells
In the C3A cell line bupropion was detected at 27.263 minutes (m/z 240.1153 [M+H]+) with
a mass difference of -9.07 ppm (Figure 9.10). The expected metabolite resulting from the
metabolic activity of CYP2B6, 2-hydroxybupropion, was not observed in the mass spectra.
However two other compounds were detected at 26.880 minutes (m/z 242.1315 [M+H]+) and at
27.380 minutes (m/z 242.1295 [M+H]+) with mass differences of -3.49 and 4.79 ppm respectively
(Figure 9.11 and Figure 9.12).
The EICs of these compounds, overlaid with one another, are shown in Figure 9.9.
The likely structure of these compounds corresponds to two ketone-reduced derivatives of bupro-
pion being present existing as an isomeric pair and exhibiting some separation on the chro-
matograph. Bupropion is formulated as a racemic mixture; (R)-bupropion and (S)-bupropion.
Reduction of bupropion to an isomeric pair of metabolites, threohydrobupropion and erythrohy-
drobupropion, is known to be a metabolic pathway in the human liver [441]. Threohydrobupro-
pion is formed by the 11-hydroxysteroid dehydrogenase 1 (11β-HSD1) and erythrohydrobupro-
pion by an additional carbonyl reductase [442]. These reactions have been previously observed
to occur in human liver cytosol and microsomes and it is therefore likely that this C3A cell
line expressed 11β-HSD1 and an additional carbonyl reductases responsible for the formation
of threo- and erythro- hydrobupropion [443]. Further metabolism of this enantiomeric pair is
then conducted by CYP2C19. As this further biotransformation was not observed it is therefore
likely that there is no expression of CYP2C19 in this cell line.
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Figure 9.9: Overlaid EICs of bupropion, erythrohydrobupropion and threohydrobupropion fol-
lowing incubation with the C3A cell line.
Figure 9.10: LC-MS analysis and structure of bupropion following incubation with the C3A
cell line.
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Figure 9.11: LC-MS analysis and structure of erythro-/threo- hydrobupropion following incu-
bation with the C3A cell line.
Figure 9.12: LC-MS analysis and structure of erythro-/threo- hydrobupropion following incu-
bation with the C3A cell line.
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DMSO-treated C3A Cells
Following incubation with the DMSO-treated cell line, bupropion was detected at 27.219 min-
utes (m/z 240.1161 [M+H]+ with a mass difference of -4.72 ppm (Figure 9.13). The expected
hydroxylated metabolite was not found to be present. The ketone-reduced derivatives that
were observed in the non-treated cells were also not present. This indicates a decrease in
the metabolic activities of the 11β-HSD1/carbonyl reductase responsible for the formation of
threo-/erythro- hydrobupropion [442].
Figure 9.13: LC-MS analysis and structure of bupropion following incubation with the DMSO-
treated C3A cell line.
HepaRG Cells
Following incubation with the HepaRG cell line, bupropion was detected at 26.644 minutes
(m/z 240.1152 [M+H]+) with a mass difference of -1.04 ppm (Figure 9.15).
Two hydroxybupropion compounds were detected on the mass spectra at 21.012 minutes (m/z
256.1110 [M+H]+ with a mass difference of -4.21 ppm, Figure 9.16) and 21.178 minutes (m/z
256.1102 [M+H]+ with a mass difference of -1.37 ppm, Figure 9.17).
Another two hydroxybupropion compounds were detected at 22.023 minutes (m/z 256.1101
[M+H]+ with a mass difference of 0.90 ppm, Figure 9.18) and 22.188 minutes (m/z 256.1100
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[M+H]+ with a mass difference of -0.57 ppm, Figure 9.19).
These pairs of hydroxybupropion compounds can be tentatively detected as two enantiomeric
pairs, with one pair consisting of S,S-hydroxybupropion and R,R-hydroxybupropion. The for-
mation of S,S-hydroxybupropion and R,R-hydroxybupropion is characterised by the formation
of a morpholine ring system containing both nitrogen and oxygen atoms (Figure 9.20). There-
fore two chiral centres are present. As two chiral centres exist in S,S-hydroxybupropion and
R,R-hydroxybupropion, the possibility exists of four diastereoisomers with the addition of S,R-
and R,S- hydroxybupropion. However only the R,R- and S,S- enantiomers have been observed
to be formed metabolically from R-/S-bupropion and it is postulated that this is a result of
steric hindrance in the molecule [444]. The second pair of enantiomers is likely to correspond to
S-4’-hydroxybupropion and R-4’-hydroxybupropion (Figure 9.20). The [M+H]+ adducts with
a m/z of 238.0993 and of 238.0995 (Figures 9.18 and 9.19 respectively) are likely to correspond
to the loss of water from the molecule (Figure 9.20).
These hydroxybupropion metabolites have been previously detected and reported in human
plasma and at least some of them are thought to be formed by CYP2B6 [445-447]. Re-
search has shown that bupropion (100 µM) is metabolised to S,S-hydroxybupropion and R,R-
hydroxybupropion by CYP2C19, CYP3A4 and CYP1A2 although at levels of 2, 0.4 and 0.1
% respectively when compared to CYP2B6 [448]. Bupropion (1 µM) is metabolised to S,S-
hydroxybupropion and R,R-hydroxybupropion by CYP2C19, CYP3A4 and CYP1A2 at lev-
els of 7, 10 and 2 % respectively when compared to CYP2B6 [448]. The formation of 4′-
hydroxybupropion is thought to be mainly conducted by CYP2C19 with a very minor contri-
bution from CYP2B6 [448]. Therefore, it is likely that both CYP2B6 and CYP2C19 are present
in the HepaRG cell line.
Two ketone-reduced bupropion derivatives were detected at 26.230 minutes (m/z 242.1304
[M+H]+ with a mass difference of 2.01 ppm, Figure 9.21) and 26.777 minutes (m/z 242.1305
[M+H]+ with a mass difference of 0.38 ppm, Figure 9.22). This pair of ketone-reduced bupro-
pion derivatives are again likely to correspond to the isomeric pair of metabolites, threo- and
erythro- hydrobupropion, that were detected in the C3A cells and are thought to be formed by
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11β-HSD-1 [442,448,449].
A ketone-reduced hydroxylated bupropion derivative was detected at 29.593 minutes (m/z
258.1263 [M+H]+ with a mass difference of 0.38 ppm, Figure 9.23). This metabolic pathway
follows the formation of erythro- and threo- hydrobupropion (which was observed in these cells)
and has been previously reported [442,448,449]. However, whilst a pair of diastereoisomers is
typically detected, only one compound was observed here and it may be that chromatographic
separation of the pair of diastereoisomers did not occur in this analysis. The formation of
erythro-/threo- hydrobupropion is thought to be catalysed by CYP2C19 [448]. This provides
further evidence that CYP2C19 is present in the HepaRG cell line as well as CYP2B6.
The stacked EICs for bupropion and the metabolites observed can be viewed in Figure 9.14.
The metabolic pathways observed in this Section for bupropion can be visualised in Figure
9.24.
Figure 9.14: Stacked EICs for bupropion and its metabolites following incubation with the
HepaRG cell line.
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Figure 9.15: LC-MS analysis and structure of bupropion following incubation with the HepaRG
cell line.
Figure 9.16: LC-MS analysis of R,R-hydroxybupropion or S,S-hydroxybupropion (Figure 9.16
and Figure 9.17) or S-4’-hydroxybupropion or R-4’-hydroxybupropion (Figure 9.18 and Figure
9.19) following incubation with the HepaRG cell line.
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Figure 9.17: LC-MS analysis of R,R-hydroxybupropion or S,S-hydroxybupropion (Figure 9.16
and Figure 9.17) or S-4’-hydroxybupropion or R-4’-hydroxybupropion (Figure 9.18 and Figure
9.19) following incubation with the HepaRG cell line.
Figure 9.18: LC-MS analysis of R,R-hydroxybupropion or S,S-hydroxybupropion (Figure 9.16
and Figure 9.17) or S-4’-hydroxybupropion or R-4’-hydroxybupropion (Figure 9.18 and Figure
9.19) following incubation with the HepaRG cell line.
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Figure 9.19: LC-MS analysis of R,R-hydroxybupropion or S,S-hydroxybupropion (Figure 9.16
and Figure 9.17) or S-4’-hydroxybupropion or R-4’-hydroxybupropion (Figure 9.18 and Figure
9.19) following incubation with the HepaRG cell line.
Figure 9.20: Structures of the two pairs of diastereoisomers observed in the LC-MS analysis in
Figures 9.16, 9.17, 9.18 and 9.19 following incubation with the HepaRG cell line.
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Figure 9.21: LC-MS analysis of S,S-threohydrobupropion or R,S-erythrohydrobupropion or S,R-
erythrohydrobupropion or R,R-threohydrobupropion following incubation with the HepaRG cell
line.
Figure 9.22: LC-MS analysis of S,S-threohydrobupropion or R,S-erythrohydrobupropion or S,R-
erythrohydrobupropion or R,R-threohydrobupropion following incubation with the HepaRG cell
line.
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Figure 9.23: LC-MS analysis and structure of erythro- or threo- 4’-OH-hydrobupropion follow-
ing incubation with the HepaRG cell line.
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Figure 9.24: Metabolic pathways and structures of bupropion and its metabolites as observed
in this work.
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9.2.3 CYP2C19
C3A Cells
Following incubation with the C3A cell line, omeprazole was detected at 23.884 minutes (m/z
346.1224 [M+H]+ with a mass difference of -3.40 ppm, Figure 9.26). An adduct with a m/z of
368.1048 and a mass difference of 2.22 ppm was also observed, corresponding to the [M+Na]+
species.
No hydroxylated metabolite was observed. However, a deoxygenated compound was observed
at 28.462 minutes (m/z 330.1266 [M+H]+ with a mass difference of 1.17 ppm,Figure 9.27).
This was tentatively detected as omeprazole sulfide, with the loss of an oxygen atom from the
sulfoxide group.
The TIC and the extracted EICs for omeprazole and omeprazole sulfide can be viewed in Figure
9.25.
Omeprazole sulfide was an unexpected byproduct of cell culture and to identify the source of
this compound, omeprazole was incubated in cell culture media for 24 hours in the absence of
cells. Following analysis with a dual-ESI-TOF both omeprazole (m/z 346.1218 [M+H]+ with
a mass difference of 0.78 ppm) and omeprazole sulfide (m/z 330.1264 [M+Na]+ with a mass
difference of 1.82 ppm) were observed (Figure 9.28). This indicates that it is a degradation
product formed. The potentially confounding and unwanted presence of this compound, means
that omeprazole is unlikely to be a suitable probe for CYP2C19. As a result of this sample
being run on a less-sensitive mass spectrometer with no liquid-chromatography separation, the
mass spectrum had poor sensitivity. Details of the analysis of these two compounds can be
found in Section 2.10.6.
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Figure 9.25: TIC and overlaid EICs for omeprazole and omeprazole sulfide following incubation
with the C3A cell line.
Figure 9.26: LC-MS analysis and structure of omeprazole following incubation with the C3A
cell line.
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Figure 9.27: LC-MS analysis and structure of omeprazole sulfide following incubation with the
C3A cell line.
Figure 9.28: Expanded (m/z 308 - 362) MS analysis and structures of omeprazole and omepra-
zole sulfide in cell culture medium.
148 Chapter 9. Metabolic Characterisation of the C3A and HepaRG Cell Lines
DMSO-Treated C3A Cells
Following incubation with the DMSO-treated cell line omeprazole was detected at 24.768 min-
utes (m/z 346.1231 [M+H]+ with a mass difference of -2.57 ppm, Figure 9.30). An adduct
with a m/z of 368.1038 and a mass difference of -1.09 ppm corresponding to the [M+Na]+ was
also observed.
The expected metabolite of omeprazole formed by CYP2C19, 5-hydroxyomeprazole, was not
observed. Omeprazole sulfide was again detected at 28.797 minutes (m/z 330.1266 [M+H]+
with a mass difference of -0.12 ppm, Figure 9.31) and is likely to be a degradation product.
The TIC and overlaid EICs for omeprazole and omeprazole sulfide can be seen in Figure 9.29.
Figure 9.29: TIC and overlaid EICs for omeprazole and omeprazole sulfide following incubation
with the DMSO-treated C3A cell line.
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Figure 9.30: LC-MS analysis and structure of omeprazole following incubation with the DMSO-
treated C3A cell line.
Figure 9.31: LC-MS analysis and structure of omeprazole sulfide following incubation with the
DMSO-treated C3A cell line.
150 Chapter 9. Metabolic Characterisation of the C3A and HepaRG Cell Lines
HepaRG Cells
In the HepaRG cells, omeprazole was detected at 23.139 minutes (m/z 346.1231 [M+H]+ with
a mass difference of -3.50 ppm, Figure 9.33). An [M+Na]+ adduct with a m/z of 368.1048 and
a mass difference of 2.22 ppm was also observed.
Omeprazole sulfide was observed at 28.059 minutes (m/z 330.1270 [M+H]+, with a mass dif-
ference of -0.23 ppm, Figure 9.34). A peak at 29.235 minutes corresponding to an adduct
with a m/z of 362.1154 ([M+H]+) and a mass difference of 4.19 ppm was also observed (Figure
9.35). Both omeprazole sulfone and 5-hydroxyomeprazole share the same molecular mass of
361 g mol-1. Therefore both compounds would be expected to produce the same m/z of 362
([M+H]+). The formation of omeprazole sulfone is thought to be mediated by CYP3A4 and
the formation of 5-hydroxyomeprazole by CYP2C19 [450].
When omeprazole sulfone was injected as a standard onto the LC-MS instrument it eluted
at 30.250 minutes (m/z 362.1169 [M+H]+) rather than 29.235 minutes as observed in the
HepaRG sample. In addition, when pure omeprazole sulfone was run as a sample (see Section
2.10.6 it produced a peak on the m/z spectrum that had an m/z 384.0986 (Figure 9.36).
This m/z corresponds to the [M+Na]+ adduct. No such adduct was observed to form in the
HepaRG cells, making it likely that 5-hydroxyomeprazole was observed in the HepaRG cells
rather than omeprazole sulfone. The formation of 5-hydroxyomeprazole is therefore suggestive
of the presence of CYP2C19.
The TIC and overlaid EIcs for omeprazole sulfide and 5-hydroxyomeprazole can be seen in
Figure 9.32.
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Figure 9.32: TIC and overlaid EICs for omeprazole sulfide and 5-hydroxyomeprazole following
incubation with the HepaRG cell line.
Figure 9.33: LC-MS analysis and structure of omeprazole following incubation with the HepaRG
cell line.
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Figure 9.34: LC-MS analysis and structure of omeprazole sulfide following incubation with the
HepaRG cell line.
Figure 9.35: LC-MS analysis and structure of 5-hydroxyomeprazole following incubation with
the HepaRG cell line.
9.2. Results 153
Figure 9.36: LC-MS analysis and spectra of omeprazole sulfone as a standard in the absence
of cells.
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9.2.4 CYP2C9
C3A Cells
Following incubation with the C3A cell line, diclofenac was detected at 38.818 minutes (m/z
296.0243 [M+H]+ with a mass difference of -1.08 ppm, Figure 9.37). No metabolite was
observed for diclofenac. Two ions with m/z s of 250.0185 and 215.0492 (both [M+H]+) corre-
sponding to loss of the carboxylic acid group and further loss of hydrogen chloride respectively
were also observed.
Figure 9.37: LC-MS analysis and structure of diclofenac following incubation with the C3A cell
line.
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DMSO-treated C3A Cells
Following incubation with the DMSO-treated cell line diclofenac was detected at 38.601 minutes
(m/z 296.0239 [M+H]+ with a mass difference of 0.51 ppm, Figure 9.38). In similarity to the
untreated C3A cells, no metabolite was observed for diclofenac. Two ions with m/z s of 250.0183
and 215.0439 (both [M+H]+) corresponding to loss of the carboxylic acid group and further
loss of hydrogen chloride respectively were also observed.
Figure 9.38: LC-MS analysis and structure of diclofenac following incubation with the DMSO-
treated C3A cell line.
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HepaRG Cells
In the HepaRG cells diclofenac was detected at 38.425 minutes (m/z 296.0240 [M+H]+) with
no metabolite present (Figure 9.39). CYP2C9 has previously been reported to be expressed
in the HepaRG cell line using diclofenac as a substrate with a concentration of 20 µM [277].
The use of diclofenac as a CYP2C9 probe at a concentration of 90 µM in primary human
hepatocytes and 1 µM in human liver microsomes has also been reported [451,452]. In this
work a concentration of 5 µM was used as this is both common and close to determined
Km values for diclofenac [453]. Concentrations of 5 and 10 µM are the most commonly used
concentrations according to a review of cytochrome P450 substrates [454]. Nonetheless the
substrate concentration used in this work may simply have been too low to allow sufficient
quantity of the hydroxylated metabolite to be produced. Two ions with m/z s of 250.0170 and
215.0501 (both [M+H]+) corresponding to loss of the carboxylic acid group and further loss of
hydrogen chloride respectively were also observed.
Figure 9.39: LC-MS analysis and structure of diclofenac in HepaRG C3A cells.
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9.2.5 CYP2D6
C3A Cells
Following incubation with the C3A cell line, dextromethorphan was detected at 29.997 minutes
(m/z 272.1997 [M+H]+ with a mass difference of 2.72 ppm, Figure 9.41). Its O-demethylated
metabolite, dextrorphan, was detected at 29.464 minutes (m/z 258.1844 [M+H]+ with a mass
difference of 4.06 ppm, Figure 9.42). The dextromethorphan to dextrorphan ratio was 3:1
indicating the presence of CYP2D6. The overlaid EICs for dextromethorphan and dextorphan
can be seen in Figure 9.40.
Figure 9.40: Overlaid EICs of dextromethorphan and dextrorphan following incubation with
the C3A cell line.
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Figure 9.41: LC-MS analysis and structure of dextromethorphan following incubation with the
C3A cell line.
Figure 9.42: LC-MS analysis and structure of dextrorphan following incubation with the C3A
cell line.
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DMSO-treated C3A Cells
Following incubation with the DMSO-treated C3A cell line, dextromethorphan was detected
at 29.997 minutes (m/z 272.2013 [M+H]+ with a mass difference of -0.99 ppm, Figure 9.44).
Dextorphan was detected at 29.431 minutes (m/z 258.1853 [M+H]+ with a mass difference of
1.31 ppm, Figure 9.45). The area ratio was approximately 255:1 in favour of the dextromethor-
phan. This in contrast to the 3:1 ratio detected in the untreated set. The indication of this is
a reduction in the metabolic activity observed for the DMSO-treated C3A cells. A potentially
similar reduction in metabolic activity was also observed for the metabolism of bupropion to
threo-/erythro- hydrobupropion. The overlaid EICs for dextromethorphan and dextorphan can
be seen in Figure 9.43.
Figure 9.43: Overlaid EICs of dextromethorphan and dextrorphan following incubation with
the DMSO-treated C3A cell line.
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Figure 9.44: LC-MS analysis and structure of dextromethorphan following incubation with the
DMSO-treated C3A cell line.
Figure 9.45: LC-MS analysis and structure of dextrorphan following incubation with the
DMSO-treated C3A cell line.
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HepaRG Cells
In the HepaRG cells, dextromethorphan was detected at 29.682 minutes (m/z 272.2012 [M+H]+)
and its metabolite dextrorphan was detected at 29.119 minutes (m/z 258.1853 [M+H]+) (Fig-
ures 9.48 and 9.48 respectively). The ratio of dextromethorphan to dextorphan was approx-
imately 5:1. The HepaRG cell line is derived from an individual who reportedly had a low
expression of CYP2D6 resulting in a relatively low proportion of this enzyme compared to the
other CYP enzymes it expresses [274,277]. Nonetheless it was found to be expressed in this
work. The overlaid EICs for dextromethorphan and dextorphan can be seen in Figure 9.46.
Figure 9.46: Overlaid EICs of dextromethorphan and dextrorphan following incubation with
the HepaRG cell line.
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Figure 9.47: LC-MS analysis and structure of dextromethorphan following incubation with the
HepaRG cell line.
Figure 9.48: LC-MS analysis and structure of dextrorphan following incubation with the Hep-
aRG cell line.
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9.2.6 CYP3A4/5
C3A Cells
Following incubation with the C3A cell line, testosterone was detected at 36.787 minutes (m/z
289.2155 [M+H]+ with a mass difference of 1.8 ppm, Figure 9.49). No metabolite was observed
for testosterone. Other published work has reported the presence of CYP3A4 in the C3A cell
line [269]. However following incubation with testosterone, the metabolites produced were 16
β -hydroxytesterone and androstenedione rather than the expected CYP3A4 metabolite, 6β-
hydroxytestosterone [269]. CYP3A4 activity in C3A cells has also been reported to be minimal
and below the detection limit when measured with the P450-Glo assay (Promega). This utilises
a luminescent method to detect CYP3A4 activity [455].
Figure 9.49: LC-MS analysis and structure of testosterone following incubation with the C3A
cell line.
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DMSO-treated C3A Cells
Following incubation with the DMSO-treated C3A cell line, testosterone was detected at 36.787
minutes (m/z 289.2161 [M+H]+ with a mass difference of 0.34 ppm, Figure 9.50). There was
no observation of the hydroxylated metabolite.
Figure 9.50: LC-MS analysis and structure of testosterone following incubation with the DMSO-
treated C3A cell line.
HepaRG Cells
In the HepaRG cells testosterone was detected at 36.553 minutes (m/z 289.2162 [M+H]+ with
a mass difference of -0.17 ppm, Figure 9.54). A metabolite was detected at 38.129 minutes
(m/z 287.2004 [M+H]+ with a mass difference of -7.99 ppm) and was tentatively detected as
androstenedione (Figure 9.55). Androstenedione is known to be formed from testosterone
by 17-hydroxysteroid dehydrogenase (HSD) [456]. Additionally CYP2C19 and CYP2C9 are
known to catalyse the oxidation of testosterone to androstenedione [458]. Another metabolite,
detected as a hydroxylated metabolite of testosterone, was detected at 27.559 minutes (m/z
305.2108 [M+H]+ with a mass difference of 0.84 ppm, m/z 327.1933 [M+Na]+ with a mass
difference of -1.20 ppm) (Figure 9.56).
The TIC and EIC for testosterone can be seen in Figure 9.51, for andronstenedione in Figure
9.52 and for a hydroxytestosterone metabolite in Figure 9.53. Although multiple peaks were
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observed on the EIC for a m/z of 305, only the peak at 27.559 minutes had an additional
[M+Na]+ adduct with a m/z of 327.1933 to provide additional confirmation of the presence of
a hydroxylated metabolite. However it is entirely possible that other hydroxylated metabolites
were produced from testosterone by the HepaRG cell line.
The majority of testosterone metabolites (88.2 %) are thought to be produced by CYP3A4
[459]. The other contributory enzymes are thought to be CYP3A5 and CYP3A7, responsible
for 7.1 % and 2.2 % of testosterone metabolism respectively [459]. Of the metabolites produced
by CYP3A4, 6β-hydroxytestosterone is the most prominent followed by 15β-hydroxytesterone
and 2β-hydroxytesterone [459]. Without further analysis using NMR it is impossible to as-
sign an exact site of hydroxylation on testosterone in this work. However, given that 6β-
hydroxytesterone is the most prominent metabolite it can be tentatively assumed that this is
the metabolite observed in this work. As all hydroxylated metabolites are mainly formed by
CYP3A4 this indicates that CYP3A4 was present in the HepaRG cells used in this study. An-
other method of identifying the exact metabolite produced would have been to run all expected
hydroxylated metabolites as standards on the LC-MS and match the compound observed here
to a mass spectra/retention time. Unfortunately standards were not readily available when
this work was conducted and this confirmatory step was not carried out. Therefore only one
hydroxylated metabolite with both [M+H]+ and [M+Na]+ adducts was postulated as being
present in this study.
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Figure 9.51: TIC and EIC of testosterone following incubation with the HepaRG cell line.
Figure 9.52: TIC and EIC of andronstenedione following incubation with the HepaRG cell line.
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Figure 9.53: TIC and EIC of a hydroxytestosterone metabolite following incubation with the
HepaRG cell line.
Figure 9.54: LC-MS analysis and structure of testosterone following incubation with the Hep-
aRG cell line.
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Figure 9.55: LC-MS analysis and structure of andronstenedione following incubation with the
HepaRG cell line.
Figure 9.56: LC-MS analysis, structure and possible hydroxylation sites for hydroxytestosterone
following incubation with the HepaRG cell line, A (6β), B (15β) and C (2β).
9.2. Results 169
T
ab
le
9.
1:
L
C
-M
S
d
at
a
fo
r
co
m
p
ou
n
d
s
ob
se
rv
ed
fo
ll
ow
in
g
th
e
in
cu
b
at
io
n
of
te
st
su
b
st
ra
te
s
in
th
e
C
3A
,
D
M
S
O
-t
re
at
ed
an
d
H
ep
aR
G
ce
ll
li
n
es Te
st
su
b
st
ra
te
C
el
l
li
n
e
C
o
m
p
o
u
n
d
s
o
b
se
rv
ed
R
et
en
ti
o
n
ti
m
e
(m
in
)
m
/
z
M
o
st
li
k
el
y
a
d
d
u
ct
O
b
se
rv
ed
n
eu
tr
a
l
m
a
ss
T
h
eo
re
ti
ca
l
m
a
ss
M
a
ss
d
iff
er
en
ce
(p
p
m
)
P
h
en
a
ce
ti
n
C
3
A
P
h
en
a
ce
ti
n
2
9
.2
5
6
1
8
0
.1
0
1
3
[M
+
H
]+
1
7
9
.0
9
4
1
1
7
9
.0
9
4
6
2
.9
3
P
a
ra
ce
ta
m
o
l
1
5
2
.0
7
0
5
[M
+
H
]+
1
5
1
.0
6
3
3
1
5
1
.0
6
3
3
0
.1
3
D
M
S
O
-C
3
A
P
h
en
a
ce
ti
n
2
8
.9
7
7
1
8
0
.1
0
1
3
[M
+
H
]+
1
7
9
.0
9
4
4
1
7
9
.0
9
4
6
1
.5
1
P
a
ra
ce
ta
m
o
l
2
8
.9
7
7
1
5
2
.0
6
8
8
[M
+
H
]+
1
5
1
.0
6
3
3
1
5
1
.0
6
3
3
0
.3
8
H
ep
a
R
G
P
h
en
a
ce
ti
n
2
8
.9
9
1
1
8
0
.1
0
1
8
[M
+
H
]+
1
7
9
.0
9
4
6
1
7
9
.0
9
4
6
0
.2
6
P
a
ra
ce
ta
m
o
l
6
.0
9
8
1
5
2
.0
6
9
5
[M
+
H
]+
1
5
1
.0
6
2
3
1
5
1
.0
6
3
3
7
.1
1
1
6
9
.0
9
7
1
[M
+
N
H
4
]+
1
5
1
.0
6
3
3
1
5
1
.0
6
3
3
0
.2
6
B
u
p
ro
p
io
n
C
3
A
B
u
p
ro
p
io
n
2
7
.2
6
3
2
4
0
.1
1
5
3
[M
+
H
]+
2
3
9
.1
0
9
9
2
3
9
.1
0
7
7
-9
.0
7
E
ry
th
ro
/
th
re
o
b
u
p
ro
p
io
n
2
6
.8
8
0
2
4
2
.1
3
1
5
[M
+
H
]+
2
4
1
.1
2
4
2
2
4
1
.1
2
3
3
-3
.4
9
E
ry
th
ro
/
th
re
o
b
u
p
ro
p
io
n
2
7
.3
8
0
2
4
2
.1
2
9
5
[M
+
H
]+
2
4
1
.1
2
2
2
2
4
1
.1
2
3
3
4
.7
9
D
M
S
O
-C
3
A
B
u
p
ro
p
io
n
2
7
.2
1
9
2
4
0
.1
1
6
1
[M
+
H
]+
2
3
9
.1
0
8
8
2
3
9
.1
0
7
7
-4
.7
2
H
ep
a
R
G
B
u
p
ro
p
io
n
2
6
.6
4
4
1
8
4
.0
5
2
3
[M
-t
B
u
+
H
]+
1
8
3
.0
4
5
0
1
8
3
.0
4
5
1
0
.2
8
2
4
0
.1
1
5
2
[M
+
H
]+
2
3
9
.1
0
7
9
2
3
9
.1
0
7
7
-1
.0
4
H
y
d
ro
x
y
b
u
p
ro
p
io
n
2
1
.0
1
2
2
5
6
.1
1
1
0
[M
+
H
]+
2
5
5
.1
0
3
7
2
5
5
.1
0
2
6
-4
.2
1
H
y
d
ro
x
y
b
u
p
ro
p
io
n
2
1
.1
7
8
2
5
6
.1
1
0
2
[M
+
H
]+
2
5
5
.1
0
3
0
2
5
5
.1
0
2
6
-1
.3
7
H
y
d
ro
x
y
b
u
p
ro
p
io
n
2
2
.0
2
3
2
3
8
.0
9
9
3
[M
-H
2
O
+
H
]+
2
3
7
.0
9
2
1
2
3
7
.0
9
2
0
-0
.3
2
2
5
6
.1
1
0
1
[M
+
H
]+
2
5
5
.1
0
2
8
2
5
5
.1
0
2
6
-0
.9
0
H
y
d
ro
x
y
b
u
p
ro
p
io
n
2
2
.1
8
8
2
3
8
.0
9
9
5
[M
-H
2
O
+
H
]+
2
3
7
.0
9
2
2
2
3
7
.0
9
2
0
-0
.5
9
2
5
6
.1
1
0
0
[M
+
H
]+
2
5
5
.1
0
2
8
2
5
5
.1
0
2
6
-0
.5
7
K
et
o
n
e-
re
d
u
ce
d
b
u
p
ro
p
io
n
2
6
.2
3
0
2
4
2
.1
3
0
4
[M
+
H
]+
2
4
1
.1
2
2
9
2
4
1
.1
2
3
3
2
.0
1
K
et
o
n
e-
re
d
u
ce
d
b
u
p
ro
p
io
n
2
6
.2
7
7
1
6
8
.0
5
7
5
[M
-t
B
u
-H
2
O
+
H
]+
1
6
7
.0
5
0
2
1
6
7
.0
5
0
2
-0
.1
4
1
8
6
.0
6
9
6
[M
-t
B
u
+
H
]+
1
8
5
.0
6
1
8
1
8
5
.0
6
0
7
-5
.9
6
2
4
2
.1
3
0
5
[M
+
H
]+
2
4
1
.1
2
3
3
2
4
1
.1
2
3
3
0
.3
8
K
et
o
n
e-
re
d
u
ce
d
h
y
d
ro
x
y
b
u
p
ro
p
io
n
2
9
.5
9
3
2
5
8
.1
2
6
3
[M
+
H
]+
2
5
7
.1
1
9
0
2
5
7
.1
1
8
3
-3
.0
3
O
m
ep
ra
zo
le
C
3
A
O
m
ep
ra
zo
le
2
3
.8
8
4
3
4
6
.1
2
2
4
[M
+
H
]+
3
4
5
.1
1
5
1
3
4
5
.1
1
4
7
-1
.2
2
3
6
8
.1
0
4
5
[M
+
N
a
]+
3
4
5
.1
1
5
2
3
4
5
.1
1
4
7
-1
.4
3
O
m
ep
ra
zo
le
su
lfi
d
e
2
8
.4
6
2
3
3
0
.1
2
6
6
[M
+
H
]+
3
2
9
.1
1
9
4
3
2
9
.1
1
9
8
1
.1
7
D
M
S
O
-C
3
A
O
m
ep
ra
zo
le
2
4
.7
6
8
3
4
6
.1
2
3
0
[M
+
H
]+
3
4
5
.1
1
5
6
3
4
5
.1
1
4
7
-2
.5
7
3
6
8
.1
0
3
8
[M
+
N
a
]+
3
4
5
.1
1
5
1
3
4
5
.1
1
4
7
-1
.0
9
O
m
ep
ra
zo
le
su
lfi
d
e
2
8
.7
9
7
3
3
0
.1
2
6
6
[M
+
H
]+
3
2
9
.1
1
9
8
3
2
9
.1
1
9
8
-0
.1
2
H
ep
a
R
G
O
m
ep
ra
zo
le
2
3
.1
3
9
3
4
6
.1
2
3
1
[M
+
H
]+
3
4
5
.1
1
5
9
3
4
5
.1
1
4
7
-3
.5
0
3
6
8
.1
0
4
8
[M
+
N
a
]+
3
4
5
.1
1
5
5
3
4
5
.1
1
4
7
2
.2
2
H
y
d
ro
x
y
o
m
ep
ra
zo
le
2
9
.2
3
5
3
6
2
.1
1
5
4
[M
+
H
]+
3
6
1
.1
0
8
1
3
6
1
.1
0
9
6
4
.1
9
O
m
ep
ra
zo
le
su
lfi
d
e
2
8
.0
5
9
3
3
0
.1
2
7
0
[M
+
H
]+
3
2
9
.1
1
9
9
3
2
9
.1
1
9
8
-0
.2
3
D
ic
lo
fe
n
a
c
C
3
A
D
ic
lo
fe
n
a
c
3
8
.8
1
8
2
9
6
.0
2
4
3
[M
+
H
]+
2
9
5
.0
1
7
2
9
5
.0
1
6
7
-1
.0
8
D
M
S
O
-C
3
A
D
ic
lo
fe
n
a
c
3
8
.6
0
1
2
9
6
.0
2
3
9
[M
+
H
]+
2
9
5
.0
1
6
5
2
9
5
.0
1
6
7
0
.5
1
H
ep
a
R
G
D
ic
lo
fe
n
a
c
3
8
.4
2
5
2
9
6
.0
2
4
0
[M
+
H
]+
2
9
5
.0
1
6
5
2
9
5
.0
1
6
7
0
.6
7
D
ex
tr
o
m
et
h
o
rp
h
a
n
C
3
A
D
ex
tr
o
m
et
h
o
rp
h
a
n
2
9
.9
9
7
2
7
2
.1
9
9
7
[M
+
H
]+
2
7
1
.1
9
2
5
2
7
1
.1
9
3
6
4
.0
6
D
ex
tr
o
rp
h
a
n
2
9
.4
6
4
2
5
8
.1
8
4
4
[M
+
H
]+
2
5
7
.1
7
7
3
2
5
7
.1
7
8
2
.7
2
D
M
S
O
-C
3
A
D
ex
tr
o
m
et
h
o
rp
h
a
n
2
9
.9
9
7
2
7
2
.2
0
1
3
[M
+
H
]+
2
7
1
.1
9
3
9
2
7
1
.1
9
3
6
-0
.9
9
D
ex
tr
o
rp
h
a
n
2
9
.4
3
1
2
5
8
.1
8
5
3
[M
+
H
]+
2
5
7
.1
7
8
3
2
5
7
.1
7
8
0
-1
.3
1
H
ep
a
R
G
D
ex
tr
o
m
et
h
o
rp
h
a
n
2
9
.6
8
2
2
7
2
.2
0
1
2
[M
+
H
]+
2
7
1
.1
9
3
9
2
7
1
.1
9
3
6
-1
.1
2
D
ex
tr
o
rp
h
a
n
2
9
.1
1
9
2
5
8
.1
8
5
3
[M
+
H
]+
2
5
7
.1
7
8
0
2
5
7
.1
7
8
0
-0
.1
7
T
es
to
st
er
o
n
e
C
3
A
T
es
to
st
er
o
n
e
3
6
.7
8
7
2
8
9
.2
1
5
5
[M
+
H
]+
2
8
8
.2
0
8
4
2
8
8
.2
0
8
9
1
.8
D
M
S
O
-C
3
A
T
es
to
st
er
o
n
e
3
6
.7
8
7
2
8
9
.2
1
6
1
[M
+
H
]+
2
8
8
.2
0
8
8
2
8
8
.2
0
8
9
0
.3
4
H
ep
a
R
G
T
es
to
st
er
o
n
e
3
6
.5
5
3
2
8
9
.2
1
6
2
[M
+
H
]+
2
8
8
.2
0
9
0
2
8
8
.2
0
8
9
-0
.1
7
H
y
d
ro
x
y
te
st
o
st
er
o
n
e
2
2
.5
2
0
3
0
5
.2
1
0
8
[M
+
H
]+
3
0
4
.2
0
3
6
3
0
4
.2
0
3
8
0
.8
4
3
2
7
.1
9
3
3
[M
+
N
a
]+
3
0
4
.2
0
4
2
3
0
4
.2
0
3
8
1
.2
0
A
n
d
ro
st
en
ed
io
n
e
3
8
.1
2
9
2
8
7
.2
0
0
4
[M
+
H
]+
2
6
4
.2
1
1
0
2
6
4
.2
0
8
9
-7
.9
9
170 Chapter 9. Metabolic Characterisation of the C3A and HepaRG Cell Lines
9.3 Discussion
Following the administration of 1 % DMSO and subsequent culturing, the hepatocellular car-
cinoma cell line Huh7 has been previously observed to cease division and enter a terminally
differentiated state [460]. In this research no cessation of cellular division was observed. The
DMSO-treated C3A cell line continued to divide and required passaging, although at a lower
rate of every 4 - 5 days rather than 2 - 3 days. Both the C3A cells and DMSO-treated cells
were seeded at a density of 3.3 × 105 cells mL-1. Estimated cell counts were 6.0 × 105 cells
mL-1 for the C3A cells and 4.5 × 105 cells mL-1 for the DMSO-treated C3A cells after 48 hours
of incubation. Cells were counted using a haemocytometer as detailed in Section 2.10.3. This
indicates that despite the rate of cellular division decreasing, cell growth and viability were not
completely inhibited.
CYP1A2 was not found to be expressed in the C3A cells or the DMSO-treated C3A cells.
However its expression was evident in the HepaRG cells as a result of the biotransforma-
tion of phenacetin to paracetamol. In addition the [M+NH4]
+ adduct was also observed for
paracetamol, providing further evidence for the presence of paracetamol in the samples and
demonstrating CYP1A2 activity in the HepaRG cells.
Following culture of the C3A cells with bupropion, metabolites were observed indicating CYP2B6
metabolism. The metabolites were tentatively detected as an isomeric pair corresponding to
threo- and erythro-hydrobupropion. The formation of these metabolites in known to be fa-
cilitated by 11β-HSD1 and a carbonyl reductase [442,443]. Further metabolism was expected
by CYP2C19, however this was not observed in this work. Threo- and erythro- hydrobupro-
pion were not detected following incubation with the DMSO-treated C3A cell line, indicating
a reduction in metabolic activity. In contrast to the C3A cells, the HepaRG cell line was
metabolically-active as indicated by the presence of the seven metabolites observed. Two pairs
of products, tentatively detected as diastereoisomers, of hydroxylated bupropion metabolites
were observed. S,S-hydroxybupropion and R,R-hydroxybupropion metabolites are believed to
be produced by CYP2B6 [445-447]. CYP2C19 is thought to contribute to the majority of the
formation of 4’-hydroxybupropion [448]. This provides evidence for the presence of CYP2C19 as
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well as CYP2B6 in these HepaRG cells. Metabolites 5 and 6 were detected as ketone-reduced
bupropion derivatives corresponding to the threo- and erythro- hydrobupropion metabolites
observed in the C3A cell line and formed by 11-HSD-1 [442,448,449]. Further hydroxylation
of threo-/erythro- hydrobupropion is known to be mediated by CYP2C19 [448]. This did not
occur in the C3A cell line but in the HepaRG cell line a single erythro-/threo- hydrobupropion
metabolite was observed although chromatographic separation of an isomeric pair may not have
occurred. Therefore, based on the CYP2B6 probe, bupropion, CYP2C19 is also likely to be
present in the HepaRG cell line.
After CYP3A4, CYP2C19 is perhaps the second most important enzyme for benzodiazepine
metabolism [234-242]. Although S-mephenytoin is the recommended probe for CYP2C19, dif-
ficulties were encountered in sourcing this substrate [279]. Therefore it was substituted for
omeprazole which is a commonly-used CYP2C19 probe [461,462]. Omeprazole is known to un-
dergo a sulfoxidation pathway via CYP3A4, thereby making it a dual probe for these enzymes
[463].
The CYP2C9 probe, diclofenac, was not observed to undergo metabolism in the C3A cells, the
DMSO-treated C3A cells or the HepaRG cells. The metabolism of diclofenac has previously
been reported in HepaRG cells although with a greater substrate concentration of 20 µM
compared to the concentration of 5 µM in this work [277]. The concentration of 5 µM diclofenac
was chosen as it is close to the Km value for diclofenac and is commonly used [453,454]. The
Km value is often used as a guideline for the concentration of a substrate for metabolic studies
[453,454]. However this concentration may have been too low to generate a detectable level
of and any future studies should aim to test a higher concentration. CYP2C9 is known to be
involved in the demethylation of benzodiazepines such as flunitrazepam and diazepam although
it plays a minor role when compared to other enzymes such as CYP3A4, CYP2C19 and CYP2B6
[240,464].
CYP2D6 was found to be present in the C3A cell line and the DMSO-treated C3A cell line as a
result of the detection of the dextromethorphan metabolite, dextorphan. A potential decrease in
the metabolic activity of CYP2D6 was observed, as assessed by the ratio of dextromethorphan
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to its metabolite dextorphan which decreased following incubation with the DMSO-treated cell
line. A similar decrease was also noted following incubation with the DMSO-treated cell line for
the conversion of bupropion to erythro-/hydro-bupropion by the 11β-HSD1 and/or a carbonyl
reductase.
In previously published work, culturing the HepG2 cell line (the parent cell line of the C3A
cell line) with 1 % DMSO did not increase the levels of CYP3A4 [465]. No metabolites for the
substrate for CYP3A4, testosterone, were detected in either the C3A or the DMSO-treated C3A
cells in this study. However hydroxylation to a hydroxytestosterone metabolite was observed
in the HepaRG cell line as was the reductive metabolic formation of androstenedione was
also observed. The majority of benzodiazepine metabolism is thought to be mediated by
CYP3A4 and therefore the HepaRG cell line represents the best choice for studying the in
vitro metabolism of NPS-benzodiazepines [234-242]. The exact position of hydroxylation on
the testosterone metabolite could not be assigned, however it is likely the 6-hydroxytesterone
metabolite given that this is the most common [459]. In addition, the formation of omeprazole
sulfoxide from omeprazole (the CYP2C19 probe) provides supporting evidence for the presence
of CYP3A4 [454].
Although the HepaRG cell line did not appear to express CYP2C9, this cell line likely represents
the best choice in order to study the in vitro metabolic pathways of NPS-benzodiazepines.
Chapter 10
The in vitro Characterisation of the
Metabolism of NPS-benzodiazepines
10.1 Introduction
Prior knowledge of the metabolites formed from new psychoactive substances is valuable as
it can aid in the detection of these compounds and interpretation of toxicological results in
biological samples submitted for testing [255]. Although parallels between metabolic pathways
of structurally similar benzodiazepines can be drawn in order to predict metabolites of NPS- in
silico, unexpected metabolites can still be observed. One such example is the debromination of
the NPS-benzodiazepine flubromazepam as reported in the literature [251]. Characterisation of
metabolites formed in vitro is often conducted with human liver microsomes and cryopreserved
human hepatocytes. NPS-benzodiazepines have been routinely assessed using cryopreserved hu-
man hepatocytes, human liver microsomes and self-ingestion experiments [247,257,315]. How-
ever the evaluation of NPS-benzodiazepine metabolism in human hepatocellular carcinoma cell
lines has not yet been reported. The work presented in this Section represents the first at-
tempt at characterising the metabolism of NPS-benzodiazepines with a human hepatocellular
carcinoma cell line. The HepaRG cell line was found to be extremely metabolically active in
the work in Section 9 and therefore the investigation NPS-benzodiazepine metabolism was con-
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ducted using this cell line. Differences between the metabolites produced by the HepaRG cell
line and those produced in studies using other methods will be valuable in order to judge which,
if any, of the in vitro methods is the most suitable for assessing the formation of metabolites
from NPS-benzodiazepines.
The NPS-benzodiazepines chosen for the metabolic study are listed below. These NPS-benzodiazepines
were chosen as they represent a range of generic benzodiazepine structures including thieno-
triazolodiazepines (deschloroetizolam and etizolam) and triazolobenzodiazepines (flubromazo-
lam, nitrazolam and pyrazolam), with the rest being 1,4-benzodiazepines. Additionally they
exhibit a wide range of different structural features such as hydroxylation at position 3 (3-
hydroxyphenazepam), methylation at position 3 (meclonazepam), a pyridine ring rather than a
phenyl ring (pyrazolam), nitro substitutions (nitrazolam and meclonazepam) and a substitution
at position 4’ on the phenyl ring (4’-chlorodiazepam).
1. 3-Hydroxyphenazepam
2. 4’-Chlorodiazepam
3. Desalkylflurazepam
4. Deschloroetizolam
5. Diclazepam
6. Etizolam
7. Flubromazepam
8. Flubromazolam
9. Meclonazepam
10. Nitrazolam
11. Phenazepam
12. Pyrazolam
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10.2 Results
10.2.1 3-Hydroxyphenazepam
3-Hydroxyphenazepam is an active metabolite of the NPS-benzodiazepine phenazepam, con-
tributing to its pharmacological effect in humans, however it is also an NPS-benzodiazepine
itself. 3-Hydroxyphenazepam was detected at 33.594 minutes (m/z 364.9684 [M+H]+ with a
mass difference of 0.82 ppm, Figure 10.1). An adduct with a m/z of 386.9499 and a mass dif-
ference of 1.27 ppm, corresponding to the [M+Na]+ adduct was also detected. No metabolites
were observed in this work. In the literature an in vitro study using human liver microsomes
have also reported the absence of phase I metabolites of 3-hydroxyphenazepam [81]. Other
3-hydroxylated benzodiazepines such as oxazepam, lorazepam and temazepam are metabolised
via phase II metabolic pathways such as glucuronidation [81,363].
Figure 10.1: LC-MS analysis and structure of 3-hydroxyphenazepam following incubation with
the HepaRG cell line.
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10.2.2 4′-Chlorodiazepam
4’-Chlorodiazepam was detected at 40.884 minutes (m/z 319.0402 [M+H]+ with a mass differ-
ence of -1.24 ppm, Figure 10.4). A demethylated metabolite was detected at 38.168 minutes
(m/z 305.0241 [M+H]+ with a mass difference of 0.10 ppm) and a hydroxylated metabolite was
detected at 38.135 minutes (m/z 335.0362 [M+H]+ with a mass difference of -4.03 ppm) (Fig-
ures 10.5 and 10.6 respectively). Demethylation of 4’-chlorodiazepam is likely to occur on the
N1 nitrogen atom and hydroxylation on the C3 carbon atom in a similar manner to diazepam
[466]. 4’-Chlorodiazepam is structurally similar to diazepam, differing only by the addition of
a chlorine atom on the 4’ position. Diazepam produces three metabolites, a 3-hydroxylated
metabolite, a 1-demethylated metabolite and a metabolite that is both 3-hydroxylated and
1-demethylated, oxazepam [466]. However a metabolite that was both 3-hydroxylated and
1-demethylated was not observed in this work for 4’-chlorodiazepam.
The EICs for 4’-chlorodiazepam and its metabolites can be seen in Figure 10.2 with an enlarged
version in Figure 10.3 to view the separation of the demethylated and hydroxylated metabolites.
Figure 10.2: Overlaid EICs of 4′-chlorodiazepam and its demethylated and hydroxylated
metabolites following incubation with the HepaRG cell line.
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Figure 10.3: Enlarged, overlaid EICs of 4′-chlorodiazepam and its demethylated and hydroxy-
lated metabolites following incubation with the HepaRG cell line.
Figure 10.4: LC-MS analysis and structure of 4′-chlorodiazepam following incubation with the
HepaRG cell line.
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Figure 10.5: LC-MS analysis and structure of an N-demethylated metabolite of 4′-
chlorodiazepam following incubation with the HepaRG cell line.
Figure 10.6: LC-MS analysis and structure of a hydroxylated metabolite of 4’-chlorodiazepam
following incubation with the HepaRG cell line.
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10.2.3 Desalkylflurazepam
Desalkylflurazepam was detected at 34.433 minutes (m/z 289.0538 [M+H]+ with a mass dif-
ference of 0.02 ppm, Figure 10.7). No further metabolites were detected. Desalkylflurazepam
is itself a pharmacologically active metabolite of several benzodiazepines including flurazepam
and flutoprazepam [467,468]. A hydroxylated (position 3) metabolite of desalkylflurazepam has
been reported to occur in trace amounts following ingestion of flurazepam or flutoprazepam
[467,468]. This hydroxylated metabolite was not observed although the possibility of occur-
rence cannot be ruled out as it is the likely step prior to glucuronide conjugation via phase II
metabolism [467,468]. This may be a limitation of the use of the hepatocellular carcinoma cell
line used in this work and in similarity to the work presented in Section 9, the concentration
used (10 µM) may have been too low to produce a significant concentration of a potential
metabolite.
Figure 10.7: LC-MS analysis and structure of desalkylflurazepam following incubation with the
HepaRG cell line.
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10.2.4 Deschloroetizolam
Deschloroetizolam eluted at 34.269 minutes (m/z 309.1176 [M+H]+ with a mass difference of
-2.48 ppm, Figure 10.9). An adduct with a m/z of 331.0990 and mass difference of -0.70 ppm,
corresponding to the [M+Na]+ adduct, was also detected. A hydroxylated metabolite was ob-
served at 22.276 minutes (m/z 325.1139 [M+H]+ with a mass difference of -6.51 ppm, Figure
10.10). A sodiated [M+Na]+ adduct with a ( m/z) of 347.0926 and a mass difference of -1.07
ppm was also detected. Deschloroetizolam has previously been reported as being metabolised
to three hydroxylated metabolites and one dihydroxylated metabolite [257]. Only one hydrox-
ylated metabolite was observed here with the exact position of hydroxylation unable to be
detected without NMR. It has been suggested that hydroxylation could take place on either
the 9-methyl, 2-ethyl or 6 positions [257]. The deschloroetizolam:hydroxydeschloroetizolam
ratio was 1:35 showing that metabolism was significant. Multiple hydroxylated metabolites
could have potentially been formed and produced no separation on the LC-MS. As they would
all have the same masses, being singularly hydroxylated, they would also have the same m/z
ratios.
The overlaid EIC of deschloroetizolam and its hydroxylated metabolite observed here can be
seen in Figure 10.8.
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Figure 10.8: Overlaid EICs of deschloroetizolam and its hydroxylated metabolite following
incubation with the HepaRG cell line.
Figure 10.9: LC-MS analysis and structure of deschloroetizolam following incubation with the
HepaRG cell line.
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Figure 10.10: LC-MS analysis and structure of a hydroxylated metabolite of deschloroetizolam
following incubation with the HepaRG cell line with the potential sites of hydroxylation circled.
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10.2.5 Diclazepam
Diclazepam was detected at 37.901 minutes (m/z of 319.0399 [M+H]+ with a mass difference
of -0.94 ppm, Figure 10.12). A hydroxylated metabolite was detected at 35.631 minutes (m/z
335.0349 [M+H]+ with a mass difference of -0.41 ppm, Figure 10.13). The probable site of
hydroxylation was position 3 to form the benzodiazepine lormetazepam, as reported previously
in the literature [247]. A demethylated metabolite (with demethylation occurring on position 1),
delorazepam, was also detected at 35.267 minutes (m/z 305.0243 [M+H]+ with a mass difference
of -0.41 ppm, Figure 10.14). Both of these metabolites have been previously reported in a study
involving self-ingestion [247]. Diclazepam is a structural isomer of another NPS-benzodiazepine
in this work, 4’-chlorodiazepam, differing only by the placement of the chlorine atom on the
phenyl ring. It follows a similar pattern of metabolism with one hydroxylated metabolite and
one demethylated metabolite.
The overlaid EICs of diclazepam, delorazepam and lormetazepam can be seen in Figure 10.11.
Figure 10.11: Overlaid EICs of diclazepam, delorazepam and lormetazepam following incuba-
tion with the HepaRG cell line.
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Figure 10.12: LC-MS analysis and structure of diclazepam following incubation with the Hep-
aRG cell line.
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Figure 10.13: LC-MS analysis and structure of lormetazepam following incubation with the
HepaRG cell line.
Figure 10.14: LC-MS analysis and structure of delorazepam following incubation with the
HepaRG cell line.
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10.2.6 Etizolam
Etizolam was detected at 36.649 minutes (m/z 343.0784 [M+H]+ with a mass difference of 1.20
ppm, Figure 10.15). An adduct with a m/z of 365.0592 and a mass difference of 0.49 ppm,
corresponding to the [M+Na]+ ion was also observed.
Three monohydroxylated products were also detected. The first of these was at 28.466 minutes
with adducts corresponding to the [M+H]+ (m/z 359.0730 with a mass difference of -0.48 ppm),
[M+Na]+ (m/z 381.0547 with a mass difference of 0.21 ppm) and the [M+K]+ (m/z 397.0283
with a mass difference of 0.91 ppm) species ( 10.17).
The second monohydroxylated product was observed at 32.358 minutes with adducts corre-
sponding to the [M+H]+ (m/z 359.0729 with a mass difference of 2.66 ppm) and the [M+Na]+
(m/z 381.0547 with a mass difference of 0.21 ppm) species ( 10.18).
The final monohydroxylated product was observed at 32.789 minutes with adducts correspond-
ing to the [M+H]+ (m/z 359.0725 with a mass difference of 0.80 ppm) and the [M+Na]+ (m/z
381.0577 with a mass difference of -8.37 ppm) species ( 10.19).
The overlaid EICs of the three hydroxylated metabolites of etizolam can be seen in Figure
10.16.
Etizolam has previously been reported as producing two monohydroxylated metabolites with
hydroxylation occurring on the 2-ethyl and 9-methyl groups [317]. Another potential site for
hydroxylation on etizolam exists on position 6 (Figure 1.2D) and is thought to occur for
structurally-similar thienodiazepines such as metizolam and deschloroetizolam [81,257]. Hy-
droxylation has also been suggested to occur on a triazole nitrogen atom for metizolam [469].
The aforementioned metabolites for structurally-similar thienodiazepines to etizolam suggest
that hydroxylation at position 6 is possible and that this may be a cause behind the three
monohydroxylated metabolites observed.
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Figure 10.15: LC-MS analysis and structure of etizolam following incubation with the HepaRG
cell line.
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Figure 10.16: Overlaid EICs of the three hydroxylated metabolites of etizolam following incu-
bation with the HepaRG cell line.
Figure 10.17: LC-MS analysis of a hydroxylated metabolite of etizolam following incubation
with the HepaRG cell line with the potential sites of hydroxylation circled.
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Figure 10.18: LC-MS analysis of a hydroxylated metabolite of etizolam following incubation
with the HepaRG cell line with the potential sites of hydroxylation circled.
Figure 10.19: LC-MS analysis of a hydroxylated metabolite of etizolam following incubation
with the HepaRG cell line with the potential sites of hydroxylation circled.
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10.2.7 Flubromazepam
Flubromazepam was detected with at 34.894 minutes (m/z 333.0038 [M+H]+ with a mass
difference of -1.44 ppm, 10.22).A hydroxylated metabolite was detected at 32.790 minutes
(m/z 348.9973 [M+H]+ with a mass difference of 2.59 ppm, Figure 10.23) and a potential
debrominated metabolite was detected at 34.894 minutes (m/z 255.0928 [M+H]+ with a mass
difference of 0.55 ppm, Figure 10.24). Both of these metabolites have been reported in the
literature [251]. In common with other 1,4-benzodiazepines, hydroxylation is thought to occur
at position 3 [251].
The peak areas for flubromazepam and debrominated flubromazepam can be seen in the overlaid
EICs in Figure 10.20. An enlarged EIC to show the hydroxylated metabolite is shown in Figure
10.20.
Figure 10.20: Overlaid EICs of flubromazepam and debrominated flubromazepam following
incubation with the HepaRG cell line.
10.2. Results 191
Figure 10.21: Enlarged, overlaid EICs of flubromazepam and its metabolites following incuba-
tion with the HepaRG cell line.
Figure 10.22: LC-MS analysis of flubromazepam following incubation with the HepaRG cell
line.
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Figure 10.23: LC-MS analysis of a hydroxylated metabolite of flubromazepam following incu-
bation with the HepaRG cell line.
Figure 10.24: LC-MS analysis of debrominated flubromazepam following incubation with the
HepaRG cell line.
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10.2.8 Flubromazolam
Flubromazolam eluted at 35.057 minutes (m/z 371.0306 [M+H]+ with a mass difference of
-0.86 ppm, Figure 10.25). A sodiated adduct with a m/z of 393.0120 ([M+Na]+) and a mass
difference of 0.16 ppm was also observed. No metabolites were detected following incubation
with the HepaRG cells. Minor amounts of two monohydroxylated metabolites for flubromazo-
lam have been reported following incubation with cryopreserved human hepatocytes [[315]. A
monohydroxylated and a dihydroxylated metabolite have also been reported following incuba-
tion with HLMs [257]. A single monohydroxylated metabolite has been reported following a
study involving self-ingestion [470].
Figure 10.25: LC-MS analysis of flubromazolam following incubation with the HepaRG cell
line.
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10.2.9 Meclonazepam
Following incubation with the HepaRG cell line, meclonazepam was detected at 35.631 min-
utes (m/z 330.0640 [M+H]+ with a mass difference of 0.32 ppm) with no metabolites detected
(Figure 10.26). A nitro-reduced derivative, 7-aminomeclonazepam, has been previously re-
ported [314]. A monohydroxylated metabolite, with hydroxylation thought to occur on the
3-methyl group has also been reported [257]. This monohydroxylated metabolite has only been
reported in human liver microsomes and is not thought to occur in incubations with primary
human hepatocytes [471]. In a study involving authentic human urine samples monohydroxy-
lated metabolites of meclonazepam were not reported and only the 7-aminomecloanzepam was
observed [472].
Clonazepam is a structurally-similar benzodiazepine to meclonazepam, lacking only the 3-
methyl substituent. In experiments involving human ingestion, cryopreserved human hepato-
cytes and HLMs, 7-aminomeclonazepam was most abundant in human urine followed by cryop-
reserved human hepatocytes [314]. Following incubation with HLMs only minimal amounts of
7-aminomeclonazepam were formed under standard conditions (NADPH regenerating system
in potassium phosphate buffer, 0.1 M, pH 7.4, at 37 °C). When the HLMs were incubated in an
atmosphere containing nitrogen, the amount of 7-aminomeclonazepam produced was 140 times
greater [311].
In reported incubations with HLMs, the benzodiazepine flunitrazepam, also containing a 7-
nitro substitution, failed to produce a reduced 7-amino metabolite [241,473,474]. However this
7-amino metabolite of flunitrazepam has been observed to occur in both human urine and blood
[475,476].
Following incubation with the HepaRG cell line, meclonazepam may not be metabolised to
detectable concentrations of 7-aminomeclonazepam.
Nitro-containing benzodiazepines are known to be unstable when stored in biological matrices
for long periods of time. For example, levels of meclonazepam decrease when it is stored in glass
tubes at -20 °C for three months but the same decrease is not observed when meclonazepam
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stored in polypropylene tubes at -20 °C [477]. Decreases are also observed when stored at
ambient temperatures of 20 °C for one day in both glass and polypropylene tubes [477]. The
7-amino metabolites of the benzodiazepines clonazepam, nitrazepam and flunitrazepam have
been found to be unstable in blood and water when stored at -20 °C for two months [478]. After
eight months of storage at -20 °C in a liver homogenate matrix, the levels of 7-aminoclonazepam
and 7-aminoflunitrazepam decreased by 90 % and 75 % respectively [479]. The samples in this
study were initially collected in polypropylene tubes and then transferred to glass tubes for
solvent evaporation. This extended period of time at ambient temperature, some of it in glass
tubes may have hastened the decomposition of metabolites.
The nitro-group on the structurally-related benzodiazepine clonazepam is thought to be reduced
by CYP3A4 [235]. However CYP3A4 was clearly present in the HepaRG cells as judged by the
metabolism of the testosterone control.
Figure 10.26: LC-MS analysis of meclonazepam following incubation with the HepaRG cell
line.
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10.2.10 Nitrazolam
Nitrazolam was detected at 32.804 minutes (m/z 320.1143 [M+H]+ with a mass difference of
-0.29 ppm and m/z 342.0969 [M+Na]+ with a mass difference of -2.38 ppm, Figure 10.28) and a
metabolite corresponding to the 8-nitro reduction was detected at 23.892 minutes (m/z 290.1409
[M+H]+ with a mass difference of -3.05 ppm, Figure 10.29 respectively). 8-Aminonitrazolam
has been previously reported in HLMs [81]. A monohydroxylated metabolite has also been
reported in HLMs, with hydroxylation thought to occur on the 4- or α (1-methyl) position,
however no such metabolite was observed here [81].
The overlaid EICs for nitrazolam and its 8-amino metabolite can be seen in Figure 10.27.
For a similar triazolobenzodiazepine containing a nitro group, flunitrazolam, no hydroxylated
metabolite was detected in either human urine or following incubation with HLMs and only
the 8-aminoflunitrazolam was observed in HLMs [480]. Another similar triazolobenzodiazepine,
clonazolam, produces both hydroxylated and nitro-reduced metabolites in human urine [481].
Only two benzodiazepines in this work contained a nitro group; meclonazepam and nitrazolam.
Whilst no nitro-reduced metabolite of meclonazepam was detected, the nitro-reduced (8-amino)
metabolite of nitrazolam was detected in this study. If it can be tentatively assumed that the
same enzyme is responsible for the metabolic reduction of the amino moiety, then some other
factor may have been responsible for the lack of an amino metabolite for meclonazepam. This
could possibly be related to the issue of benzodiazepine stability during storage, as discussed
previously for meclonazepam. However, the exact reason is unclear and may be related to extra
stability conferred upon the molecule by the presence of a triazole ring.
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Figure 10.27: Overlaid EICs of nitrazolam and its 8-amino metabolite following incubation
with the HepaRG cell line.
Figure 10.28: LC-MS analysis of nitrazolam following incubation with the HepaRG cell line.
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Figure 10.29: LC-MS analysis of 8-aminonitrazolam following incubation with the HepaRG cell
line.
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10.2.11 Phenazepam
Phenazepam was detected as the [M+H]+ adduct at 35.788 minutes with an m/z ratio of
348.9741 and a mass difference of -1.33 ppm (Figure 10.30). The expected phase I hydroxylated
metabolite, 3-hydroxyphenazepam, was not detected. In one study involving oral ingestion in
humans, no significant amounts of 3-hydroxyphenazepam (detection limit 3 ng mL-1) have
been reported to occur [482]. Another study suggests the presence of 3-hydroxyphenazepam
and another metabolite, 2-amino-5-bromo,chloro-aminobenzophenone, in human urine following
oral ingestion [483]. The main metabolite of phenazepam, 3-hydroxyphenazepam, is known to
be thermally unstable leading to sensitivity issues when using analytical techniques such as
GC-MS [484]. Degradation during storage may well have occurred leading to a level of 3-
hydroxyphenazepam that would be undetectable with the current analytical method.
Figure 10.30: LC-MS analysis of phenazepam following incubation with the HepaRG cell line.
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10.2.12 Pyrazolam
Pyrazolam was detected at 30.809 minutes (m/z 354.0346 [M+H]+ with a mass difference of
0.23 ppm and m/z 376.0164 [M+Na]+ with a mass difference of 0.95 ppm, Figure 10.31).
No metabolites were detected in the mass spectra. Experiments involving self-ingestion in
humans have reported no metabolites for pyrazolam and it was postulated that this because
the individual involved in the study had a low expression of CYP2D6 [485]. However other
research suggests that two metabolites are observed in human urine involving hydroxylation
on the diazepine ring at position 4 and hydroxylation on the methyl group at position 1 [258].
Neither of these metabolites were observed in this work.
Figure 10.31: LC-MS analysis of pyrazolam following incubation with the HepaRG cell line.
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10.3 Discussion
Although metabolites were observed for eight of the twelve benzodiazepines following incuba-
tion with the HepaRG cell line, the metabolites detected were different from those previously
reported. A substrate concentration of 10 µM was utilised in this work and this concentration
has been reported previously for flubromazolam and meclonazepam in cryopreserved human
hepatocytes and human liver microsomes [314,315]. A greater concentration of 20 µM for clon-
azolam, deschloroetizolam, flubromazolam and meclonazepam in human liver microsomes has
also been utilised and reported in literature [257]. For the thienodiazepine metizolam, a con-
centration of 90 µM has been reported in human liver microsomes [469]. None of the previous
studies in the literature were conducted using human hepatocellular carcinoma cell lines such as
the HepaRG cell line used in this work. A potential reason for the lack of metabolites observed
in this work may have been that the concentration of 10 µM produced metabolite concentra-
tions that were below the limits of detection. Unfortunately the limits of detection were not
calculated in this study and determining these would be valuable in any future work. The
stability of some of the benzodiazepines, especially those containing a nitro group, may have
affected the observed results as decomposition may have occurred prior to analysis, reducing
the analytes to an undetectable concentration with the current method. Although the samples
were stored at -20 °C prior to analysis, a lower storage temperature may have reduced any de-
composition that occurred. Alternatively, a shorter time between extraction and analysis may
have reduced the likelihood of decomposition, however this was an external factor not subject
to control in this study.
Unfortunately, as HepaRG is a single-use cell line, the metabolic characterisation experiments
were unable to be repeated. This is a potential limitation behind their use in vitro to determine
the metabolic pathways of new psychoactive substances. A hepatocellular carcinoma cell line
such as the C3A cell line would be more suitable as they can undergo regular cellular division
and passaging. However in this study (Section 9) the C3A cell line did not produce suitable
levels of CYP450 enzymes for use in a phase I metabolic study.
Only two of the 12 NPS-benzodiazepines in this work, diclazepam and flubromazepam, followed
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the exact metabolic patterns that have been observed previously [247,251].
Three of the NPS-benzodiazepines in this work produced no metabolites in contrast to reports
in the literature of them producing in vitro metabolites (flubromazolam, meclonazepam and
pyrazolam) [257,258,314,315,471]. Both of these benzodiazepines had only been characterised
in human urine and human liver microsomes and the use of hepatocytes in this work may have
affected the metabolites produced.
Two of the NPS-benzodiazepines produced a lower number of metabolites than have been pre-
viously reported (deschloroetizolam and nitrazolam) [81,257]. Deschloroetizolam produced one
hydroxylated metabolite compared to the four metabolites reported in literature [257]. Nitra-
zolam only produced one nitro-reduced metabolite in contrast to the additional hydroxylated
metabolite reported in literature [81]. However meclonazepam, also containing a nitro-group,
did not produce a nitro-reduced metabolite. The observed difference could be as a result of
the differing structures, nitrazolam is a triazolobenzodiazepine while meclonazepam is a 1,4-
benzodiazepine. The enzyme(s) responsible for metabolism may have had a greater affinity for
the nitro-containing triazolobenzodiazepines.
Two of the NPS-benzodiazepines, desalkylflurazepam and phenazepam, did not produce the
expected hydroxylated metabolites (position 3). Neither of these two NPS-benzodiazepines have
undergone in vitro studies previously with both having a hydroxylated metabolite observed in
vivo [467,468,482,483].
The differences in the various techniques used (human liver microsomes, authentic in vivo
samples in human urine, cryopreserved human hepacotyes and the HepaRG cell line in this
work) may have contributed to the lack of metabolites observed for some benzodiazepines.
As mentioned earlier, cryopreserved human hepatocytes are often considered the ‘gold standard’
for in vitro metabolic studies and express a range of phase I and phase II enzymes that are
more akin to those found in the human body. The analysis of NPS-benzodiazepines and their
metabolites in human urine, following self-ingestion, is of course also likely to produce the
expected metabolites depending on the metabolic phenotype of the individual. Compared to
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these methods, human hepatocellular carcinoma cell lines be deficient in some phase I enzymes
or they may have a lower activity in cell culture.
However, the stability issues mentioned, especially for nitro-containing benzodiazepines (e.g.
meclonazepam and nitrazolam) and their metabolites could also have played a role.
Another factor mentioned previously was the substrate concentration, with 20 µM being re-
ported for NPS-benzodiazepines incubated with HLMs. Further experiments incubating the
NPS-benzodiazepines with the HepaRG cell line over a larger concentration range would be
desirable in order to confirm these results.
Chapter 11
Final Discussion and Future Work
11.1 Final Discussion
The aim of the work presented in this thesis was to investigate the physicochemical and phar-
macokinetic properties of emerging benzodiazepines that have appeared as new psychoactive
substances. The emergence and spread of these NPS-benzodiazepines has necessitated investi-
gation of their properties in order to predict their pharmacokinetics and explain their effects
through understanding their pharmacodynamics [16].
As with any compound, whether it be a pharmaceutical drug or a new psychoactive substance,
suitable analytical methods are required for their detection, identification and quantitation
[351,352]. In order for results to be reliable full validation is required. The HPLC-DAD and
GC-MS methods in Section 3 were suitably validated for the analysis of a variety of NPS-
benzodiazepines. Although these methods were only utilised as intermediate steps in order
to calculate log D7.4, plasma protein binding and the blood to plasma ratio, their versatil-
ity indicates that they could find utility in future investigations of the pharmacokinetics or
physiochemical properties of NPS-benzodiazepines, however this would be dependent upon
them achieving sufficient chromatographic separation of emerging NPS-benzodiazepines. The
HPLC-DAD method in Section 3 had limits of detection and quantitation that were similar to
those previously published in the literature for benzodiazepines such as alprazolam (LOQ 300
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ng mL-1 versus 144.6 ng mL-1 in this work) and diazepam, oxazepam and temazepam (LOD 50
ng mL-1, LOQ 100 ng mL-1) [355,356]. The methods described in the literature also used HPLC-
DAD [355,356]. In addition, the simplicity of the method was advantageous as it consisted of
an isocratic flow used and mobile phases of acetonitrile and a phosphate buffer.However the
disadvantage of these methods are that gradient elutions are often more appropriate for the
chromatographic separation of compounds.
The method presented in Section 4 for determining log D7.4 was found to be suitable upon
comparison with published values in the literature. Although not a high-throughput method,
the high accuracy (as assessed by the closeness of experimental to literature values) and pre-
cision (as assessed by the repeatability of the measurements) of the method are indicative of
its appropriateness in this case. Precision was excellent with the greatest standard deviation
for test benzodiazepines being 0.05 log units. All test benzodiazepines had similar experimen-
tal values to their literature values such as a log D7.4 of 2.81 for diazepam versus a literature
range of 2.79 - 2.99 [367-370]. Temazepam produced the greatest difference between exper-
imental and literature values with a log D7.4 of 2.32 in this work versus reported values of
1.79 - 2.19 in the literature [367,369]. As a result of the various methods employed there is
known to be a large variation in literature values and a standardised method is desirable for
comparison [372,375]. The proposed method of using a sodium phosphate buffer with a con-
centration of 0.01 M for future determinations was found to be suitable in this instance and
appears to be one of the most common methods in the literature; therefore it may be suit-
able for this method to be used more-widely in future [375,377]. The log D7.4 of a compound
affects several pharmacokinetic parameters such as its absorption and plasma protein binding
and knowledge of this parameter allows for more accurate predictions and interpretations of
pharmacokinetics [110,112,116-118,486]. A large variation in lipophilicity values was observed
for the NPS-benzodiazepines in question; pyrazolam was the least lipophilic with a log D7.4
of 0.97 and phenazepam was the most lipophilic with a log D7.4 of 3.25. The apparent low
lipophilicity for pyrazolam was postulated to be as a result of its molecular structure including
a pyridin-2-yl ring system. Incorporation of benzodiazepines with a range of structures and
log D7.4 values into future predictive software packages may prove useful in order to accurately
11.1. Final Discussion 207
predict the log D7.4 of these compounds. ACD/I-Lab returned the closest predicted values to
experimental values for log D7.4 average absolute errors 0.18 and 0.28 for the test benzodi-
azepines and NPS-benzodiazepines respectively. Errors of 0.18 and 0.28 on a logarithmic scale
are fairly large errors and to date experimental values would prove more useful than theoretical
values.
The pKa of a compound is important as it aids in the formation of a larger picture of the
pharmacokinetic properties of a compound when used with other parameters such as log D7.4
and pKa values for a set of NPS-benzodiazepines were determined in Section 5 [106,141,143].
The determination of the pKa of compounds using capillary electrophoresis is widely-used and
can be automated thus improving its efficiency [156,157]. The use of capillary electrophoresis
in pKa determinations has been well reviewed and measurements from different instruments are
directly comparable [154,155]. Furthermore, capillary electrophoresis instruments are common
in analytical laboratories rather than specific instruments that can only measure pKa. The
measured pKa values had values comparable to those in the literature with an accuracy of un-
der 0.20 units and a precision of under 0.07 units [161]. 3-Hydroxyphenazepam had the lowest
pKa1 value of 1.25 while deschloroetizolam had the highest pKa1 value of 4.19. Phenazepam
had the lowest pKa2 value of 11.24 and 3-hydroxyphenazepam had the highest of 11.96. Sev-
eral relationships between pKa values and atomic substitutions were postulated, such as the
addition of a chlorine substituent on the 4 position of a 1,4-benzodiazepine does not greatly
affect its pKa. These relationships may prove useful in any future model capable of accurately
predicting the pKa of NPS-benzodiazepines. ADMET Predictor returned the closest predicted
values to experimental values for pKa with an absolute average error of 0.4 for both the test
benzodiazepines and the NPS-benzodiazepines set. However several errors were too large for
the theoretical values to be of any use; for example a pKa of 2.98 predicted for flubromazolam
by ADMET Predictor versus an experimental pKa of 2.07. In addition, multiple erroneous sites
of protonation were theorised by all three software packages. The derivation of relationships
between molecular substitutions and pKa is therefore important if future predictive models are
to be improved.
Section 6 of this work dealt with the experimental determination of the plasma protein binding.
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The plasma protein binding of a compound is one of the most important pharmacokinetic
parameters that can be determined in vitro and equilibrium dialysis is often considered the
gold-standard for this measurement [176]. Plasma protein binding is important both from a
standalone point of view but also to aid in the prediction of pharmacokinetic properties such
as the volume of distribution [168]. As a result of the concentration-independence of plasma
protein binding for benzodiazepines, greater concentrations of 20 µM were used as these were
detectable by the previously-discussed and validated HPLC-DAD method in Section 3. The low
standard deviation and high-precision for the experimental plasma protein binding values when
compared to the literature values indicates that the proposed method with a concentration of
20 µM and an equilibration time of 24 hours was suitable. All plasma protein binding values
for the test benzodiazepines were within their literature ranges, other than for prazepam where
an experimental value of 97.4 % was determined versus a single literature value of 97 % [395].
The maximum standard deviation for the test benzodiazepines was 1.8 % for nitrazepam.
Pyrazolam experienced the lowest plasma protein binding of 78.7 % while phenazepam had a
plasma protein binding of 98.3 % and the majority of the plasma protein binding values were
explainable by comparison of their molecular structures and substitutions. With regards to the
predictive software, ACD/I-Lab returned the closest predicted values to experimental values for
both plasma protein binding with average absolute errors of 4.4 % for the test benzodiazepines
and 3.0 % for the NPS-benzodiazepines. Larger errors were observed, for example ACD/I-
Lab predicted a plasma protein binding of 89.5 % for alprazolam whereas its experimental
plasma protein binding was 71.6 %. The large variations in individual errors, as exemplified
by alprazolam, means that experimental data for these NPS-benzodiazepines is currently of
greater utility than that generated from predictive software.
Following on from the determination of log D7.4, pKa and plasma protein binding in Sections 4,
5 and 6 respectively, these values were used to predict the volume of distribution at steady state
in Section 7. This was performed using the Øie-Tozer equation [208]. A low mean-fold error
of 1.11 was derived in this work compared to a 1.86 mean-fold error reported elsewhere in the
literature [107]. However a much higher error was observed for the only thienotriazolodiazepine
in the dataset, brotizolam, which was 2.21. Again, as with the parameters used to predict the
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volume of distribution at steady state, inclusion of a wider dataset may improve the predictive
power of this model.
The blood to plasma ratio of six NPS-benzodiazepines was experimentally determined in Section
8. One problem encountered was that errors were observed in the literature for the stated blood
to plasma concentration ratio; for example the commonly quoted value of 1.00 for nitrazepam
appeared to be derived from experiments performed with rabbits [429]. Large variations also
existed in the literature for blood to plasma concentration ratios and blood to plasma partition
coefficients, even for the selected test compounds. For example, chlorpromazine had a Ke/p
range of 0.52 - 2.17 and quinine had a Ke/p range of 0.93 - 3.44 [422-424,427,428]. This again
highlights the difficulty of gathering accurate pharmacokinetic data. Despite this, the values
determined for NPS-benzodiazepines were similar to benzodiazepine blood to plasma concen-
tration values listed in the literature. The lowest blood to plasma concentration ratio found
was 0.57 for phenazepam which is similar to other benzodiazepines that experience a great
degree of plasma protein binding such as diazepam [426]. The highest value observed was 1.18
for pyrazolam and it was theorised that this was as a result of its low plasma protein binding.
In order to detect illicit compounds and interpret toxicological results, knowledge of the
metabolic pathways of compounds is necessary [255]. The metabolic pathways are often de-
termined in vitro using human hepatocellular carcinoma cell lines. However the metabolic
capacities of any cell line must be determined prior to their incubation with new substances
amd in Section 9 of this work, the metabolic activities of the HepaRG and C3A cell lines
were compared [278]. The C3A cell line had previously only been characterised with regards
to the CYP3A4 and CYP1A2 enzymes in the literature and characterisation with the six key
metabolic enzymes (CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6 and CYP3A4) was con-
ducted. Only the CYP2D6 enzyme was found to be expressed in the C3A cell line. Metabolic
expression of enzymes is known to be inducible by DMSO and such an attempt was made in
this work with the C3A cell line [271,272]. Unfortunately no apparent increase in metabolic
capability was observed and instead a potential decrease was observed. The HepaRG cell line
was found to be much more suitable than the C3A cell line for the study of the metabolic path-
ways of NPS-benzodiazepines as a result of its expression of the CYP1A2, CYP2D6, CYP3A4,
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CYP2C19, CYP2B6 enzymes. The CYP2C9 was not observed but a contributing factor may
have been the low concentration of the substrate, diclofenac, used in the incubation.
The metabolic pathways of a range of NPS-benzodiazepines were investigated in Section 10.
Knowledge of these metabolic pathways is important for interpretation of forensic and toxico-
logical analyses and prediction of future metabolic activity [255]. Although a number of the
NPS-benzodiazepines followed previously-observed metabolic pathways, a number of them did
not. They either failed to produce metabolites or produced previously-unobserved metabolites
(e.g. etizolam). This serves to highlight a potential limitation of only using one method of
studying the in vitro metabolism of new psychoactive substances.
11.2 Future Work
From the discussed problems with the theoretical predictions from various software packages,
experimental data for the log D7.4, pKa and plasma protein binding of NPS-benzodiazepines
is currently of greater use. Experimental values are more reliable and accurate than those
generated in a theoretical manner. The determination of log D7.4, pKa and plasma protein
binding for more NPS-benzodiazepines, for example the other 21 NPS-benzodiazepines reported
to the EMCDDA, could be evaluated in future. A suitably-large dataset could then be utilised
in order to derive a theoretical model more capable of accurately predicting these values. This
would allow for a more rapid prediction of pharmacokinetic parameters such as the volume of
distribution.
In a similar manner to the log D7.4, pKa and plasma protein binding, compilation of a larger
dataset for the volume of distribution at steady state could increase the predictive capability
of the discussed model. However this comes with limitations as experimental volume of dis-
tribution values for the benzodiazepines are lacking. The incorporation of compounds with a
similar structure into the model, which also have experimental volume of distribution values,
could be a potential solution to improving the model.
The HepaRG cell line appeared to express five of the six key CYP450 enzymes under investiga-
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tion but the CYP2C9 enzyme did not appear to be present based upon the lack of turnover of
diclofenac into its metabolite. Although unrelated to the investigation of NPS-benzodiazepines,
if the metabolic experiments in the HepaRG cell line were to be repeated with a range of differ-
ent diclofenac concentrations then an optimum concentration could be determined and it could
be seen whether this enzyme was present.
It may prove useful to repeat the HepaRG metabolic experiments in order to determine whether
they are truly suitable for investigating the metabolic pathways of NPS-benzodiazepines. Re-
peating the experiments with a range of concentrations to study whether a concentration of
10 µM either inhibited metabolism or produced too-low a concentration of metabolite to be
detected. Comparison of the metabolism of NPS-benzodiazepines in the HepaRG cell line with
their metabolism in human liver microsomes could additionally be performed.
Although the HepaRG cells are known to express phase II enzymes such as UDP-
glucuronosyltransferase, no phase II metabolites were detected in this work [487,488]. As ben-
zodiazepines are further transformed by phase II reactions such as glucuronidation and acety-
lation, knowledge of these processes for NPS-benzodiazepines is important [489,490]. Greater
incubation times at a higher substrate concentration could provide these phase II metabolic
products in vitro.
As cell culture has already been successfully utilised in this research to study the metabolic
pathways of NPS-benzodiazepines, it could also be used to assess other parameters. Once of
these parameters could be the permeability of the intestinal wall to the NPS-benzodiazepines
and study their absorption through this membrane. This can be performed in vitro using the
Caco-2 cell line [491,492]. This has been performed for other drugs of abuse such as cannabi-
noids, alkaloids from the psychoactive plant khat, 3-methylenedioxyamphetamine (MDMA) and
other amphetamine derivatives [493-496]. The apparent permeability of a compound through
the Caco-2 cell line is often considered a gold-standard for assessing compound absorption in
the body [497,498].
As discussed in Section 1.9 regarding the pharmacology of benzodiazepines, their mechanism
of action lies with their ability to bind to the GABAA receptor and modulate its response
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to the neurotransmitter GABA. As the majority of GABAA receptors lie within the brain,
benzodiazepines must firstly cross the blood-brain barrier in order to bind to these receptors.
The Madin Darby canine kidney (MDCK) cell line is commonly used to assess the propensity of
a compound to cross the blood-brain barrier because of its expression of the MDR1 gene which
encodes for the P-glycoprotein. Although only one protein is assessed, the P-glycoprotein is
one of the most important eﬄux transporters in the brain and therefore this assay allows a
good estimation of blood-brain barrier penetration [499-502].
The clearance of NPS-benzodiazepines from the human body could also be investigated with
an in vitro approach. This has been shown previously for multiple drugs where the rate of
clearance is firstly calculated for the compound in human liver microsomes or hepatocytes and
then scaled up to calculate the clearance for the human body [503].
From the previous discussion it is clear that there are still a large amount of parameters that
could be determined in vitro such as phase II metabolism, in-depth phase I metabolic com-
parison, clearance, intestinal permeability and blood-brain barrier penetration. Additionally,
increased knowledge of the log D7.4, pKa and plasma protein binding of benzodiazepines could
allow for more-detailed structure-activity relationships to be formed. If such parameters could
be accurately predicted then this would greatly reduce the time required for experimental mea-
surements and greatly increase the size of datasets available for the prediction of more complex
parameters such as the volume of distribution.
References
[1] APA. Diagnostic and Statistical Manual of Mental Disorders (4th Ed.)1994.
[2] Crocq MA. Historical and cultural aspects of mans relationship with addictive drugs.
Dialogues Clin. Neurosci. 2007; 9: 355-361.
[3] Barratt MJ, Seear K, Lancaster K. A critical examination of the definition of psychoac-
tive effect in Australian drug legislation. Int. J. Drug Policy 2017; 40: 16-25., doi:
10.1016/j.drugpo.2016.10.002.
[4] European Monitoring Centre for Drugs and Drug Addiction. New psychoactive substances
in Europe. EU early Warn. Syst. 2015; 12., doi: 10.2810/372415.
[5] Lande A. The Single Convention on Narcotic Drugs, 1961. Int. Organ. 1962; 16: 776-797.,
doi: 10.1017/S0020818300011620.
[6] UNODC. Schedules of the Convention on Psychotropic Substances of 1971, as at 25
September 2013.2013.
[7] Banning Psychoactive Substances: A Slippery Slope. EBioMedicine 2015; 2: 613-614.,
doi: 10.1016/j.ebiom.2015.07.016.
[8] Brandt SD, King LA, Evans-Brown M. The new drug phenomenon. Drug Test. Anal.
2014; 6: 587-597., doi: 10.1002/dta.1686.
[9] UNODC. The challenge of new psychoactive substances. A Report from the Global
SMART Programme March 2013. 2013;
213
214 Chapter 11. Final Discussion and Future Work
[10] Prosser JM, Nelson LS. The Toxicology of Bath Salts: A Review of Synthetic Cathinones.
J. Med. Toxicol. 2012; 8: 33-42., doi: 10.1007/s13181-011-0193-z.
[11] Dean BV, Stellpflug SJ, Burnett AM, Engebretsen KM. 2C or Not 2C: Phenethylamine
Designer Drug Review. J. Med. Toxicol. 2013; 9: 172-178., doi: 10.1007/s13181-013-
0295-x.
[12] Arbo MD, Bastos ML, Carmo HF. Piperazine compounds as drugs of abuse. Drug Alcohol
Depend. 2012; 122: 174-185., doi: 10.1016/j.drugalcdep.2011.10.007.
[13] Arajo AM, Carvalho F, Bastos M de L, Guedes de Pinho P, Carvalho M. The hallucino-
genic world of tryptamines: an updated review. Arch. Toxicol. 2015; 89: 1151-1173.,
doi: 10.1007/s00204-015-1513-x.
[14] Seely KA, Lapoint J, Moran JH, Fattore L. Spice drugs are more than harmless
herbal blends: A review of the pharmacology and toxicology of synthetic cannabi-
noids. Prog. Neuro-Psychopharmacology Biol. Psychiatry 2012; 39: 234-243., doi:
10.1016/j.pnpbp.2012.04.017.
[15] Prekupec MP, Mansky PA, Baumann MH. Misuse of Novel Synthetic Opioids. J. Addict.
Med. 2017; 11: 256-265., doi: 10.1097/ADM.0000000000000324.
[16] Manchester KR, Lomas EC, Waters L, Dempsey FC, Maskell PD. The emergence of new
psychoactive substance (NPS) benzodiazepines: A review. Drug Test. Anal. 2018; 10:
37-53., doi: 10.1002/dta.2211.
[17] El-Menyar A, Mekkodathil A, Al-Thani H, Al-Motarreb A. Khat use: History and heart
failure. Oman Med. J. 2015; 30: 77-82., doi: 10.5001/omj.2015.18.
[18] Singh D, Mu¨ller CP, Vicknasingam BK. Kratom (Mitragyna speciosa) dependence, with-
drawal symptoms and craving in regular users. Drug Alcohol Depend. 2014; 139: 132-
137., doi: 10.1016/j.drugalcdep.2014.03.017.
[19] Feng LY, Battulga A, Han E, Chung H, Li JH. New psychoactive substances of
natural origin: A brief review. J. Food Drug Anal. 2017; 25: 461-471., doi:
11.2. Future Work 215
10.1016/j.jfda.2017.04.001.
[20] EMCDDA. EMCDDA-Europol 2007 Annual Report on the Implementation of Council
Decision 2005/387/JHA2008.
[21] EMCDDA. EMCDDA-Europol 2014 Annual Report on the Implementation of Council
Decision 2005/387/JHA,2015.
[22] EMCDDA. EMCDDA-Europol 2015 Annual Report on the Implementation of Council
Decision 2005/387/JHA,2016.
[23] EMCDDA. EMCDDA-Europol 2016 Annual Report on the Implementation of Council
Decision 2005/387/JHA2017.
[24] EMCDDA-Europol. EMCDDA-Europol 2017 Annual Report on the Implementation of
Council Decision 2005/387/JHAn.d.
[25] EMCDDA. EMCDDA-Europol 2005 Annual Report on the Implementation of Council
Decision 2005/387/JHA2006.
[26] EMCDDA. EMCDDA-Europol 2008 Annual Report on the Implementation of Council
Decision 2005/387/JHA2009.
[27] EMCDDA. EMCDDA-Europol 2011 Annual Report on the Implementation of Council
Decision 2005/387/JHA2012.
[28] EMCDDA. EMCDDA-Europol 2012 Annual Report on the Implementation of Council
Decision 2005/387/JHA2013.
[29] EMCDDA. EMCDDA-Europol 2013 Annual Report on the Implementation of Council
Decision 2005/387/JHA2014.
[30] EMCDDA. EMCDDA-Europol 2009 Annual Report on the Implementation of Council
Decision 2005/387/JHA2010.
[31] EMCDDA. EMCDDA-Europol 2016 Annual Report on the Implementation of Council
Decision 2005/387/JHA2017.
216 Chapter 11. Final Discussion and Future Work
[32] Mehdi T. Benzodiazepines Revisited. Br. J. Med. Pract. 2012; 5: a501., doi:
10.1093/jat/bkt075.
[33] Lo´pez-Munoz F, a´lamo C, Garc´ıa-Garc´ıa P. The discovery of chlordiazepoxide and the
clinical introduction of benzodiazepines: Half a century of anxiolytic drugs. J. Anxiety
Disord. 2011; 25: 554-562.
[34] Riemann D, Perlis ML. The treatments of chronic insomnia: A review of benzodiazepine
receptor agonists and psychological and behavioral therapies. Sleep Med. Rev. 2009; 13:
205-214.
[35] Schaefer TJ, Hafner JW. Are Benzodiazepines Effective for Alcohol Withdrawal? Ann.
Emerg. Med. 2013; 62: 2013.
[36] Sirven JI, Waterhouse E. Management of Status Epilepticus. Am. Fam. Physician 2003;
68: 469-476.
[37] Rund DA, Ewing JD, Mitzel K, Votolato N. The use of intramuscular benzodiazepines
and antipsychotic agents in the treatment of acute agitation or violence in the emergency
department. J. Emerg. Med. 2006; 31: 317-324.
[38] Ashton H. Guidelines for the Rational Use of Benzodiazepines: When and What to Use.
Drugs 1994; 48: 25-40., doi: 10.2165/00003495-199448010-00004.
[39] Ashton H. The diagnosis and management of benzodiazepine dependence. Curr. Opin.
Psychiatry 2005; 18: 249-255.
[40] Longo LP, Johnson B. Addiction: Part I. Benzodiazepines–side effects, abuse risk and
alternatives. Am. Fam. Physician 2000; 61: 2121-2128., doi: 10.1016/j.osfp.2012.10.001.
[41] Uzun S, Kozumplik O, Jakovljevi M, Sedi B. Side effects of treatment with benzodi-
azepines inPsychiatr. Danub. 2010 pp.90-93.
[42] Ashton H. Protracted withdrawal syndromes from benzodiazepines. J. Subst. Abuse
Treat. 1991; 8: 19-28., doi: 10.1016/0740-5472(91)90023-4.
11.2. Future Work 217
[43] Busto U, Sellers EM, Naranjo CA, Cappell H, et al. Withdrawal reaction after long-
term therapeutic use of benzodiazepines. N. Engl. J. Med. 1986; 315: 854-859., doi:
10.1056/nejm198610023151403.
[44] Morgan WW. Abuse liability of barbiturates and other sedative-hypnotics. Adv. Alcohol
Subst. Abus. 1990; 9: 67-82., doi: 10.1080/J251v09n0105.
[45] Brett J, Murnion B. Management of benzodiazepine misuse and dependence. Aust. Pre-
scr. 2015; 38: 152-155., doi: 10.18773/austprescr.2015.055.
[46] Cole JO, Chiarello RJ. The benzodiazepines as drugs of abuse. J. Psychiatr. Res. 1990;
24: 135-144., doi: 10.1016/0022-3956(90)90045-R.
[47] Obrien CP. Benzodiazepine use, abuse, and dependence. J. Clin. Psychiatry
2005; 66 Suppl 2: 28-33., doi: papers3://publication/uuid/17204236-1A80-46FE-81A4-
0A5D2339D7CA.
[48] Jones JD, Mogali S, Comer SD. Polydrug abuse: A review of opioid and ben-
zodiazepine combination use. Drug Alcohol Depend. 2012; 125: 8-18., doi:
10.1016/j.drugalcdep.2012.07.004.
[49] Vogel M, Kno¨pfli B, Schmid O, Prica M, et al. Treatment or high: benzodiazepine use in
patients on injectable heroin or oral opioids. Addict. Behav. 2013; 38: 2477-2484.
[50] Navaratnam V, Foong K. Opiate dependence–the role of benzodiazepines. Curr. Med.
Res. Opin. 1990; 11: 620-630., doi: 10.1185/03007999009112688.
[51] Lintzeris N, Mitchell TB, Bond A, Nestor L, Strang J. Interactions on mixing diazepam
with methadone or buprenorphine in maintenance patients. J. Clin. Psychopharmacol.
2006; 26: 274-283., doi: 10.1097/01.jcp.0000219050.33008.61.
[52] Backmund M, Meyer K, Henkel C, Soyka M, et al. Co-consumption of benzodiazepines
in heroin users, methadone-substituted and codeine-substituted patients. J. Addict. Dis.
2005; 24: 17-29., doi: 10.1300/J069v24n0402.
218 Chapter 11. Final Discussion and Future Work
[53] Pick CG. Antinociceptive interaction between alprazolam and opioids. Brain Res. Bull.
1997; 42: 239-243., doi: 10.1016/S0361-9230(96)00265-1.
[54] Primeaux SD, Wilson SP, McDonald AJ, Mascagni F, Wilson MA. The role of delta opioid
receptors in the anxiolytic actions of benzodiazepines. Pharmacol. Biochem. Behav.
2006; 85: 545-554., doi: 10.1016/j.pbb.2006.09.025.
[55] Cox RF, Collins MA. The effects of benzodiazepines on human opioid receptor binding
and function. Anesth. Analg. 2001; 93: 354-358., doi: 10.1213/00000539-200108000-
00024.
[56] Poisnel G, Dhilly M, Le Boisselier R, Barre L, Debruyne D. Comparison of five
benzodiazepine-receptor agonists on buprenorphine-induced mu-opioid receptor regula-
tion. J. Pharmacol. Sci. 2009; 110: 36-46., doi: 10.1254/jphs.08249FP.
[57] Walker BM, Ettenberg A. Benzodiazepine modulation of opiate reward. Exp. Clin.
Psychopharmacol. 2001; 9: 191-197., doi: 10.1037/1064-1297.9.2.191.
[58] Chen KW, Berger CC, Forde DP, DAdamo C, et al. Benzodiazepine use and misuse
among patients in a methadone program. BMC Psychiatry 2011; 11:, doi: 10.1186/1471-
244X-11-90.
[59] White JM, Irvine RJ. Mechanisms of fatal opioid overdose. Addiction 1999; 94: 961-972.,
doi: 10.1046/j.1360-0443.1999.9479612.x.
[60] Me´garbane B, Hreiche R, Pirnay S, Marie N, Baud FJ. Does high-dose buprenorphine
cause respiratory depression? Possible mechanisms and therapeutic consequences. Toxi-
col. Rev. 2006; 25: 79-85., doi: 10.2165/00139709-200625020-00002.
[61] Webster LR. Considering the Risks of Benzodiazepines and Opioids Together. Pain Med.
2010; 11: 801-802., doi: 10.1111/j.1526-4637.2010.00873.x.
[62] Kalyuzhny AE, Dooyema J, Wessendorf MW. Opioid- and GABA(A)-receptors are
co-expressed by neurons in rat brain. Neuroreport 2000; 11: 2625-2628., doi:
10.1097/00001756-200008210-00004.
11.2. Future Work 219
[63] Hollister LE. Interactions between alcohol and benzodiazepines. Recent Dev. Alcohol.
1990; 8: 233-9.
[64] Jedeikin R, Bruderman I, Menutti D, Hoffman S. Prolonged respiratory center depression
after alcohol and benzodiazepines. Chest 1985; 87: 262-264., doi: 10.1378/chest.87.2.262.
[65] National Records of Scotland, Drug-related Deaths in Scotland in 2017, 2018.
[66] SA Handley, JD Ramsey RF. Substance misuse-related poisoning deaths, England and
Wales, 1993-2016. Drug Sci. Policy Law 2018; 4: 1-18., doi: 10.1177/2050324518767445.
[67] Weaver MF. Prescription sedative misuse and abuse. Yale J. Biol. Med. 2015; 88:
247-256.
[68] Pedersen W, Lavik NJ. Adolescents and benzodiazepines: prescribed use, selfmedica-
tion and intoxication. Acta Psychiatr. Scand. 1991; 84: 94-98., doi: 10.1111/j.1600-
0447.1991.tb01427.x.
[69] Kapil V, Green JL, Lait C Le, Wood DM, Dargan PI. Misuse of benzodiazepines and
Z-drugs in the UK. Br. J. Psychiatry 2014; 205: 407-408.
[70] Clarify AW. Diazepam, Alcohol, and Barbiturate Abuse. Br. Med. J. 1971; 4: 340., doi:
10.1136/bmj.4.5783.340.
[71] Hanna SM. A case of oxazepam (serenid D) dependence. Br. J. Psychiatry 1972; 120:
443-445., doi: 10.1192/bjp.120.557.443.
[72] Glatt MM. Benzodiazepines. Br. Med. J. 1967; 2: 444.
[73] Nutt D, King LA, Saulsbury W, Blakemore C. Development of a rational scale to assess
the harm of drugs of potential misuse. Lancet 2007; 369: 1047-1053., doi: 10.1016/S0140-
6736(07)60464-4.
[74] Gitto R, Zappala` M, Sarro G De, Chimirri A. Design and development of 2,3-
benzodiazepine (CFM) noncompetitive AMPA receptor antagonists. Farm. 2002; 57:
129-134.
220 Chapter 11. Final Discussion and Future Work
[75] Brogden RN, Heel RC, Speight TM, Avery GS. Clobazam: A Review of its Pharma-
cological Properties and Therapeutic Use in Anxiety. Drugs 1980; 20: 161-178., doi:
10.2165/00003495-198020030-00001.
[76] Hammer H, Ebert B, Jensen HS, Jensen AA. Functional characterization of the 1,5-
benzodiazepine clobazam and its major active metabolite n-desmethylclobazam at hu-
man GABAA receptors expressed in xenopus laevis oocytes. PLoS One 2015; 10:, doi:
10.1371/journal.pone.0120239.
[77] Sanna E, Pau D, Tuveri F, Massa F, et al. Molecular and Neurochemical Evaluation
of the Effects of Etizolam on GABAA Receptors under Normal and Stress Conditions.
Arzneimittelforschung 2011; 49: 88-95., doi: 10.1055/s-0031-1300366.
[78] Maskell PD, De Paoli G, Nitin Seetohul L, Pounder DJ. Phenazepam: The drug
that came in from the cold. J. Forensic Leg. Med. 2012; 19: 122-125., doi:
10.1016/j.jflm.2011.12.014.
[79] OConnell CW, Sadler CA, Tolia VM, Ly BT, et al. Overdose of etizolam: the abuse and
rise of a benzodiazepine analog. Ann. Emerg. Med. 2015; 65: 465-466.
[80] Mitsushima T, Ueki S. [Psychopharmacological effects of flutazolam (MS-4101) (authors
transl)]. Nihon Yakurigaku Zasshi. 1978; 74: 959-979., doi: 10.1254/fpj.74.959.
[81] Moosmann B, Bisel P, Franz F, Huppertz LM, Auwarter V. Characterization and in vitro
phase I microsomal metabolism of designer benzodiazepines - an update comprising ad-
inazolam, cloniprazepam, fonazepam, 3-hydroxyphenazepam, metizolam and nitrazolam.
J. Mass Spectrom. 2016; 51: 1080-1089., doi: 10.1002/jms.3840.
[82] Katselou M, Papoutsis I, Nikolaou P, Spiliopoulou C, Athanaselis S. Metabolites replace
the parent drug in the drug arena. The cases of fonazepam and nifoxipam. Forensic
Toxicol. 2017; 35: 1-10., doi: 10.1007/s11419-016-0338-5.
[83] US Patent. US 3136815, 1964.
11.2. Future Work 221
[84] Hester JBJ, Rudzik AD, VonVoigtlander PF. 1-(Aminoalkyl)-6-aryl-4-H-s-triazolo[4,3-
a][1,4]benzodiazepines with antianxiety and antidepressant activity. J. Med. Chem. 1980;
23: 392-402., doi: 10.1021/jm00178a009.
[85] German Patent, DE2005276C3, 1978.
[86] Medical Products Agency Sweden. https://lakemedelsverket.se/overgripande/Lagar–
regler/Yttranden-enligt-lagen-om-forstorande-av-vissa-halsofarliga-
missbrukssubstanser/, 2018.
[87] Hester JB, Von Voigtlander P. 6-Aryl-4H-s-Triazolo[4,3-a][1,4]benzodiazepines. Influence
of 1-Substitution on Pharmacological Activity. J. Med. Chem. 1979; 22: 1390-1398., doi:
10.1021/jm00197a021.
[88] Hester Jr. JB, Rudzik AD, Kamdar B V. 6-phenyl-4H-s-triazolo[4,3-
a][1,4]benzodiazepines which have central nervous system depressant activity. J
Med Chem 1971; 14: 1078-1081.
[89] Medical Products Agency Sweden. https://lakemedelsverket.se/overgripande/Lagar–
regler/Yttranden-enligt-lagen-om-forstorande-av-vissa-halsofarliga-
missbrukssubstanser/, 2018.
[90] Weber K H, Daniel H. Heteroaromaten mit anellierten Siebenringen, IV
Thieno[3,2f][1,2,4]triazolo[4,3a[1,4]diazepin6on und Folgeprodukte. Liebigs Ann.
der Chemie 1979; 1979: 328-333., doi: 10.1002/jlac.197919790305.
[91] European Patent. EP 0158267, 1985.
[92] Patent U. US 3523939, 1970.
[93] Gesundheit o¨sterreich GmbH. EWS-EU: new psychoactive substances.
[94] Tahara T, Araki K, Shiroki M, Matsuo H MT. Syntheses and structure-activity relation-
ships of 6-aryl-4H-s-triazolo[3,4-c]thieno[2,3-e] [1,4]diazepines. Arzneimittelforschung1
978; 28: 1153-1158.
222 Chapter 11. Final Discussion and Future Work
[95] Belgian Early Warning System on Drugs. NPS detected in EU 2018.
[96] Sternbach LH, Fryer RI, Metlesics W, Sach G, Stempel A. Quinazolines and 1,4-
Benzodiazepines. V. o-Aminobenzophenones. J. Org. Chem. 1962; 27: 3781-3788.
[97] Hester JB, Rudzik AD, Kamdar B V. 6-phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepines
which have central nervous system depressant activity. J. Med. Chem. 1971; 14: 1078-
1081.
[98] US Patent. US 4155913, 1979.
[99] German Patent. DE 1812252A1, 1969.
[100] US Patent. US 4031078, 1977.
[101] US Patent. US 3904641, 1975.
[102] US Patent. US 3987052, 1976.
[103] US Patent. US 3954728, 1979.
[104] US Patent. US 3678036, 1963.
[105] Gesundheit o¨sterreich GmbH. EWS-EU: new psychoactive substances.
[106] Kerns EH, Di L. Physicochemical profiling: overview of the screens. Drug Discov. Today.
Technol. 2004; 1: 343-348.
[107] Lombardo F, Obach RS, Shalaeva MY, Gao F. Prediction of Human Volume of Distri-
bution Values for Neutral and Basic Drugs. 2. Extended Data Set and Leave-Class-Out
Statistics. J. Med. Chem. 2004; 47: 1242-1250., doi: 10.1021/jm030408h.
[108] IUPAC. Compendium of Chemical Terminology. 2014.
[109] Xing L, Glen RC. Novel Methods for the Prediction of logP, pKa, and logD. J. Chem.
Inf. Model. 2002; 42: 796-805.
11.2. Future Work 223
[110] Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational
approaches to estimate solubility and permeability in drug discovery and development
settings. Adv. Drug Deliv. Rev. 1997; 23: 3-25.
[111] Spector AA, Yorek MA. Membrane lipid composition and cellular function. J. Lipid Res.
1985; 26: 1015-1035.
[112] Liu X, Testa B, Fahr A. Lipophilicity and its relationship with passive drug permeation.
Pharm. Res. 2011; 28: 962-977.
[113] Leeson PD, Springthorpe B. The influence of drug-like concepts on decision-making in
medicinal chemistry. Nat. Rev. Drug Discov. 2007; 6: 881-890.
[114] Sanguinetti MC, Jiang C, Curran ME, Keating MT. A Mechanistic Link between an Inher-
ited and an Acquired Cardiac Arrhythmia: HERG Encodes the IKr Potassium Channel.
Cell 1995; 81: 299-307.
[115] Kawai Y, Tsukamoto S, Ito J, Akimoto K, Takahashi M. A Risk Assessment of Human
Ether-a-Go-Go-Related Gene Potassium Channel Inhibition by Using Lipophilicity and
Basicity for Drug Discovery. Chem. Pharm. Bull. 2011; 59: 1110-1116.
[116] La´zn´ıcˇek M, La´zn´ıcˇkova´ A. The effect of lipophilicity on the protein binding and blood
cell uptake of some acidic drugs. J. Pharm. Biomed. Anal. 1995; 13: 823-828.
[117] Begley DJ. ABC transporters and the blood-brain barrier. Curr. Pharm. Des. 2004; 10:
1295-312., doi: 10.2174/1381612043384844.
[118] Schinkel AH. P-Glycoprotein, a gatekeeper in the blood-brain barrier. Adv. Drug Deliv.
Rev. 1999; 36: 176-194.
[119] Tanaka E. Clinically important pharmacokinetic drug-drug interactions: role of cy-
tochrome P450 enzymes. J. Clin. Pharm. Ther. 1998; 23: 403-416.
[120] Guengerich FP. Cytochrome p450 and chemical toxicology. Chem. Res. Toxicol. 2008;
21: 70-83.
224 Chapter 11. Final Discussion and Future Work
[121] Lewis DF V, Lake BG, Dickins M. Quantitative structure-activity relationships (QSARs)
in inhibitors of various cytochromes P450: The importance of compound lipophilicity. J.
Enzyme Inhib. Med. Chem. 2007; 22: 1-6.
[122] Lewis DF V, Jacobs MN, Dickins M. Compound lipophilicity for substrate binding to
human P450s in drug metabolism. Drug Discov. Today 2004; 9: 530-537.
[123] Testa B, Crivori P, Reist M, Carrupt PA. The influence of lipophilicity on the pharma-
cokinetic behavior of drugs: Concepts and examples. Perspect. Drug Discov. Des. 2000;
19: 179-211., doi: 10.1023/A:1008741731244.
[124] Arnott JA, Planey SL. The influence of lipophilicity in drug discovery and design. Expert
Opin. Drug Discov. 2012; 7: 863-875., doi: 10.1517/17460441.2012.714363.
[125] Grassy G, Chavanieu A. Molecular Lipophilicity: A Predominant Descriptor for QSAR
inChemogenomics Chem. Genet. (Eds: E. Marechal, S. Roy, L. Lafaneche`re) Springer,
Berlin 2011 pp.153-170.
[126] Dearden JC. Partitioning and lipophilicity in quantitative structure-activity relationships.
Environ. Health Perspect. 1985; VOL. 61: 203-228., doi: 10.2307/3430073.
[127] Roy K, Das RN. A Review on Principles, Theory and Practices of 2D-QSAR.2014.
[128] Griffin CE, Kaye AM, Bueno FR, Kaye AD. Benzodiazepine pharmacology and central
nervous system-mediated effects. Ochsner J. 2013; 13: 214-23.
[129] Garc´ıa DA, Perillo MA. Benzodiazepine localisation at the lipid-water interface: Ef-
fect of membrane composition and drug chemical structure. Biochim. Biophys. Acta
- Biomembr. 1999; 1418: 221-231., doi: 10.1016/S0005-2736(99)00040-1.
[130] Aaltonne L, Kanto J, Iisalo E, Koski K, et al. The Passage of Flunitrazepam into Cere-
brospinal Fluid in Man. Acta Pharmacol. Toxicol. (Copenh). 1981; 48: 364-368., doi:
10.1111/j.1600-0773.1981.tb01633.x.
11.2. Future Work 225
[131] Arendt RM, Greenblatt DJ, Liebisch DC, Luu MD, Paul SM. Determinants of benzodi-
azepine brain uptake: lipophilicity versus binding affinity. Psychopharmacology (Berl).
1987; 93: 72-76., doi: 10.1007/BF02439589.
[132] Nilsson A. Pharmacokinetics of benzodiazepines and their antagonists. Baillieres. Clin.
Anaesthesiol. 1991; 5: 615-634.
[133] Litvin AA, Kolyvanov GB, Zherdev VP, Arzamastsev AP. Relationship between physic-
ochemical characteristics and pharmacokinetic parameters of 1,4-benzodiazepine deriva-
tives. Pharm. Chem. J. 2004; 38: 583-586., doi: 10.1007/s11094-005-0034-y.
[134] Tomkova´ J, Sˇvidrnoch M, Maier V, Ondra P. Analysis of selected designer benzodiazepines
by ultra high performance liquid chromatography with high-resolution time-of-flight mass
spectrometry and the estimation of their partition coefficients by micellar electrokinetic
chromatography. J. Sep. Sci. 2017; 40: 2037-2044., doi: 10.1002/jssc.201700069.
[135] Poulin P, Theil FP. Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-
based prediction of volume of distribution. J. Pharm. Sci. 2002; 91: 129-156., doi:
10.1002/jps.10005.
[136] Lu D, Chambers P, Wipf P, Xie XQ, et al. Lipophilicity screening of novel drug-like
compounds and comparison to clogP. J. Chromatogr. A 2012; 1258: 161-167., doi:
[137] Wenlock MC, Potter T, Barton P, Austin RP. A method for measuring the lipophilic-
ity of compounds in mixtures of 10. J. Biomol. Screen. 2011; 16: 348-355., doi:
10.1177/1087057110396372.
[138] Csizmadia F, Tsantili-Kakoulidou A, Panderi I, Darvas F. Prediction of distribution co-
efficient from structure. 1. Estimation method. J. Pharm. Sci. 1997; 86: 865-871., doi:
10.1021/js960177k.
[139] Mannhold R, Poda GI, Ostermann C, Tetko I V. Calculation of molecular lipophilicity:
State-of-the-art and comparison of log P methods on more than 96,000 compounds. J.
Pharm. Sci. 2009; 98: 861-893., doi: 10.1002/jps.21494.
226 Chapter 11. Final Discussion and Future Work
[140] Kah M, Brown CD. Log D: Lipophilicity for ionisable compounds. Chemosphere 2008;
72: 1401-1408., doi: 10.1016/j.chemosphere.2008.04.074.
[141] Manallack DT. The pKa Distribution of Drugs: Application to Drug Discovery. Perspect.
Medicin. Chem. 2007; 1: 25-38.
[142] Jelfs S, Ertl P, Selzer P. Estimation of pKa for druglike compounds using semiempirical
and information-based descriptors. J. Chem. Inf. Model. 2007; 47: 450-459., doi:
10.1021/ci600285n.
[143] Avdeef a. Physicochemical profiling (solubility, permeability and charge state). Curr.
Top. Med. Chem. 2001; 1: 277-351., doi: 10.2174/1568026013395100.
[144] Smith DA, Beaumont K, Maurer TS, Di L. Volume of Distribution in Drug Design. J.
Med. Chem. 2015; 58: 5691-5698., doi: 10.1021/acs.jmedchem.5b00201.
[145] Tracy TS. Drug Absorption and Distrubition inMod. Pharmacol. with Clin. Appl. 2004
pp.20-47.
[146] Kirch W, Go¨rg KG. Clinical pharmacokinetics of atenolol-a review. Eur. J. Drug Metab.
Pharmacokinet. 1982; 7: 81-91.
[147] Pichette V, P du Souich. Role of the kidneys in the metabolism of furosemide: its
inhibition by probenecid. J. Am. Soc. Nephrol. 1996; 7: 345-349.
[148] Lombardo F, Obach RS, Shalaeva MY, Gao F. Prediction of Volume of Distribution Values
in Humans for Neutral and Basic Drugs Using Physicochemical Measurements and Plasma
Protein Binding Data. J. Med. Chem. 2002; 45: 2867-2876., doi: 10.1021/jm0200409.
[149] Giaginis C, Tsantili-Kakoulidou A, Theocharis S. Applying Quantitative Structure-
Activity Relationship (QSAR) Methodology for Modeling Postmortem Redistribution of
Benzodiazepines and Tricyclic Antidepressants. J. Anal. Toxicol. 2014; 38: 242-248., doi:
10.1093/jat/bku025.
11.2. Future Work 227
[150] Xie X, Steiner SH, Bickel MH. Kinetics of distribution and adipose tissue storage as
a function of lipophilicity and chemical structure. II. Benzodiazepines. Drug Metab.
Dispos. 1991; 19: 15-19.
[151] Simpson NJK, Martha WJM. Introduction to Solid-Phase Extraction.2000.
[152] Moffat AC, Osselton DM, Widdop B, Watts J. Clarkes Analysis of Drugs and Poison2011.
[153] Barrett J, Smyth WF, Davidson IE. An examination of acidbase equilibria of 1,4ben-
zodiazepines by spectrophotometry. J. Pharm. Pharmacol. 1973; 25: 387-393., doi:
10.1111/j.2042-7158.1973.tb10033.x.
[154] Reijenga J, A van Hoof, A van Loon, Teunissen B. Development of Methods for the
Determination of pKa Values. Anal. Chem. Insights 2013; 8: 53-71.
[155] Babi S, Horvat AJM, Pavlovi DM, Ka sˇtelan-Macan M. Determination of pKa values of
active pharmaceutical ingredients. Trends Anal. Chem. 2007; 26: 1043-1061.
[156] Nowak P, Woniakiewicz M, Kocielniak P. Application of capillary electrophoresis in de-
termination of acid dissociation constant values. J. Chromatogr. A 2015; 1377: 1-12.
[157] Poole SK, Patel S, Dehring K, Workman H, Poole CF. Determination of acid dissociation
constants by capillary electrophoresis. J. Chromatogr. A 2004; 1037: 445-454., doi:
10.1016/j.chroma.2004.02.087.
[158] Gluck S, Cleveland Jr. JA. Investigation of experimental approaches to the determination
of pKa values by capillary electrophoresis. J. Chromatogr. A 1994; 680: 49-56., doi:
10.1016/0021-9673(94)80051-0.
[159] IUPAC. Compendium of Chemical Terminology2014.
[160] Gluck S, Cleveland Jr. JA. Investigation of experimental approaches to the determination
of pKa values by capillary electrophoresis. J. Chromatogr. A 1994; 680: 49-56., doi:
10.1016/0021-9673(94)80051-0.
228 Chapter 11. Final Discussion and Future Work
[161] Poole SK, Patel S, Dehring K, Workman H, Poole CF. Determination of acid dissociation
constants by capillary electrophoresis. J. Chromatogr. A 2004; 1037: 445-454., doi:
10.1016/j.chroma.2004.02.087.
[162] Liao C, Nicklaus MC. Comparison of Nine Programs Predicting pKa Values of Pharma-
ceutical Substances. J. Chem. Inf. Model. 2009; 49: 2801-2812.
[163] Stang PJ, Anderson AG. Hammett and Taft Substituent Constants for the Mesylate, To-
sylate, and Triflate Groups. J. Org. Chem. 1976; 41: 781-785., doi: 10.1021/jo00867a007.
[164] Darke SG, Ross JE, Hall WD. Benzodiazepine use among injecting heroin users. Med. J.
Aust. 1995; 162: 645-647.
[165] Dobbin M, Martyres RF, Clode D, De Crespigny FEC. Association of benzodiazepine
injection with the prescription of temazepam capsules. Drug Alcohol Rev. 2003; 22:
153-157., doi:
[166] Colmenarejo G. In Silico Prediction of Plasma and Tissue Protein Binding inRef. Modul.
Chem. Mol. Sci. Chem. Eng. 2014.
[167] Colmenarejo G. In Silico Prediction of Plasma and Tissue Protein Binding inRef. Modul.
Chem. Mol. Sci. Chem. Eng. 2014.
[168] Schmidt S, Gonzalez D, Derendorf H. Significance of protein binding in pharmacokinetics
and pharmacodynamics. J. Pharm. Sci. 2010; 99: 1107-1122., doi: 10.1002/jps.21916.
[169] Bohnert T, Gan L-S. Plasma protein binding: From discovery to development. J. Pharm.
Sci. 2013; 102: 2953-2994., doi: 10.1002/jps.23614.
[170] Routledge PA. The plasma protein binding of basic drugs. Br. J. Clin. Pharmacol. 1986;
22: 499-506.
[171] Tamura A, Kawase F, Sato T, Fujii T. Binding of chlorpromazine, phenytoin and aspirin
to the erythrocytes and lipoproteins in whole human blood. J. Pharm. Pharmacol. 1987;
39: 740-742.
11.2. Future Work 229
[172] Piafsky KM, Borga´ O, Odar-Cederlo¨f I, Johansson C, Sjo¨qvist F. Increased plasma protein
binding of propranolol and chlorpromazine mediated by disease-induced elevations of
plasma alpha1 acid glycoprotein. N. Engl. J. Med. 1978; 299: 1435-1439.
[173] Bickel MH. Binding of chlorpromazine and imipramine to red cells, albumin, lipoproteins
and other blood components. J. Pharm. Pharmacol. 1975; 27: 733-738.
[174] Bailey DN, Briggs JR. The binding of selected therapeutic drugs to human serum alpha-1
acid glycoprotein and to human serum albumin in vitro. Ther. Drug Monit. 2004; 26:
40-43.
[175] Gibaldi M, Levy G, McNamara PJ. Effect of plasma protein and tissue binding on the bio-
logic half-life of drugs. Clin. Pharmacol. Ther. 1978; 24: 1-4., doi: 10.1002/cpt19782411.
[176] Ghafourian T, Amin Z. QSAR Models for the Prediction of Plasma Protein Binding.
BioImpacts 2013; 3: 21-27.
[177] Pellegatti M, Pagliarusco S, Solazzo L, Colato D. Plasma protein binding and blood-free
concentrations: which studies are needed to develop a drug? Expert Opin. Drug Metab.
Toxicol. 2011; 7: 1009-1020., doi: 10.1517/17425255.2011.586336.
[178] Arendt RM, Greenblatt DJ, deJong RH, Bonin JD, et al. In vitro correlates of benzodi-
azepine cerebrospinal fluid uptake, pharmacodynamic action and peripheral distribution.
J Pharmacol Exp Ther 1983; 227: 98-106.
[179] Bohnert T, Gan L-S. Plasma protein binding: From discovery to development. J. Pharm.
Sci. 2013; 102: 2953-2994., doi: 10.1002/jps.23614.
[180] Fanali G, Cao Y, Ascenzi P, Trezza V, et al. Binding of 9-tetrahydrocannabinol and
Diazepam to Human Serum Albumin. IUBMB Life 2011; 63: 446-451.
[181] Fasano M, Curry S, Terreno E, Galliano M, et al. The Extraordinary Ligand Binding
Properties of Human Serum Albumin. IUBMB Life 2005; 57: 787-796.
[182] Sudlow G, Birkett DJ, Wade DN. The Characterization of Two Specific Drug Binding
Sites on Human Serum Albumin. Mol. Pharmacol. 1975; 11: 824-832.
230 Chapter 11. Final Discussion and Future Work
[183] Sudlow G, Birkett DJ, Wade DN. Further characterization of specific drug binding sites
on human serum albumin. Mol. Pharmacol. 1976; 12: 1052-1061.
[184] Dockal M, Carter DC, Ru¨ker F. The Three Recombinant Domains of Human Serum
Albumin. J. Biol. Chem. 1999; 274: 29303-29310., doi: 10.1074/jbc.274.41.29303.
[185] Zsila F, Bikadi Z, Malik D, Hari P, et al. Evaluation of drug-human serum albumin bind-
ing interactions with support vector machine aided online automated docking. Bioinfor-
matics 2011; 27: 1806-1813.
[186] Mu¨ller W, Wollert U. Characterization of the Binding of Benzodiazepines to Human
Serum Albumin . Naunyn Schmiedebergs Arch. Pharmacolology 1973; 280: 229-237.
[187] Chuang VT, Otagiri M. Flunitrazepam, a 7-nitro-1,4-benzodiazepine that is unable to
bind to the indole-benzodiazepine site of human serum albumin. Biochim. Biophys.
Acta 2001; 1546: 337-345.
[188] Maruyama T, Furuie MA, Hibino S, Otagiri M. Comparative Study of Interaction Mode
of Diazepines with Human Serum Albumin and a,-Acid Glycoprotein . J. Pharm. Sci.
1992; 81: 16-20.
[189] Moschitto LJ, Greenblatt DJ. Concentration-independent plasma protein binding of
benzodiazepines. J. Pharm. Pharmacol. 1983; 35: 179-180., doi: 10.1111/j.2042-
7158.1983.tb04302.x.
[190] Klotz U, Antonin KH, Bieck PR. Pharmacokinetics and plasma binding of diazepam in
man, dog, rabbit, guinea pig and rat. J. Pharmacol. Exp. Ther. 1976; 199: 67-73.
[191] Greenblatt DJ, Wright CE. Clinical pharmacokinetics of alprazolam. Therapeutic impli-
cations. Clin. Pharmacokinet. 1993; 24: 453-471.
[192] Zhang F, Xue J, Shao J, Jia L. Compilation of 222 drugs plasma protein binding
data and guidance for study designs. Drug Discov. Today 2012; 17: 475-485., doi:
10.1016/j.drudis.2011.12.018.
11.2. Future Work 231
[193] Divoll M, Greenblatt DJ. Binding of diazepam and desmethyldiazepam to plasma protein:
Concentration-dependence and interactions. Psychopharmacology (Berl). 1981; 75: 380-
382., doi: 10.1007/BF00435857.
[194] Barre´ J, Chamouard JM, Houin G, Tillement JP. Equilibrium dialysis, ultrafiltration, and
ultracentrifugation compared for determining the plasma-protein-binding characteristics
of valproic acid. Clin. Chem. 1985; 31: 60-64.
[195] Ghafourian T, Amin Z. QSAR models for the prediction of plasma protein binding. Bioim-
pacts 2013; 3: 21-7., doi: 10.5681/bi.2013.011.
[196] Kratochwil NA, Huber W, Mu¨ller F, Kansy M, Gerber PR. Predicting plasma protein
binding of drugs: a new approach. Biochem. Pharmacol. 2002; 64: 1355-1374., doi:
10.1016/S0006-2952(02)01074-2.
[197] Sun L, Yang H, Li J, Wang T, et al. In Silico Prediction of Compounds Binding to Human
Plasma Proteins by QSAR Models. ChemMedChem 2017;, doi: 10.1002/cmdc.201700582.
[198] Rodgers SL, Davis a M, van de Waterbeemd H. Time-series QSAR analysis of hu-
man plasma protein binding data. Qsar Comb. Sci. 2007; 26: 511-521., doi:
10.1002/qsar.200630114.
[199] Colmenarejo G, Alvarez-Pedraglio A, Lavandera JL. Cheminformatic models to predict
binding affinities to human serum albumin. J. Med. Chem. 2001; 44: 4370-4378., doi:
10.1021/jm010960b.
[200] Votano JR, Parham M, Hall LM, Hall LH, et al. QSAR modeling of human serum protein
binding with several modeling techniques utilizing structure-information representation.
J. Med. Chem. 2006; 49: 7169-7181., doi: 10.1021/jm051245v.
[201] Toutain PL, Bousquet-Me´lou A. Volumes of distribution inJ. Vet. Pharmacol. Ther.
2004 pp.441-453.
[202] Jones DR, Hall SD, Jackson EK, Branch R a, Wilkinson GR. Brain uptake of benzodi-
azepines: effects of lipophilicity and plasma protein binding. J. Pharmacol. Exp. Ther.
232 Chapter 11. Final Discussion and Future Work
1988; 245: 816-822.
[203] Treiman DM. Pharmacokinetics and clinical use of benzodiazepines in the manage-
ment of status epilepticus. Epilepsia 1989; 30 Suppl 2: S4-S10., doi: 10.1111/j.1528-
1157.1989.tb05824.x.
[204] Lin JH. Tissue distribution and pharmacodynamics: a complicated relationship. Curr.
Drug Metab. 2006; 7: 39-65., doi: 10.2174/138920006774832578.
[205] Benet LZ, Zia-Amirhosseini P. Basic principles of pharmacokinetics inToxicol. Pathol.
1995 pp.115-123.
[206] Berry LM, Li C, Zhao Z, Al BET. Species Differences in Distribution and Prediction
of Human Vss from Preclinical Data. Drug Metab. Dispos. 2011; 39: 2103-2116., doi:
10.1124/dmd.111.040766.for.
[207] Freitas AA, Limbu K, Ghafourian T. Predicting volume of distribution with decision tree-
based regression methods using predicted tissue:plasma partition coefficients. J. Chem-
inform. 2015; 7:, doi: 10.1186/s13321-015-0054-x.
[208] Jones R Do, Jones HM, Rowland M, Gibson CR, et al. PhRMA CPCDC initiative
on predictive models of human pharmacokinetics, part 2: Comparative assessment of
prediction methods of human volume of distribution. J. Pharm. Sci. 2011; 100: 4074-
4089., doi: 10.1002/jps.22553.
[209] Valko´ KL, Nunhuck SB, Hill AP. Estimating unbound volume of distribution and tis-
sue binding by in vitro HPLC-based human serum albumin and immobilised artifi-
cial membrane-binding measurements. J. Pharm. Sci. 2011; 100: 849-862., doi:
10.1002/jps.22323.
[210] Jantos R, Schuhmacher M, Veldstra JL, Bosker WM, Klo¨pping-Ketelaars I, Touliou K,
Sardi GM, Brookhuis KA, Ramaekers JG, Mattern R SG. Determination of blood/serum
ratios of different forensically relevant analytes in authentic samples. Arch. Kriminol.
2011; 227: 188-203.
11.2. Future Work 233
[211] Hinderling PH. Red blood cells: a neglected compartment in pharmacokinetics and phar-
macodynamics. Pharmacol. Rev. 1997; 49: 279-295.
[212] Jones AW, Larsson H. Distribution of diazepam and nordiazepam between plasma and
whole blood and the influence of hematocrit. Ther. Drug Monit. 2004; 26: 380-385., doi:
10.1097/00007691-200408000-00007.
[213] Launiainen T, Ojanper?? I. Drug concentrations in post-mortem femoral blood compared
with therapeutic concentrations in plasma. Drug Test. Anal. 2014; 6: 308-316., doi:
10.1002/dta.1507.
[214] Boy RG, Henseler J, Ramaekers JG, Mattern R, Skopp G. A comparison between ex-
perimental and authentic blood/serum ratios of 3,4-methylenedioxymethamphetamine
and 3,4-methylenedioxyamphetamine. J. Anal. Toxicol. 2009; 33: 283-286., doi:
10.1093/jat/33.5.283.
[215] Hanson VW, Buonarati MH, Baselt RC, Wade NA, et al. Comparison of 3H- and 125I-
radioimmunoassay and gas chromatography/mass spectrometry for the determination of
delta 9-tetrahydrocannabinol and cannabinoids in blood and serum. J. Anal. Toxicol.
1983; 7: 96-102.
[216] Widman M, Agurell S, Ehrnebo M, Jones G. Binding of (+)- and (-)-delta-1-
tetrahydrocannabinols and (minus)-7-hydroxy-delta-1-tetrahydrocannabinol to blood
cells and plasma proteins in man. J. Pharm. Pharmacol. 1974; 26: 914-916., doi:
10.1111/j.2042-7158.1974.tb09207.x.
[217] Schwilke EW, Karschner EL, Lowe RH, Gordon AM, et al. Intra-and intersub-
ject whole blood/plasma cannabinoid ratios determined by 2-dimensional, electron
impact GC-MS with cryofocusing. Clin. Chem. 2009; 55: 1188-1195., doi:
10.1373/clinchem.2008.114405.
[218] Cook CE, Brine DR, Jeffcoat AR, Hill JM, et al. Phencyclidine disposition after intra-
venous and oral doses. Clin. Pharmacol. Ther. 1982; 31: 625-34.
234 Chapter 11. Final Discussion and Future Work
[219] Ye M, Nagar S, Korzekwa K. A physiologically based pharmacokinetic model to predict
the pharmacokinetics of highly protein-bound drugs and the impact of errors in plasma
protein binding. Biopharm. Drug Dispos. 2016; 37: 123-141., doi: 10.1002/bdd.1996.
[220] Yang J, Jamei M, Yeo KR, Rostami-Hodjegan A, Tucker GT. Misuse of the well-
stirred model of hepatic drug clearance. Drug Metab. Dispos. 2007;, doi:
10.1124/dmd.106.013359.
[221] Uchimura T, Kato M, Saito T, Kinoshita H. Prediction of human blood-to-plasma drug
concentration ratio. Biopharm. Drug Dispos. 2010; 31: 286-97., doi: 10.1002/bdd.711.
[222] Noble C, Mardal M, Bjerre Holm N, Stybe Johansen S, Linnet K. In vitro studies on
flubromazolam metabolism and detection of its metabolites in authentic forensic samples.
Drug Test. Anal. 2017; 9: 1182-1191., doi: 10.1002/dta.2146.
[223] Yu S, Li S, Yang H, Lee F, et al. A novel liquid chromatography/tandem mass spectrom-
etry based depletion method for measuring red blood cell partitioning of pharmaceutical
compounds in drug discovery. Rapid Commun. Mass Spectrom. 2005; 19: 250-254., doi:
10.1002/rcm.1777.
[224] Almazroo OA, Miah MK, Venkataramanan, Almazroo, O. A., Miah, M. K., Venkatara-
manan R (2017). DM in the LC in LD https://doi. org/10. 1016/j. cld. 2016.
08. 00. R. Drug Metabolism in the Liver. Clin. Liver Dis. 2017; 21: 1-20., doi:
10.1016/j.cld.2016.08.001.
[225] Griffin CE, Kaye AM, Bueno FR, Kaye AD. Benzodiazepine pharmacology and central
nervous system-mediated effects. Ochsner J. 2013; 13: 214-23.
[226] Xu C, Li CY-T. Induction of Phase I, II and III Drug Metabolism/Transport by Xenobi-
otics . Arch. Pharm. Res. 2005; 28: 249-268.
[227] Omiecinski CJ, Heuvel JP Vanden, Perdew GH, Peters JM. Xenobiotic Metabolism, Dis-
position, and Regulation by Receptors: From Biochemical Phenomenon to Predictors of
Major Toxicities. Toxicol. Sci. 2011; 120: S49-S75.
11.2. Future Work 235
[228] Jancova P, Anzenbacher P, Anzenbacherova E. PHASE II DRUG METABOLIZING EN-
ZYMES. Biomed. Pap. Med. Fac. Univ. Palacky, Olomouc, Czechoslov. 2010; 154:
103-116.
[229] Rendic S, F J di Carlo. Human cytochrome P450 enzymes: a status report summarizing
their reactions, substrates, inducers, and inhibitors. Drug Metab. Rev. 1997; 29: 413-580.
[230] McKinnon RA, Sorich MJ, Ward MB. Cytochrome P450 Part 1: Multiplicity and Func-
tion. J. Pharm. Pract. Res. 2008; 38: 55-57.
[231] Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: Regulation of
gene expression, enzyme activities, and impact of genetic variation. Pharmacol. Ther.
2013; 138: 103-141.
[232] Riner TL, Penning TM. Role of aldo-keto reductase family 1 (AKR1) enzymes in human
steroid metabolism. Steroids 2014; 79: 49-63., doi: 10.1016/j.steroids.2013.10.012.
[233] Casey Laizure S, Herring V, Hu Z, Witbrodt K, Parker RB. The role of human car-
boxylesterases in drug metabolism: Have we overlooked their importance? Pharma-
cotherapy 2013; 33: 210-222., doi: 10.1002/phar.1194.
[234] Fukasawa T, Suzuki A, Otani K. Effects of genetic polymorphism of cytochrome P450
enzymes on the pharmacokinetics of benzodiazepines. J. Clin. Pharm. Ther. 2007; 32:
333-341.
[235] Seree EJ, Pisano PJ, Placidi M, Rahmani R, Barra YA. Identification of the human and
animal hepatic cytochromes P450 involved in clonazepam metabolism. Fundam. Clin.
Pharmacol. 1993; 7: 69-75.
[236] Miura M, Otani K, Ohkubo T. Identification of human cytochrome P450 enzymes involved
in the formation of 4-hydroxyestazolam from estazolam. Xenobiotica. 2005; 35: 455-465.,
doi: 10.1080/00498250500111612.
[237] Molanaei H, Stenvinkel P, Qureshi AR, Carrero JJ, et al. Metabolism of alprazolam (a
marker of CYP3A4) in hemodialysis patients with persistent inflammation. Eur. J. Clin.
236 Chapter 11. Final Discussion and Future Work
Pharmacol. 2012; 68: 571-577.
[238] Park JY, Kim KA, Park PW, Lee OJ, et al. Effect of CYP3A5*3 genotype on the phar-
macokinetics and pharmacodynamics of alprazolam in healthy subjects. Clin. Pharmacol.
Ther. 2006; 79: 590-599.
[239] Patki KC, L L Von Moltke, Greenblatt DJ. In vitro metabolism of midazolam, triazolam,
nifedipine, and testosterone by human liver microsomes and recombinant cytochromes
p450: role of cyp3a4 and cyp3a5. Drug Metab. Dispos. 2003; 31: 938-944.
[240] Hesse LM, Venkatakrishnan K, L L von Moltke, Shader RI, Greenblatt DJ. CYP3A4
Is the Major CYP Isoform Mediating the in Vitro Hydroxylation and Demethylation of
Flunitrazepam. Drug Metab. Dispos. 2001; 29: 133-140.
[241] Kilicarslan T, Haining RL, Rettie AE, Busto U, et al. Flunitrazepam Metabolism by
Cytochrome P450s 2C19 and 3A4. Drug Metab. Dispos. 2001; 29: 460-465.
[242] Venkatakrishnan K, Von Moltke LL, Duan SX, Fleishaker JC, et al. Kinetic character-
ization and identification of the enzymes responsible for the hepatic biotransformation
of adinazolam and N-desmethyladinazolam in man. J. Pharm. Pharmacol. 1998; 50:
265-274., doi: 10.1111/j.2042-7158.1998.tb06859.x.
[243] Coller JK, Somogyi AA, Bochner F. Flunitrazepam oxidative metabolism in human liver
microsomes: involvement of CYP2C19 and CYP3A4. Xenobiotica 1999; 29: 973-986.
[244] Mandrioli R, Mercolini L, Raggi M. Benzodiazepine Metabolism: An Analytical Perspec-
tive. Curr. Drug Metab. 2008; 9: 827-844., doi: 10.2174/138920008786049258.
[245] Oda M, Kotegawa T, Tsutsumi K, Ohtani Y, et al. The effect of itraconazole on the
pharmacokinetics and pharmacodynamics of bromazepam in healthy volunteers. Eur. J.
Clin. Pharmacol. 2003; 59: 615-619., doi: 10.1007/s00228-003-0681-4.
[246] Onof S, Hatanaka T, Miyazawa S, Tsutsui M, et al. Human liver microsomal diazepam
metabolism using cDNA-expressed cytochrome P450s: Role of CYP2B6, 2C19 and the
3A subfamily. Xenobiotica 1996; 26: 1155-1166., doi: 10.3109/00498259609050260.
11.2. Future Work 237
[247] Moosmann B, Bisel P, Auwa¨rter V. Characterization of the designer benzodiazepine di-
clazepam and preliminary data on its metabolism and pharmacokinetics. Drug Test.
Anal. 2014; 6: 757-763., doi: 10.1002/dta.1628.
[248] Fracasso C, Confalonieri S, Garattini S, Caccia S. Single and multiple dose pharmacoki-
netics of etizolam in healthy subjects. Eur. J. Clin. Pharmacol. 1991; 40: 181-185., doi:
10.1007/BF00280074.
[249] Meyer MR, Bergstrand MP, Helander A, Beck O. Identification of main human urinary
metabolites of the designer nitrobenzodiazepines clonazolam, meclonazepam, and nifoxi-
pam by nano-liquid chromatography-high-resolution mass spectrometry for drug testing
purposes. Anal. Bioanal. Chem. 2016; 408: 3571-3591.
[250] Peppers MP. Benzodiazepines for alcohol withdrawal in the elderly and in patients with
liver disease. Pharmacotherapy 1996; 16: 49-57.
[251] Moosmann B, Huppertz LM, Hutter M, Buchwald A, et al. Detection and identification
of the designer benzodiazepine flubromazepam and preliminary data on its metabolism
and pharmacokinetics. J. Mass Spectrom. 2013; 48: 1150-1159.
[252] Wells PG, Mackenzie PI, Chowdhury JR, Guillemette C, et al. Glucuronidation and the
UDP-Glucuronosyltransferases in health and disease. Drug Metab. Dispos. 2004; 32:
281-290.
[253] Mandrioli R, Mercolini L, Raggi M. Benzodiazepine Metabolism: An Analytical Perspec-
tive. Curr. Drug Metab. 2008; 9: 827-844., doi: 10.2174/138920008786049258.
[254] Olivera M, Mart´ınez C, Gervasini G, Carrillo JA, et al. Effect of common NAT2 variant
alleles in the acetylation of the major clonazepam metabolite, 7-aminoclonazepam. Drug
Metab. Lett. 2007; 1: 3-5.
[255] Ekins S, Ring BJ, Grace J, McRobie-Belle DJ, Wrighton S a. Present and future in vitro
approaches for drug metabolism. J. Pharmacol. Toxicol. Methods 2001; 44: 313-24., doi:
S1056-8719(00)00110-6 [pii].
238 Chapter 11. Final Discussion and Future Work
[256] Vikingsson S, Wohlfarth A, Andersson M, Gre´en H, et al. Identifying Metabolites of
Meclonazepam by High-Resolution Mass Spectrometry Using Human Liver Microsomes,
Hepatocytes, a Mouse Model, and Authentic Urine Samples. AAPS J. 2017; 19: 736-742.,
doi: 10.1208/s12248-016-0040-x.
[257] Huppertz LM, Bisel P, Westphal F, Franz F, et al. Characterization of the four designer
benzodiazepines clonazolam, deschloroetizolam, flubromazolam, and meclonazepam, and
identification of their in vitro metabolites. Forensic Toxicol. 2015; 33: 388-395.
[258] Pettersson Bergstrand M, Meyer MR, Beck O, Helander A. Human urinary metabolic
patterns of the designer benzodiazepines flubromazolam and pyrazolam studied by liquid
chromatography-high resolution mass spectrometry. Drug Test. Anal. 2018; 10: 496-506.,
doi: 10.1002/dta.2243.
[259] Moosmann B, Bisel P, Auwa¨rter V. Characterization of the designer benzodiazepine di-
clazepam and preliminary data on its metabolism and pharmacokinetics. Drug Test.
Anal. 2014; 6: 757-763.
[260] Bergstrand M, Richter L, Maurer H, Wagmann L, Meyer M. In vitro glucuronidation
of designer benzodiazepines by human UDP glucuronyltransferases. Drug Test. Anal.
2018;, doi: 10.1002/dta.2463.
[261] Gerets HHJ, Tilmant K, Gerin B, Chanteux H, et al. Characterization of primary human
hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in
response to inducers and their predictivity for the detection of human hepatotoxins. Cell
Biol. Toxicol. 2012; 28: 69-87.
[262] Donato MT, Lahoz A, Castell J V, Go´mez-Lecho´n MJ. Cell lines: a tool for in vitro drug
metabolism studies. Curr Drug Metab. 2008; 9: 1-11., doi: 10.2174/138920008783331086.
[263] Shulman M, Nahmias Y. Long-term culture and coculture of primary rat and human
hepatocytes. Methods Mol. Biol. 2013; 945: 287-302., doi: 10.1007/978-1-62703-125-
717.
11.2. Future Work 239
[264] Lee J, Liu X. The conduct of drug metabolism studies considered good practice
(II): in vitro experiments. Curr Drug Metab. 2007 2007; 8: 822-829., doi:
10.2174/138920007782798207.
[265] Westerink WMA, Schoonen WGEJ. Cytochrome P450 enzyme levels in HepG2 cells and
cryopreserved primary human hepatocytes and their induction in HepG2 cells. Toxicol.
Vitr. 2007; 21: 1581-1591.
[266] Wilkening S, Stahl F, Bader A. Comparison of primary human hepatocytes and hepatoma
cell line Hepg2 with regard to their biotransformation properties. Drug Metab. Dispos.
2003; 31: 1035-1042.
[267] U.S. Permanent Human Hepatocyte Cell Line and Its Use in a Liver Assist Device (LAD)
, 1994.
[268] Gaskell H, Sharma P, Colley HE, Murdoch C, et al. Characterization of a functional C3A
liver spheroid model. Toxicol. Res. (Camb). 2016; 5: 1053-1065.
[269] Nelson LJ, Morgan K, Treskes P, Samuel K, et al. Human Hepatic HepaRG Cells Main-
tain an Organotypic Phenotype with High Intrinsic CYP450 Activity/Metabolism and
Significantly Outperform Standard HepG2/C3A Cells for Pharmaceutical and Therapeu-
tic Applications. Basic Clin. Pharmacol. Toxicol. 2017; 120: 30-37.
[270] Wenum M van, Adam AAA, Hakvoort TBM, Hendriks EJ, et al. Selecting Cells for
Bioartificial Liver Devices and the Importance of a 3D Culture Environment: A Func-
tional Comparison between the HepaRG and C3A Cell Lines. Int. J. Biol. Sci. 2016; 12:
964-978., doi: 10.7150/ijbs.15165.
[271] Choi S, B. Sainz J, Corcoran P, Uprichard S, Jeong H. Characterization of increased
drug metabolism activity in dimethyl sulfoxide (DMSO)-treated Huh7 hepatoma cells.
Xenobiotica 2009; 39: 205-217.
[272] Nikolaou N, Green CJ, Gunn PJ, Hodson L, Tomlinson JW. Optimizing human hepa-
tocyte models for metabolic phenotype and function: effects of treatment with dimethyl
sulfoxide (DMSO). Physiol. Rep. 2016; 4: e12944.
240 Chapter 11. Final Discussion and Future Work
[273] Gripon P, Rumin S, Urban S, Seyec J Le, et al. Infection of a human hepatoma cell line
by hepatitis B virus. Proc. Natl. Acad. Sci. U. S. A. 2002; 99: 15655-15660.
[274] Guillouzo A, Corlu A, Aninat C, Glaise D, et al. The human hepatoma HepaRG cells:
A highly differentiated model for studies of liver metabolism and toxicity of xenobiotics.
Chem. Biol. Interact. 2007; 168: 66-73.
[275] Kanebratt KP, Andersson TB. HepaRG cells as an in vitro model for evaluation of cy-
tochrome P450 induction in humans. Drug Metab. Dispos. 2008; 36: 137-145.
[276] Lambert CB, Spire C, Claude N, Guillouzo A. Dose- and time-dependent effects of phe-
nobarbital on gene expression profiling in human hepatoma HepaRG cells. Toxicol. Appl.
Pharmacol. 2009; 234: 345-360.
[277] Lu¨bberstedt M, Mu¨ller-Vieira U, Mayer M, Biemel KM, et al. HepaRG human hepatic cell
line utility as a surrogate for primary human hepatocytes in drug metabolism assessment
in vitro. J. Pharmacol. Toxicol. Methods 2011; 63: 59-68.
[278] Hewitt NJ, Hewitt P. Phase I and II enzyme characterization of two sources of HepG2
cell lines. Xenobiotica 2004; 34: 243-256.
[279] Huang SM, Strong JM, Zhang L, Reynolds KS, et al. Drug interactions/review: New
era in drug interaction evaluation: US Food and Drug Administration update on CYP
enzymes, transporters, and the guidance process. J. Clin. Pharmacol. 2008; 48: 662-670.,
doi: 10.1177/0091270007312153.
[280] Kirchmair J, Go¨ller AH, Lang D, Kunze J, et al. Predicting drug metabolism: experiment
and/or computation? Nat. Rev. Drug Discov. 2015; 14: 387-404.
[281] Olsen RW, Sieghart W. GABA A receptors: subtypes provide diversity of function and
pharmacology. Neuropharmacology 2009; 56: 141-148.
[282] Olsen RW, Sieghart W. International Union of Pharmacology. LXX. Subtypes of gamma-
aminobutyric acid(A) receptors: classification on the basis of subunit composition, phar-
macology, and function. Update. Pharmacol. Rev. 2008; 60: 243-260.
11.2. Future Work 241
[283] Baumann SW, Baur R, Sigel E. Individual properties of the two functional agonist sites
in GABAA receptors. J. Neurosci. 2003; 23: 11158-11166., doi: 23/35/11158 [pii].
[284] Sigel E. Mapping of the Benzodiazepine Recognition Site on GABA-A Receptors. Curr.
Top. Med. Chem. 2002; 2: 833-839.
[285] Wang Q, Han Y, Xue H. Ligands of the GABAA Receptor Benzodiazepine Binding Site.
CNS Drug Rev. 2006; 5: 125-144.
[286] Sieghart W, Sperk G. Subunit Composition, Distribution and Function of GABA-
A Receptor Subtypes. Curr. Top. Med. Chem. 2002; 2: 795-816., doi:
10.2174/1568026023393507.
[287] Hosie AM, Wilkins ME, Smart TG. Neurosteroid binding sites on GABAA receptors.
Pharmacol. Ther. 2007; 116: 7-19., doi: 10.1016/j.pharmthera.2007.03.011.
[288] Carpenter TS, Lau EY, Lightstone FC. Identification of a possible secondary picrotoxin-
binding site on the GABAA receptor. Chem. Res. Toxicol. 2013; 26: 1444-1454., doi:
10.1021/tx400167b.
[289] Sigel E, Steinmann ME. Structure, Function, and Modulation of GABAA Receptors. J.
Biol. Chem. 2012; 287: 40224-40231.
[290] McCormick DA. GABA as an inhibitory neurotransmitter in human cerebral cortex. J.
Neurophysiol. 1989; 62: 1018-1027., doi: 10.1152/jn.1989.62.5.1018.
[291] Gallager DW, Mallorga P, Thomas JW, Tallman JF. GABA-benzodiazepine interactions:
physiological, pharmacological and developmental aspects. Fed Proc 1980; 39: 3043-3049.
[292] Haefely W. Benzodiazepine interactions with GABA receptors. Neurosci. Lett. 1984; 47:
201-206., doi: 10.1016/0304-3940(84)90514-7.
[293] Bianchi MT, Botzolakis EJ, Lagrange AH, Macdonald RL. Benzodiazepine mod-
ulation of GABAAreceptor opening frequency depends on activation context: A
patch clamp and simulation study. Epilepsy Res. 2009; 85: 212-220., doi:
10.1016/j.eplepsyres.2009.03.007.
242 Chapter 11. Final Discussion and Future Work
[294] Bateson AN. The benzodiazepine site of the GABAA receptor: an old target with new
potential? Sleep Med. 2004; 5: S9-S15., doi: 10.1016/S1389-9457(04)90002-0.
[295] Maddalena DJ, Johnston GA. Prediction of receptor properties and binding affinity of
ligands to benzodiazepine/GABAA receptors using artificial neural networks. J Med
Chem 1995; 38: 715-724.
[296] Holmes P V, Drugan RC. Differential effects of anxiogenic central and peripheral benzo-
diazepine receptor ligands in tests of learning and memory. Psychopharmacology (Berl).
1991; 104: 249-254.
[297] Papadopoulos V, Baraldi M, Guilarte TR, Knudsen TB, et al. Translocator protein (18
kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its
structure and molecular function. Trends Pharmacol. Sci. 2006; 27: 402-409.
[298] Papadopoulos V, Lecanu L. Translocator protein (18 kDa) TSPO: An emerging thera-
peutic target in neurotrauma. Exp. Neurol. 2009; 219: 53-57.
[299] Rupprecht R, Rammes G, Eser D, Baghai TC, et al. Translocator protein (18 kD) as
target for anxiolytics without benzodiazepine-like side effects. Science (80-. ). 2009; 325:
490-493.
[300] Rupprecht R, Papadopoulos V, Rammes G, Baghai TC, et al. Translocator protein (18
kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. Nat.
Rev. Drug Discov. 2010; 9: 971-988.
[301] Casellas P, Galiegue S, Basile AS. Peripheral benzodiazepine receptors and mitochondrial
function. Neurochem. Int. 2002; 40: 475-486.
[302] Gavish M, Katz Y, Bar-Ami S, Weizman R. Biochemical, Physiological, and Pathological
Aspects of the Peripheral Benzodiazepine Receptor. J. Neurochem. 1992; 58: 1589-1601.
[303] Gavish M, Bachman I, Shoukrun R, Katz Y, et al. Enigma of the Peripheral Benzodi-
azepine Receptor. Pharmacol. Rev. 1999; 51: 629-650.
11.2. Future Work 243
[304] Persona K, Madej K, Knihnicki P, Piekoszewski W. Analytical methodologies for the
determination of benzodiazepines in biological samples. J. Pharm. Biomed. Anal. 2015;
113: 239-264., doi: 10.1016/j.jpba.2015.02.017.
[305] Segura M, Barbosa J, Torrens M, Farre´ M, et al. Analytical methodology for the detection
of benzodiazepine consumption in opioid-dependent subjects. J. Anal. Toxicol. 2001; 25:
130-136., doi: 10.1093/jat/25.2.130.
[306] Nasir Uddin M. An Overview on Total Analytical Methods for the Detection of 1,4-
Benzodiazepines. Pharm. Anal. Acta 2014; 05:, doi: 10.4172/2153-2435.1000303.
[307] Kim J, Lee S, In S, Choi H, Chung H. Validation of a simultaneous analytical method
for the detection of 27 benzodiazepines and metabolites and zolpidem in hair using LC-
MS/MS and its application to human and rat hair. J. Chromatogr. B Anal. Technol.
Biomed. Life Sci. 2011; 879: 878-886., doi: 10.1016/j.jchromb.2011.02.038.
[308] Ashri NY, Abdel-Rehim M. Sample treatment based on extraction techniques in biological
matrices. Bioanalysis 2011; 3: 2003-2018., doi: 10.4155/bio.11.201.
[309] Toninandel L, Seraglia R. Matrix effect, signal suppression and enhancement in LC-ESI-
MS. Adv. LC-MS Instrum. 2007; 72: 193.
[310] Buszewski B, Szultka M. Past, Present, and Future of Solid Phase Extraction: A Review.
Crit. Rev. Anal. Chem. 2012; 42: 198-213., doi: 10.1080/07373937.2011.645413.
[311] Andrade-Eiroa A, Canle M, Leroy-Cancellieri V, Cerda` V. Solid-phase extraction of or-
ganic compounds: A critical review (Part I). TrAC - Trends Anal. Chem. 2016; 80:
641-654., doi: 10.1016/j.trac.2015.08.015.
[312] El Balkhi S, Chaslot M, Picard N, Dulaurent S, et al. Characterization and identifica-
tion of eight designer benzodiazepine metabolites by incubation with human liver micro-
somes and analysis by a triple quadrupole mass spectrometer. Int. J. Legal Med. 2017;
10.1007/s00414-017-1541-6.
244 Chapter 11. Final Discussion and Future Work
[313] Mortele´ O, Vervliet P, Gys C, Degreef M, et al. In vitro Phase I and Phase II metabolism
of the new designer benzodiazepine cloniprazepam using liquid chromatography coupled
to quadrupole time-of-flight mass spectrometry. J. Pharm. Biomed. Anal. 2018; 153:
158-167., doi: 10.1016/j.jpba.2018.02.032.
[314] Vikingsson S, Wohlfarth A, Andersson M, Green H, et al. Identifying Metabolites
of Meclonazepam by High-Resolution Mass Spectrometry Using Human Liver Micro-
somes, Hepatocytes, a Mouse Model, and Authentic Urine Samples. AAPS J. 2017;, doi:
10.1208/s12248-016-0040-x.
[315] Wohlfarth A, Vikingsson S, Roman M, Andersson M, et al. Looking at flubromazolam
metabolism from four different angles: metabolite profiling in human liver microsomes,
human hepatocytes, mice and authentic human urine samples with liquid chromatog-
raphy high-resolution mass spectrometry . Forensic Sci. Int. 2017; 274: 55-63., doi:
10.1016/j.forsciint.2016.10.021.
[316] Inoue H, Maeno Y, Iwasa M, Matoba R, Nagao M. Screening and determination of ben-
zodiazepines in whole blood using solid-phase extraction and gas chromatography/mass
spectrometry. Forensic Sci.Int. 2000; 113: 367-373., doi: 10.1016/S0379-0738(00)00226-7.
[317] Nakamae T, Shinozuka T, Sasaki C, Ogamo A, et al. Case report: Etizolam and its
major metabolites in two unnatural death cases. Forensic Sci. Int. 2008; 182: e1-e6., doi:
10.1016/j.forsciint.2008.08.012.
[318] Morini L, Vignali C, Polla M, Sponta A, Groppi A. Comparison of extraction procedures
for benzodiazepines determination in hair by LC-MS/MS. Forensic Sci. Int. 2012; 218:
53-56., doi: 10.1016/j.forsciint.2011.10.013.
[319] Kaliszan R. High Performance Liquid Chromatographic Methods and Procedures of Hy-
drophobicity Determination. Quantitative Structure-Activity Relationships. 1990; 9:
83-87., doi: 10.1002/qsar.19900090202.
[320] Aguilar M-I. Reversed-Phase High-Performance Liquid Chromatography. HPLC Pept.
Proteins Methods Protoc. 2004; 251: 9-22., doi: 10.1385/1-59259-742-4:9.
11.2. Future Work 245
[321] Sˇulekova´ M, Huda´k A, Smcova´ M. The determination of food dyes in vitamins by RP-
HPLC. Molecules 2016; 21:, doi: 10.3390/molecules21101368.
[322] Swartz M. HPLC detectors: A brief review. J. Liq. Chromatogr. Relat. Technol. 2010;
33: 1130-1150., doi: 10.1080/10826076.2010.484356.
[323] Hussain SZ, Maqbool K. GC-MS: Principle, Technique and its application in Food Science.
INT J CURR SCI 2014; 13: 116-126.
[324] Gunnar T, Ariniemi K, Lillsunde P. Determination of 14 benzodiazepines and hydroxy
metabolites, zaleplon and zolpidem as tert-butyldimethylsilyl derivatives compared with
other common silylating reagents in whole blood by gas chromatography-mass spectrom-
etry. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2005; 818: 175-189., doi:
10.1016/j.jchromb.2004.12.032.
[325] Tiscione N, Shan X, Alford I, Yeatman D. Quantitation of benzodiazepines in whole blood
by electron impact-gas chromatography-mass spectrometry. J. Anal. Toxicol. 2008; 32:
644-652.
[326] Siuzdak G. An Introduction to Mass Spectrometry Ionization: An Excerpt from
The Expanding Role of Mass Spectrometry. Biotechnology 2004; 50-63., doi:
10.1016/j.jala.2004.01.004.
[327] Mbughuni MM, Jannetto PJ, Langman LJ. Mass Spectrometry Applications for Toxicol-
ogy. Ejifcc 2016; 27: 272-287.
[328] Ho CS, Lam CWK, Chan MHM, Cheung RCK, et al. Electrospray ionisation mass
spectrometry: principles and clinical applications. Clin. Biochem. 2003; 24: 3-12., doi:
10.1146/annurev.bi.64.070195.001531.
[329] Mbughuni MM, Jannetto PJ, Langman LJ. Mass Spectrometry Applications for Toxicol-
ogy. Ejifcc 2016; 27: 272-287.
[330] Chernushevich I V., Loboda A V., Thomson BA. An introduction to quadrupole-time-of-
flight mass spectrometry. J. Mass Spectrom. 2001; 36: 849-865., doi: 10.1002/jms.207.
246 Chapter 11. Final Discussion and Future Work
[331] El-Aneed A, Cohen A, Banoub J. Mass spectrometry, review of the basics: Electrospray,
MALDI, and commonly used mass analyzers. Appl. Spectrosc. Rev. 2009; 44: 210-230.,
doi: 10.1080/05704920902717872.
[332] Boesl U. Time-of-flight mass spectrometry: Introduction to the basics. Mass Spectrom.
Rev. 2017; 36: 86-109., doi: 10.1002/mas.21520.
[333] Roman M, Strom L, Tell H, Josefsson M. Liquid chromatography/time-of-flight mass
spectrometry analysis of postmortem blood samples for targeted toxicological screening.
Anal. Bioanal. Chem. 2013; 405: 4107-4125., doi: 10.1007/s00216-013-6798-0.
[334] Mandema JW, Sansom LN, Dios-Vie`itez MC, Hollander-Jansen M, Danhof M.
Pharmacokinetic-pharmacodynamic modeling of the electroencephalographic effects of
benzodiazepines. Correlation with receptor binding and anticonvulsant activity. J. Phar-
macol. Exp. Ther. 1991; 257: 472-8.
[335] ICH guidelines. Q2(R1): Validation of Analytical Procedures: Text
and Methodology. Int. Conf. Harmon. 2005; 1994: 17., doi:
http://www.ich.org/fileadmin/PublicWebSite/ICHProducts/Guidelines/Quality/Q2R1/Step4/Q2R1Guideline.pdf.
[336] Gu H, Liu G, Wang J, Aubry AF, Arnold ME. Selecting the correct weighting factors
for linear and quadratic calibration curves with least-squares regression algorithm in bio-
analytical LC-MS/MS assays and impacts of using incorrect weighting factors on curve
stability, data quality, and assay perfo. Anal. Chem. 2014;, doi: 10.1021/ac5018265.
[337] Duer WC, Ogren PJ, Meetze A, Kitchen CJ, et al. Comparison of ordinary, weighted,
and generalized least-squares straight-line calibrations for LC-MS-MS, GC-MS, HPLC,
GC, and enzymatic assay. J. Anal. Toxicol. 2008;, doi: 10.1093/jat/32.5.329.
[338] ACD/I-Lab. https://ilab.acdlabs.com/iLab2/. 2018.
[339] ChemAxon MarvinSketch. https://chemaxon.com/products/marvin. 2018.
[340] Simulations Plus ADMET Predictor. https://www.simulations-
plus.com/software/admetpredictor/. 2018.
11.2. Future Work 247
[341] Miller JM, Blackburn AC, Shi Y, Melzak AJ, Ando HY. Semi-empirical relationships
between effective mobility, charge, and molecular weight of pharmaceuticals by pressure-
assisted capillary electrophoresis: Applications in drug discovery. Electrophoresis 2002;
23: 2833-2841., doi: 10.1002/1522-2683(200209)23:17¡2833::AID-ELPS2833¿3.0.CO;2-7.
[342] Banker MJ, Clark TH, Williams JA. Development and validation of a 96-well equilibrium
dialysis apparatus for measuring plasma protein binding. J. Pharm. Sci. 2003; 92:
967-974., doi: 10.1002/jps.10332.
[343] Atherton JC. Acid-base balance: maintenance of plasma pH. Anaesth. Intensive Care
Med. 2009; 10: 557-561., doi: 10.1016/j.mpaic.2009.08.005.
[344] PreADMET. https://preadmet.bmdrc.kr/. 2018
[345] Ihaka K, Gentleman R. R: A language for data analysis and graphics. J. Comput. Graph.
Stat. 1996; 5: 299-314.
[346] Dixit V, Hariparsad N, Desai P, Unadkat JD. In vitro LC-MS cocktail assays to simul-
taneously determine human cytochrome P450 activities. Biopharm. Drug Dispos. 2007;,
doi: 10.1002/bdd.552.
[347] Wang JJ, Guo JJ, Zhan J, Bu HZ, Lin JH. An in-vitro cocktail assay for assessing
compound-mediated inhibition of six major cytochrome P450 enzymes. J. Pharm. Anal.
2014;, doi: 10.1016/j.jpha.2014.01.001.
[348] Schaefer N, Peters B, Schmidt P, Ewald AH. Development and validation of two LC-
MS/MS methods for the detection and quantification of amphetamines, designer am-
phetamines, benzoylecgonine, benzodiazepines, opiates, and opioids in urine using tur-
bulent flow chromatography. Anal. Bioanal. Chem. 2013; 405: 247-258., doi:
10.1007/s00216-012-6458-9.
[349] Miraghaei S, Mohammadi B, Babaei A, Keshavarz S, Bahrami G. Development and valida-
tion of a new HPLC-DAD method for quantification of sofosbuvir in human serum and its
comparison with LC-MS/MS technique: Application to a bioequivalence study. J. Chro-
matogr. B 2017; 1063: 118-122., doi: https://doi.org/10.1016/j.jchromb.2017.06.047.
248 Chapter 11. Final Discussion and Future Work
[350] Erni F, Steuer W, Bosshardt H. Automation and validation of HPLC-systems. Chro-
matographia 1987; 24: 201-207., doi: 10.1007/BF02688481.
[351] Al-Hawasli H, Al-Khayat MA, Al-Mardini MA. Development of a validated HPLC method
for the separation and analysis of a Bromazepam, Medazepam and Midazolam mixture.
J. Pharm. Anal. 2012; 2: 484-491., doi: 10.1016/j.jpha.2012.05.001.
[352] Uddin MN, Samanidou VF, Papadoyannis IN. Development and validation of an HPLC
method for the determination of benzodiazepines and tricyclic antidepressants in biolog-
ical fluids after sequential SPE. J. Sep. Sci. 2008;, doi: 10.1002/jssc.200800079.
[353] Manchester KR, Maskell PD, Waters L. Experimental versus theoretical log D7.4, pKa
and plasma protein binding values for benzodiazepines appearing as new psychoactive
substances. Drug Test. Anal. 2018;, doi: 10.1002/dta.2387.
[354] Bridwell H, Dhingra V, Peckman D, Roark J, Lehman T. Perspectives on Method Val-
idation: Importance of Adequate Method Validation. Qual. Assur. J. n.d.; 13: 72-77.,
doi: 10.1002/qaj.473.
[355] Pe´rez-Lozano P, Garc´ıa-Montoya E, Orriols A, Miarro M, et al. Development and vali-
dation of a new HPLC analytical method for the determination of alprazolam in tablets.
J. Pharm. Biomed. Anal. 2004;, doi: 10.1016/j.jpba.2003.12.012.
[356] M. El-Gizawy S. Simultaneous Determination of Diazepam, Oxazepam and Temazepam
in Spiked Urine By Hplc. Anal. Lett. - ANAL LETT 2000; 33: 629-638.
[357] Mercolini L, Mandrioli R, Amore M, Raggi MA. Separation and HPLC analysis of 15
benzodiazepines in human plasma. J. Sep. Sci. 2008;, doi: 10.1002/jssc.200800212.
[358] Bazmi E, Behnoush B, Akhgari M, Bahmanabadi L. Quantitative analysis of benzodi-
azepines in vitreous humor by high-performance liquid chromatography. SAGE Open
Med. 2016;, doi: 10.1177/2050312116666243.
[359] Perez ER, Knapp JA, Horn CK, Stillman SL, et al. Comparison of LC-MS-MS and
GC-MS analysis of benzodiazepine compounds included in the drug demand reduction
11.2. Future Work 249
urinalysis program. J. Anal. Toxicol. 2016;, doi: 10.1093/jat/bkv140.
[360] Krone N, Hughes BA, Lavery GG, Stewart PM, et al. Gas chromatography/mass spec-
trometry (GC/MS) remains a pre-eminent discovery tool in clinical steroid investigations
even in the era of fast liquid chromatography tandem mass spectrometry (LC/MS/MS).
J. Steroid Biochem. Mol. Biol. 2010;, doi: 10.1016/j.jsbmb.2010.04.010.
[361] Araujo P. Key aspects of analytical method validation and linearity evaluation. J. Chro-
matogr. B Anal. Technol. Biomed. Life Sci. 2009;, doi: 10.1016/j.jchromb.2008.09.030.
[362] Blachut D, Bykas-Streˆkowska M, Taracha E, Szukalski B. Application of Gas Chromatog-
raphy/mass spectrometry (GC/MS) to the analysis of benzodiazepines. Probl. Forensic
Sci. 2004; 59: 5-37.
[363] Valentine JL, Middleton R, Sparks C. Identification of urinary benzodiazepines and their
metabolites: Comparison of automated HPLC and GC-MS after immunoassay screening
of clinical specimens. J. Anal. Toxicol. 1996; 20: 416-424., doi: 10.1093/jat/20.6.416.
[364] Papoutsis II, Athanaselis SA, Nikolaou PD, Pistos CM, et al. Development and valida-
tion of an EI-GC-MS method for the determination of benzodiazepine drugs and their
metabolites in blood: Applications in clinical and forensic toxicology. J. Pharm. Biomed.
Anal. 2010;, doi: 10.1016/j.jpba.2010.01.027.
[365] Lakshmi HimaBindu MR, Angala Parameswari S, Gopinath C. A review on GC-MS and
method development and validation. Int. J. Pharm. Qual. Assur. 2013;
[366] Damien R, Daval S, Souweine B, Deteix P, et al. Rapid gas chromatography/mass spec-
trometry quinine determination in plasma after automated solid-phase extraction. Rapid
Commun. Mass Spectrom. 2006;, doi: 10.1002/rcm.2625.
[367] Benet LZ, Broccatelli F, Oprea TI. BDDCS Applied to Over 900 Drugs. AAPS J. 2011;
13: 519-547., doi: 10.1208/s12248-011-9290-9.
[368] Giaginis C, Theocharis S, Tsantili-Kakoulidou A. Contribution to the standardization
of the chromatographic conditions for the lipophilicity assessment of neutral and basic
250 Chapter 11. Final Discussion and Future Work
drugs. Anal. Chim. Acta 2006; 573-574: 311-318., doi: 10.1016/j.aca.2006.03.074.
[369] Hansch C, Bjo¨rkroth JP, Leo A. Hydrophobicity and central nervous system agents: On
the principle of minimal hydrophobicity in drug design. J. Pharm. Sci. 1987; 76: 663-
687., doi: 10.1002/jps.2600760902.
[370] Lombardo F, Shalaeva MY, Tupper KA, Gao F. ElogD o ct: A Tool for Lipophilicity
Determination in Drug Discovery. 2. Basic and Neutral Compounds. J. Med. Chem.
2001; 44: 2490-2497., doi: 10.1021/jm0100990.
[371] Di L, Kerns EH. Drug-Like Properties: Concepts, Structure Design and Methods from
ADME to Toxicity OptimizationElsevier, London, U.K.,2016.
[372] Unger SH, Chiang GH. Octanol-Physiological Buffer Distribution Coefficients of
Lipophilic Amines by Reversed-Phase High-Performance Liquid Chromatography and
Their Correlation with Biological Activity. J. Med. Chem. 1981; 24: 262-270., doi:
10.1021/jm00135a006.
[373] McLure JA, Miners JO, Birkett DJ. Nonspecific binding of drugs to human liver micro-
somes. Br. J. Clin. Pharmacol. 2000; 49: 453-461.
[374] Alimuddin M, Grant D, Bulloch D, Lee N, et al. Determination of log D via Automated
Microfluidic Liquid-Liquid Extraction. J. Med. Chem. 2008; 51: 5140-5142.
[375] Alelyunas YW, Pelosi-Kilby L, Turcotte P, Kary M-B, Spreen RC. A high throughput
dried DMSO Log D lipophilicity measurement based on 96-well shake-flask and atmo-
spheric pressure photoionization mass spectrometry detection. J. Chromatogr. A 2010;
1217: 1950-1955.
[376] Ferreira LA, Chervenak A, Placko S, Kestranek A, et al. Effect of ionic composition on
the partitioning of organic compounds in octanol-buffer systems. RSC Adv. 2015; 5:
20574-20582., doi: 10.1039/c5ra01402f.
[377] Wang P H, Lien EJ. Effects of different buffer species on partition coefficients of drugs
used in quantitative structure-activity relationships. J. Pharm. Sci. 1980; 69: 662-668.,
11.2. Future Work 251
doi: 10.1002/jps.2600690614.
[378] Sangster J. OctanolWater Partition Coefficients of Simple Organic Compounds. J. Phys.
Chem. Ref. Data 1989; 18: 1111-1229., doi: 10.1063/1.555833.
[379] Costa EC, Cassamale TB, Carvalho DB, Bosquiroli LSS, et al. Antileishma-
nial activity and structure-activity relationship of triazolic compounds derived from
the neolignans grandisin, veraguensin, and machilin G. Molecules 2016; 21:, doi:
10.3390/molecules21060802.
[380] Chu W, Rothfuss J, Zhou D, MacH RH. Synthesis and evaluation of isatin analogs
as caspase-3 inhibitors: Introduction of a hydrophilic group increases potency in a
whole cell assay. Bioorganic Med. Chem. Lett. 2011; 21: 2192-2197., doi:
10.1016/j.bmcl.2011.03.015.
[381] Klopman G, Li JY, Wang S, Dimayuga M, et al. Computer Automated log P Calculations
Based on an Extended Group Contribution Approach. J. Chem. Inf. Comput. Sci. 1994;
34: 752-781., doi: 10.1021/ci00020a009.
[382] Moffat AC, Osselton MD, Widdop B, Watts J. Clarkes Analysis of Drugs and Poison-
sPharmaceutical Press, London, U.K.,2011.
[383] Graf E, El-Menshawy M. pK- und Vk-Messungen an Benzodiazepinen. Pharm. Unserer
Zeit 1977; 6: 171-178., doi: 10.1002/pauz.19770060602.
[384] Shayesteh TH, Radmehr M, Khajavi F, Mahjub R. Application of chemometrics in de-
termination of the acid dissociation constants (pKa) of several benzodiazepine derivatives
as poorly soluble drugs in the presence of ionic surfactants. Eur. J. Pharm. Sci. 2015;
69: 44-50., doi: 10.1016/j.ejps.2014.12.013.
[385] Bacalum E, Cheregi M, David V. Retention behaviour of some benzodiazepines in solid-
phase extraction using modified silica adsorbents having various hydrophobicities. Rev.
Roum. Chim. 2015; 60: 891-898.
252 Chapter 11. Final Discussion and Future Work
[386] Barrett J, Smyth WF, Davidson IE. An examination of acid-base equilibria of 1,4-
benzodiazepines by spectrophotometry. J. Pharm. Pharmacol. 1973; 25: 387-393., doi:
10.1111/j.2042-7158.1973.tb10033.x.
[387] Gautam L, Sharratt SD, Cole MD. Drug facilitated sexual assault: Detection and stability
of benzodiazepines in spiked drinks using gas chromatography-mass spectrometry. PLoS
One 2014; 9:, doi: 10.1371/journal.pone.0089031.
[388] Groves JA, Smyth WF. Polarographic study of flurazepam and its major metabolites.
Analyst 1981; 106: 890., doi: 10.1039/an9810600890.
[389] World Health Organisation (WHO). Expert Committee on Drug Dependence Thirty-
Seventh Meeting: Etizolam Pre-Review ReportGeneva2015.
[390] Reijenga J, van Hoof A, van Loon A, Teunissen B. Development of Methods for the
Determination of pKa Values. Anal. Chem. Insights 2013;, doi: 10.4137/ACI.S12304.
[391] Manchester J, Walkup G, Rivin O, You Z. Evaluation of pKa Estimation Methods on 211
Druglike Compounds. J. Chem. Inf. Model. 2010; 50: 565-571.
[392] Meloun M, Bordovska´ S. Benchmarking and validating algorithms that estimate pK a
values of drugs based on their molecular structures. Anal. Bioanal. Chem. 2007; 389:
1267-1281., doi: 10.1007/s00216-007-1502-x.
[393] Abernethy D, Greenblatt D, Locniskar A, Ochs H, et al. Obesity effects on nitrazepam
disposition. Br. J. Clin. Pharmacol. 1986; 22: 551-557., doi: 10.1111/j.1365-
2125.1986.tb02934.x.
[394] Kangas L, Allonen H, Lammintausta R, Salonen M, Pekkarinen A. Pharmacokinetics of
Nitrazepam in Saliva and Serum after a Single Oral Dose. Acta Pharmacol. Toxicol.
(Copenh). 1979; 45: 20-24., doi: 10.1111/j.1600-0773.1979.tb02354.x.
[395] G. Seyffart. Drug Dosage in Renal InsufficiencySpringer Science Business Media, New
York, USA2012.
11.2. Future Work 253
[396] Miller LG, Greenblatt DJ, Abernethy DR, Friedman H, et al. Kinetics, brain uptake, and
receptor binding characteristics of flurazepam and its metabolites. Psychopharmacology
(Berl). 1988; 94: 386-391., doi: 10.1007/BF00174694.
[397] Verbeeck RK, Cardinal JA, Wallace SM. Effect of age and sex on the plasma bind-
ing of acidic and basic drugs. Eur. J. Clin. Pharmacol. 1984; 27: 91-97., doi:
10.1007/BF00553161.
[398] Grainger-Rousseau TJ, McElnay JC, Collier PS. The influence of disease on plasma pro-
tein binding of drugs. Int. J. Pharm. 1989; 54: 1-13., doi: 10.1016/0378-5173(89)90159-2.
[399] Kochansky CJ, McMasters DR, Lu P, Koeplinger KA, et al. Impact of pH on
plasma protein binding in equilibrium dialysis. Mol. Pharm. 2008; 5: 438-448., doi:
10.1021/mp800004s.
[400] Curran RE, Claxton CRJ, Hutchison L, Harradine PJ, et al. Control and Measurement
of Plasma pH in Equilibrium Dialysis: Influence on Drug Plasma Protein Binding. Drug
Metab. Dispos. 2011; 39: 551 LP - 557.
[401] Wanwimolruk S, Birkett DJ. The effects of NB transition of human serum albumin on the
specific drug-binding sites. Biochim. Biophys. Acta (BBA)/Protein Struct. Mol. 1982;
709: 247-255., doi: 10.1016/0167-4838(82)90467-8.
[402] Lucek RW, Coutinho CB. The role of substituents in the hydrophobic binding of the
1,4-benzodiazepines by human plasma proteins. Mol. Pharmacol. 1976; 12: 612-619.
[403] Mandona JW, Tuk B, Steveninck AL van, Breimer DD, et al. Pharmacokinetic-
pharmacodynamic modeling of the central nervous system effects of midazolam and its
main metabolite α-hydroxymidazolam in healthy volunteers. Clin. Pharmacol. Ther.
1992; 51: 715-728.
[404] Ait-Daoud N, Hamby AS, Sharma S, Blevins D. A Review of Alprazolam Use, Misuse,
and Withdrawal. J. Addict. Med. 2018;, doi: 10.1097/ADM.0000000000000350.
254 Chapter 11. Final Discussion and Future Work
[405] Lombardo F, Jing Y. In Silico Prediction of Volume of Distribution in Human. Extensive
Data Set and the Exploration of Linear and Non-linear Methods Coupled with Molecular
Interaction Fields Descriptors. J. Chem. Inf. Model. 2016; 56: 2042-2052.
[406] Heizmann P, Eckert M, Ziegler W. Pharmacokinetics and bioavailability of midazo-
lam in man. Br. J. Clin. Pharmacol. 1983; 16: 43S-49S., doi: 10.1111/j.1365-
2125.1983.tb02270.x.
[407] Fleishaker JC, Friedman H, Pollock SR. Extent and variability of the first-pass elimination
of adinazolam mesylate in healthy male volunteers. Pharm. Res. 1991; 8: 162-167.
[408] Ogata M, Tahara T, Nishimura T. NMR Spectroscopic Characterization of Adinazolam
Mesylate: pH-Dependent Structure Change in Aqueous Solution and Active Methylene.
J. Pharm. Sci. 1995; 84: 786-790.
[409] Obach RS, Lombardo F, Waters NJ. Trend Analysis of a Database of Intravenous Phar-
macokinetic Parameters in Humans for 670 Drug Compounds. Drug Metab. Dispos.
2008; 36: 1385-1405.
[410] Moffat AC, Osselton DM, Widdop B, Watts J. Clarkes Analysis of Drugs and Poison2011.
[411] Pfendt LB, Popovi G V., Damjanovi T, Sladi DM. Protolytic equilibria of bromazepam.
J. Serbian Chem. Soc. 2002; 67: 187-195., doi: 10.2298/JSC0203187P.
[412] Yamada Y, Sakurai K, Nakamura K, Sawada Y, Iga T. Prediction of Alteration of Appar-
ent Volume of Distribution of Drugs in Hepatic Disease. Drug Metab. Pharmacokinet.
1993; 8: 283-293.
[413] Jochemsen R, Joeres RP, Wesselman JGJ, Richter E, Breimer DD. Pharmacokinetics
of oral brotizolam in patients with liver cirrhosis. Br. J. Clin. Pharmacol. 1983; 16
Supplem: 315S-322S.
[414] Gallo B, Alonso RM, Madariaga JM, Patriarche GJ, Vire´ JC. Spectrophotometric Study
of Acid-Base Equilibrium of a Thienotriazolodiazepine, Brotizolam, Determination in
Pharmaceutical Formulations. Anal. Lett. 1986; 19: 1853-1865.
11.2. Future Work 255
[415] Hilal SH, Y El-Shabrawy, Carreira LA, Karickhoff SW, et al. Estimation of the ionization
pKa of pharmaceutical substances using the computer program SPARC. Talanta 1996;
43: 607-619.
[416] Tognoni G, Gomeni R, Maio D De, Alberti GG, et al. Pharmacokinetics of N-
demethyldiazepam in patients suffering from insomnia and treated with nortriptyline.
Br. J. Clin. Pharmacol. 1975; 2: 227-232.
[417] Kyburz E. New trends in minor tranquilizers inMed. Chem. Adv. (Eds: F. G. De Las
Heras, S. Vega) Pergamon, Oxford and New York, 1981 pp.355-368.
[418] Gerecke M. Chemical structure and properties of midazolam compared with other ben-
zodiazepines. Br. J. Clin. Pharmacol. 1983; 16 Supplem: 11S-16S.
[419] Shayesteh TH, Radmehr M, Khajavi F, Mahjub R. Application of chemometrics in deter-
mination of the acid dissociation constants (pKa) of several benzodiazepine derivatives as
poorly soluble drugs in the presence of ionic surfactants. Eur. J. Clin. Pharmacol. 2015;
10: 44-50.
[420] Konishi M, Hirai K, Mori Y. Kinetics and mechanism of the equilibrium reaction of
triazolam in aqueous solution. J. Pharm. Sci. 1982; 71: 1328-1334.
[421] Lan N, Chen J. Differential Effects of 4-Chlorodiazepam on Expressed Human GABAA
Receptors. J. Neurochem. 1995; 1-5.
[422] Lund A. The Distribution of Chlorpromazine between Plasma and Erythrocytes.
Acta Pharmacol. Toxicol. (Copenh). n.d.; 47: 300-304., doi: 10.1111/j.1600-
0773.1980.tb03658.x.
[423] Linnoila M, Dorrity F. Measurement of Plasma and Erythrocyte Chlorpromazine and
NMonodesmethylchlorpromazine Levels by Gas Chromatography with a Nitrogen Sen-
sitive Detector. Acta Pharmacol. Toxicol. (Copenh). 1978; 42: 264-270., doi:
10.1111/j.1600-0773.1978.tb02199.x.
256 Chapter 11. Final Discussion and Future Work
[424] Shibata Y, Takahashi H, Ishii Y. A convenient in vitro screening method for predicting
in vivo drug metabolic clearance using isolated hepatocytes suspended in serum. Drug
Metab. Dispos. 2000; 28: 1518-1523.
[425] Hand CW, Rutterford M, Smith RF, Moore RA. Analysis of Benzodiazepines in Whole
Blood, Plasma and Urine by 125-1 Immunoassay in11th Int. Counc. Alcohol, Drugs
Traffic Saf. Conf. 1989 pp.893-897.
[426] Sa¨ila¨ J. Comparing the Concentrations of Drugs and Medicines In Whole Blood, Plasma
and Oral Fluid Samples of Drivers Suspected of Driving Under the Influence, 2009.
[427] Kwakye RA, Kuntworbe N, Ofori-Kwakye K, Osei YA. Detection, quantification, and
investigation of the red blood cell partitioning of cryptolepine hydrochloride. J. Pharm.
Pharmacogn. Res. 2018; 6: 260-270.
[428] Imawaka H, Ito K, Kitamura Y, Sugiyama K, Sugiyama Y. Prediction of human bioavail-
ability from human oral administration data and animal pharmacokinetic data without
data from intravenous administration of drugs in humans. Pharm. Res. 2009; 26: 1881-
1889., doi: 10.1007/s11095-009-9902-6.
[429] Yokogawa K, Nakashima E, Ishizaki J, Maeda H, et al. Relationships in the Structure–
Tissue Distribution of Basic Drugs in the Rabbit. Pharm. Res. 1990; 7: 691-696., doi:
10.1023/A:1015803202857.
[430] Grayson ML, Cosgrove SE, Crowe S, Hope W, et al. Anti-Parasitic Drugs inKucers Use
Antibiot. Sixth Ed. A Clin. Rev. Antibacterial, Antifung. Antivir. Drugs CRC Press,
Boca Raton, Florida, U.S., 2010 p.2014.
[431] Deguchi T, Watanabe N, Kurihara A, Igeta K, et al. Human pharmacokinetic predic-
tion of UDP-glucuronosyltransferase substrates with an animal scale-up approach. Drug
Metab. Dispos. 2011; 39: 820-829., doi: 10.1124/dmd.110.037457.
[432] Fleishaker JC, Friedman H, Pollock SR. Extent and Variability of the First-Pass Elim-
ination of Adinazolam Mesylate in Healthy Male Volunteers. Pharm. Res. An Off. J.
Am. Assoc. Pharm. Sci. 1991; 8: 162-167., doi: 10.1023/A:1015875516834.
11.2. Future Work 257
[433] Smink B, Hofman BJ, Dijkhuizen A, Lusthof KJ, de Gier JJ, Egberts AC UD. The
concentration of oxazepam and oxazepam glucuronide in oral fluid, blood and serum
after controlled administration of 15 and 30 mg oxazepam. Br. J. Clin. Pharmacol.
2008; 66: 556-560., doi: 10.1111/j.1365-2125.2008.03252.x.
[434] Barceloux D. Medical Toxicology of Drug Abuse: Synthetized Chemicals and Psychoactive
Plants. Med. Toxicol. Drug Abus. 2012; 788-804., doi: 10.1002/9781118105955.
[435] Salamone SJ, Ed. . Benzodiazepines and GHB: Detection and PharmacologyHumana
Press, New York, USA2001.
[436] Weaver R, Graham KS, Beattie IG, Riley RJ. Cytochrome P450 inhibition using re-
combinant proteins and mass spectrometry/multiple reaction monitoring technology in a
cassette incubation. Drug Metab. Dispos. 2003;, doi: 10.1124/dmd.31.7.955.
[437] Xu YF, Lu W, Rabinowitz JD. Avoiding misannotation of in-source fragmentation
products as cellular metabolites in liquid chromatography-mass spectrometry-based
metabolomics. Anal. Chem. 2015;, doi: 10.1021/ac504118y.
[438] Elkayam T, Amitay-Shaprut S, Dvir-Ginzberg M, Harel T, Cohen S. Enhancing
the Drug Metabolism Activities of C3A A Human Hepatocyte Cell LineBy Tissue
Engineering Within Alginate Scaffolds. Tissue Eng. 2006; 12: 1357-1368., doi:
10.1089/ten.2006.12.1357.
[439] Cox SK, Hamner T, Bartges J. Determination of acetaminophen and phenacetin in porcine
microsomal samples. J. Liq. Chromatogr. Relat. Technol. 2003; 26: 925-935., doi:
10.1081/JLC-120018893.
[440] Zhai X, Lu Y. Development and validation of a simple LC method for the determination
of phenacetin, coumarin, tolbutamide, chlorzoxazone, testosterone and their metabolites
as markers of cytochromes 1A2, 2A6, 2C11, 2E1 and 3A2 in rat microsomal medium.
Pharmazie 2013; 68: 19-26., doi: 10.1691/ph.2013.2108.
[441] Masters AR, McCoy M, Jones DR, Desta Z. Stereoselective method to quantify bupro-
pion and its three major metabolites, hydroxybupropion, erythro-dihydrobupropion, and
258 Chapter 11. Final Discussion and Future Work
threo-dihydrobupropion using HPLC-MS/MS. J. Chromatogr. B Anal. Technol. Biomed.
Life Sci. 2016; 1015-1016: 201-208., doi: 10.1016/j.jchromb.2016.02.018.
[442] Meyer A, Vuorinen A, Zielinska AE, Strajha P, et al. Formation of threohydrobupro-
pion from bupropion is dependent on 11β-hydroxysteroid dehydrogenase 1. Drug Metab.
Dispos. 2013; 41: 1671-1678.
[443] Molnari JC, Myers AL. Carbonyl reduction of bupropion in human liver. Xenobiotica
2012; 42: 550-561.
[444] Coles R, Kharasch ED. Stereoselective metabolism of bupropion by cytochrome P4502B6
(CYP2B6) and human liver microsomes. Pharm. Res. 2008; 25: 1405-1411., doi:
10.1007/s11095-008-9535-1.
[445] Sager JE, Choiniere JR, Chang J, Stephenson-Famy A, et al. Identification and Structural
Characterization of Three New Metabolites of Bupropion in Humans. ACS Med. Chem.
Lett. 2016; 7:, doi: 10.1021/acsmedchemlett.6b00189.
[446] Faucette SR, Hawke RL, Lecluyse EL, Shord SS, et al. Validation of bupropion hydrox-
ylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug
Metab. Dispos. 2000; 28: 1222-1230.
[447] Hesse LM, Venkatakrishnan K, Court MH, Von Moltke LL, et al. CYP2B6 mediates the in
vitro hydroxylation of bupropion: Potential drug interactions with other antidepressants.
Drug Metab. Dispos. 2000; 28: 1176-1183.
[448] Sager JE, Price LSL, Isoherranen N. Stereoselective metabolism of bupropion to OH-
bupropion, threohydrobupropion, erythrohydrobupropion, and 49-OH-bupropion in vitro.
Drug Metab. Dispos. 2016; 44: 1709-1719., doi: 10.1124/dmd.116.072363.
[449] Connarn JN, Zhang X, Babiskin A, Sun D. Metabolism of Bupropion by carbonyl re-
ductases in liver and intestine. Drug Metab. Dispos. 2015; 43: 1019-1027., doi:
10.1124/dmd.115.063107.
11.2. Future Work 259
[450] Tassaneeyakul W, Tassaneeyakul W, Vannaprasaht S, Yamazoe Y. Formation of omepra-
zole sulphone but not 5-hydroxyomeprazole is inhibited by grapefruit juice. Br. J. Clin.
Pharmacol. 2000;, doi: 10.1046/j.1365-2125.2000.00122.x.
[451] Pillai VC, Strom SC, Caritis SN, Venkataramanan R. A sensitive and specific CYP cock-
tail assay for the simultaneous assessment of human cytochrome P450 activities in primary
cultures of human hepatocytes using LC-MS/MS. J. Pharm. Biomed. Anal. 2013; 74:
126-132.
[452] Liu LY, Han YL, Zhu JH, Yu Q, et al. A sensitive and high-throughput LC-MS/MS
method for inhibition assay of seven major cytochrome P450s in human liver microsomes
using an in vitro cocktail of probe substrates. Biomed. Chromatogr. 2015; 29: 437-444.,
doi: 10.1002/bmc.3294.
[453] Wang J-J, Guo J-J, Zhan J, Bu H-Z, Lin JH. An in-vitro cocktail assay for assessing
compound-mediated inhibition of six major cytochrome P450 enzymes . J. Pharm. Anal.
2014; 4: 270-278.
[454] Spaggiari D, Geiser L, Daali Y, Rudaz S. A cocktail approach for assessing the in vitro
activity of human cytochrome P450s: An overview of current methodologies. J. Pharm.
Biomed. Anal. 2014; 101: 221-237., doi: 10.1016/j.jpba.2014.03.018.
[455] Liu Y, Flynn TJ, Xia M, Wiesenfeld PL, Ferguson MS. Evaluation of CYP3A4 inhibition
and hepatotoxicity using DMSO-treated human hepatoma HuH-7 cells. Cell Biol. Toxicol.
2015; 31: 221-230., doi: 10.1007/s10565-015-9306-9.
[456] Fouad Mansour M, Pelletier M, Boulet MM, Mayrand D, et al. Oxidative activity
of 17-hydroxysteroid dehydrogenase on testosterone in male abdominal adipose tissues
and cellular localization of 17-HSD type 2. Mol. Cell. Endocrinol. 2015;, doi:
10.1016/j.mce.2015.06.016.
[457] Yamazaki H, Shimada T. Progesterone and testosterone hydroxylation by cytochromes
P450 2C19, 2C9, and 34 in human liver microsomes. Arch. Biochem. Biophys. 1997;,
doi: 10.1006/abbi.1997.0302.
260 Chapter 11. Final Discussion and Future Work
[458] Choi MH, Skipper PL, Wishnok JS, Tannenbaum SR. Characterization of Testosterone
11 -Hydroxylation Catalyzed By Human Liver Microsomal Cytochromes P450. Pharma-
cology 2005;, doi: 10.1124/dmd.104.003327.mors.
[459] Usmani KA, Tang J. Human Cytochrome P450: Metabolism of Testosterone by CYP3A4
and Inhibition by Ketoconazole inCurr. Protoc. Toxicol. 2004.
[460] Sainz B, Chisari F V. Production of Infectious Hepatitis C Virus by Well-Differentiated,
Growth-Arrested Human Hepatoma-Derived Cells. J. Virol. 2006; 80: 10253-10257.
[461] Tolonen A, Petsalo A, Turpeinen M, Uusitalo J, Pelkonen O. In vitro interaction cocktail
assay for nine major cytochrome P450 enzymes with 13 probe reactions and a single
LC/MSMS run: Analytical validation and testing with monoclonal anti-CYP antibodies.
J. Mass Spectrom. 2007;, doi: 10.1002/jms.1239.
[462] Testino SA, Patonay G. High-throughput inhibition screening of major human cytochrome
P450 enzymes using an in vitro cocktail and liquid chromatography-tandem mass spec-
trometry. J. Pharm. Biomed. Anal. 2003; 30: 1459-1467., doi: 10.1016/S0731-
7085(02)00480-6.
[463] Abelo A, Andersson TB, Antonsson M, Naudot AK, et al. Stereoselective metabolism of
omeprazole by human cytochrome P450 enzymes. Drug Metab. Dispos. 2000;
[464] Onof S, Hatanaka T, Miyazawa S, Tsutsui M, et al. Human liver microsomal diazepam
metabolism using cDNA-expressed cytochrome P450s: Role of CYP2B6, 2C19 and the
3A subfamily. Xenobiotica 1996; 26: 1155-1166., doi: 10.3109/00498259609050260.
[465] Mowbray CA, Howard A, Morsman J, Hirst BH. Differentiation of HepG2 and Huh7 cells
using dimethyl sulfoxide. FASEB J. 2010; 24: lb654.
[466] Hooper WD, Watt JA, Mckinnon GE, Reelly PEB. Metabolism of diazepam and related
benzodiazepines by human liver microsomes. Eur. J. Drug Metab. Pharmacokinet. 1992;
17: 51-59., doi: 10.1007/BF03189988.
11.2. Future Work 261
[467] Weinfeld RE, Miller KF. Determination of the major urinary metabolite of flurazepam in
man by high-performance liquid chromatography. J. Chromatogr. 1981; 223: 123-130.
[468] Barzaghi N, Leone L, Monteleone M, Tomasini G, Perucca E. Pharmacokinetics of flu-
toprazepam, a novel benzodiazepine drug, in normal subjects. Eur. J. Drug Metab.
Pharmacokinet. 1989; 14: 293-298.
[469] Kintz P, Richeval C, Jamey C, Ameline A, et al. Detection of the designer benzodiazepine
metizolam in urine and preliminary data on its metabolism. Drug Test. Anal. 2016;, doi:
10.1002/dta.2099.
[470] Huppertz LM, Moosmann B, Auwa¨rter V. Flubromazolam - Basic pharmacokinetic eval-
uation of a highly potent designer benzodiazepine. Drug Test. Anal. 2018; 10: 206-211.,
doi: 10.1002/dta.2203.
[471] Richter LHJ, Maurer HH, Meyer MR. New psychoactive substances: Studies on the
metabolism of XLR-11, AB-PINACA, FUB-PB-22, 4-methoxy--PVP, 25-I-NBOMe, and
meclonazepam using human liver preparations in comparison to primary human hepato-
cytes, and human urine. Toxicol. Lett. 2017;, doi: 10.1016/j.toxlet.2017.07.901.
[472] Meyer MR, Bergstrand MP, Helander A, Beck O. Identification of main human urinary
metabolites of the designer nitrobenzodiazepines clonazolam, meclonazepam, and nifoxi-
pam by nano-liquid chromatography-high-resolution mass spectrometry for drug testing
purposes. Anal Bioanal Chem 2016; 408: 3571-3591., doi: 10.1007/s00216-016-9439-6.
[473] Coller JK, Somogyi AA, Bochner F. Quantification of flunitrazepams oxidative metabo-
lites, 3-hydroxyflunitrazepam and desmethylflunitrazepam, in hepatic microsomal incu-
bations by high-performance liquid chromatography. J. Chromatogr. B Biomed. Appl.
1998; 719: 87-92., doi: 10.1016/S0378-4347(98)00383-1.
[474] Tanaka E, Nakamura T, Terada T, Shinozuka T, Honda K. Preliminary study of the
in vitro interaction between alcohol, high-dose flunitrazepam and its three metabolites
using human liver microsomes. Basic Clin. Pharmacol. Toxicol. 2005; 96: 88-90., doi:
10.1111/j.1742-7843.2005.pto960113.x.
262 Chapter 11. Final Discussion and Future Work
[475] Negrusz a, Moore CM, Stockham TL, Poiser KR, et al. Elimination of 7-
aminoflunitrazepam and flunitrazepam in urine after a single dose of Rohypnol. J. Foren-
sic Sci. 2000; 45: 1031-40.
[476] Hasegawa K, Wurita A, Minakata K, Gonmori K, et al. Postmortem distribution of
flunitrazepam and its metabolite 7-aminoflunitrazepam in body fluids and solid tissues
in an autopsy case: Usefulness of bile for their detection. Leg. Med. 2015; 17: 394-400.,
doi: 10.1016/j.legalmed.2015.06.002.
[477] Coassolo P, Aubert C, Cano JP. Plasma determination of 3-methylclonazepam by capil-
lary gas chromatography. J. Chromatogr. 1985; 338: 347-355.
[478] Robertson MD, Drummer OH. Stability of nitrobenzodiazepines in postmortem blood. J.
Forensic Sci. 1998; 43: 5-8.
[479] Mata DC. Stability of 26 sedative hypnotics in six toxicological matrices at different
storage conditions. J. Anal. Toxicol. 2016;, doi: 10.1093/jat/bkw084.
[480] Ameline A, Richeval C, Gaulier J-M, Raul J-S, Kintz P. Detection of the designer ben-
zodiazepine flunitrazolam in urine and preliminary data on its metabolism. Drug Test.
Anal. n.d.; 0:, doi: 10.1002/dta.2480.
[481] Meyer MR, Bergstrand MP, Helander A, Beck O. Identification of main human urinary
metabolites of the designer nitrobenzodiazepines clonazolam, meclonazepam, and nifoxi-
pam by nano-liquid chromatography-high-resolution mass spectrometry for drug testing
purposes. Anal. Bioanal. Chem. 2016; 408: 3571-3591., doi: 10.1007/s00216-016-9439-6.
[482] Zherdev VP, Caccia S, Garattini S, Ekonomov AL. Species differences in phenazepam
kinetics and metabolism. Eur. J. Drug Metab. Pharmacokinet. 1982; 7: 191-196.
[483] Ekonomov AL, Zherdev VP, Rodionov AP, Vikhlyaev YI. Metabolism of the new
psychotropic agent phenazepam. Pharm. Chem. J. 1980; 13: 681-685., doi:
10.1007/BF00789513.
11.2. Future Work 263
[484] Crichton ML, Shenton CF, Drummond G, Beer LJ, et al. Analysis of phenazepam and
3-hydroxyphenazepam in post-mortem fluids and tissues. Drug Test. Anal. 2015; 7:
926-936., doi: 10.1002/dta.1790.
[485] Moosmann B, Hutter M, Huppertz LM, Ferlaino S, et al. Characterization of the designer
benzodiazepine pyrazolam and its detectability in human serum and urine. Forensic
Toxicol. 2013; 31: 263-271., doi: 10.1007/s11419-013-0187-4.
[486] Tetko I V., Poda GI. Application of ALOGPS 2.1 to predict log D distribution coef-
ficient for pfizer proprietary compounds. J. Med. Chem. 2004; 47: 5601-5604., doi:
10.1021/jm049509l.
[487] Hoekstra R, Nibourg GAA, Van Der Hoeven T V., Plomer G, et al. Phase 1 and phase 2
drug metabolism and bile acid production of HepaRG cells in a bioartificial liver in absence
of dimethyl sulfoxide. Drug Metab. Dispos. 2013;, doi: 10.1124/dmd.112.049098.
[488] Kanebratt KP, Andersson TB. Evaluation of HepaRG cells as an in vitro model for human
drug metabolism studies. Drug Metab. Dispos. 2008;, doi: 10.1124/dmd.107.020016.
[489] Miller ME, Garland WA, Min BH, Ludwick BT, et al. Clonazepam acetylation in fast
and slow acetylators. Clin. Pharmacol. Ther. 1981;, doi: 10.1038/clpt.1981.170.
[490] Court MH, Duan SX, Guillemette C, Journault K, et al. Stereoselective conjugation of ox-
azepam by human UDP-glucuronosyltransferases (UGTS): S-oxazepam is glucuronidated
by UGT2B15, while R-oxazepam is glucuronidated by UGT2B7 and UGT1A9. Drug
Metab. Dispos. 2002;, doi: 10.1124/dmd.30.11.1257.
[491] de Angelis I, Turco L. Caco-2 cells as a model for intestinal absorption. Curr. Protoc.
Toxicol. 2011;, doi: 10.1002/0471140856.tx2006s47.
[492] van Breemen RB, Li Y. Caco-2 cell permeability assays to measure drug absorption.
Expert Opin. Drug Metab. Toxicol. 2005;, doi: 10.1517/17425255.1.2.175.
[493] Alhamoruni A, Lee AC, Wright KL, Larvin M, OSullivan SE. Pharmacological Effects of
Cannabinoids on the Caco-2 Cell Culture Model of Intestinal Permeability. J. Pharmacol.
264 Chapter 11. Final Discussion and Future Work
Exp. Ther. 2010;, doi: 10.1124/jpet.110.168237.
[494] Atlabachew M, Combrinck S, Viljoen AM, Hamman JH, Gouws C. Isolation and in vitro
permeation of phenylpropylamino alkaloids from Khat (Catha edulis) across oral and
intestinal mucosal tissues. J. Ethnopharmacol. 2016;, doi: 10.1016/j.jep.2016.09.012.
[495] Kuwayama K, Inoue H, Kanamori T, Tsujikawa K, et al. Uptake of 3,4-
methylenedioxymethamphetamine and its related compounds by a proton-coupled trans-
port system in Caco-2 cells. Biochim. Biophys. Acta - Biomembr. 2008;, doi:
10.1016/j.bbamem.2007.08.023.
[496] Crowe A, Diep S. pH dependent eﬄux of methamphetamine derivatives and their re-
versal through human Caco-2 cell monolayers. Eur. J. Pharmacol. 2008;, doi:
10.1016/j.ejphar.2008.06.090.
[497] Bittermann K, Goss KU. Predicting apparent passive permeability of Caco-2 and
MDCK cell-monolayers: A mechanistic model. PLoS One 2017;, doi: 10.1371/jour-
nal.pone.0190319.
[498] Alsenz J, Haenel E. Development of a 7-Day, 96-Well Caco-2 Permeability Assay
with High-Throughput Direct UV Compound Analysis. Pharm. Res. 2003;, doi:
10.1023/B:PHAM.0000008043.71001.43.
[499] Czupalla CJ, Liebner S, Devraj K. In vitro models of the blood-brain barrier. Methods
Mol. Biol. 2014;, doi: 10.1016/j.fsi.2018.05.062.
[500] Dolghih E, Jacobson MP. Predicting eﬄux ratios and blood-brain barrier penetration from
chemical structure: Combining passive permeability with active eﬄux by P-glycoprotein.
ACS Chem. Neurosci. 2013;, doi: 10.1021/cn3001922.
[501] Doan KMM. Passive Permeability and P-Glycoprotein-Mediated Eﬄux Differentiate Cen-
tral Nervous System (CNS) and Non-CNS Marketed Drugs. J. Pharmacol. Exp. Ther.
2002;, doi: 10.1124/jpet.102.039255.
11.2. Future Work 265
[502] Wang Q, Rager JD, Weinstein K, Kardos PS, et al. Evaluation of the MDR-MDCK cell
line as a permeability screen for the blood-brain barrier. Int. J. Pharm. 2005;, doi:
10.1016/j.ijpharm.2004.10.007.
[503] Lu C, Li P, Gallegos R, Uttamsingh V, et al. Comparison of intrinsic clearance in liver
microsomes and hepatocytes from rats and humans: Evaluation of free fraction and uptake
in hepatocytes. Drug Metab. Dispos. 2006;, doi: 10.1124/dmd.106.010793.
Appendix A
Publications
266
R E V I EW
The emergence of new psychoactive substance (NPS)
benzodiazepines: A review
Kieran R. Manchester1 | Emma C. Lomas1 | Laura Waters1 | Fiona C. Dempsey2 |
Peter D. Maskell3
1School of Applied Sciences, Queensgate
Campus, University of Huddersfield,
Huddersfield, UK
2MedAnnex Ltd, 1 Summerhall Place,
Techcube 3.5, Edinburgh, EH9 1PL, UK
3School of Science, Engineering and
Technology, Abertay University, Dundee, UK
Correspondence
Peter D. Maskell, School of Science,
Engineering and Technology, Abertay
University, Dundee, UK.
Email: p.maskell@abertay.ac.uk
The market for new psychoactive substances has increased markedly in recent years and there is
now a steady stream of compounds appearing every year. Benzodiazepines consist of only a
fraction of the total number of these compounds but their use and misuse has rapidly increased.
Some of these benzodiazepines have only been patented, some of them have not been previously
synthesised, and the majority have never undergone clinical trials or tests. Despite their structural
and chemical similarity, large differences exist between the benzodiazepines in their pharmacoki-
netic parameters and metabolic pathways and so they are not easily comparable. As benzodiaze-
pines have been clinically used since the 1960s, many analytical methods exist to quantify them in
a variety of biological matrices and it is expected that these methods would also be suitable for
the detection of benzodiazepines that are novel psychoactive substances. Illicitly obtained benzo-
diazepines have been found to contain a wide range of compounds such as opiates which pre-
sents a problem since the use of them in conjunction with each other can lead to respiratory
depression and death. This review collates the available information on these benzodiazepines
and provides a starting point for the further investigation of their pharmacokinetics which is
clearly required.
KEYWORDS
benzodiazepine, drug abuse, legal highs, NPS
1 | THE USE AND MISUSE OF
BENZODIAZEPINES
The use and misuse of new psychoactive substances (or ‘legal highs’)
has increased significantly around the world in the past 10 years1
and has to date showed no signs of slowing. In Europe alone, the total
number of new compounds reported by the European Monitoring
Centre for Drugs and Drug Addiction (EMCDDA) has risen rapidly
since 2007 with 101 new psychoactive substances reported to the
EMCDDA in 20142 and 98 in 2015.3 The majority of these
compounds have been synthetic cannabinoids, cathinones, and phen-
ylethylamines.2 One group of these compounds, the benzodiazepines,
has received limited attention but their use has increased significantly
in the past few years. The abuse potential for benzodiazepines was
recognised early in their use and led to 35 benzodiazepines being
placed under control by the UN Convention on Psychotropic
Substances 1971.4 Benzodiazepines are one of the most prescribed
groups of drugs around the world with the limited available data
suggesting that 5.6% of Americans filled a benzodiazepine prescription
in 2013.5 In England, over 5 million doses of diazepam alone were
dispensed in 2014, whilst the total number of prescriptions issued
for benzodiazepines stood at more than 10.4 million, indicating their
widespread use.6 Benzodiazepines are also linked to a significant
number of deaths, both via abuse as a drug in their own right and as
part of a deliberate polypharmacy regime.7 They are commonly impli-
cated in cases of opioid overdoses, where benzodiazepines are
detected in 50–80% of heroin‐related deaths and in 40–80% of meth-
adone‐related deaths in various countries around the world.7 Benzodi-
azepines also account for around 28–45% of drug‐induced deaths in
Europe.2 A study of 1500 people in 2014 used an internet‐based
survey to investigate the reasons for the abuse of benzodiazepines
and Z‐drugs in the United Kingdom (Z‐drugs such as zopiclone and
zolpidem are structurally different from benzodiazepines but also act
via the γ‐aminobutyric acid type‐A (GABAA) receptor). The study
found that most abuse of Z‐drugs and benzodiazepines occurred
because users were trying to alleviate stress, to help with sleep, or to
get high.8 Unfortunately, the study did not differentiate between
benzodiazepines or Z‐drugs but because of their similar effects it is
Received: 13 February 2017 Revised: 11 April 2017 Accepted: 26 April 2017
DOI: 10.1002/dta.2211
Drug Test Anal. 2017;1–17. Copyright © 2017 John Wiley & Sons, Ltd.wileyonlinelibrary.com/journal/dta 1
likely that they are used interchangeably. When used in combination
with other drugs (such as opioids/opiates) the aim of benzodiazepine
use is typically to enhance and/or prolong the high or to reduce the
withdrawal effects of the other drugs.9
Outside normal prescription methods, benzodiazepines are
obtained via various routes such as diversion of prescriptions, the illicit
market, and internet purchasing, which is thought to be a rising
trend.10 In 2016, the Research and Development (RAND) corporation
published a report suggesting that the UK had the second largest num-
ber of online vendors of illegal drugs on the darknet (with the USA
first) but that UK vendors averaged the most transactions per month.11
In recent years, an increasing number of NPS‐benzodiazepines
have appeared for sale in various countries. Novel psychoactive
substances are defined by the United Nations Office on Drugs and
Crime as ‘substances of abuse, either in a pure form or a preparation,
that are not controlled by the 1961 Single Convention on Narcotic
Drugs or the 1971 Convention on Psychotropic Substances, but which
may pose a public health threat’.12 These novel psychoactive
substances are often sold online and labelled for use as ‘research
chemicals’ only, even though they are implicitly intended for human
consumption. Many of these NPS‐benzodiazepines have never
undergone the clinical testing that is required of licensed medicines
and the increasing availability of them may therefore pose serious
health risks to polydrug users and benzodiazepine‐dependent patients
who can no longer obtain their prescription and may turn to other
means of obtaining benzodiazepines. We introduce the general classi-
fication of benzodiazepines (duration of action, half‐life and chemical
structure), their mechanism of action and review what is known to date
about these NPS‐benzodiazepines including user experiences, their
pharmacology, pharmacokinetics, and analytical detection. This data
is summarised inTable 1 and was obtained from a variety of published
journal articles except the user experiences which were obtained from
chat and comments on internet forums such as Reddit,13 Bluelight,14
Flashback,15 and UK Chemical Research.16 Caution should be taken
when interpreting these user experiences as any experiences are
subjective and users may have ingested other compounds at the same
time. Instead they serve as a rough guide as to the likely effects that
may be expected.
2 | THE RISE OF THE NPS‐
BENZODIAZEPINES
The first illicit benzodiazepines identified in Europe to the EMCDDA
were phenazepam (fenazepam) and nimetazepam in 2007.17
Phenazepam is a prescription drug in the former Soviet bloc.18 In the
intervening years, it was detected in an increasing number of cases
around the world.19-25 This led to it being scheduled in the UK and
other countries.26-28 Recently, phenazepam was placed in schedule
VI of the 1971 UN Drug Control Convention.29 The benzodiazepine‐
derivative etizolam was the next compound to be detected to the
EMCDDA in 2011.30 It belongs to a class of compounds known as
thienodiazepines and is commonly prescribed in Japan.31 The naming
of benzodiazepines and their derivatives is discussed in the next
section of this review – Classification of benzodiazepines. Its
appearance mirrored that of phenazepam; a prescription drug in a
country outside the UK which subsequently found its way to the UK
market. Pyrazolam was the next benzodiazepine to appear on the
market and was notable as this was the first benzodiazepine to appear
that was not a prescription drug in any country.32 Following this,
multiple benzodiazepines were reported to the EMCDDA that have not
been licensed for clinical use anywhere in the world. These
benzodiazepines include flubromazepam and diclazepam in 201333 along
withmeclonazepam, nifoxipam, and deschloroetizolam (a thienodiazepine)
in 2014.34 Clonazolam and flubromazolam are also thought to have first
appeared in 201410 and were subsequently reported to the EMCDDA.
Various other benzodiazepines such as adinazolam, nitrazolam, and
metizolam (another thienodiazepine) have all been reported to the
EMCDDA in the 2015 implementation report.35 Two other benzodiaze-
pines, 3‐hydroxyphenazepam (a metabolite of phenazepam18) and
flutazolam (a Japanese prescription drug36) have been detected separately
in tablets seized in Sweden in 2015 by the Medical Products Agency
(MPA), with the use and spread of flutazolam being monitored and
3‐hydroxyphenazepam being subject to an investigation by the
MPA.37 Flunitrazolam, desmethylflunitrazepam (also known as
fonazepam), and cloniprazepam were also detected by the MPA in
2016.38 Bromazolam,39 desalkylflurazepam (also known as
norflurazepam),39 and 4‐chlorodiazepam (also known as Ro5–4864)40
are also thought to have appeared at various points in 2016. The years
that these benzodiazepines appeared and their year of patent (if
available) has been summarised in Table 2 and the timeline can be
viewed in Figure 1. Currently hundreds of benzodiazepines have been
patented and described in the scientific literature and these are not
expected to be the last benzodiazepines that are detected in the so‐
called explosion of novel psychoactive substances.
NPS‐benzodiazepines and thienodiazepines were implicated in
nine drug‐related deaths in England and Wales between 2013 and
2014 as either being the cause of death or as having contributed to
death.41 In 2016, the Psychoactive Substances Act was introduced in
the UK42 with the aim of stopping the cat and mouse game of an
NPS being produced to circumvent legislation, being controlled, and
then another being produced. This legislation restricts the production,
sale, and supply of drugs that are psychoactive. Following the introduc-
tion of this Act, that a fall in supply and use of NPS‐benzodiazepines
may be expected. However, phenazepam and etizolam are now both
controlled benzodiazepines in the UK under the Misuse of Drugs Act
(1971)43 but are still regularly identified in post‐mortem cases and in
drug‐impaired drivers in the UK.21,22
2.1 | Classification of benzodiazepines
Benzodiazepines have traditionally been classified in one of three
ways, either by:
1. Their duration of action. Benzodiazepines that have durations of
action under 24 h are short‐acting while those with durations of
action above 24 h are long‐acting.44
2. Their elimination half‐life (t½). Typically, this consists of four
classifications: ultra‐short (t½, <6 h), short (t½, 6 h), intermediate
(t½ 6–24 h), and long (t½ > 24 h). The reason for these four
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classifications is because the duration of action of the
benzodiazepines can be extended by active metabolites.45-47
3. Their chemical structure. The core structure of benzodiazepines is
a diazepine ring fused to a benzene ring. A phenyl ring is usually
attached to the diazepine ring (Figure 2). Most common benzodi-
azepines are 1,4‐benzodiazepines (Figure 2A) (e.g. diazepam46)
but 1,5‐benzodiazepines (Figure 2B) (e.g. clobazam48) also exist.
A whole host of derivatives of this basic benzodiazepine structure
are possible. Some of them involve the addition of another cyclic
system to the molecule, for example a triazole ring (Figure 2C)
(e.g. alprazolam49), imidazole ring (Figure 2D) (e.g. midazolam50)
or oxazole ring (Figure 2E) (e.g. cloxazolam51). Others involve
replacement of the benzene ring with a thiophene or pyridine ring.
One such group of benzodiazepine derivatives are the
thienodiazepines (e.g. etizolam52) (Figure 2F). They differ in
structure by the replacement of a benzene ring with a thiophene
ring but they have similar anticonvulsant, anxiolytic and
sedative properties.52-54 Thienotriazolodiazepines (Figure 2G)
(e.g. brotizolam54) have a triazole ring fused to the diazepine ring,
much like the triazolobenzodiazepines. 2,3‐benzodiazepines such
as tofisopam exist55 (Figure 2H) but despite them having the ben-
zodiazepine ring structure they exhibit different pharmacological
properties compared with the other benzodiazepines; they act
via the 2‐amino‐3‐(3‐hydroxy‐5‐methylisoxazol‐4‐yl)propionic
acid (AMPA) glutamate receptor but still exhibit anxiolyticT
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TABLE 2 Benzodiazepine patent years and EMCDDA report years
Compound Year patented
Year reported to
the EMCDDA
3‐hydroxyphenazepam Not reported 201637,46
4‐chlorodiazepam (Ro5–4864) 1964131 201640
Adinazolam 1976132 201535
Bromazolam 1976133 201639
Clonazolam 1971 [194] 201435
Cloniprazepam Not reported 2015134
Desalkylflurazepam Not reported 201639
Deschloroetizolam 1998 [196] 201434
Desmethylflunitrazepam
(fonazepam)
1963 [197] 201638
Diclazepam 1964 [198] 201333
Etizolam 1978 [199] 201130
Flubromazepam 1962 [200] 201333
Flubromazolam 1978 [201] 201434
Flunitrazolam Not reported 201638
Flutazolam 1970 [202] 201537
Meclonazepam 1975 [203] 201434
Metizolam 1988 [204] 201535
Nifoxipam 1985 [205] 201434
Nimetazepam 1963 [206] 200717
Nitrazolam 1971 [194] 201535
Phenazepam 1974 [207] 200717
Pyrazolam 1979 [208] 201232
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activity.56,57 To the best of the authors' knowledge there are no
reports of abuse of 2,3‐benzodiazepines. It may only be possible
to classify the NPS‐benzodiazepines by structure until more infor-
mation becomes available. Despite being structurally different,
thienodiazepines will be grouped together with benzodiazepines
as NPS‐benzodiazepines in this review.
3 | MECHANISM OF ACTION OF
BENZODIAZEPINES
The main sites of action of benzodiazepines in the human body are
gamma‐Aminobutyric acid A (GABAA) receptors. GABAA receptors
are ligand‐gated ion channels which are endogenously activated by
gamma‐Aminobutyric acid (GABA), the major inhibitor neurotransmit-
ter in the central nervous system (CNS).58 Their structure consists of
five protein subunits that surround a central pore through which Cl−
ions can permeate.58 Binding of GABA to the receptor triggers the
chloride ion pore to open leading to an inhibition of neural signals.
There are seven receptor subunit families (α 1–6, β 1–3 γ 1–3, δ, ε,
π, θ) but the most common GABAA receptor combination is α2β2γ,
which comprises around 43% of all GABAA receptors in the CNS, with
10 other combinations also identified.59,60 These isoforms are prefer-
entially distributed within specific regions of the CNS.61 As a result,
the receptors have different pharmacological properties and this helps
to explain the differing pharmacological effects observed with the ben-
zodiazepines. The role of GABAA receptor subunits and addiction has
been reviewed by Tan et al.,62 with the α1 subunit containing GABAA
receptors thought to be those that are involved in the addictive
properties of benzodiazepines.62-64 Benzodiazepines bind between
the α1 and γ2 subunits at a site that is distinct from the GABA binding
site. They act as positive allosteric modulators, increasing the affinity
of GABA to the receptor and potentiating the response of the receptor
to GABA.65 Ethanol also binds to the GABAA receptor
66 as do another
class of drugs, the barbiturates.67 An exception to the benzodiazepines
binding to the GABAA receptor can be found for 4‐chlorodiazepam
(Ro5–4864) which recently appeared as an NPS‐benzodiazepine.40
4‐chlorodiazepam binds exclusively to the translocator protein
(18 kDa) (TSPO 18 kDa),68 initially known as the peripheral benzodiaz-
epine receptor.69 TSPO (18 kDa) is found throughout the body and has
a variety of biological functions which have been extensively
reviewed69-71 and it is thought to have considerable potential
FIGURE 1 Timeline of the reporting of NPS‐
benzodiazepines to the EMCDDA
FIGURE 2 Structure of benzodiazepines and derivatives
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therapeutic value as a pharmacological target.72,73 Certain compounds
that bind to TSPO (18 kDa) can exhibit typical benzodiazepine effects
such as being anxiolytic without causing some side effects associated
with benzodiazepine use such as sedation.74 However 4‐
chlorodiazepam has been found to induce anxiety and cause convul-
sions in rats despite being a sedative.75,76 Other benzodiazepines such
as diazepam also experience some binding to TSPO (18 kDa)70,77 but
the majority of their pharmacological effects result from the binding
of them to GABAA receptors.
71
3.1 | Benzodiazepine pharmacokinetics
The pharmacokinetics of benzodiazepines vary widely. The most
common route of administration for prescription benzodiazepines is
oral but they are also given intramuscularly, intravenously, or
rectally.44 When administered orally, there is a wide variation between
the time taken to reach tmax.
44 For example, the NPS‐benzodiazepine
phenazepam reaches a tmax between 2 and 4 h following a 2 mg dose
78
while flubromazepam is only thought to reach tmax after 11.8 h
following a 4 mg dose.79 The time of day that benzodiazepines are
administered can affect tmax; triazolam exhibits a tmax of ~13 min when
taken in the morning compared with ~22 min when taken in the
evening. The half‐life (t½) was similarly affected (2.94 h in the morning
versus 3.77 h in the evening).80 It was thought that this is because of
the longer fasting period prior to the dose.80
Benzodiazepines can have vastly differing half‐lives and this has
been well reviewed.44 An important point of note is that the half‐life
of active benzodiazepine metabolites can be far greater than that of
the parent benzodiazepine. For example, desmethyldiazepam (also
known as nordazepam) is an active metabolite of several
benzodiazepines and can have a half‐life of 96 ± 34 h following oral
administration of prazepam45 or 120 h following diazepam.46 Similarly,
desalkylflurazepam is the active metabolite of flurazepam and can
have a half‐life of 40–144 h following oral administration.47
Desalkylflurazepam is now known to be sold as a NPS.39 The main
monohydroxylated metabolite of the NPS‐benzodiazepine
flubromazepam can be detected in urine up to 28 days following inges-
tion compared to 6 days and 20 h for the parent compound indicating a
higher half‐life for the metabolite.79 Similarly, diclazepam is found only
in very low concentrations in serum and urine for just over four days.
However, its metabolites are detectable for longer time periods:
delorazepam is detectable for 6 days in urine and 10 days in serum; lor-
azepam is detectable for 19 days in both serum and urine; and
lormetazepam is detectable for 11 days in urine.81
As well as the variations discussed for maximum plasma concen-
trations and half‐lives, other pharmacokinetic parameters exhibit large
differences for the benzodiazepines. For example, triazolam has a
bioavailability of 44%82 versus a bioavailability of 97% for diazepam,83
diazepam is 97% bound to plasma proteins84 while alprazolam is only
70% bound to plasma proteins.85 Volumes of distribution also differ;
oxazepam and the NPS‐benzodiazepine flubromazepam have rela-
tively low volumes of distribution (0.27 l kg‐186 and 0.73 l kg−1,79
respectively) versus a high volume of distribution of 4.4 l kg−1 for
flunitrazepam.87
The differences briefly mentioned mean that the pharmacokinet-
ics of benzodiazepines cannot be easily compared and specific knowl-
edge of their individual pharmacokinetic parameters is required to
understand how they behave in the body. Typical blood concentra-
tions, half‐lives, and volumes of distribution (where known) for the
NPS‐benzodiazepines is provided in Table 1.
The majority of drug metabolism occurs in the liver, primarily by
oxidative metabolism mediated by the cytochrome P450 (CYP450)
family of enzymes.99 CYP3A4 is the enzyme most commonly involved
in the metabolism of benzodiazepines.114 However other enzymes are
also involved in the metabolism of benzodiazepines such as CYP3A5,
CYP2C19, CYP2B6, CYP2C18, and CYP2C9.115 The CYP3A4 enzyme
can also conjugate benzodiazepines containing a nitro group with a
glutathione group which can result in cytotoxicity in the liver.114
Polymorphisms in metabolic enzymes can lead to an alteration in the
metabolism of specific drugs. There is only limited evidence that
polymorphisms of CYP3A4/5 clinically affect benzodiazepine metabo-
lism.116 However, CYP2C19 polymorphisms have been shown to
influence the metabolism of benzodiazepines to a significant degree
particularly with clobazam,117 etizolam,118 and diazepam.119,120 In
one study subjects who were CYP2C19 poor metabolisers exhibited
an elimination half‐life for diazepam which was twice that of normal
metabolisers.121 The effect of polymorphisms could not only lead to
greater toxicity but also a longer detection window after administra-
tion. The phase II metabolic pathways of benzodiazepines have been
less widely studied but are thought to involve uridine 5′‐diphospho‐
glucuronosyltransferase (UGT) enzymes particularly UGT2B15,122
UGT1A9,123 UGT2B7,123 and UGT1A4.124 Polymorphisms in
N‐acetyltransferase 2 (NAT2) enzymes can affect the metabolism of
benzodiazepines that undergo N‐acetylation. This has been observed
for a metabolite of clonazepam, 7‐aminoclonazepam, where variant
NAT2 polymorphisms caused a reduction in the rate of its
metabolism.125
To detect benzodiazepine use, it is important to be able to detect
the parent drug as well as any metabolites. Depending on the type of
benzodiazepine ‘class’ and the additional chemical substituent groups
on the core structure the benzodiazepines undergo similar phase I
metabolism. The common metabolic pathways for 1,4‐benzodiaze-
pines and some triazolo/imidazobenzodiazepines are shown in
Figures 3 and 4, respectively. Oxidation is the primary phase I meta-
bolic pathway observed for most benzodiazepines. Typically, this
involves hydroxylation on the same carbon atom on the diazepine
ring, either labelled as position‐3 (e.g. phenazepam110) or position 4
(e.g. clonazolam10). Hydroxylation at the α‐position is also thought to
occur for some benzodiazepines (e.g. flubromazolam10). N‐demethyla-
tion of the tertiary amine located on the diazepine ring of diclazepam
has been described81 whilst benzodiazepines containing a nitro group
(e.g. meclonazepam10) undergo reduction. For phase II metabolism,
benzodiazepines that contain hydroxyl groups typically undergo phase
II glucuronide conjugation (e.g. lorazepam and oxazepam126) without
any phase I metabolism. Benzodiazepines containing a 3‐hydroxy
group typically have a shorter duration of action as they are directly
metabolised to glucuronidated forms that are inactive.127 Some
benzodiazepines can be detected as benzophenones (they are either
directly metabolised to these compounds or experience some form
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of physical degradation) in urine after administration of the parent drug
(e.g. alprazolam,128 nitrazepam,129 and phenazepam130). The structures
of the NPS‐benzodiazepines are provided in Figures 2A–2H and
Tables 2–6 and their metabolic routes are provided in Figures 3 and 4,
and Table 8.
Once benzodiazepines are metabolised they are mainly eliminated
in urine with between <1% and ~20% of the parent drug excreted
unchanged with glucuronidated forms being the most common metab-
olites.44 As benzodiazepines follow common patterns it should be pos-
sible to predict the likely metabolites and routes of elimination of the
NPS‐benzodiazepines.
To detect the use of NPS‐benzodiazepines, give appropriate
clinical treatment people who have been exposed to the NPS‐
benzodiazepines, and interpret their blood/plasma concentrations, it
is important to have pharmacokinetic, analytical, and clinical data. With
this in mind, we have collated the current available data on the
NPS‐benzodiazepines within this review.
4 | ANALYTICAL DETECTION OF NPS‐
BENZODIAZEPINES
It is important in toxicological analysis that analytical methodology can
detect, identify, and quantify drugs in a large number of matrices. As
benzodiazepines are routinely used in clinical practice throughout the
world, many methods exist for their detection and quantification. The
analytical methodologies for the determination of benzodiazepines in
biological samples (blood, plasma, vitreous, oral fluid, hair, nails, and
others) have been recently reviewed.137,138 It is also important to
understand whether analytical methodologies are likely to detect
previously unknown benzodiazepines. The common methodological
sequence during systematic toxicological analysis is detection, identifi-
cation and then finally quantitation.139 Toxicology laboratories
commonly utilise immunoassays for presumptive detection before
confirmation with other analytical techniques because of the large
numbers of samples they may acquire. The advantage of the use of
an immunoassay for screening is the lack of absolute selectivity of
FIGURE 3 General metabolic pathways for 1,4‐benzodiazepines
FIGURE 4 General metabolic pathways for triazolobenzodiazepines
(also applies to imidazobenzodiazepines)
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immunoassay antibodies that target the general structure of drug (such
as benzodiazepines) rather that the specific drug (such as diazepam or
phenazepam).140 Two recent publications investigating the cross
reactivity of standard commercial immunoassay drug screening to
new NPS‐benzodiazepines in both blood and urine have shown that
new NPS‐benzodiazepines would be detected by current immunoas-
say screens.141,142 Potential misidentification could occur however
for structural isomers such as diclazepam and 4‐chlorodiazepam
(Ro5–4864).143 It is likely that new, as yet unknown, benzodiazepines
would be detected by current commercial benzodiazepine immunoas-
says. This hypothesis was backed up by data from the Swedish
STRADA project (a project that monitors the occurrence and trends
of new psychoactive substances) where 390 clinical samples tested
positive in a benzodiazepine immunoassay screen and subsequently
tested negative in a classical LC–MS/MS benzodiazepine screen.
Later, 40% of these samples were confirmed as containing NPS‐
benzodiazepines.144 Following the presumptive detection of benzo-
diazepines confirmation and quantitation are needed. Typically, high
performance liquid chromatography (HPLC)145,146 with or without a
mass spectrometer is used but gas chromatography–mass spectrom-
etry (GC–MS)111,147 and capillary electrophoresis148 have been
utilised. As the NPS‐benzodiazepines are extremely similar in struc-
ture to clinically used benzodiazepines, it is expected that they
would be able to be detected using similar methods. Liquid chroma-
tography‐time of flight‐mass spectrometry (LC‐TOF‐MS) currently
gives the best methodology for the detection of any emerging
NPS‐benzodiazepines, as it is possible to search for compounds
based on the molecular formula alone,149 although care needs to
be taken with any isomers that may lead to misidentification. Sam-
ple preparation is an important step in the detection and quantita-
tion of NPS‐benzodiazepines. The two common techniques used
are that of liquid–liquid extraction (LLE) and solid‐phase extraction
TABLE 3 1,4‐benzodiazepine‐based NPS structures
From Figure 2A
Compound R1 R2’ R3 R7
3‐hydroxyphenazepam H Cl OH Br
4‐chlorodiazepam (Ro5–4864) CH3 H H Cl Note: 4‐chlorophenyl ring instead
of phenyl ring at position 6
Cloniprazepam Methylcyclopropane Cl H NO2
Desalkylflurazepam H F H Cl
Desmethylflunitrazepam (fonazepam) H F H NO2
Diclazepam CH3 Cl H NO2
Flubromazepam H F H Br
Meclonazepam H Cl CH3 NO2
Nifoxipam H F OH NO2
Nimetazepam H H OH NO2
Phenazepam H Cl H Br
TABLE 4 Triazolobenzodiazepine‐based NPS structures
From Figure 2C
Compound R1 R2’ R8
Adinazolam CH2N(CH¬3)2 H Cl
Bromazolam CH3 H Br
Clonazolam CH3 Cl NO2
Flubromazolam CH3 F Br
Flunitrazolam CH3 F NO2
Nitrazolam CH3 H NO2
Pyrazolam
CH3 None Br Note: Pyridine ring instead of phenyl ring at position 6
TABLE 5 Thienotriazolodiazepine‐based NPS structures
From Figure 2G
Compound R2 R2’ R9
Deschloroetizolam CH2CH3 H CH3
Etizolam CH2CH3 Cl CH3
Metizolam CH2CH3 Cl H
TABLE 6 Oxazolobenzodiazepine‐based NPS structures
From Figure 2E
Compound R2’ R7 R10
Flutazolam F CH2CH2OH Cl
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(SPE).139 SPE gives advantages amongst others of higher selectivity
and increased extraction efficiency and recovery over LLE.150 This
could, however, be a disadvantage when trying to identify new
compounds that have not previously been detected and may not
elute from a specific SPE column.
One extraction technique that is becoming increasingly popular is
quick, easy, cheap, effective, rugged, safe (QuEChERS) a hybrid LLE‐
SPE method.151 The use of a primary and secondary amine phase
(PSA) allows easier removal of complex matrix components such as
blood.152 The QuEChERS technique has been shown to increase the
recoveries of benzodiazepines extracted from various biological
matrices such as blood and urine153 and from milk‐based alcoholic
drinks (where benzodiazepines are often added illicitly) which provides
a complex matrix for extraction as a result of the high number of
proteins and fatty acids.154
The methods that are currently available for the detection and
quantitation of NPS‐benzodiazepines in body fluids are listed in
Table 7. LC–MS has been used to detect both flubromazepam and its
metabolites in urine and serum79 and also pyrazolam.113 Pyrazolam
does not appear to produce metabolites according to one study113
but is detectable in serum for up to 50 h but it is excreted in urine
for up to 6 days following ingestion of 1 mg which provides a fairly
large window of detection for analysis.113 Diclazepam is found only
in very low concentrations for just over four days following ingestion
of 1 mg.81 However its metabolites are discernible for longer time
periods with delorazepam detectable for 6 days in urine and 10 days
in serum, lorazepam 19 days in both serum and urine and
lormetazepam 11 days in urine.81 Flubromazepam and its metabolites
also exhibit a low level of detection in urine using immunoas-
says.79,142,161 However, using LC–MS, the monohydroxylated metabo-
lite was detectable for 28 days following ingestion in the urine
samples, compared with 23 days in the plasma samples providing an
extremely long window of detection for the drug.79 Other
NPS‐benzodiazepines would be expected to be similarly detectable.
The metabolic pathways for benzodiazepines are fairly similar
(Figures 3 and 4) and this allows metabolites to be predicted and
actively searched for when analyzing samples using techniques such
as LC–MS.157,162 As a result of the aforementioned similar metabolic
pathways, care must be taken when interpreting the apparent
presence of a metabolite. For example, diclazepam is metabolised to
lorazepam, lormetazepam, and delorazepam which are all prescription
drugs.81 Likewise, 3‐hydroxyphenazepam has been sold on its own as
an NPS‐benzodiazepine but is a metabolite from both phenazepam18
and a Russian prescription benzodiazepine cinazepam.163
Desalkylflurazepam is a metabolite of several drugs including
flurazepam,164 midazolam,165 and the Japanese prescription drugs
flutoprazepam166 and fludiazepam.167
5 | NPS‐BENZODIAZEPINE STABILITY
With any detection, identification, and quantification of a drug, it is
important to have information on the stability of the drug and any
possible changes in the drug concentration that may happen during
transportation and/or storage.168 There have been numerous studies
on the stability of benzodiazepines in matrices such as blood and urine
at temperatures from 20°C to −80°C.169-172 Nitrobenzodiazepines
(such as flunitrazepam, clonazepam, and nitrazepam) and chlordiaz-
epoxide have been found to be the most unstable especially in bacte-
rially‐contaminated specimens.169,173 Two studies have been carried
out investigating the stability of NPS‐benzodiazepines (pyrazolam,
diclazepam, flubromazepam, meclonazepam, phenazepam, etizolam,
nifoxipam, deschloroetizolam, clonazolam, flubromazolam and
flutazolam) but only in urine for 1 month and 7 months.157,174 These
studies showed that flubromazepam, clonazolam, nifoxipam, and
meclonazepam (the latter three are nitrobenzodiazepines) were unsta-
ble in urine (at ambient temperature and at −4°C). Meclonazepam was
only detected at 8% of its original concentration after 4 weeks at −4°C
and −20°C after 4 weeks). Meclonazepam has also been shown to be
unstable in plasma in glass, but not in polypropylene tubes at −20°
C.159 These studies indicate that any future nitrobenzodiazepines are
likely to be unstable and suggest that all NPS‐benzodiazepines should
be investigated for stability and that they should all be collected in
tubes containing fluoride oxalate (1%) and then stored at the lowest
temperature possible (ideally −20°C or lower) before analysis.
6 | PREDICTION OF THE
PHARMACOLOGICAL, TOXICOLOGICAL, AND
PHARMACOKINETIC PROPERTIES OF
BENZODIAZEPINES
The lack of both in vivo and in vitro pharmacological testing of the new
psychoactive substances that are emerging can be overcome to an
extent with the use of quantitative structure activity relationship
(QSAR) modelling. This technique creates a model that relates biologi-
cal activity to structural descriptors of the compound and is based on a
learning set with known biological activity. Systematic in vivo and
in vitro work has also been carried out to investigate the structural
characteristics that relate to pharmacological activity. From these stud-
ies estimations of activity of novel 1,4–benzodiazepines (Figure 2A)
can be estimated for half‐life (t½), volume of distribution (VD), bioavail-
ability (F)175 as well as the potential toxicity of benzodiazepines,176
showing that hydrazone fragments, primary amines and saturated het-
erocyclic ring systems lead to increases in toxicity.176 The biological
activity of benzodiazepines was initially studied by Hester who deter-
mined the effects of substituents on the biological activity. This deter-
mined that triazolobenzodiazepines (Figure 2C) were more potent than
the corresponding 1,4‐benzodiazepine.177,178 As for the 1,4–benzodi-
azepines, the R1, R3, R7 and R2’ positions (Figure 2A) are important
for biological activity.179,180 The removal of the phenyl group removes
the GABA potentiation by the compound but it can still bind to the
GABA site.181 QSAR studies identified the relative importance of each
site to activity and which functional groups could be added at various
positions for optimal biological activity. The R7 position was the most
important position for increasing receptor affinity (30% in the
QSAR model) with the 10 optimal functional groups being
CH2CF3 > I > Br > CF3 > Cl > C(CH3)3 > NO2 > F > N3 > CH = CH2.
182
At the R1 position (37% in the QSAR model) the most optimal groups
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were OH > F > NH2 > H > NHOH > C2H5 > Cl > CF3 > Br > CH3
183 and
the tert‐butyl substitution led to inactivity.184 At the R2’ position
(15% in the QSAR model) the order of the most optimal groups was
NO2 > F > CN > Cl > CF3.
182,185 The influence that substitution at the
R3 position has on biological activity is unclear and difficult to predict
because of the formation of enantiomeric forms186,187 but it is thought
to have limited influence on the biological activity.188 In the literature,
there are measured binding affinities for desmethylflunitrazepam
(fonazepam) and meclonazepam (log IC50) of 0.176 and 0.079 respec-
tively with predicted values of 0.565 and 0.357, respectively.186,187
These results show that although QSAR can be useful for prediction it
is not a replacement for traditional in vivo and in vitro testing.
7 | THE COMPOSITION OF ILLICITLY‐SOLD
NPS‐BENZODIAZEPINES
A major issue with the purchase of drugs online is that there is no
guarantee of the quality of composition. Alprazolam is one of the most
widely‐prescribed benzodiazepines in the world therefore it is not
surprising that it is often illicitly sold. However, thewide variety of drugs
that are sold and stated to contain alprazolam is both remarkable and
concerning. Mimic alprazolam tablets have been found to contain mela-
tonin189 or the opioid fentanyl.183 EcstasyData.org is an independent
testing laboratory, created primarily to reduce the potential harm of
illicit ecstasy by providing data on the composition of ecstasy tablets.184
However, a variety of other drugs are often sent in and tested. This
independent testing laboratory utilise GC–MS, thin layer chromatogra-
phy (TLC) and colour tests for analysing and identifying the materials
that are supplied to them.184 Other drugs that have been found in
alprazolam tablets include other clinically‐used benzodiazepines, syn-
thetic cannabinoids, synthetic opiates, Z‐drugs, piperazines, barbitu-
rates and clinically‐used anaesthetics and antihistamines. Clonazepam
tablets have been identified as containing the NPS‐benzodiazepine
clonazolam.184 Etizolam tablets have been found to contain alprazolam,
flubromazepam (an NPS‐benzodiazepine) and diphenylprolinol, a com-
pound used as a designer drug.184 Diclazepam tablets have been identi-
fied as containing nimetazepam,184 a widely prescribed and abused
drug in southeast Asia190 and an NPS‐benzodiazepine in Europe itself17
and some illicit tablets of nimetazepam (also known as Ermin 5) have
been found to contain phenazepam.191 In addition, in the 2016
EMCDDA drug report it was noted that alprazolam tablets had been
identified as containing flubromazolam and diazepam tablets had been
identified to contain phenazepam.3 This is a huge problem for drug
users as theymay be inadvertently taking a drug potentially many times
more harmful than expected because of the lack of information regard-
ing drug–drug interactions. As mentioned previously, it is well known
that the concurrent use of opioids, opiates and benzodiazepines can
increase the risk of death.7,192 There have been sporadic reports of
the use of benzodiazepines as either diluents or adulterants in heroin
however this does not appear to be as common.193 The majority of
the data from EcstasyData.org is from the United States but samples
are sent in fromacross theworldwithmany appearing to have been pur-
chased online in China.184With the increase of NPS‐benzodiazepines in
recent years, this may become even more problematic.TA
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TABLE 8 Metabolic pathways and metabolites of NPS‐benzodiazepines
Compound Major phase I metabolites (both in vivo and in vitro) Reference(s)
3‐hydroxyphenazepam None known Moosmann 134
4‐chlorodiazepam (Ro5–
4864)
There appears to be a lack of information on the metabolic routes of this benzodiazepine but they
are possibly similar to those observed for diclazepam such as N‐demethylation and 3‐
hydroxylation
No reference
Adinazolam N‐desmethyladinazolam
N,N‐didesmethyladinazolam
α‐hydroxyadinazolam, Estazolam
Moosmann 134
Fraser 132
Bromazolam No experimental studies to date but possible metabolites are hydroxylation at the α or 4 positions
as is the case with other triazolobenzodiazepines
No reference
Clonazolam 7‐aminoclonazolam, 7‐acetaminoclonazolam
Hydroxyclonazolam
Huppertz 10, Meyer 133
Cloniprazepam Monohydroxylated cloniprazepam
Clonazepam (dealkylation)
Reduction of the 7‐nitro to a 7‐amino group
7‐aminoclonazepam (dealkylation and reduction)
Hydroxylation and dealkylation
Hydroxylation and dealkylation
Oxidation of the 3‐hydroxy group to a 3‐keto group
Moosmann 134
Desalkylflurazepam It is unclear as to whether this would go further phase I metabolism or instead proceed directly to
phase II metabolism as is the case when it is a metabolite from flurazepam
Breimer 47
Deschloroetizolam Monohydroxylation (probable 9‐methyl)
Monohydroxylation (probable 2‐ethyl)
Monohydroxylation (probable position 6)
Dihydroxylation (positions undetermined)
Huppertz 10, El Balkhi 104
Desmethylflunitrazepam
(fonazepam)
3‐hydroxynorflunitrazepam
Monohydroxylation (position undetermined)
7‐aminonorflunitrazepam
Moosmann 134
Diclazepam Delorazepam, lorazepam
Lormetazepam
Moosmann 81, El Balkhi 104
Etizolam Hydroxylation on the α‐carbon of the 9‐methyl group
(also known as α‐hydroxyetizolam)
Hydroxylation on the α‐carbon of the 2‐ethyl group
(also known as 8‐hydroxyetizolam)
El Balkhi 104, Fracasso 135
Flubromazepam Monohydroxylation (possibly 3‐hydroxy, undetermined)
Debromination and monohydroxylation (possibly 3‐hydroxy, undetermined)
Monohydroxylation (either on the phenyl ring or the benzene ring, undetermined)
Moosmann 79, El Balkhi 104
Flubromazolam α‐hydroxyflubromazepam
4‐hydroxyflubromazepam
Dihydroxylation (α‐hydroxy and 4‐hydroxy)
Huppertz 10, El Balkhi 104
Flunitrazolam No experimental studies to date but possible metabolites are reduction of the 8‐nitro group to an
8‐amino group and hydroxylation at position 4 of the diazepine ring.
No reference
Flutazolam Oxazole ring‐opening and elimination
The above metabolite is thought to be the main metabolite present in plasma but other metabolic
pathways do exist:
N1‐dealkylation (loss of CH2CH2OH), 3‐hydroxylation
Hydroxylation on either the fluorophenyl or chlorophenyl ring
Both N1‐dealkylation and 3‐hydroxylation
Mitsubishi‐Tanabe‐
Pharma‐Corporation 36
Meclonazepam 7‐aminomeclonazepam, 7‐acetaminomeclonazepam El Balkhi 104, Meyer 133
Metizolam 2 mono‐hydroxylated compounds
Di‐hydroxylated compound
Hydroxylation (likely to be 2‐ethyl or 6‐ position)
Kintz 100, Moosmann 134
Nifoxipam 7‐aminonifoxipam, 7‐acetaminonifoxipam El Balkhi 104, Meyer 133
Nimetazepam Nitrazepam, 7‐aminonimetazepam Wang 136
Nitrazolam 8‐aminonitrazolam
Mono hydroxylated metabolite (likely either 4‐ or α‐ position)
Moosmann 134
Phenazepam 3‐hydroxyphenazepam
Hydroxylation and methoxy addition (positions undetermined)
Zherdev 18, Maskell 110
Pyrazolam No detectable metabolites in serum or urine Moosmann 113
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8 | SUMMARY
The use and abuse of benzodiazepines is already common throughout
the world. In recent years, there has been a large increase in the num-
ber of novel psychoactive substances. Benzodiazepines are only a
small subsection of the total number of novel psychoactive substances
but that number is steadily increasing. NPS‐benzodiazepines are
appearing in a variety of countries across the world. NPS‐
thienodiazepines are appearing at a much slower rate, perhaps because
of a lower usage clinically and the already widespread availability of
benzodiazepines. NPS‐benzodiazepines have been implicated in
deaths in England and Wales and the increasing availability of all novel
psychoactive substances led to the introduction of the Psychoactive
Substances Act within the UK in 2016. It remains to be seen whether
this will affect the supply and use of NPS‐benzodiazepines because
phenazepam and etizolam were placed under control in the UK under
the Misuse of Drugs Act 1971 but are still regularly identified in post‐
mortem cases and in drug‐impaired drivers within the UK. The same
may be expected for the NPS‐benzodiazepines. The pharmacokinetics
and metabolic pathways of NPS‐benzodiazepines are not currently
well understood and there can be huge variation in pharmacokinetic
parameters between individual compounds. Further investigation is
clearly needed to establish the exact pharmacology of these novel psy-
choactive substances.
REFERENCES
1. UNODC (United Nations Office on Drugs and Crime). World drug
report 2016. Available at: https://www.unodc.org/documents/colom-
bia/2016/WDR/WORLD_DRUG_REPORT_2016_web.pdf [March
2017].
2. EMCDDA (European Monitoring Centre for Drugs and Drug Addic-
tion)‐Europol. European drug report: Trends and Developments
2015. Available at: http://www.emcdda.europa.eu/attachements.
cfm/att_239505_EN_TDAT15001ENN.pdf [March 2017].
3. EMCDDA (European Monitoring Centre for Drugs and Drug Addic-
tion)‐Europol. European drug report: Trends and Developments
2016. Available at: http://www.emcdda.europa.eu/system/files/pub-
lications/2637/TDAT16001ENN.pdf [March 2017].
4. UNODC (United Nations Office on Drugs and Crime). The Interna-
tional drug control conventions, schedules of the Convention on
psychotropic substances of 1971 as at 4 November 2015.
5. Bachhuber MA, Hennessy S, Cunningham CO, Starrels JL. Increasing
benzodiazepine prescriptions and overdose mortality in the United
States 1996–2013. Am J Public Health. 2016;106:686‐688.
6. Health and Social Care Information Centre. Prescriptions dispensed in
the community, Statistics for England ‐ 2004‐2014. 2015.
7. Jones JD, Mogali S, Comer SD. Polydrug abuse: A review of opioid and
benzodiazepine combination use. Drug Alcohol Depend. 2012;125:8‐
18.
8. Kapil V, Green JL, Lait CL, Wood DM, Dargan PI. Misuse of benzodiaz-
epines and Z‐drugs in the UK. Brit J Psychiat. 2014;205:407‐408.
9. Vogel M, Knöpfli B, Schmid O, et al. Treatment or "high": Benzodiaze-
pine use in patients on injectable heroin or oral opioids. Addict Behav.
2013;38:2477‐2484.
10. Huppertz L, Bisel P, Westphal F, Franz F, Auwärter V, Moosmann B.
Characterization of the four designer benzodiazepines clonazolam,
deschloroetizolam, flubromazolam, and meclonazepam, and identifica-
tion of their in vitro metabolites. Forensic Toxicol. 2015;33:388‐395.
11. RAND Corporation, Internet‐facilitated drugs trade: An analysis of the
size, scope and the role of the Netherlands, 2016, Available from
http://www.rand.org/pubs/research_reports/RR1607.html [31 May
2017]
12. UNODC (United Nations Office on Drugs and Crime). The challenge
of new psychoactive substances. Available at: https://www.unodc.
org/documents/scientific/NPS_2013_SMART.pdf [31 May 2017].
13. Reddit. Available at: www.reddit.com [31 May 2017].
14. Bluelight. Available at: www.bluelight.org [31 May 2017].
15. Flashback. Available at: https://www.flashback.org/t2805464 [31
May 2017].
16. UK chemical research. Available at: https://www.ukchemicalresearch.
org/Thread‐N‐Desalkylflurazepam‐Norflurazepam [31 May 2017].
17. EMCDDA (European Monitoring Centre for Drugs and Drug Addic-
tion). EMCDDA–Europol 2007 Annual report on the implementation
of Council Decision 2005/387/JHA. Available at: http://www.
emcdda.europa.eu/system/files/publications/503/2007_Implementa-
tion_report_281403.pdf [31 May 2017].
18. Zherdev VP, Caccia S, Garattini S, Ekonomov AL. Species differences
in phenazepam kinetics and metabolism. Eur J Drug Metab
Pharmacokinet. 1982;7:191‐196.
19. Чекулаев МИ, Владимировна MT, Барсегян СC. Опасность
феназепама как уличного наркотика. 3доровье и образование в
XXI веке. 2015;17:85‐86.
20. Zhu B‐L, Meng L, Zheng K‐F. Analysis of the new psychoactive sub-
stance of phenazepam. Chin J Forensic Sci. 2014;6:44
21. McAuleya A, Hecht G, Barnsdale L, et al. Mortality related to novel
psychoactive substances in Scotland, 2012: An exploratory study. Int
J Drug Policy. 2015;26:461‐467.
22. Shearer K, Bryce C, Parsons M, Torrance H. Phenazepam: A review of
medico‐legal deaths in south Scotland between 2010 and 2014.
Forensic Sci Int. 2015;254:197‐204.
23. Simonsen KW, Edvardsen HME, Thelander G, et al. Fatal poisoning in
drug addicts in the Nordic countries in 2012. Forensic Sci Int.
2015;248:172‐180.
24. Kriikku P, Wilhelm L, Rintatalo J, Hurme J, Kramer J, Ojanperä I.
Phenazepam abuse in Finland: Findings from apprehended drivers,
post‐mortem cases and police confiscations. Forensic Sci Int.
2012;10:1‐3.
25. Stephenson JB, Golz DE, Brasher MJ. Phenazepam and its effects on
driving. J Anal Toxicol. 2013;37:25‐29.
26. Government of Finland, Valtioneuvoston asetus huumausaineina
pidettävistä aineista, valmisteista ja kasveista annetun
valtioneuvoston asetuksen liitteen IV muuttamisesta, Available at:
http://www.finlex.fi/fi/laki/alkup/2014/20140589 [31 May 2017].
27. Government of China, 关于印发《非药用类麻醉药品和精神药品列管
办法》的通知. Available at: http://www.sfda.gov.cn/WS01/CL0056/
130753.html [31 May 2017].
28. U.K. Government, Import ban of new 'legal high' phenazepam intro-
duced, Available at: https://www.gov.uk/government/news/import‐
ban‐of‐new‐legal‐high‐phenazepam‐introduced [31 May 2017].
29. UN Commission on Narcotic Drugs. Inclusion of Phenazepam in
schedule iv of the Convention on psychotropic substances of 1971.
2016
30. EMCDDA (European Monitoring Centre for Drugs and Drug Addic-
tion)‐Europol. EMCDDA–Europol 2011 Annual report on the
implementation of Council Decision 2005/387/JHA, 2011. Available
at: http://www.emcdda.europa.eu/system/files/publications/689/
EMCDDA‐Europol_Annual_Report_2011_2012_final_335568.pdf
[31 May 2017].
31. Mitsubishi‐Tanabe‐Pharma‐Corporation, 2016. Available at: https://
medical.mt‐pharma.co.jp/di/file/if/f_dep.pdf [31 May 2017].
32. EMCDDA. (European Monitoring Centre for Drugs and Drug
Addiction)‐Europol. EMCDDA–Europol 2012 Annual report on the
implementation of Council Decision 2005/387/JHA, 2012. Available
at: http://www.emcdda.europa.eu/system/files/publications/734/
MANCHESTER ET AL. 13
EMCDDA‐Europol_2012_Annual_Report_final_439477.pdf [31 May
2017].
33. EMCDDA (European Monitoring Centre for Drugs and Drug Addic-
tion)‐Europol. EMCDDA‐Europol 2013 Annual report on the
implementation of Council Decision 2005/387/JHA, 2013. Available
at: http://www.emcdda.europa.eu/system/files/publications/814/
TDAN14001ENN_475519.pdf [31 May 2017].
34. EMCDDA (European Monitoring Centre for Drugs and Drug Addic-
tion)‐Europol. EMCDDA‐Europol 2014 Annual report on the
implementation of Council Decision 2005/387/JHA, 2014. Available
at: http://www.emcdda.europa.eu/system/files/publications/1018/
TDAN15001ENN.pdf [31 May 2017].
35. EMCDDA (European Monitoring Centre for Drugs and Drug Addic-
tion)‐Europol. EMCDDA–Europol 2015 Annual report on the
implementation of Council Decision 2005/387/JHA, 2016. Available
at: http://www.emcdda.europa.eu/system/files/publications/1018/
TDAN15001ENN.pdf [31 May 2017].
36. Mitsubishi‐Tanabe‐Pharma‐Corporation, 2009. Available at: https://
medical.mt‐pharma.co.jp/di/file/if/f_crm.pdf [31 May 2017].
37. Medical Products Agency Sweden, 2016. Available at: https://
lakemedelsverket.se/overgripande/Lagar‐‐regler/Yttranden‐enligt‐
lagen‐om‐forstorande‐av‐vissa‐halsofarliga‐missbrukssubstanser/ [31
May 2017].
38. Medical Products Agency Sweden, 2016. Available at: https://www.
folkhalsomyndigheten.se/documents/tillsyn‐regelverk/klassificering‐
missbrukssubstanser/substanser/n‐desmetylflunitrazepam.pdf [31
May 2017].
39. Austrian Public Health Institute, 2016. Available at: https://forum.
goeg.at/EwsForum/default.aspx?g=posts&m=270 [31 May 2017].
40. National forensic laboratory Slovenia, 2016. Available at: http://www.
policija.si/apps/nfl_response_web/0_Analytical_Reports_final/Ro5‐
4864_(Chlorodiazepam)‐ID‐1567‐16_rpt‐110816.pdf [31 May 2017].
41. Office for National Statistics, Deaths Related to Drug Poisoning in
England and Wales: 2014 registrations, 2014. Available from: http://
www.ons.gov.uk/ons/rel/subnational‐health3/deaths‐related‐to‐
drug‐poisoning/england‐and‐wales‐‐‐2014/index.html [31 May
2017].
42. UKGovernment. Psychoactive substances bill. 2015, Available at: https://
www.gov.uk/government/collections/psychoactive‐substances‐bill‐2015
[31 May 2017].
43. UK government. Misuse of drugs act, 1971.
44. Drummer OH. The Forensic Pharmacology of Drugs of Abuse. Arnold,
UK; 2001.
45. Smith MT, Evans LEJ, Eadie MJ, Tyre JH. Pharmacokinetics of
prazepam in man. Eur J Clin Pharmacol. 1979;16:141‐147.
46. Mandelli M, Tognoni G, Garattini S. Clinical pharmacokinetics of diaz-
epam. Clin Pharmacokinet. 1978;3:72‐91.
47. Breimer DD, Jochemsen R. Clinical pharmacokinetics of hypnotic ben-
zodiazepines. Brit J Clin Pharmacol. 1983;16:277S‐278S.
48. Gerhards HJ. Neuropharmacological profile of clobazam, a new 1′,5′‐
benzodiazepine. Psychopharmacol. 1978;58:27‐33.
49. Greenblatt DJ, Moltke LLv, Harmatz JS, Ciraulo DA, Shader RI. Alpraz-
olam pharmacokinetics, metabolism, and plasma levels: Clinical
implications. J Clin Psychiatry. 1993;54:4‐14.
50. Smith MT, Eadie MJ, Brophy TOR. The pharmacokinetics of midazo-
lam in man. Eur J Clin Pharmacol. 1981;19:271‐278.
51. Fischer‐Cornelssen KA. Multicenter trials and complementary studies
of cloxazolam, a new anxiolytic drug. Arzneimittelforschung.
1981;31:1757‐1765.
52. Bertolino A, Mastucci E, Porro V, et al. Etizolam in the treatment of
generalized anxiety disorder: A controlled clinical trial. J Int Med Res.
1989;17:455‐460.
53. Casacchiaa M, Bolinoa F, Ecarib U. Etizolam in the treatment of gener-
alized anxiety disorder: A double‐blind study versus placebo. Curr Med
Res Op. 1990;12:215‐223.
54. Langley MS, Clissold SP. Brotizolam. A review of its pharmacodynamic
and pharmacokinetic properties, and therapeutic efficacy as an hyp-
notic. Drugs. 1988;35:104‐122.
55. Rundfeldt C, Socała K, Wlaź P. The atypical anxiolytic drug, tofisopam,
selectively blocks phosphodiesterase isoenzymes and is active in the
mouse model of negative symptoms of psychosis. J Neural Transm.
2010;117:1319‐1325.
56. Gitto R, Zappalà M, Sarro GD, Chimirri A. Design and development of
2,3‐benzodiazepine (cfm) noncompetitive ampa receptor antagonists.
Il Farmaco. 2002;57:129‐134.
57. Horváth EJ, Horváth K, Hámori T, Fekete MI, Sólyom S, Palkovits M.
Anxiolytic 2,3‐benzodiazepines, their specific binding to the basal gan-
glia. Prog Neurobiol. 2000;60:309‐342.
58. GABAA (Γ‐aminobutyric acid). Brit J Clin Pharmacol. 2009;158(Suppl
1):S110‐S112.
59. Olsen RW, Sieghart W. International Union of Pharmacology. Lxx.
Subtypes of gamma‐aminobutyric acid(a) receptors: Classification on
the basis of subunit composition, pharmacology, and function.
Update. Pharmacol Rev. 2008;60:243‐260.
60. Olsen RW, Sieghart W. GABAA receptors: Subtypes provide diversity
of function and pharmacology. Neuropharmacology. 2009;56:141‐148.
61. Sieghart W, Sperk G. Subunit composition, distribution and function
of GABAA receptor subtypes. Curr Top Med Chem. 2002;2:795‐816.
62. Tan KR, Rudolph U, Lüscher C. Hooked on benzodiazepines: GABAA
receptor subtypes and addiction. Trends Neurosci. 2011;34:188‐197.
63. Heikkinen AE, Möykkynen TP, Korpi ER. Long‐lasting modulation of
glutamatergic transmission in Vta dopamine neurons after a single
dose of benzodiazepine agonists. Neuropsychopharmacology.
2009;34:290‐298.
64. Tan KR, Brown M, Labouèbe G, et al. Neural bases for addictive prop-
erties of benzodiazepines. Nature. 2010;463:769‐774.
65. Sigel E, Steinmann ME. Structure, function, and modulation of GABAA
receptors. J Biol Chem. 2012;287:40224‐40231.
66. Grobin AC, Matthews DB, Devaud LL, Morrow AL. The role of
GABAA receptors in the acute and chronic effects of ethanol.
Psychopharmacol. 1998;139:2‐19.
67. Olsen RW. GABA‐benzodiazepine‐barbiturate receptor interactions. J
Neurochem. 1981;37:1‐13.
68. Holmes PV, Drugan RC. Differential effects of anxiogenic central and
peripheral benzodiazepine receptor ligands in tests of learning and
memory. Psychopharmacol. 1991;104:249‐254.
69. Papadopoulos V, Baraldi M, GuilarteTR, et al. Translocator protein (18
Kda): New nomenclature for the peripheral‐type benzodiazepine
receptor based on its structure and molecular function. Trends
Pharmacol Sci. 2006;27:402‐409.
70. Casellas P, Galiegue S, Basile AS. Peripheral benzodiazepine receptors
and mitochondrial function. Neurochem Int. 2002;40:475‐486.
71. Gavish M, Bachman I, Shoukrun R, et al. Enigma of the peripheral ben-
zodiazepine receptor. Pharmacol Rev. 1999;51:629‐650.
72. Rupprecht R, Papadopoulos V, Rammes G, et al. Translocator protein
(18 Kda) (Tspo) as a therapeutic target for neurological and psychiatric
disorders. Nat Rev Drug Discov. 2010;9:971‐988.
73. Papadopoulos V, Lecanu L. Translocator protein (18 Kda) Tspo: An
emerging therapeutic target in neurotrauma. Exp Neurol.
2009;219:53‐57.
74. Rupprecht R, Rammes G, Eser D, et al. Translocator protein (18 Kd) as
target for anxiolytics without benzodiazepine‐like side effects. Sci-
ence. 2009;325:490‐493.
75. Pellow S, File SE. Anxiolytic and anxiogenic drug effects on explor-
atory activity in an elevated plus‐maze: A novel test of anxiety in
the rat. Pharmacol Biochem Behav. 1986;24:525‐529.
14 MANCHESTER ET AL.
76. File SE, Green AR, Nutt DJ, Vincent ND. On the convulsant action of
Ro 5‐4864 and the existence of a micromolar benzodiazepine binding
site in rat brain. Psychopharmacol. 1984;82:199‐202.
77. Gavish M, Katz Y, Bar‐Ami S, Weizman R. Biochemical, physiological,
and pathological aspects of the peripheral benzodiazepine receptor.
J Neurochem. 1991;58:1589‐1601.
78. Lomas EC, Maskell PD. Phenazepam: More information coming in
from the cold. J Forensic Leg Med. 2015;36:61‐62.
79. Moosmann B, Huppertz L, Hutter M, Buchwald A, Ferlaino S,
Auwärter V. Detection and identification of the designer benzodiaze-
pine flubromazepam and preliminary data on its metabolism and
pharmacokinetics. J Mass Spectrom. 2013;48:1150‐1159.
80. Smith RB, Kroboth PD, Phillips JP. Temporal variation in triazolam
pharmacokinetics and pharmacodynamics after oral administration. J
Clin Pharmacol. 1986;26:120‐124.
81. Moosmann B, Bisel P, Auwärter V. Characterization of the designer
benzodiazepine diclazepam and preliminary data on its metabolism
and pharmacokinetics. Drug Test Anal. 2014;6:757‐763.
82. Kroboth PD, McAuley JW, Kroboth FJ, Bertz RJ, Smith RB. Triazolam
pharmacokinetics after intravenous, oral, and sublingual administra-
tion. J Clin Psychopharmacol. 1995;15:259‐262.
83. Ochs HR, Otten H, Greenblatt DJ, Dengler HJ. Diazepam absorption:
Effects of age, sex, and billroth gastrectomy. Dig Dis Sci. 1982;27:225‐
230.
84. Klotz U, Antonin KH, Bieck PR. Pharmacokinetics and plasma binding
of diazepam in man, dog, rabbit, guinea pig and rat. J Pharmacol Exp
Therapeut. 1976;199:67‐73.
85. Garzone PD, Kroboth PD. Pharmacokinetics of the newer benzodiaz-
epines. Clin Pharmacokinet. 1989;16:337‐364.
86. Sonne J, Loft S, Døssing M, et al. Bioavailability and pharmacokinetics
of oxazepam. Eur J Clin Pharmacol. 1988;35:385‐389.
87. Boxenbaum HG, Posmanter HN, Macasieb T, et al. Pharmacokinetics
of Flunitrazepam following single‐ and multiple‐dose oral administra-
tion to healthy human subjects. J Pharmacokinet Biopharm.
1978;6:283‐293.
88. Crichton ML, Shenton CF, Drummond G, Beer LJ, Seetohul LN,
Maskell PD. Analysis of phenazepam and 3‐hydroxyphenazepam in
post‐mortem fluids and tissues. Drug Test Anal. 2015;7:926‐936.
89. Ajir K, Smith M, Lin KM, et al. The pharmacokinetics and pharmacody-
namics of adinazolam: Multi‐ethnic comparisons. Psychopharmacol.
1997;129:265‐270.
90. Fleishaker JC, Hulst LK, Smith TC, Friedman H. Clinical pharmacology
of adinazolam and N‐desmethyladinazolam mesylate following single
intravenous infusions of each compound in health volunteers. Eur J
Clin Pharmacol. 1992;42:287‐294.
91. Fleishaker JC, Phillips JP. Adinazolam pharmacokinetics and behav-
ioral effects following administration of 20‐60 mg oral doses of its
Mesylate salt in healthy volunteers. Psychopharmacol. 1989;99:34‐39.
92. Fleishaker JC, Wright CE. Pharmacokinetic and Pharmacodynamic
comparison of immediate‐release and sustained‐release adinazolam
mesylate tablets after single‐ and multiple‐dose administration. Pharm
Res. 1992;9:457‐463.
93. Venkatakrishnan K, Culm KE, Ehrenberg BL, et al. Kinetics and dynam-
ics of intravenous adinazolam, n‐desmethyl adinazolam, and
alprazolam in healthy volunteers. J Clin Pharmacol. 2005;45:529‐537.
94. Bluelight. Available at: http://www.bluelight.org/vb/threads/791664‐
Flunitrazolam [31 May 2017].
95. Høiseth G, Tuv SS, Karinen R. Blood concentrations of new designer
benzodiazepines in forensic cases. Forensic Sci Int. 2016;268:35‐38.
96. Bluelight. Available at: http://www.bluelight.org/vb/threads/775400‐
Cloniprazepam [31 May 2017].
97. Reddit. Available at: https://www.reddit.com/r/researchchemicals/
comments/5gciof/fonazepam_first_thoughts/ [31 May 2017].
98. Flashback. [cited 2017 January]; Available from: https://www.flash-
back.org/t2650660 [31 May 2017].
99. Xu C, Li CY‐T, Kong A‐NT. Induction of phase I, ii and iii drug metab-
olism/transport by xenobiotics. Arch Pharm Res. 2005;28:249‐268.
100. Kintz P, Richeval C, Jamey C, et al. Detection of the designer benzodi-
azepine metizolam in urine and preliminary data on its metabolism.
Drug Test Anal. 2016. https://doi.org/10.1002/dta.2099.
101. Lukasik‐Glebocka M, Sommerfeld K, Tezyk A, Zielinska‐Psuja B,
Panienski P, Zaba C. Flubromazolam‐‐a new life‐threatening designer
benzodiazepine. Clin Toxicol (Phila). 2016;54:66‐68.
102. Mitsubishi Tanabe Pharma Corporation. Available at: https://medical.
mt‐pharma.co.jp/di/file/if/f_crm.pdf [31 May 2017].
103. UK chemical research. Available at: https://www.ukchemicalresearch.
org/Thread‐meclonazepam [31 May 2017].
104. El Balkhi S, Chaslot M, Picard N, et al. Characterization and identifica-
tion of eight designer benzodiazepine metabolites by incubation with
human liver microsomes and analysis by a triple quadrupole mass
spectrometer. Int J Leg Med. 2017; https://doi.org/10.1007/s00414‐
00017‐01541‐00416
105. Katselou M, Papoutsis I, Nikolaou P, Spiliopoulou C, Athanaselis S.
Metabolites replace the parent drug in the drug arena. The cases of
fonazepam and nifoxipam. Forensic Toxicol. 2017;35:1‐10.
106. PMDA (Pharmaceutical and medical devices Agency) Japan. 2017.
Available at: http://www.info.pmda.go.jp/go/pack/1124004F1042_
2_09/ [31 May 2017].
107. JAPIC (Japan Pharmaceutical information center). 2005. Available at:
http://www.japic.or.jp/service/whats_new/japicnews/pdf/254.pdf
[31 May 2017].
108. Yakuzaishiharowa. 2017. Available at: http://yakuzaishiharowa.com/
medical_pharmacy/bz‐medicine.html [31 May 2017].
109. UK chemical research. Available at: https://www.ukchemicalresearch.
org/Thread‐Nitrazolam [31 May 2017].
110. Maskell PD, De‐Paoli G, Seetohul LN, Pounder DJ. Phenazepam: The
drug that came in from the cold. J Forensic Leg Med. 2012;19:122‐125.
111. Kerrigan S, Mellon MB, Hinners P. Detection of phenazepam in
impaired driving. J Anal Toxicol. 2013;37:605‐610.
112. Lomas EC, Maskel PD. Phenazepam: More information coming in
from the cold. J Forensic Leg Med. 2015;36:61‐62.
113. Moosmann B, Hutter M, Huppertz LM, Ferlaino S, Redlingshöfer L,
Auwärter V. Characterization of the designer benzodiazepine
pyrazolam and its detectability in human serum and urine. Forensic
Toxicol. 2013;31:263‐271.
114. Mizuno K, Katoh M, Okumura H, et al. Metabolic activation of benzo-
diazepines by Cyp3a4. Drug Metab Dispos. 2009;37:345‐351.
115. Fukasawa T, Suzuki A, Otani K. Effects of genetic polymorphism of
cytochrome P450 enzymes on the pharmacokinetics of benzodiaze-
pines. J Clin Pharm Therapeut. 2007;32:333‐341.
116. Whirl‐Carrillo M, McDonagh EM, Hebert JM, et al.
Pharmacogenomics knowledge for personalized medicine. Clin
Pharmacol Therapeut. 2012;92:414‐417.
117. Parmeggiani A, Posar A, Sangiorgi S, Giovanardi‐Rossi P. Unusual
sideeffects due to clobazam: A case report with genetic study of
Cyp2c19. Brain Dev. 2004;26:63‐66.
118. Fukasawa T, Yasui‐Furukori N, Suzuki A, Inoue Y, Tateishi T, Otani K.
Pharmacokinetics and pharmacodynamics of etizolam are influenced
by polymorphic Cyp2c19 activity. Eur J Clin Pharmacol.
2005;61:791‐795.
119. Sohn DR, Kusaka M, Ishizaki T, et al. Incidence of S‐mephenytoin
hydroxylation deficiency in a Korean population and the
interphenotypic differences in diazepam pharmacokinetics. Clin
Pharmacol Therapeut. 1992;52:160‐169.
120. Goldstein JA. Clinical relevance of genetic polymorphisms in the
human Cyp2c subfamily. Brit J Clin Pharmacol. 2001;52:349‐355.
MANCHESTER ET AL. 15
121. Bertilsson L, Henthorn TK, Sanz E, Tybring G, Säwe J, Villén T. Impor-
tance of genetic factors in the regulation of diazepam metabolism:
Relationship to S‐Mephenytoin, but not debrisoquin, hydroxylation
phenotype. Clin Pharmacol Therapeut. 1989;45:348‐355.
122. Court MH, Hao Q, Krishnaswamy S, et al. Udp‐glucuronosyltransfer-
ase (Ugt) 2b15 pharmacogenetics: Ugt2b15 D85y genotype and
gender are major determinants of oxazepam glucuronidation by
human liver. J Pharmacol Exp Therapeut. 2004;310:656‐665.
123. Court MH, Duan SX, Guillemette C, et al. Stereoselective conjugation
of oxazepam by human udp‐glucuronosyltransferases (Ugts): S‐oxaze-
pam is glucuronidated by Ugt2b15, while R‐oxazepam is
glucuronidated by Ugt2b7 and Ugt1a9. Drug Metab Dispos.
2002;30:1257‐1265.
124. Bourcier K, Hyland R, Kempshall S, et al. Investigation into Udp glucu-
ronosyltransferase (Ugt) enzyme kinetics of imidazole‐ and triazole
containing antifungal drugs in human liver microsomes and recombi-
nant Ugt enzymes. Drug Metab Dispos. 2010;38:923‐929.
125. Olivera M, Martínez C, Gervasini G, et al. Effect of common Nat2 var-
iant alleles in the acetylation of the major clonazepam metabolite, 7‐
Aminoclonazepam. Drug Metab Lett. 2007;1:3‐5.
126. Peppers MP. Benzodiazepines for alcohol withdrawal in the elderly
and in patients with liver disease. Pharmacotherapy. 1996;16:49‐57.
127. Mozayani A, Raymon L. Handbook of Drug Interactions: A Clinical and
Forensic Guide. New York: Springer Science & Business Media; 2003.
128. Fraser AD, BryanW, Isner AF. Urinary screening for alprazolam and its
major metabolites by the Abbott Adx and Tdx analyzers with confir-
mation by GC/MS. J Anal Toxicol. 1991;15:25‐29.
129. Inoue T, Niwaguchi T. Determination of nitrazepam and its main
metabolites in urine by thin‐layer chromatography and direct densi-
tometry. J Chromatogr. 1985;339:163‐169.
130. Kopanitsa MV, Zhuk OV, Zinkovsky VG, Krishtal OA. Modulation of
GABAA receptor‐mediated currents by phenazepam and its metabo-
lites. Naunyn Schmiedebergs Arch Pharmacol. 2001;364:1‐8.
131. Rasanen I, Ojanperä I, Vuori E. Quantitative screening for benzodiaz-
epines in blood by dual‐column gas chromatography and comparison
of the results with urine immunoassay. J Anal Toxicol. 2000;24:46‐53.
132. Fraser AD, Isner AF, Bryan W. Urinary screening for adinazolam and
its major metabolites by the emit D.A.U. And FPIA benzodiazepine
assays with confirmation by HPLC. J Anal Toxicol. 1993;17:427‐431.
133. Meyer MR, Bergstrand MP, Helander A, Beck O. Identification of main
human urinary metabolites of the designer nitrobenzodiazepines
clonazolam, meclonazepam, and nifoxipam by nano‐liquid chromatog-
raphy‐high‐resolution mass spectrometry for drug testing purposes.
Anal Bioanal Chem. 2016;408:3571‐3591.
134. Moosmann B, Bisel P, Franz F, Huppertz LM, Auwarter V. Character-
ization and in vitro phase I microsomal metabolism of designer
benzodiazepines ‐ an update comprising adinazolam, cloniprazepam,
fonazepam, 3‐hydroxyphenazepam, metizolam and nitrazolam. J Mass
Spectrom. 2016;51:1080‐1089.
135. Fracasso C, Confalonieri S, Garattini S, Caccia S. Single and multiple
dose pharmacokinetics of etizolam in healthy subjects. Eur J Clin
Pharmacol. 1991;40:181‐185.
136. Wang KC, Cheng MC, Hsieh CL, Hsu JF, Wu JD, Lee CK. Determina-
tion of nimetazepam and 7‐aminonimetazepam in human urine by
using liquid chromatography‐tandem mass spectrometry. Forensic Sci
Int. 2013;224:84‐89.
137. Uddin MN, Samanidou VF, Papadoyannis IN. An overview on total
analytical methods for the detection of 1,4‐benzodiazepines.
Pharmaceutica Analytica Acta. 2014;5:1‐13.
138. Persona K, Madej K, Knihnicki P, Piekoszewski W. Analytical method-
ologies for the determination of benzodiazepines in biological
samples. J Pharm Biomed Anal. 2015;113:239‐264.
139. Moffat AC, Osselton MD, Widdop B, Watts J. Clarke's Analysis of
Drugs and Poisons. Fourth ed. London, UK: Pharmaceutical Press;
2011.
140. Krasowski MD, Pizon AF, Siam MG, Giannoutsos S, Iyer M, Ekins S.
Using molecular similarity to highlight the challenges of routine immu-
noassay‐based drug of abuse/toxicology screening in emergency
medicine. BMC Emerg Med. 2009;9:5
141. O'Connor LC, Torrance HJ, McKeown DA. Elisa detection of
phenazepam, etizolam, pyrazolam, flubromazepam, diclazepam and
delorazepam in blood using Immunalysis® benzodiazepine kit. J Anal
Toxicol. 2016;40:159‐161.
142. Pettersson Bergstrand M, Helander A, HanssonT, Beck O. Detectabil-
ity of designer benzodiazepines in Cedia, emit ii plus, Heia, and Kims ii
immunochemical screening assays. Drug Test Anal. 2016;9:640.
143. Pellow S, File SE. Behavioural actions of Ro 5‐4864: A peripheral‐type
benzodiazepine? Life Sci. 1984;35:229‐240.
144. Pettersson Bergstrand M, Helander A, Beck O. Development and
application of a multi‐component LC–Ms/Ms method for determina-
tion of designer benzodiazepines in urine. J Chromatogr B.
2016;1035:104‐110.
145. Lambert WE, Meyer E, Xue‐Ping Y, Leenheer APD. Screening, identi-
fication, and quantitation of benzodiazepines in postmortem samples
by HPLC with photodiode array detection. J Anal Toxicol. 1995;19:35‐
40.
146. Akerman KK, Jolkkonen J, Parviainen M, Penttilä I. Analysis of
lowdose benzodiazepines by HPLC with automated solid‐phase
extraction. Clin Chem. 1996;42:1412‐1416.
147. Yegles M, Mersch F, Wennig R. Detection of benzodiazepines and
other psychotropic drugs in human hair by GC/MS. Forensic Sci Int.
1997;84:211‐218.
148. McClean S, O'Kane E, Hillis J, Smyth WF. Determination of 1,4‐ben-
zodiazepines and their metabolites by capillary electrophoresis and
high‐performance liquid chromatography using ultraviolet and
electrospray ionisation mass spectrometry. J Chromatogr A.
1999;838:273‐291.
149. Roman M, Strom L, Tell H, Josefsson M. Liquid chromatography/time‐
of‐flight mass spectrometry analysis of postmortem blood samples for
targeted toxicological screening. Anal Bioanal Chem. 2013;405:4107‐
4125.
150. Soriano T, Jurado C, Menendez M, Repetto M. Improved solid‐phase
extraction method for systematic toxicological analysis in biological
fluids. J Anal Toxicol. 2001;25:137‐143.
151. Anzillotti L, Odoardi S, Strano‐Rossi S. Cleaning up blood samples
using a modified “Quechers” procedure for the determination of drugs
of abuse and benzodiazepines by UPLC–MSMS. Forensic Sci Int.
2014;243:99‐106.
152. Usui K, Hayashizaki Y, Hashiyada M, Funayama M. Rapid drug extrac-
tion from human whole blood using a modified Quechers extraction
method. Leg Med. 2012;14:286‐296.
153. Westland JL, Dorman FL. Quechers extraction of benzodiazepines in
biological matrices. J Pharmaceut Anal. 2013;3:509‐517.
154. Famiglini G, Capriotti F, Palma P, Termopoli V, Cappiello A. The rapid
measurement of benzodiazepines in a milk‐based alcoholic beverage
using Quechers extraction and GC‐MS analysis. J Anal Toxicol.
2015;39:306‐312.
155. Peng GW. Assay of adinazolam in lasma by liquid chromatography. J
Pharm Sci. 1984;73:1173‐1175.
156. Vikingsson S, Wohlfarth A, Andersson M, et al. Identifying metabolites
of meclonazepam by high‐resolution mass spectrometry using human
liver microsomes, hepatocytes, a mouse model, and authentic urine
samples. AAPS J. 2017;19:736.
157. Bergstrand MP, Helander A, Beck O. Development and application of
a multi‐component LC–MS/MS method for determination of designer
benzodiazepines in urine. J Chromatogr B. 2016;1035:104‐110.
158. Nakamae T, Shinozuka T, Sasaki C, et al. Case report: Etizolam and its
major metabolites in two unnatural death cases. Forensic Sci Int.
2008;182:e1‐e6.
16 MANCHESTER ET AL.
159. Coassolo P, Aubert C, Cano JP. Plasma determination of 3‐
methylclonazepam by capillary gas chromatography. J Chromatogr.
1985;338:347‐355.
160. Ékonomov AL, Zherdev VP. Method of quantitative gas‐chromato-
graphic determination of phenazepam and its metabolite 3‐
hydroxyphenazepam in plasma. Pharmaceut Chem J. 1980;14:579‐
582.
161. O'Connor LC, Torrance HJ, McKeown DA. Elisa detection of
phenazepam, etizolam, pyrazolam, flubromazepam, diclazepam and
delorazepam in blood using Immunalysis benzodiazepine kit. J Anal
Toxicol. 2016;40:159‐161.
162. El Balkhi S, Chaslot M, Picard N, et al. Characterization and identifica-
tion of eight designer benzodiazepine metabolites by incubation with
human liver microsomes and analysis by a triple quadrupole mass
spectrometer. Int J Leg Med. 2017. https://doi.org/10.1007/s00414-
017-1541-6.
163. Zhuk OV, Zinkovsky VG, Schukin SI, Sivachenko AV. Biotransforma-
tion, pharmacokinetics and pharmacodynamics of cinazepam.
Pharmacol Rep. 2007;59:60‐61.
164. Schwartz MA, Postma E. Metabolism of flurazepam, a benzodiaze-
pine, in man and dog. J Pharm Sci. 1970;59:1800‐1806.
165. Heizmann P, Eckert M, Ziegler WH. Pharmacokinetics and bioavail-
ability of midazolam in man. Brit J Clin Pharmacol. 1983;16:43S‐49S.
166. Barzaghi N, Leone L, Monteleone M, Tomasini G, Perucca E. Pharma-
cokinetics of flutoprazepam, a novel benzodiazepine drug, in normal
subjects. Eur J Drug Metab Pharmacokinet. 1989;14:293‐298.
167. Nakatsuka I, Shimizu H, Asami Y, KatohT, Hirose A, Yoshitake A. Ben-
zodiazepines and their metabolites: Relationship between binding
affinity to the benzodiazepine receptor and pharmacological activity.
Life Sci. 1985;36:113‐119.
168. Skopp G. Preanalytic aspects in postmortem toxicology. Forensic Sci
Int. 2004;142:75‐100.
169. Robertson MD, Drummer OH. Stability of nitrobenzodiazepines in
postmortem blood. J Forensic Sci. 1998;43:5‐8.
170. El Mahjoub A, Staub C. Stability of benzodiazepines in whole blood
samples stored at varying temperatures. J Pharm Biomed Anal.
2000;23:1057‐1063.
171. Skopp G, Potsch L, Konig I, Mattern R. A preliminary study on the sta-
bility of benzodiazepines in blood and plasma stored at 4 degrees C.
Int J Leg Med. 1998;111:1‐5.
172. Melo P, Bastos ML, Teixeira HM. Benzodiazepine stability in postmor-
tem samples stored at different temperatures. J Anal Toxicol.
2012;36:52‐60.
173. Levine B, Blanke RV, Valentour JC. Postmortem stability of benzodi-
azepines in blood and tissues. J Forensic Sci. 1983;28:102‐115.
174. Watson SSKH, O'Connor L, McKeown DA. Determination of the sta-
bility of 10 novel benzodiazepines and 3 metabolites in urine using
LC‐MS/MS. 6th Annual Meeting of the United Kingdom and Ireland
Association of Forensic Toxicologists (UKIAFT), Manchester, UK,
2016 [ 31 May 2017].
175. Artemenko AG, Kuz'min VE, Muratov EN, Polishchuk PG, Borisyuk IY,
Golovenko NY. Influence of the structure of substituted benzodiaze-
pines on their pharmacokinetic properties. Pharmaceut Chem J.
2009;43:454‐462.
176. Kar S, Roy K. Predictive toxicity modelling of benzodiazepine drugs
using multiple in silico approaches: Descriptor‐based Qstr,
groupbased Qstr and 3d‐toxicophore mapping. Mol Simul.
2015;41:345‐355.
177. Hester JB, Duchamp DJ, Chidester CG. A synthetic approach to new
1,4‐benzodiazepine derivatives. Tetrahedron Lett. 1971;12:1609‐
1612.
178. Meguro K, Kuwada Y. Syntheses and structures of 7‐chloro‐2‐
hydrazino‐5‐phenyl‐3h‐1,4‐benzodiazepines and some isomeric
1,4,5‐benzotriazocines. Tetrahedron Lett. 1970;11:4039‐4042.
179. Sternbach LH. The benzodiazepine story. J Med Chem. 1979;22:1‐7.
180. Childress SJ, Gluckman MI. 1,4‐benzodiazepines. J Pharm Sci.
1964;53:577‐590.
181. Whitwam JG, Amrein R. Pharmacology of flumazenil. Acta
Anaesthesiol Scand Suppl. 1995;108:3‐14.
182. Maddalena DJ, Johnston GAR. Prediction of receptor properties and
binding affinity of ligands to benzodiazepine/GABAA receptors using
artificial neural networks. J Med Chem. 1995;38:715‐724.
183. Zalkind S. 'Death pill': Fentanyl disguised as other drugs linked to
spike in US overdoses. 2016. Available at: https://www.theguardian.
com/society/2016/may/10/fentanyl‐drug‐overdoses‐xanax‐pain-
killers [31 May 2017].
184. Ecstasydata.Org. Available at: https://www.ecstasydata.org/
resultsphp?start=0&search_field=all&s=etizolam [31 May 2017].
185. Oilman NW, Sternbach LH. Quinazolines and 1,4‐benzodiazepines. Li.
The synthesis of the T‐butyl analog of diazepam. J Heterocycl Chem.
1971;8:297‐300.
186. Borea PA. De novo analysis of receptor binding affinity data of benzo-
diazepines. Arzneimittelforschung. 1983;33:1086‐1088.
187. Haefely EKW, Gerecke M, Mohler H. Recent advances in the molecu-
lar pharmacology of benzodiazepine receptors and in the structure
activity relationships of their agonists and antagonists. Adv Drug Res.
1985;14:165‐322.
188. So SS, Karplus M. Genetic neural networks for quantitative structure
activity relationships: Improvements and application of benzodiaze-
pine affinity for benzodiazepine/GABAA receptors. J Med Chem.
1996;39:5246‐5256.
189. The Drug Enforcement Administration (DEA). Mimic alprazolam tablet
(actually containing melatonin) seized in New York. Microgram Bulle-
tin. 2009;42:80
190. Chong YK, Kaprawi MM, Chan KB. The quantitation of nimetazepam
in erimin‐5 tablets and powders by reverse‐phase HPLC. Microgram
Journal. 2004;2:27‐33.
191. LimWJL, Yap ATW, Mangudi M, Koh HB, Tang ASY, Chan KB. Detec-
tion of phenazepam in illicitly manufactured erimin 5 tablets. DrugTest
Anal. 2016;9:293‐305.
192. Megarbane B, Pirnay S, Borron SW, et al. Flunitrazepam does not alter
cerebral distribution of buprenorphine in the rat. Toxicol Lett.
2005;157:211‐219.
193. Broséus J, Gentile N, Esseiva P. The cutting of cocaine and heroin: A
critical review. Forensic Sci Int. 2016;262:73‐83.
How to cite this article: Manchester KR, Lomas EC, Waters L,
Dempsey FC, Maskell PD. The emergence of new psychoactive
substance (NPS) benzodiazepines: A review. Drug Test Anal.
2017;1–17. https://doi.org/10.1002/dta.2211
MANCHESTER ET AL. 17
Contents lists available at ScienceDirect
Science & Justice
journal homepage: www.elsevier.com/locate/scijus
The use of a quantitative structure-activity relationship (QSAR) model to
predict GABA-A receptor binding of newly emerging benzodiazepines
Laura Watersa,⁎, Kieran R. Manchestera, Peter D. Maskellb, Caroline Haegemanc, Shozeb Haiderc
a School of Applied Sciences, University of Huddersﬁeld, Huddersﬁeld, UK
b School of Science, Engineering and Technology, Abertay University, Dundee, UK
c School of Pharmacy, University College London, London, UK
A R T I C L E I N F O
Keywords:
Benzodiazepines
QSAR
Biological activity
Prediction
New psychoactive substances
GABAA receptor
A B S T R A C T
The illicit market for new psychoactive substances is forever expanding. Benzodiazepines and their derivatives
are one of a number of groups of these substances and thus far their number has grown year upon year. For both
forensic and clinical purposes it is important to be able to rapidly understand these emerging substances.
However as a consequence of the illicit nature of these compounds, there is a deﬁciency in the pharmacological
data available for these ‘new’ benzodiazepines. In order to further understand the pharmacology of ‘new’ ben-
zodiazepines we utilised a quantitative structure-activity relationship (QSAR) approach. A set of 69 benzodia-
zepine-based compounds was analysed to develop a QSAR training set with respect to published binding values
to GABAA receptors. The QSAR model returned an R2 value of 0.90. The most inﬂuential factors were found to be
the positioning of two H-bond acceptors, two aromatic rings and a hydrophobic group. A test set of nine random
compounds was then selected for internal validation to determine the predictive ability of the model and gave an
R2 value of 0.86 when comparing the binding values with their experimental data. The QSAR model was then
used to predict the binding for 22 benzodiazepines that are classed as new psychoactive substances. This model
will allow rapid prediction of the binding activity of emerging benzodiazepines in a rapid and economic way,
compared with lengthy and expensive in vitro/in vivo analysis. This will enable forensic chemists and tox-
icologists to better understand both recently developed compounds and prediction of substances likely to emerge
in the future.
1. Introduction
Benzodiazepines and their derivatives are routinely prescribed for a
variety of medical conditions as anxiolytic, anti-insomnia and anti-
convulsant drugs, acting on the gamma-aminobutyric acid type A
(GABAA) receptor [1,2]. The endogenous neurotransmitter for the
GABAA receptor is gamma-aminobutyric acid (GABA), the binding of
which reduces the excitability of the cell [3]. Benzodiazepines po-
tentiate the response of the GABAA receptor to GABA which results in
far less cellular excitability which, in physiological terms, results in
sedation and relaxation [1].
In these circumstances benzodiazepines are medically beneﬁcial by
alleviating stress and agitation in patients through their anxiolytic ef-
fects. However, as a result of their psychoactive eﬀects, benzodiaze-
pines have a long history of abuse and are often illicitly obtained [4–6].
In more recent years a steady stream of benzodiazepines have appeared
on the illicit market that have either been newly-synthesised or are li-
censed as prescription drugs in another country but not in the home
country [7–10]. These are termed ‘new psychoactive substances’ (NPS)
[11,12]. The majority of these emerging benzodiazepines have not
undergone standard pharmaceutical trials and can be quite variant in
their eﬀects and potentially dangerous in their activity [13]. Although
relatively safe when used as medically prescribed, concurrent use of
benzodiazepines and opioids (either prescribed or abused) can lead to
respiratory depression and death [4,14,15]. When benzodiazepines are
not carefully prescribed and monitored, they can cause a variety of side
eﬀects including tolerance and dependency if taken long-term and
sudden withdrawal can cause medical problems including anxiety and
insomnia [16–18]. These NPS benzodiazepines have already been re-
ported in a number of overdose cases, driving under the inﬂuence of
drugs (DUID) cases and hospital admissions [8,19–22]. The lack of
control and safety over these illicit benzodiazepines is a prevalent issue
and it is likely that it will become an even more worrying trend as their
misuse continues to rise.
Benzodiazepines are a diverse group of psychoactive compounds
with a central structural component consisting of a benzene ring and a
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diazepine ring (Fig. 1). A whole host of derivatives exist which include
triazolobenzodiazepines, thienotriazolobenzodiazepines and imidazo-
benzodiazepines (see Supplementary information Fig. S1 and Table S1).
Quantitative structure-activity relationship (QSAR) models attempt
to correlate molecular structure to biological activity, often using a
variety of molecular descriptors such as physiochemical, topological,
electronic and steric properties [23]. Typically, a set of compounds
whose biological activity is known is used to create a ‘training’ dataset
and a model. This model can then be used to predict the unknown
biological activity of compounds with a similar structure or to explore
the structural features that are important for the speciﬁc biological
activity in question. QSAR has been extensively used for a variety of
reasons such as compound development in the pharmaceutical industry
and the pharmacological interpretation of drug-related deaths [24–26].
In terms of applications towards new psychoactive substances, the
predictive power of QSAR has been mainly applied to cannabinoid
binding to the CB1 and CB2 receptors [27–29] but has also been used to
examine the biological activity of hallucinogenic phenylalkylamines
[30], the binding of phenylalkylamines, tryptamines and LSD to the 5-
HT2A receptor [31] and methcathinone selectivity for dopamine (DAT),
norepinephrine (NAT) and serotonin transporters (SERT) [32]. Cur-
rently, the majority of novel benzodiazepines have not been analysed to
determine their physicochemical and biological properties as this
would require a substantial investment in both time and money. It is for
this reason that a fast, yet economical method to predict their proper-
ties is desirable.
QSAR has previously been applied to benzodiazepines to predict
bioavailability, absorption rate, clearance, half-life and volume of dis-
tribution for a group of benzodiazepines. This study included phena-
zepam [33], a benzodiazepine that appeared as an NPS in 2007 [34].
Other benzodiazepines (such as etizolam) only appeared as new psy-
choactive substances in the years following the publication of this
study. Furthermore, the application of a QSAR methodology has been
used for modelling post-mortem redistribution of benzodiazepines
where a good model was obtained (R2 = 0.98) in which energy, ioni-
sation and molecular size were found to exert signiﬁcant impact [35].
Quantitative structure-toxicity relationships (QSTR) have been used to
correlate the toxicity of benzodiazepines to their structure in an attempt
to predict the toxicity of these compounds [36]. More recently, a study
reported the use of QSTR whereby it was concluded that it is possible to
identify structural fragments responsible for toxicity (the presence of
amine and hydrazone substitutions as well as saturated heterocyclic
ring systems resulted in a greater toxicity) and potentially use this in-
formation to create new, less toxic benzodiazepines for medical use
[37].
Various QSAR models have been used to correlate benzodiazepine
structure to GABAA receptor binding and tease apart the complex re-
lationship between various substituents and their eﬀect on activity
[38–43] although none have speciﬁcally attempted to predict binding
values for benzodiazepines that are new psychoactive substances.
In this study we focus on the relationship between the structure of
characterised benzodiazepines and GABAA receptor binding, expressed
as the logarithm of the reciprocal of concentration (log 1/c) where c is
the molar inhibitory concentration (IC50) required to displace 50% of
[3H]-diazepam from rat cerebral cortex synaptosomal preparations
[41]. The purpose of this work is to create a QSAR model that can be
used to predict the potential biological activity of the newly-emerging
benzodiazepines to help understand, and therefore minimise their
harmful potential in a faster time scale compared with in vitro/in vivo
testing.
2. Methods and materials
2.1. Selection of the dataset
The binding data for the benzodiazepines was used as obtained from
the literature, experimentally determined using spectrometric mea-
surements of [3H]-diazepam displacement [44]. Benzodiazepines were
selected from four categories; 1,4-benzodiazepines, triazolobenzodia-
zepines, imidazobenzodiazepines and thienotriazolobenzodiazepines.
Benzodiazepines that did not have deﬁnitive binding values (i.e. listed
values were simply stated as> 1000 or> 5000) were excluded. For
simplicity benzodiazepines with atypical atoms or substituents (e.g. Ro
07-9238 which contained a sodium atom and Ro 05-5065 which con-
tained a naphthalene ring) were also excluded. Benzodiazepines that
also had atypical substitutions (i.e. positions R6, R8 and R9 from Fig. 1
which are not found in medically-used benzodiazepines or indeed those
that are new psychoactive substances) were also excluded. In total, 88
benzodiazepines were selected for the training dataset.
2.2. QSAR/software and data analysis method
The 88 benzodiazepines were converted from SMILES to 3D struc-
tures based on Merck Molecular Force Field (MMFF) atom type and
force ﬁeld optimisation. These compounds were then aligned by
common substructure and conﬁrmation to Ro 05-306. Subsequently,
the aligned compounds were clustered by Atomic Property Fields (APF)
to identify benzodiazepines with poor alignment. The APF method,
designed by MolSoft, uses the assignment of a 3D pharmacophore po-
tential on a continuously distributed grid using physio-chemical prop-
erties of the selected compound(s) to classify or superimpose com-
pounds. These properties include: hydrogen bond donors, acceptors,
Sp2 hybridisation, lipophilicity, size, electropositivity/negativity and
charge [45,46]. Poorly aligned benzodiazepines identiﬁed by APF
clustering were subjected to re-alignment using APF-based ﬂexible su-
perimposition. At this point, 10 benzodiazepines with poor alignment
were removed to improve model accuracy. (Supplementary information
Table S1).
From the remaining 78 aligned compounds, 9 compounds were
selected using a random number generator based on atmospheric noise.
These compounds were removed from the training set and used for ﬁnal
model validation. The residual 69 compounds were used as the training
set to build a 3D QSAR model, as shown in Fig. 2.
The APF 3D QSAR method was used where, for each of the 69
aligned compounds, the seven physicochemical properties were calcu-
lated and pooled together. Based on the activity data obtained from
literature and the 3D aligned structures for the known compounds,
weighted contributions for each APF component were obtained to allow
quantitative activity predictions for unknown compounds. The optimal
weight distributions were assigned by partial least-squares (PLS)
Fig. 1. The basic structural formula for benzodiazepines considered in this work.
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methodology, where the optimal number of latent vectors for PLS was
established by leave-one-out cross-validation on the training set. Then
the weighted contributions were added together. The 9 compounds for
validation and unknown compounds were assigned predicted binding
values by calculating their ﬁt within the combined QSAR APF. Any
unknown benzodiazepines were subjected to the conversion and
alignment protocol before predicted binding data was obtained. The
above steps were conducted using Molsoft's ICM Pro software [47].
Further analysis of the PLS model fragment contributions from the
69 compounds was conducted using SPCI software. Here, a 2D QSAR
model was built using the same PLS methodology as above.
Additionally, a consensus model was created from averaging the pre-
dictions of PLS, gradient boosting, support vector machine and random
forest modelling methods. The compounds were then subjected to au-
tomatic fragmentation and contribution calculations, which resulted in
information on 11 key contributing groups [48]. Using Ligand Scout
with default settings, four ligand-based pharmacophore models were
created using compounds with binding values of 6.0–9.0, 7.0–9.0,
8.0–9.0 and 8.5–9.0, as exempliﬁed in Fig. 3.
Ten benzodiazepines that had the highest predicted binding values
were docked into a modelled GABAA5 receptor using ICM software. The
GABAA5 receptor model was generated by homology modelling, using
the crystal structure of a human GABA(A)R-beta3 homopentamer (PDB
id 4COF) as a template. A pre-deﬁned binding site containing co-crys-
tallised benzodiazepine is already present in the template, which was
retained in the ﬁnal model. Modeller software was used to generate the
homology models [49]. The ﬁnal chosen model was energy minimized
using the ACEMD software [50]. The stereochemistry was checked
using Procheck and ProSA software [51,52]. The benzodiazepine in the
allosteric binding site on the GABAA5 receptor was used as a chemical
template to dock NPS-benzodiazepines and the best-scoring conforma-
tions were analysed.
The distances between principle physiochemical properties and
their weights in the pharmacophore model were calculated using the
software LigandScout [53].
3. Results and discussion
The data that was used to create the QSAR model (i.e. benzodia-
zepine structural substitutions and experimentally-observed binding
values) is provided in the Supplementary information (Table S1).
From the pharmacophore model visualised in Fig. 3 for highly
bound benzodiazepines (log 1/c of 8.0–9.0), it is evident that important
binding features for the benzodiazepines were the positioning of two H-
bond acceptors, two aromatic rings and a hydrophobic group all with
weights of 1.0.
The predicted binding values are not presented here but are listed in
Supplementary Information (Table S1). They can be visualised in Fig. 4
as a plot of the observed binding value versus the predicted binding
value.
Nine compounds were selected at random from the QSAR training
set and their binding values estimated using the model as a system of
Fig. 2. Alignment of 69 training set benzodiazepines shown in two orientations.
Fig. 3. Pharmacophore model of 33 compounds with binding values 8.0–9.0.
Fig. 4. Literature (i.e. observed) binding values (log 1/c) vs. QSAR predicted binding
values ﬁt with a partial least squares (PLS) regression (R2 = 0.90).
Fig. 5. Literature (i.e. observed) binding values (log 1/c) vs. QSAR predicted binding
values for 9 compounds randomly selected for internal validation (R2 = 0.86).
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Table 1
Structural information and predicted binding values for 1,4-benzodiazepines.
Name Substitutions Log 1/c predicted Basic structure
R7 R1 R2′ R3
Diclazepam Cl CH3 Cl – 8.39
Desalkylﬂurazepam Cl – F – 8.44
Meclonazepam NO2 – Cl CH3 8.52
Phenazepam Br – Cl – 8.12
Desmethylﬂunitrazepam NO2 – F – 8.46
3-hydroxyphenazepam Br – Cl OH 8.42
Flubromazepam F – Br – 8.37
Nifoxipam NO2 – F OH 8.63
Cloniprazepam NO2 – Cl C3H5CH3 7.83
Nimetazepam NO2 CH3 – – 7.87
4-chlorodiazepama Cl CH3 – – 7.88
a 4-chlorodiazepam has a Cl substituted on the R4′ position of the phenyl ring.
Table 2
Structural information and predicted binding values for triazolobenzodiazepines.
Name Substitutions Log 1/c predicted Basic structure
R8 R1 R2′ R4
Flubromazolam Br CH3 F – 8.77
Clonazolam NO2 CH3 Cl – 8.86
Flunitrazolam NO2 CH3 F – 8.88
Bromazolam NO2 CH3 – – 8.25
Adinazolam Cl CH3N(CH3)2 – – 7.18
Pyrazolama Br CH3 – – 7.79
Nitrazolam NO2 CH3 – – 8.34
a Pyrazolam has a 2-pyridyl ring at position 6 rather than a phenyl ring.
Table 3
Structural information and predicted binding values for thienotriazolodiazepines.
Name Substitutions Log 1/c predicted Basic structure
R9 R2 R2′
Deschloroetizolam CH3 CH2CH3 – 7.96
Etizolam CH3 CH2CH3 Cl 8.64
Metizolam – CH2CH3 Cl 8.34
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internal validation. These estimated values were then compared to the
experimental binding values (Fig. 5).
The QSAR model was then used to predict the binding for 22 ben-
zodiazepines that are classed as new psychoactive substances. The re-
sults are divided in to four categories depending upon the nature of the
substitutions, as shown in Tables 1, 2, 3 and 4.
Five compounds were present in the training dataset but have also
appeared as new psychoactive substances; adinazolam,
desalkylﬂurazepam, desmethylﬂunitrazepam (fonazepam), etizolam
and meclonazepam. The experimental binding values from the litera-
ture and the predicted binding values are displayed in Table 5.
The NPS-benzodiazepine with the highest predicted log 1/c value
was ﬂunitrazolam with 8.88, closely followed by clonazolam with 8.86.
However, based upon experimental data, meclonazepam with a log 1/c
value of 8.92 (8.52 predicted) actually exhibited the greatest binding
aﬃnity. Only two benzodiazepines in the training set experimental
values had a log 1/c value of 8.92; these were meclonazepam and
brotizolam with the rest falling below this point. In general, the lim-
itations to this model are most likely caused by the small size of the data
set. It is widely reported that QSAR models have poorer predictive
capabilities with training sets under 100 compounds [54,55]. More-
over, the diversity of substitutions within the small set of training
compounds, created diﬃculties with APF superimposition and therefore
may have reduced the accuracy of the model predictors. Secondary
modelling with SPCI highlighted these limitations and demonstrated
the existing dataset was less suitable for PLS 2D QSAR modelling [48].
However, the consensus from multiple modelling methods improves the
predictive power of the 2D QSAR model. Additionally, as experimental
errors in the training set are ampliﬁed both by the logarithmic scale and
when calculating the weighted contributions, consistency and accuracy
in the initial experimental values are essential for a strong QSAR model.
Ideally, further improvements to the model could be made by using a
larger training dataset with lower diversity yet this cannot be achiev-
able as a consequence of limitations on literature data available.
From these docking studies with the modelled GABAA5 receptor it
can be seen that they only partially occupy the available volume at the
allosteric binding site (exempliﬁed in Fig. 6 for ﬂunitrazolam). From
the ten compounds that had the greatest binding aﬃnity, four had non-
bonded interactions with the T80 region within the receptor, two had
non-bonded interactions with the K182 and S231 regions respectively.
There were also stacking interactions with the Y96 region for four of the
compounds. Therefore the possibility is that the binding is not com-
pletely optimal for these benzodiazepines and that with a modiﬁed
chemical structure, a greater binding aﬃnity could be theoretically
possible. The reality exists that a benzodiazepine with an optimised
binding aﬃnity could emerge onto the illicit drugs market and could
potentially (but not necessarily) exhibit a greater potency.
The 10 compounds with the greatest binding aﬃnity for the re-
ceptor are listed in Table 6 (lower scores indicate a greater binding
eﬀect).
There are 35 benzodiazepines and their derivatives currently subject
to international control, 30 of these compounds had binding values
listed in the original source [44]. The average log 1/c value for these 30
Table 4
Structural information and a predicted binding value for an oxazolobenzodiazepine.
Name Substitutions Log 1/c predicted Basic structure
R10 R7 R2′
Flutazolam Cl CH2CH2OH F 6.83
Table 5
Observed and predicted binding values for new psychoactive substances.
Compound Log 1/c
observed
Log 1/c
predicted
% (log 1/c
obs.) / (log 1/c
pred.)
Adinazolam 6.87 7.18 95.9%
Desalkylﬂurazepam 8.70 8.44 103.1%
Desmethylﬂunitrazepam
(fonazepam)
8.82 8.46 104.3%
Etizolam 8.51 8.64 98.5%
Meclonazepam 8.92 8.52 104.7%
Fig. 6. Visualisation of the NPS-benzodiazepine ﬂunitrazolam binding to the allosteric
site of the GABAA5 receptor.
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controlled compounds was 7.57. Out of these compounds, 43% (13 out
of 30) had a log 1/c value that was> 8.00. The average log 1/c value
for the whole training dataset was 7.81 and 48% of the compounds (33
out of 69) had a log 1/c value that was> 8.00. These values are fairly
similar, however when comparing the results of the benzodiazepines
that are new psychoactive substances, the average log 1/c value that
was predicted was 8.22 and 68% of the compounds (15 out of 22) had a
log 1/c value that was> 8.00. From this it is appears that benzodia-
zepines that are appearing as new psychoactive substances are more
likely to have a greater binding aﬃnity at the GABAA receptor. Whether
this trend is deliberate is unclear.
A log 1/c value of 7.88 was obtained for 4-chlorodiazepam (Ro 5-
4864). This suggests a relatively high aﬃnity for the GABAA receptor
when compared with the log 1/c values for clinically-used benzodia-
zepines; the binding value for diazepam is 8.09 and 8.40 for triazolam.
However it has been reported that the experimental value for 4-chlor-
odiazepam (Ro-4864) is actually 3.79 (i.e. an IC50 value of 160,500 nM)
in one dataset when compared with a log 1/c of 7.80 for diazepam and
8.72 for triazolam in the same dataset [56]. There are obvious im-
practicalities with comparing diﬀerent datasets as a result of diﬀerences
in methods (e.g. the use of [3H]-diazepam versus [3H]-ﬂunitrazepam as
a radioligand), the diﬀerences in the species used (rat vs. mouse) and
the diﬀerences in GABAA receptor expression between diﬀerent brain
homogenates. Despite this it is clear that 4-chlorodiazepam observes an
extremely low aﬃnity for GABAA receptors and one that this model did
not accurately predict. This most likely results from the deﬁcit of
compounds in the training dataset that had a similar substitution on the
R4′ position of the phenyl ring. Indeed, this model focused upon the
‘classical’ 1,4-benzodiazepine, triazolobenzodiazepine, imidazobenzo-
diazepine and thienotriazolodiazepine substitutions. Substitutions on
the R4′ position of the phenyl ring are known to exhibit strong steric
repulsion at the GABAA receptor interface and therefore compound
binding is severely inhibited [40,57]. 4-chlorodiazepam is an outlier
and atypical benzodiazepine as it does not act upon the GABAA re-
ceptor; instead exerting its pharmacological eﬀects through the trans-
locator protein 18 kDa (TSPO), previously known as the peripheral
benzodiazepine receptor [58,59].
The oxazolobenzodiazepine ﬂutazolam, a prescription drug in
Japan, had a predicted log 1/c binding value of 6.83 which seems ex-
tremely low compared with the other benzodiazepines in this dataset.
To the best of the authors' knowledge there exists no experimental
GABAA receptor binding data for ﬂutazolam. However other ox-
azolobenzodiazepines have low aﬃnities for the GABAA receptor such
as ketazolam with a log 1/c value of 5.89 [60] and oxazolam with a log
1/c value of 5.00 [61]. These log 1/c binding values are from additional
sources – the previous paragraph discusses the diﬃculties in comparing
binding values from diﬀerent datasets. Nonetheless it is clear that ox-
azolobenzodiazepines exhibit a much lower aﬃnity for the GABAA
receptor. If the value for ﬂutazolam is correct then this QSAR model
successfully predicted the low binding aﬃnity of ﬂutazolam despite
having no oxazolobenzodiazepines in the training dataset which serves
as an indicator to the potential strength of the model.
4. Conclusions
The emergence of benzodiazepines and their derivatives as new
psychoactive substances necessitates the investigation of their phar-
macological attributes. The use of a QSAR model is ideal to gain an
understanding into the binding properties of these substances. In this
work a QSAR model has been successfully developed to predict the
binding data for NPS-benzodiazepines. Benzodiazepines that have
emerged as new psychoactive substances appear to have a greater
binding aﬃnity to GABAA receptors than those benzodiazepines that
are used medically and are under international control. Whether this
trend will continue is uncertain. Further in vitro work would allow the
compilation of more data to improve the accuracy of this model.
However, this model does allow a rapid estimation of the binding af-
ﬁnity of emerging benzodiazepines before more detailed studies can be
carried out.
Appendix A. Supplementary data
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.scijus.2017.12.004.
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Abstract 
The misuse of benzodiazepines as new psychoactive substances is an increasing problem 
around the world. Basic physicochemical and pharmacokinetic data is required on these 
substances in order to interpret and predict their effects upon humans. Experimental log D7.4, 
pKa and plasma protein binding values were determined for 11 benzodiazepines that have 
recently appeared as new psychoactive substances (3-hydroxyphenazepam, 4’-
chlorodiazepam, desalkylflurazepam, deschloroetizolam, diclazepam, etizolam, 
flubromazepam, flubromazolam, meclonazepam, phenazepam and pyrazolam) and compared 
with values generated by various software packages (ACD/I-lab, MarvinSketch, ADMET 
Predictor and PreADMET). ACD/I-LAB returned the most accurate values for log D7.4 and 
plasma protein binding while ADMET Predictor returned the most accurate values for pKa. 
Large variations in predictive errors were observed between compounds. Experimental values 
are currently preferable and desirable as they may aid with the future ‘training’ of predictive 
models for these new psychoactive substances. 
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1. Introduction 
New psychoactive substances (NPS) are an increasing problem around the world
1
. 
Benzodiazepines are one of a number of groups of NPS that have appeared on the illicit drug 
market2. They also exist as common prescription drugs for anxiety, insomnia and other 
medical conditions
3
. Benzodiazepines were misused long before emerging as new 
psychoactive substances and a recent report highlighted the increasing illicit availability and 
misuse of a clinically-used benzodiazepine, alprazolam, often purchased from the dark web
4
. 
The new psychoactive substance benzodiazepines (referred to in this work as NPS-
benzodiazepines) have already been reported in a number of overdose cases, driving under 
the influence of drugs (DUID) cases and hospital admissions 
5–8
. The lack of control and 
safety over these NPS-benzodiazepines is a prevalent issue and it is predicted that it will 
become an even more worrying trend as their misuse continues to rise. A number of these 
compounds were originally prescription drugs such as phenazepam (Russia) as well as 
etizolam and flutazolam (Japan) 
9–11
. Some of these compounds never gained marketing 
approval (e.g. adinazolam) but the majority were simply patented and never brought to 
market and, as such, there is a deficit of physiochemical and pharmacokinetic data that would 
otherwise exist if they had undergone clinical trials 
12
. However, such information is essential 
to fully understand the pharmacological behaviour of these compounds, especially as they are 
becoming more and more prevalent on the illicit drug market. This paper focuses on two 
physiochemical properties (log D7.4 and pKa) and one pharmacokinetic property (plasma 
protein binding). 
The lipophilicity of a compound is often expressed by the term log D7.4, this is the 
distribution coefficient and represents the relative ratios of a compound in an organic and 
aqueous solvent at the physiologically-relevant pH of 7.4 
13
. Lipophilicity has various 
pharmacokinetic implications such as affecting a compound’s absorption through cell 
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membranes and its distribution in biological tissues and accordingly is important for the 
prediction of many of these pharmacokinetic parameters 
14,15
. Highly-lipophilic compounds 
typically exhibit greater plasma protein binding and can generally cross the blood-brain 
barrier with greater ease 
16,17
. The majority of the well-known, from herein referred to as 
‘classic’, benzodiazepines have comparatively high values for lipophilicity and can therefore 
partition with ease across cellular membranes and accumulate in areas of the body that are 
high in lipids 
18,19
. Furthermore, benzodiazepines also have high volumes of distribution (Vd) 
such as diazepam with a Vd at steady state of 0.88 – 1.39 L kg
-1
 
20–23
. The lipophilicity (as log 
P) of some NPS-benzodiazepines has already been published in literature 
24
. 
The acid-base dissociation constant (pKa) of a compound is typically investigated during 
pharmaceutical development and plays an important role when used in conjunction with other 
parameters such as molecular weight and lipophilicity 
25
. pKa can affect the site in the body 
where compounds are absorbed 
26
 and can also assist with the development of extraction 
methods from biological samples 
27
.  
Upon administration to the body, compounds bind to proteins present within the plasma, this 
is reflected through measurement of plasma protein binding values 
28,29
.  The fraction that is 
not bound (known as the unbound or free fraction) is responsible for the pharmacological 
effect and it is this fraction that undergoes metabolism and excretion 
18
. The majority of the 
classic benzodiazepines are highly protein-bound such as diazepam (99 % bound) but some 
experience vastly lower binding, for example bromazepam (60 % bound) 
30,31
. Reducing 
clearance (Cl) and increased plasma protein binding generally correlates with an increase in 
half-life (t1/2) of a drug 
32
.  Knowledge of plasma protein binding is therefore important to 
help characterise pharmacokinetics of drugs without in vivo studies. There has already been 
interest in the determination of these properties for new psychoactive substances, for example 
the plasma protein binding of flubromazolam (89 %) has recently been published in the 
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literature 
33
. Yet for many of the more recently synthesised benzodiazepines the percentage 
bound is as yet unknown.  
As many of these compounds have never undergone clinical trials, and are unlikely to as a 
result of the time and expense involved, it is critical that such analysis is undertaken, 
especially for the future prediction of any newly emerging psychoactive substances. The use 
of predictive software could be an attractive alternative to in vitro experiments to calculate 
these properties and this research will focus upon comparison of some predictive software 
packages with experimental values. 
2. Materials and methods 
Eight benzodiazepines that had values available in the literature for log D7.4, pKa and plasma 
protein binding were chosen to examine the suitability of the devised methods (alprazolam, 
clonazepam, diazepam, flunitrazepam, nitrazepam, oxazepam, prazepam and temazepam). 
These three properties were then investigated experimentally for a further 11, as yet, 
uncharacterised benzodiazepines, recently appearing as new psychoactive substances (3-
hydroxyphenazepam, 4’-chlorodiazepam, desalkylflurazepam, deschloroetizolam, 
diclazepam, etizolam, flubromazepam, flubromazolam, meclonazepam, phenazepam and 
pyrazolam). The chemical structures of this latter group of compounds can be found in the 
Supplementary Information.  
2.1. Materials 
4’-Chlorodiazepam, alprazolam, clonazepam, desalkylflurazepam, diazepam, flunitrazepam, 
nitrazepam, oxazepam, prazepam and temazepam were obtained from Sigma-Aldrich 
(Dorset, UK). 3-Hydroxyphenazepam, deschloroetizolam, diclazepam, etizolam, 
flubromazepam, flubromazolam, meclonazepam, phenazepam and pyrazolam were obtained 
from Chiron (Trondheim, Norway). All compounds were received as powdered solids. 
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Dimethyl sulfoxide (DMSO), methanol, phosphoric acid, sodium hydrogen phosphate 
heptahydrate, sodium dihydrogen phosphate, disodium hydrogen phosphate, acetic acid, 
sodium acetate trihydrate, boric acid, sodium hydroxide, hydrochloric acid, sodium chloride 
and octan-1-ol were purchased from Fisher Scientific (Leicestershire, UK). Phosphate 
buffered saline (PBS) tablets were purchased from Sigma-Aldrich (Dorset, UK).  
Human plasma (pooled, from three male donors and three female donors) was obtained from 
Seralab (West Sussex, UK). Plasma was received frozen with sodium citrate as an 
anticoagulant. 
2.2. Methods 
2.2.1. Determination of log D7.4 
The shake-flask method is commonly used in determining log D7.4 values 
34
. The compound 
of interest is dissolved in equal volumes of a buffer at a specified pH and an organic solvent, 
such as octanol. Following equilibration the octanol and buffer are separated and the 
concentration of the compound in each is determined. The log D7.4 is then calculated using 
Equation 1. 
 
     
                                       
                                       
 
(1) 
   
Sodium phosphate buffer (0.01 M) was formulated using deionised water (Barnstead 
UltraPure) and filtered through a 0.45 µm Nylon Phenex filter membrane (Phenomenex, 
Cheshire, UK) using a Millipore filtration apparatus (Merck Millipore, Hertfordshire, UK).  
Compounds were dissolved in methanol at a concentration of 1 mg ml
-1
. Aliquots of 
compound solution were evaporated with a flow of nitrogen using a TurboVap to yield 0.20 
mg of compound. Equal volumes (700 µl) of sodium phosphate buffer (0.01 M, pH 7.4) and 
octan-1-ol were added and the samples were vortexed for 30 seconds. 
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The samples were transferred into 1.5 mL Eppendorf microcentrifuge tubes and placed on a 
Stuart SB3 rotator (Bibby Scientific, Staffordshire UK) and rotated at 40 rpm for four hours. 
Samples were then centrifuged at 10,000 rpm for 20 minutes. The separated octanol and 
buffer phases were collected and analysed using high performance liquid chromatography 
(HPLC) coupled to a diode array detector (DAD). Further details of the method employed are 
given in Section 2.4. Each log D determination was repeated in triplicate. 
2.2.2. Determination of pKa 
Capillary electrophoresis is a common method of measuring pKa 
35
. The basic principle 
behind this technique is an applied electrical voltage which separates ions according to their 
electrophoretic mobility. When the solute is unionised it has no mobility and when an 
electrical voltage is applied and it is fully ionised it has maximum electrophoretic mobility. 
The mobility of the solute between these two extremes is a function of the dissociation 
equilibrium. The effective electrophoretic mobility of a compound can be calculated by using 
the difference in migration time between the test compound and a neutral marker 
35
. 
       
    
 
  
 
  
 
 
  
  (2) 
In Equation , ta is the migration time for the test compound (s), tm is the migration time for 
the neutral marker (s), Ld is the total length from the capillary inlet to the detection window 
(cm), Lt is the total capillary length (cm) and V is the applied voltage (V). As a result of the 
differences in pH there can be variations in electroosmotic flow but these are corrected for by 
using a neutral compound as a marker and adjusting for this in the calculation of effective 
mobility.  
     
       
            
 (3) 
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 (4) 
Equations (3) and (4) describe the relationship between the effective electrophoretic mobility 
of a compound and its pKa for benzodiazepines with one ionisable basic group and an 
ionisable basic and acidic group 
36
.  
Phosphate, acetate and borate buffers were utilised as described elsewhere with a pH spacing 
of 0.5 pH units 
36
. All buffers had an ionic strength of I=0.05 and a concentration of 0.05 M. 
Sodium chloride was used to adjust the ionic strength and hydrochloric acid (0.1 M) or 
sodium hydroxide (0.1 M) were used to adjust the pH values if necessary. The pH was 
measured with a Jenway 3505 pH meter (Jenway, Essex, UK) which was calibrated before 
use. Buffers were filtered prior to use through a 0.45 µm Nylon Phenex filter membrane 
(Phenomenex, Cheshire, UK) using a Millipore filtration apparatus (Merck Millipore, 
Hertfordshire, UK).  
Compounds were dissolved in methanol at a concentration of 1 mg ml
-1
. Solutions were 
diluted to 0.25 mg ml
-1
 with deionised water (Barnstead UltraPure) and contained DMSO as 
the electroosmotic flow marker (1 % v/v). 
DMSO (1 % v/v) in deionised water (Barnstead UltraPure) was run at each pH before 
experimental repeats to ensure that an expected electrophoretic mobility was obtained. 
Compound migration times were determined using a Beckman Coulter P/ACE MDQ 
Capillary Electrophoresis System with a diode array detector (Beckman-Coulter, High 
Wycombe, UK). The internal capillary temperature was set at 25 °C using the liquid cooling 
system. Sample injection was conducted at 1.0 psi for 10 seconds and then 20 kV voltage was 
applied during separations. The capillary was rinsed between each run in the following 
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manner; NaOH applied at 20 psi for 1.0 minute followed by the appropriate buffer for the 
next repeat at 20 psi for 2.0 minutes.  
Experimentally determined µeff values were obtained using Equation 2. The Microsoft Excel 
add-in, Solver, was used to calculate the pKa value using least-squares regression. An initial 
‘best-guess’ estimate for the pKa and α values were used to calculate theoretical effective 
mobilities and the squared difference (the residuals) between these theoretical values and 
experimental values was then calculated and then minimised by varying the values for pKa 
and α. 
For pKa measurements, accuracy is defined as a measured value being within 0.20 units from 
the literature value and precision is defined as a measured value having a repeatability that is 
equal to or less than 0.07 units 
35
. Each pKa measurement was repeated in triplicate. 
2.2.3. Determination of plasma protein binding 
Plasma protein binding values in this work were determined using the commonly-used 
method of equilibrium dialysis 
37
. In this method, the compound of interest is spiked into 
plasma. The plasma and an appropriate buffer (e.g. at desired physiological pH) are then left 
to equilibrate, separated by a semi-permeable membrane that allows free drug to pass through 
but has a molecular-weight cut off (MWCO) to prevent proteins from passing through. 
Following equilibration, the resultant concentrations of drug are determined and Equation (5) 
is used to calculate the plasma protein binding. 
Frozen plasma was thawed at room temperature prior to the experiments. The pH was 
measured with a Jenway 3505 pH meter (Jenway, Essex, UK) which was calibrated before 
use. Plasma pH was found to be within the physiological range of 7.38 – 7.42 and adjustment 
was not required 
38
. 
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PBS tablets were dissolved in deionised water (Barnstead UltraPure) to yield a buffer 
solution that contained 0.01M phosphate, 0.0027M KCl, and 0.137M NaCl, pH 7.4 at 25 °C. 
Stock solutions of compounds in DMSO at a concentration of 10 mM were created and were 
diluted with PBS prior to the experiments to yield working solutions at a concentration of 200 
µM.  
Reusable Single-Sample Fast Micro-Equilibrium Dialyzers (500 µL volume) were obtained 
from Harvard Apparatus (Cambridge, UK), as were cellulose acetate membranes with a 
MWCO of 10,000 Da.  
The membranes were soaked for 30 minutes in deionised water (Barnstead UltraPure) and 
rinsed thoroughly. Thirty µL of compound working solution was added to 270 µL of plasma 
to yield a final concentration of 20 µM of compound (final DMSO concentration 0.2 %). This 
was placed in one chamber and 500 µL of PBS was placed in the second chamber. The 
Micro-Equilibrium Dialyzers were then placed into a shaking waterbath held at 37 °C for 24 
hours. The temperature was monitored with a Sentry Thermometer (Fisher Scientific, 
Leicestershire, UK). After 24 hours had elapsed, the samples were extracted from each 
chamber, matrix matched (with blank plasma or blank buffer). Ice-cold acetonitrile at a 4:1 
ratio was then added to precipitate proteins. The samples were centrifuged at 10,000 rpm for 
20 minutes and the supernatant was recovered and evaporated using a flow of nitrogen with a 
TurboVap. The samples were then reconstituted in 200 µL of acetonitrile and analysed using 
HPLC-DAD. Details of this analysis are given in Section 2.4. Each plasma protein binding 
measurement was repeated in triplicate.  
Plasma protein binding (PPB) was calculated using the experimental plasma concentration 
(Pexp) and the experimental buffer concentration (Bexp) according to Equation (5). 
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 (5) 
For those benzodiazepines that were highly protein bound and had a concentration in the 
buffer phase that was below the limit of quantitation (LOQ), the buffer concentration was 
calculated indirectly using Equation (6) which involved the experimental plasma 
concentration and the total expected concentration (Ptot), determined using a calibration plot. 
The total expected concentration was adjusted using a previously-determined correction 
factor (CF) for the extraction efficiency (≈ 95 %). This indirectly-calculated buffer 
concentration was then input into Equation (5) to generate plasma protein binding values. 
                     (6) 
2.3. Theoretical approaches 
Theoretical log D7.4 and pKa values were generated using the free, online software ACD/I-
Lab (which makes use of the EPSRC funded National Chemical Database Service hosted by 
the Royal Society of Chemistry) and two commercial software packages; MarvinSketch 
(version 17.28.0) (ChemAxon) and ADMET Predictor (Simulations Plus). Theoretical plasma 
protein binding values were obtained from two sources used for log D7.4 and pKa; ACD/I-Lab 
and ADMET Predictor (Simulations Plus) and one source available as a free online resource, 
PreADMET (version 2.0). These software packages are all commonly used for the prediction 
of physicochemical and pharmacokinetic parameters 
39–42
. Theoretical values were compared 
with experimental values by means of the absolute difference in values. 
2.4. HPLC analysis for log D7.4 and plasma protein binding 
Analysis was achieved with a Dionex UltiMate 3000 HPLC system equipped with an 
UltiMate 3000 Pump, UltiMate 3000 Autosampler, UltiMate 3000 Column Compartment, 
UltiMate 3000 Photodiode Array Detector and Chromeleon software (Dionex, Surrey, UK). 
Separation was achieved with a Waters® Spherisorb® analytical cartridge, C18 5 µm 80 Å 
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(4.6 × 150 mm) with an attached guard cartridge identically packed to the analytical cartridge 
(Waters, Hertfordshire, UK). The internal column temperature was kept constant at 25 °C and 
a flow rate of 0.8 mL min
-1
 was set. Injection volumes for the log D7.4 experiments were 25 
µL for the octanol phase and 100 µL for the phosphate buffer phase so that a dilution step 
was not necessary. Compound concentrations were retrospectively corrected. Injection 
volumes of 100 µL were used for the plasma protein binding experiments. A 46:54 (v/v) ratio 
of acetonitrile and sodium phosphate buffer (pH 3.0, 25 mM) was applied for 25 minutes. All 
compounds eluted within this time. The eluent was monitored by UV detection at 230 nm.  
The method was validated in terms of linearity, limit of quantitation (LOQ), limit of detection 
(LOD), accuracy and precision. This was performed according to the ICH guidelines. 
2.4.1. Linearity 
The linearity of this method was measured by constructing a five-point calibration plot of the 
area under the curve (AUC) of each compound against its concentration in mg ml
-1 
(n=3) 
from 0.25 – 0.0004 mg ml-1. 
2.4.2. Limit of detection (LOD) and limit of quantitation (LOQ) 
The limits of detection and quantitation were determined from the signal-to-noise ratio. The 
baseline response of blank samples was recorded. A ratio of 10:1 for the compound response 
to the baseline response was used for the LOQ and a ratio of 3:1 for the LOD. 
2.4.3. Accuracy and precision 
Accuracy was determined through comparison of the percentage recovery at three 
concentrations (0.25, 0.01 and 0.0004 mg ml
-1
). Precision was determined from the 
calculation of the standard deviation and relative standard deviation (RSD) of the compound 
peak areas at three concentrations (0.25, 0.01 and 0.0004 mg ml
-1
). 
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3. Results and discussion 
3.1. Method validation 
3.1.1. Linearity 
The method was linear over the concentration range 0.0004 – 0.25 mg ml-1 for all 
compounds. The residual sum of squares for each compound was reasonably low indicating 
linear concentration-response and a suitable method (Table 1). 
3.1.2. LOD and LOQ 
All compounds generally had good limits of detection and quantitation (Table 1). Pyrazolam 
exhibited the lowest response to the HPLC method, with a LOQ of 263.9 ng ml
-1
 and a LOD 
of 82.0 ng ml
-1
. 
3.1.3. Accuracy and precision 
Accuracy was determined through comparison of the percentage recovery at three 
concentrations (0.25, 0.01 and 0.0004 mg ml
-1
). Percentage recovery was generally within 2 
% and thus deemed to be acceptable (Table 5). Precision was determined from the calculation 
of the standard deviation and relative standard deviation (RSD) of the compound peak areas 
at three concentrations (0.25, 0.01 and 0.0004 mg ml
-1
). High levels of precision for all 
benzodiazepines were recorded (Table 2). 
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3.2.Experimental values 
Experimental log D7.4, pKa and plasma protein binding values for all the classic and NPS- 
benzodiazepines were successfully determined and compared with theoretical values. 
3.2.1. Log D7.4 
Buffer composition is important for the determination of log D7.4 values. Use of a 0.01 M 
phosphate buffer has been shown to give an excellent correlation of distribution coefficients 
determined in the octanol-phosphate system for acidic and neutral compounds 
43
. Despite the 
basic nature of the compounds in this study, a 0.01 M sodium phosphate buffer (pH 7.4) was 
chosen and its suitability evaluated by way of a comparison between the experimental log 
D7.4 values and literature log D7.4 values. 
For the clinically-used (and previously characterised) benzodiazepines the experimental 
results obtained for log D7.4 in this study were very close to those reported elsewhere in the 
literature, thus proving the suitability of this method and also the use of the 0.01 M sodium 
phosphate buffer (pH 7.4) (Table 3).  
The majority of the NPS-benzodiazepines were fairly lipophilic with log D7.4 values above 2 
(Table 3). None of the NPS-benzodiazepines had literature-reported log D7.4 values other than 
desalkylflurazepam with 2.78 versus a value of 2.82 in this work. Phenazepam (log D7.4 of 
3.25) was observed to be the most lipophilic NPS-benzodiazepine in this dataset while 
pyrazolam (log D7.4 of 0.97) was the least lipophilic, a 190-fold difference. The reason behind 
the low lipophilicity for pyrazolam becomes more apparent when its structure is considered. 
Pyrazolam contains a pyridin-2-yl ring at position 7 rather than a phenyl ring, as is the case 
with the rest of the benzodiazepines in this study. The phenyl ring has a log D7.4  value of 
1.56 versus a log D7.4 value of 0.62 for the pyridin-2-yl ring 
44
. Replacement of a phenyl ring 
for a pyridin-2-yl ring could lead to a decrease in lipophilicity. The benzodiazepine 
bromazepam contains a pyridin-2-yl ring rather than a phenyl ring and has a log D7.4 value of 
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1.60 
45
. The addition of a triazole ring to some compounds is also known to lead to a decrease 
in the partition coefficient 
4647
. The pyridin-2-yl ring and triazole ring addition appear to lead 
to a marked decrease in lipophilicity for pyrazolam. Previous research has used log D7.4 
values in a quantitative structure-activity relationship (QSAR) model which predicted the 
post-mortem distribution of benzodiazepines and was found to contribute significantly to 
their distributive potential 
48
. Log D7.4 has also been utilised, along with plasma protein 
binding and pKa, to derive models capable of predicting the volume of distribution at steady 
state of a wide range of compounds 
49,50
.   
3.2.2. pKa 
Experimental pKa values were all within 0.20 units of their literature values for the classic 
benzodiazepines and had excellent repeatability, under 0.07 units for all the reference 
compounds (Table 4). Classic benzodiazepines either have one pKa value, for example 
flunitrazepam (1.8), or two clonazepam (1.5 and 10.5) 
51,52
. The first pKa value refers to the 
deprotonation of the nitrogen cation at position 4 and the second pKa refers to the 
deprotonation of the nitrogen atom at position 1 
51
. The deprotonation of the nitrogen atom at 
position 1 is thought to be resonance stabilised with the negatively-charged oxygen atom 
51
. 
This can be visualised in Figure 1 for clonazepam. Values of 2.83 for etizolam and 2.51 and 
11.64 for desalkylflurazepam were calculated in this work. These compared favourably to 
their previously-reported values of 2.76 for etizolam and of 2.57 and 11.76 for 
desalkylflurazepam 53,54. 
The presence of an electron-withdrawing hydroxyl group decreases the pKa2 value, as does 
the presence of an ortho-chlorine substituent on the phenyl ring 
55
. Clonazepam has this 
ortho-chlorine substituent and has a calculated pKa value of 1.55 in this work. 3-
Hydroxyphenazepam, in addition to an ortho-chlorine substituent, also has a hydroxyl group 
and therefore its low pKa value of 1.25 was not unexpected. Repeatability was generally good 
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for the NPS-benzodiazepines; 0.07 is typically the expected variance in capillary 
electrophoresis measurements 
35
. However, a variance of up to ±0.10 was observed for some 
compounds including 3-hydroxyphenazepam. This could be as a result of its pKa1 value 
(1.25) being lower than the pH of the lowest buffer used (1.50).  
3.2.3. Plasma protein binding 
A number of the benzodiazepines had concentrations in the buffer phase would have been 
below the limit of quantitation (LOQ), these were; diazepam, oxazepam, prazepam, 4’-
chlorodiazepam, flubromazepam and phenazepam. All concentrations were higher than the 
limit of detection (LOD). As mentioned in the methods section the buffer phase 
concentrations were calculated indirectly. The use of a correction factor is less desirable than 
direct measurements however, it did not appear to affect the calculated values for plasma 
protein binding when compared with literature values (Table 5).  
Values for plasma protein binding are listed in Table 5 for clinically used benzodiazepines; 
wide variations were reported in the literature for many of the benzodiazepines. Age and sex 
have both been observed as causing differences in the plasma protein binding of drugs which 
may have been a factor in these variations as many of them were determined in vivo 
56–58
.  
The experimentally derived values for the reference benzodiazepines were typically within 
the literature ranges with low variations. The majority of the NPS-benzodiazepines were 
observed to exhibit a high degree of plasma protein binding (> 90 %), i.e. similar to the 
clinically used benzodiazepines (Table 5). Literature values for the plasma protein binding of 
three NPS-benzodiazepines were available and experimental values derived in this work 
returned a consensus with these; desalkylflurazepam (experimental 95.5 % versus 96.1 – 96.5 
% literature), etizolam (experimental 92.8 % versus 93 % literature) and flubromazolam 
(experimental 89.5 % versus literature 89 %) 
24,59–61
.  
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The lowest plasma protein binding was observed for pyrazolam which was 78.7 %. Such a 
low value of plasma protein binding for a benzodiazepine is not unheralded as bromazepam 
has a reported 60 % plasma protein binding 
31
. Substitution of the phenyl ring at position-5 
for a pyridin-2-yl ring has been previously reported to lead to a large decrease in lipophilicity 
for 1,-4-benzodiazepines 
59
. The same effect could well occur for triazolobenzodiazepines.  
4’-Chlorodiazepam differs from diazepam by having an additional chlorine atom substituted 
at the 4’-position of the phenyl ring and exhibits similarly high plasma protein binding; 98.2 
% versus 99.0 % for diazepam. Diclazepam is an isomer of 4’-chlorodiazepam; identical in 
chemical formula but differing in structure with the chlorine atom being substituted at the 2’-
position of the phenyl ring. Its plasma protein binding value was calculated as being 93.8 %, 
lower than diazepam or 4’-chlorodiazepam. However diclazepam’s demethylated metabolite 
has been reported as having a plasma protein binding of 94.9 % and demethylation at the 1-
position is not thought to substantially affect plasma protein binding 
59
. Therefore, it stands to 
reason that the decreased plasma protein binding observed is most likely as a result of the 
substitution of a chlorine atom at the 2’-position. Substitution at the 2’-position with a 
chlorine atom has been observed to decrease plasma protein binding but if this substitution 
instead occurs at the 4’ position then no such decrease is observed 59. This is thought to be as 
a result of the substitution at the 2’-position affecting the rotation and orientation of the 
benzene ring and resulting in lower binding.  
3-Hydroxyphenazepam exhibited lower plasma protein binding than its parent compound, 
phenazepam; 97.7 % versus 98.3 % and this is consistent with observations that 
hydroxylation at the 3-position leads to a decrease in plasma protein binding 
59
. 
Deschloroetizolam has a reduced plasma protein binding compared to the 
thienotriazolodiazepine etizolam (87.2 % versus 92.8%). Removal of a chlorine atom from 
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position-7 has been found to decrease plasma protein binding for 1,4-benzodiazepines and a 
similar relationship may hold true for thienotriazolodiazepines 
59
.  
Desalkylflurazepam differs from flubromazepam by replacement of the bromine atom at the 
7-position by a chlorine atom. Its plasma protein binding is lower (95.5 % versus 96.2 %) 
which is consistent with literature observations that this replacement causes a decrease in 
plasma protein binding 
59
.  
Phenazepam differs from flubromazepam by replacement of the fluorine atom at the 2’-
position with a chlorine atom and exhibits an increase in plasma protein binding from 96.4 % 
to 98.3 %. Again, this is consistent with previous literature observations on 1,4-
benzodiazepines 
59
. 
3.3. Theoretical values 
3.3.1. Log D7.4 
ACD/I-Lab returned the closest predicted log D7.4 values to the experimental values for both 
the eight test benzodiazepines (average absolute error 0.18) and the 11 NPS-benzodiazepines 
(average absolute error 0.28). ADMET Predictor returned the next-closest predicted values 
with average absolute errors of 0.24 for the test benzodiazepines and 0.37 for the NPS-
benzodiazepines. MarvinSketch fared the worst, returning an average absolute error of 0.39 
for the test benzodiazepines and 0.97 for the NPS-benzodiazepines. It is therefore clear that 
all three programs had a lower accuracy in predicting the log D7.4 for the NPS-
benzodiazepines and this highlights the importance of the collection of experimental data 
especially if these models are to be improved. An example of this is for pyrazolam, with an 
experimental value of 0.97 yet ACD/I-Lab returned a value of 1.76, i.e. approximately a six-
fold difference in apparent lipophilicity. The atypical structure of pyrazolam, with its pyridin-
2-yl ring, possibly led to these large differences. Inclusion of pyrazolam along with the other 
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NPS-benzodiazepines in any future training dataset for these predictive models could 
possibly assist in the prediction of log D7.4. 
3.3.2. pKa 
ADMET Predictor returned the closest predicted values to experimental values, with an 
absolute average error of 0.4 for both the test set and the NPS set. This was closely followed 
by ACD/I-Lab which returned absolute average errors of 0.5 for both sets. MarvinSketch 
returned average absolute errors of 0.6 for the test set and 0.7 for the NPS set. MarvinSketch 
did not predict pKa1 values for oxazepam and temazepam and instead predicted two pKa2 
values for oxazepam (only one of which exists) and one pKa2 value for temazepam (only a 
pKa1 value is observed). Large errors were observed in some of the pKa values returned by 
the software. For example; a pKa of 2.45 predicted by ACD/I-Lab for deschloroetizolam 
versus an experimental pKa of 4.19, a pKa of 1.33 predicted by MarvinSketch for etizolam 
versus an experimental pKa of 2.80 and a pKa of 2.98 predicted for flubromazolam by 
ADMET Predictor versus an experimental pKa of 2.07. Additionally, all three software 
packages predicted multiple other deprotonation sites for some of the benzodiazepines which 
are not experimentally observed. The importance of obtaining accurate experimental pKa 
values is therefore clear especially if these predictive models wish to be improved upon. 
3.3.3. Plasma protein binding 
Plasma protein binding was best predicted by ACD/I-Lab which returned average absolute 
errors of 4.4 % for the test benzodiazepines and 3.0 % for the NPS-benzodiazepines. 
ADMET Predictor followed closely behind with average absolute errors of 6.8 % for the test 
benzodiazepines and 3.4 % for the NPS-benzodiazepines. PreADMET returned average 
absolute errors of 9.9 % for the test benzodiazepines and 5.0 % for the NPS-benzodiazepines. 
The software appeared to be less effective at predicting plasma protein binding of the test 
benzodiazepines than the NPS-benzodiazepines (Table 5). However an important caveat is 
that the average absolute errors for the test benzodiazepines were influenced heavily by the 
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small dataset and the presence of alprazolam; the experimental plasma protein binding was 
determined as being 71.6 % and the predicted values were 89.5 % (ACD/I-Lab), 91.2 % 
(ADMET Predictor) and 95.2% (PreADMET). Again, inclusion of a wider range of 
benzodiazepines (especially those with aberrant structures such as pyrazolam) in any training 
dataset may assist with their predictive power. 
4. Conclusions 
Log D7.4, pKa and plasma protein binding values were successfully determined in this work 
for a range of benzodiazepines that have emerged as novel psychoactive substances. The 
experimental methods presented were judged to be suitably accurate for the determination of 
these values.  
Large variations in plasma protein binding and log D7.4 were observed for the NPS-
benzodiazepines. Pyrazolam was found to be the least lipophilic NPS-benzodiazepine with a 
log D7.4 of 0.97 and experienced the lowest plasma protein binding of 78.7 %. Phenazepam 
was the most lipophilic NPS-benzodiazepine with a log D7.4 of 3.25 and a plasma protein 
binding of 98.3 %. 3-Hydroxyphenazepam had the lowest pKa1 value of 1.25 while 
deschloroetizolam had the highest pKa1 value of 4.19. Phenazepam had the lowest pKa2 
value of 11.24 and 3-hydroxyphenazepam had the highest of 11.96. 
ACD/I-Lab returned the closest predicted values to experimental values for both plasma 
protein binding and log D7.4 while ADMET Predictor returned the closest predicted values to 
experimental values for pKa. Although the average errors returned by each software package 
were often low, there were large variations in individual errors. It is therefore likely that 
experimental data for these novel psychoactive substances remains preferable to that 
generated from predictive software. The inclusion of experimental data for these NPS-
benzodiazepines could aid the predictive capability of various software packages. 
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Table 1. Linearity, LOQ and LOD data for benzodiazepines 
Compound Slope Correlation 
coefficient 
y intercept Residual 
sum of 
squares 
LOQ  
(ng ml
-1
) 
LOD 
(ng ml
-1
) 
3-Hydroxyphenazepam 4455.57 1.00 -0.55 19.40 188.9 42.9 
4’-Chlorodiazepam 4819.30 1.00 1.44 11.30 202.2 59.5 
Alprazolam 4826.85 1.00 1.36 27.07 144.6 49.8 
Clonazepam 4407.07 1.00 0.37 21.90 185.4 59.2 
Desalkylflurazepam 4283.08 1.00 -0.74 16.43 187.2 53.4 
Deschloroetizolam 4072.89 1.00 0.86 13.00 206.1 62.5 
Diazepam 4758.95 1.00 -0.74 18.41 185.5 51.8 
Diclazepam 4817.39 1.00 0.48 12.73 198.8 59.9 
Etizolam 4007.71 1.00 0.51 13.20 194.2 57.0 
Flubromazepam 4084.79 1.00 0.73 15.99 165.6 67.6 
Flubromazolam 4168.69 1.00 -0.42 10.68 177.3 47.2 
Flunitrazepam 4223.77 1.00 -0.92 13.05 159.0 51.5 
Meclonazepam 4805.99 1.00 0.87 9.15 186.4 52.5 
Nitrazepam 4367.07 1.00 -0.37 10.82 179.2 49.4 
Oxazepam 4466.93 1.00 -0.53 7.17 159.8 50.2 
Phenazepam 4149.34 1.00 -0.17 11.76 191.2 65.3 
Prazepam 4338.90 1.00 0.34 9.32 172.3 56.0 
Pyrazolam 3967.82 1.00 -0.31 14.76 263.9 82.0 
Temazepam 4646.75 1.00 -0.34 9.67 195.6 51.9 
 
  
  
This article is protected by copyright. All rights reserved. 
Table 2. Precision and accuracy data for benzodiazepines 
 
 
 
  
Compound 
Concentration (mg ml
-1
) 
0.0004 (n=3) 0.01 (n=3) 0.25 (n=3) 
Precisi
on SD 
Precisio
n RSD 
(%) 
Accurac
y (%) 
Precisio
n SD  
Precisio
n RSD 
(%) 
Accurac
y (%) 
Precisio
n SD 
Precisio
n RSD 
(%) 
Accurac
y (%) 
3-
Hydroxyphenaz
epam 
0.04 2.08 
99.39 
0.53 1.17 
100.46 
8.88 0.80 
99.17 
4’-
Chlorodiazepa
m 
0.06 1.72 
101.35 
0.47 0.93 
101.85 
10.29 0.85 
100.54 
Alprazolam 0.04 1.31 99.49 0.88 1.75 100.57 13.44 1.10 99.86 
Clonazepam 0.05 1.53 101.11 0.81 1.62 99.25 6.91 1.77 99.98 
Desalkylfluraze
pam 
0.02 1.10 
98.60 
0.27 0.62 
101.50 
7.16 0.66 
101.12 
Deschloroetizol
am 
0.04 1.58 
99.25 
0.24 0.57 
99.56 
5.81 0.57 
100.68 
Diazepam 0.02 1.16 98.90 0.59 1.24 100.98 11.69 0.97 101.23 
Diclazepam 0.02 0.70 98.92 0.54 1.07 101.49 6.46 0.54 99.10 
Etizolam 0.04 1.74 98.99 0.72 1.78 99.57 9.95 1.00 99.73 
Flubromazepa
m 
0.03 1.16 
99.21 
0.66 1.56 
101.76 
5.36 0.52 
101.34 
Flubromazolam 0.03 2.15 100.41 0.55 1.13 100.89 17.93 1.71 100.74 
Flunitrazepam 0.06 2.03 98.97 0.27 0.55 99.56 9.33 0.78 99.72 
Meclonazepam 0.02 0.81 99.43 0.31 0.63 100.35 8.49 0.71 99.46 
Nitrazepam 0.02 1.21 98.20 0.54 1.10 100.15 9.67 0.78 100.83 
Oxazepam 0.02 1.44 101.76 0.70 1.56 101.68 7.48 0.68 99.21 
Phenazepam 0.03 2.17 101.01 0.98 2.37 99.95 6.45 0.62 100.23 
Prazepam 0.05 2.15 98.63 0.67 1.54 99.78 6.51 1.66 99.51 
Pyrazolam 0.03 2.14 99.47 0.53 1.33 101.53 2.95 0.30 100.73 
Temazepam 0.03 2.05 101.74 0.65 1.40 101.27 13.64 1.18 99.55 
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Table 3. Literature, experimental (n= ≥3) and theoretical log D7.4 values for a set of classic and NPS-
benzodiazepines 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound Literature log D7.4 Experimental log D7.4 
Theoretical log D7.4 
References 
ACD/I-
LAB/I-
lab 
MarvinSketch 
ADMET 
Predictor 
Benzodiazepines 
Alprazolam 2.12 – 2.16 2.10 ±0.01 2.44 3.02 2.63 62,63 
Clonazepam 2.41 2.40 ±0.02 2.57 3.15 2.49 
45,62 
Diazepam 2.79 – 2.99 2.81 ±0.03 2.87 3.08 2.96 45,62–64 
Flunitrazepam 2.06 – 2.14 2.05 ±0.01 2.20 2.55 1.87 45,62,63 
Nitrazepam 2.13 – 2.16 2.17 ±0.03 2.03 2.55 2.49 45,62 
Oxazepam 2.13 – 2.24 2.24 ±0.05 2.04 2.92 1.95 17,45 
Prazepam 3.7 – 3.73 3.74 ±0.04 3.84 3.86 3.68 45,62 
Temazepam 1.79 – 2.19 2.32 ±0.01 2.13 2.79 2.18 45,62 
NPS-benzodiazepines 
3-Hydroxyphenazepam Not reported 2.54 ±0.01 2.67 3.69 2.40 Not reported 
4’-Chlorodiazepam Not reported 2.75 ±0.08 3.13 3.68 3.40 Not reported 
Desalkylflurazepam 2.70 2.82 ±0.09 2.71 3.15 2.74 
62 
Deschloroetizolam Not reported 2.60 ±0.03 2.43 3.45 2.82 Not reported 
Diclazepam Not reported 2.73 ±0.02 3.13 3.68 3.25 Not reported 
Etizolam Not reported 2.40 ±0.01 2.74 4.06 3.32 Not reported 
Flubromazepam Not reported 2.87 ±0.05 2.96 3.52 2.80 Not reported 
Flubromazolam Not reported 2.40 ±0.04 2.52 3.33 2.60 Not reported 
Meclonazepam Not reported 2.64 ±0.05 2.91 3.72 2.80 Not reported 
Phenazepam Not reported 3.25 ±0.04 3.52 3.98 3.19 Not reported 
Pyrazolam Not reported 0.97  ±0.01 1.76 2.36 2.03 Not reported 
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Table 4. Literature, experimental (n= ≥3) and theoretical pKa values for a set of classic and NPS benzodiazepines 
 
 
 
Compound 
Literature pKa Experimental pKa 
Theoretical pKa 
References 
ACD/I-LAB/I-
lab 
MarvinSketch ADMET Predictor 
pKa1 pKa2 pKa1 pKa2 pKa1 pKa2 pKa1 pKa2 pKa1 pKa2 
Benzodiazepines 
Alprazolam 2.4 None 2.48 ±0.01 None 2.37 None 
1.45, 
5.01 
None 0.93, 3.01 None 
65 
Clonazepam 1.49 – 1.52 
10.37 – 
10.51 
1.55 ±0.02 10.45 ±0.05 1.55 11.21 1.89 11.65 1.43 10.77 
65–67 
Diazepam 3.17 – 3.31 None 3.10 ±0.00 None 3.40 None 2.92 None 2.96 None 66,68 
Flunitrazepam 1.8 None 1.82 ±0.04 None 1.68 None 1.72 None 1.87 None 
65 
Nitrazepam 2.94 – 3.2 10.8 – 11 3.11 ±0.06 11.02 ±0.05 2.55 11.35 2.65 11.66 2.49 11.02 55,66 
Oxazepam 1.56 – 1.7 11.21 – 11.6 1.67 ±0.05 11.34 ±0.03 1.17 
10.94, 
12.75 
None 
10.65, 
12.47 
2.57 11.31 
66,67 
Prazepam 2.7 – 2.74 None 2.71 ±0.01 None 3.44 None 3.06 None 3.10 None 65,66 
Temazepam 1.31 – 1.6 None 1.45 ±0.05 None 1.58 11.66 None 10.68 2.48 None 66,69 
NPS-benzodiazepines 
3-Hydroxyphenazepam Not reported Not reported 1.25 ±0.10 11.96 ±0.09 0.13 
10.80, 
12.68 
None 
10.61, 
12.45 
1.95 11.24 Not reported 
4’-Chlorodiazepam Not reported Not reported 3.13 ±0.01 None 3.08 None 2.45 None 2.55 None Not reported 
Desalkylflurazepam 2.57 11.76 2.51 ±0.05 11.64 ±0.04 2.36 11.55 1.80 12.29 2.31 11.37 
53  
Deschloroetizolam Not reported Not reported 4.19 ±0.01 None 
0.20, 
2.45 
None 
1.31, 
5.37 
None 1.84, 3.96 None Not reported 
Diclazepam Not reported Not reported 2.31 ±0.07 None 1.75 None 2.13 None 1.95 None Not reported 
Etizolam 2.76 None 2.83 ±0.06 None 
0.10, 
2.37 
None 
1.33, 
4.55 
None 1.61, 3.31 None 
54 
Flubromazepam Not reported Not reported 3.25 ±0.10 10.74 ±0.05 2.32 11.55 1.8 12.28 2.70 11.45 Not reported 
Flubromazolam Not reported Not reported 2.07 ±0.02 None 2.27 None 
1.48, 
4.01 
None 0.96, 2.98 None Not reported 
Meclonazepam Not reported Not reported 2.10 ±0.09 11.45 ±0.07 1.70 11.24 1.65 11.57 2.10 10.88 Not reported 
Phenazepam Not reported Not reported 2.19 ±0.05 11.21 ±0.04 2.18 11.58 2.06 12.28 2.44 11.43 Not reported 
Pyrazolam Not reported Not reported 3.30 ±0.03 None 
1.30, 
2.18 
None 
1.79, 
2.75 
None 
0.65, 2.47, 
3.21 
None Not reported 
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Table 5. Literature, experimental (n= ≥3) and theoretical plasma protein binding (PPB) values for a set of classic and NPS benzodiazepines 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound Literature PPB (%) Experimental PPB (%) 
Theoretical PPB (%) 
References ACD/
I-lab 
ADMET 
Predictor 
PreADMET 
Benzodiazepines 
Alprazolam 68.4 – 76.7 71.6 ±0.5 89.5 91.2 95.2 31,70 
Clonazepam 85.4 – 86.1 85.5 ±1.2 91.9 90.9 93.3 31,70 
Diazepam 98.4 – 99 99.0 ±0.2 96.5 93.2 98.7 31,37 
Flunitrazepam 77.5 – 84.5 78.9 ±1.2 84.4 86.5 98.9 31,70 
Nitrazepam 82.1 – 88.9 88.4 ±1.8 88.5 84.3 92.0 71,72 
Oxazepam 89.0 – 98.4 96.9 ±0.1 95.6 88.9 96.7 31,70 
Prazepam ≈97 97.4 ±0.5 97.7 96.5 94.0 73 
Temazepam 92 – 96.8 94.3 ±0.1 95.4 91.1 74.3 31,70 
NPS-benzodiazepines 
3-Hydroxyphenazepam Not reported 97.7 ±0.6 92.5 93.8 90.1 Not reported 
4’-Chlorodiazepam Not reported 98.2 ±0.5 96.5 96.2 93.2 Not reported 
Desalkylflurazepam 96.1 – 96.5 95.5 ±1.5 96.1 92.8 91.4 60 
Deschloroetizolam Not reported 87.2 ±1.5 85.8 91.5 89.8 Not reported 
Diclazepam Not reported 93.8 ±1.2 96.5 95.7 97.7 Not reported 
Etizolam Not reported 92.8 ±0.6 90.2 94.7 90.8 Not reported 
Flubromazepam Not reported 96.4 ±0.9 89.0 93.2 93.9 Not reported 
Flubromazolam 89 89.5 ±0.4 87.4 91.1 92.2 
24 
Meclonazepam Not reported 88.2 ±0.5 93.0 93.0 92.3 Not reported 
Phenazepam Not reported 98.3 ±1.2 94.6 95.6 93.6 Not reported 
Pyrazolam Not reported 78.7 ±0.4 77.6 86.5 94.8 Not reported 
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Figure 1. The two sites of deprotonation and corresponding pKa values for clonazepam  
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